-DOCSTART-	-X-	-X-	O

The	DT	O	O
enzyme	JJ	O	O
cyclo-oxygenase	NN	O	B-enzyme
catalyses	VBZ	O	O
the	DT	O	O
oxygenation	NN	O	O
of	IN	O	O
arachidonic	JJ	O	B-SUBSTRATE
acid	NN	O	I-SUBSTRATE
,	,	O	O
leading	VBG	O	O
to	TO	O	O
the	DT	O	O
formation	NN	O	O
of	IN	O	O
prostaglandins	NNS	O	B-PRODUCT-OF
.	.	O	O

Recently	RB	O	O
two	CD	O	O
forms	NNS	O	O
of	IN	O	O
cyclo-oxygenase	NN	O	O
have	VBP	O	O
been	VBN	O	O
described	VBN	O	O
:	:	O	O
a	DT	O	O
constitutive	JJ	O	O
(	(	O	O
COX-1	NNP	O	O
)	)	O	O
enzyme	FW	O	O
present	JJ	O	O
in	IN	O	O
most	JJS	O	O
cells	NNS	O	O
and	CC	O	O
tissues	NNS	O	O
,	,	O	O
and	CC	O	O
an	DT	O	O
inducible	JJ	O	O
(	(	O	O
COX-2	NNP	O	O
)	)	O	O
isoenzyme	NN	O	O
observed	VBD	O	O
in	IN	O	O
many	JJ	O	O
cells	NNS	O	O
in	IN	O	O
response	NN	O	O
to	TO	O	O
pro-inflammatory	JJ	O	O
cytokines	NNS	O	O
.	.	O	O

Constitutive	JJ	O	O
and	CC	O	O
inducible	JJ	O	O
forms	NNS	O	O
of	IN	O	O
human	JJ	O	O
cyclo-oxygenase	NN	O	O
(	(	O	O
hCOX-1	JJ	O	O
and	CC	O	O
hCOX-2	JJ	O	O
)	)	O	O
were	VBD	O	O
cloned	VBN	O	O
and	CC	O	O
expressed	VBN	O	O
in	IN	O	O
insect	NN	O	O
cells	NNS	O	O
,	,	O	O
utilizing	VBG	O	O
a	DT	O	O
baculovirus	NN	O	O
expression	NN	O	O
system	NN	O	O
.	.	O	O

hCOX-1	NN	O	B-enzyme
had	VBD	O	O
a	DT	O	O
specific	JJ	O	O
activity	NN	O	O
of	IN	O	O
18.8	CD	O	O
mumol	NN	O	O
of	IN	O	O
O2/mg	NNP	O	O
with	IN	O	O
a	DT	O	O
Km	NNP	O	O
of	IN	O	O
13.8	CD	O	O
microM	NN	O	O
for	IN	O	O
arachidonate	NN	O	B-SUBSTRATE
and	CC	O	O
Vmax	NNP	O	O
.	.	O	O

of	IN	O	O
1500	CD	O	O
nmol	NN	O	O
of	IN	O	O
O2/nmol	NNP	O	O
of	IN	O	O
enzyme	NN	O	O
,	,	O	O
whereas	IN	O	O
hCOX-2	NN	O	B-enzyme
had	VBD	O	O
a	DT	O	O
specific	JJ	O	O
activity	NN	O	O
of	IN	O	O
12.2	CD	O	O
mumol	NN	O	O
of	IN	O	O
O2/mg	NNP	O	O
with	IN	O	O
a	DT	O	O
Km	NNP	O	O
of	IN	O	O
8.7	CD	O	O
microM	NN	O	O
for	IN	O	O
arachidonate	NN	O	B-SUBSTRATE
and	CC	O	O
a	DT	O	O
Vmax	NNP	O	O
.	.	O	O

of	IN	O	O
1090	CD	O	O
nmol	NN	O	O
of	IN	O	O
O2/nmol	NNP	O	O
of	IN	O	O
enzyme	NN	O	O
.	.	O	O

Indomethacin	NNP	O	O
inhibited	VBD	O	O
both	DT	O	O
hCOX-1	JJ	O	O
and	CC	O	O
hCOX-2	JJ	O	O
,	,	O	O
whereas	JJ	O	O
NS-398	NNP	O	O
and	CC	O	O
Dup-697	NNP	O	O
selectively	RB	O	O
inhibited	VBD	O	O
hCOX-2	NN	O	O
.	.	O	O

Both	DT	O	O
NS-398	NNP	O	O
and	CC	O	O
Dup-697	NNP	O	O
exhibited	VBD	O	O
time-dependent	JJ	O	O
inactivation	NN	O	O
of	IN	O	O
hCOX-2	NN	O	O
,	,	O	O
as	IN	O	O
did	VBD	O	O
indomethacin	NN	O	O
on	IN	O	O
both	DT	O	O
enzymes	NNS	O	O
.	.	O	O

The	DT	O	O
competitive	JJ	O	O
inhibitor	NN	O	O
of	IN	O	O
hCOX-1	NN	O	O
,	,	O	O
mefenamic	JJ	O	O
acid	NN	O	O
,	,	O	O
also	RB	O	O
displayed	VBD	O	O
competitive	JJ	O	O
inhibition	NN	O	O
of	IN	O	O
hCOX-2	NN	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
demonstrate	VBP	O	O
the	DT	O	O
ability	NN	O	O
to	TO	O	O
generate	VB	O	O
selective	JJ	O	O
non-steroidal	JJ	O	O
anti-inflammatory	JJ	O	O
drugs	NNS	O	O
(	(	O	O
NSAIDs	NNP	O	O
)	)	O	O
,	,	O	O
which	WDT	O	O
could	MD	O	O
provide	VB	O	O
useful	JJ	O	O
improvement	NN	O	O
therapeutically	RB	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
chronic	JJ	O	O
inflammatory	JJ	O	O
disease	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

As	IN	O	O
the	DT	O	O
substantia	NN	O	O
nigra	NN	O	O
degenerates	VBZ	O	O
in	IN	O	O
Parkinson	NNP	O	O
's	POS	O	O
disease	NN	O	O
(	(	O	O
PD	NNP	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
nigrostriatal	JJ	O	O
pathway	NN	O	O
is	VBZ	O	O
disrupted	VBN	O	O
,	,	O	O
reducing	VBG	O	O
striatal	JJ	O	O
dopamine	NN	O	O
and	CC	O	O
producing	VBG	O	O
PD	NNP	O	O
symptoms	NNS	O	O
.	.	O	O

Although	IN	O	O
dopamine	NN	O	O
does	VBZ	O	O
not	RB	O	O
readily	RB	O	O
cross	VB	O	O
the	DT	O	O
blood-brain	JJ	O	O
barrier	NN	O	O
,	,	O	O
its	PRP$	O	O
precursor	NN	O	O
,	,	O	O
levodopa	FW	O	O
,	,	O	O
does	VBZ	O	O
.	.	O	O

Levodopa	NNP	O	B-SUBSTRATE
is	VBZ	O	O
absorbed	VBN	O	O
in	IN	O	O
the	DT	O	O
small	JJ	O	O
bowel	NN	O	O
and	CC	O	O
is	VBZ	O	O
rapidly	RB	O	O
catabolized	VBN	O	O
by	IN	O	O
aromatic-L-amino-acid	JJ	O	B-enzyme
decarboxylase	NN	O	I-enzyme
(	(	O	O
AADC	NNP	O	B-enzyme
)	)	O	O
and	CC	O	O
catechol-O-methyltransferase	NN	O	B-enzyme
(	(	O	O
COMT	NNP	O	B-enzyme
)	)	O	O
.	.	O	O

Because	IN	O	O
gastric	JJ	O	O
AADC	NNP	O	B-enzyme
and	CC	O	O
COMT	NNP	O	B-enzyme
degrade	VBD	O	O
levodopa	NN	O	B-SUBSTRATE
,	,	O	O
the	DT	O	O
drug	NN	O	O
is	VBZ	O	O
given	VBN	O	O
with	IN	O	O
inhibitors	NNS	O	O
of	IN	O	O
AADC	NNP	O	O
(	(	O	O
carbidopa	NN	O	O
or	CC	O	O
benserazide	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
inhibitors	NNS	O	O
of	IN	O	O
COMT	NNP	O	O
will	MD	O	O
also	RB	O	O
enter	VB	O	O
clinical	JJ	O	O
use	NN	O	O
.	.	O	O

Although	IN	O	O
the	DT	O	O
exact	JJ	O	O
site	NN	O	O
of	IN	O	O
decarboxylation	NN	O	O
of	IN	O	O
exogenous	JJ	O	O
levodopa	NN	O	O
to	TO	O	O
dopamine	VB	O	O
in	IN	O	O
the	DT	O	O
brain	NN	O	O
is	VBZ	O	O
unknown	JJ	O	O
,	,	O	O
most	JJS	O	O
striatal	JJ	O	O
AADC	NNP	O	O
is	VBZ	O	O
located	VBN	O	O
in	IN	O	O
nigrostriatal	JJ	O	O
dopaminergic	JJ	O	O
nerve	NN	O	O
terminals	NNS	O	O
.	.	O	O

Newly	RB	O	O
synthesized	VBN	O	O
dopamine	NN	O	O
is	VBZ	O	O
stored	VBN	O	O
in	IN	O	O
the	DT	O	O
terminals	NNS	O	O
and	CC	O	O
then	RB	O	O
released	VBN	O	O
,	,	O	O
stimulating	VBG	O	O
postsynaptic	JJ	O	O
dopamine	NN	O	O
receptors	NNS	O	O
and	CC	O	O
mediating	VBG	O	O
the	DT	O	O
antiparkinsonian	JJ	O	O
action	NN	O	O
of	IN	O	O
levodopa	NN	O	O
.	.	O	O

Dopamine	NNP	O	O
agonists	VBZ	O	O
act	VBP	O	O
directly	RB	O	O
on	IN	O	O
postsynaptic	JJ	O	O
dopamine	NN	O	O
receptors	NNS	O	O
,	,	O	O
thus	RB	O	O
obviating	VBG	O	O
the	DT	O	O
need	NN	O	O
for	IN	O	O
metabolic	JJ	O	O
conversion	NN	O	O
,	,	O	O
storage	NN	O	O
,	,	O	O
and	CC	O	O
release	NN	O	O
.	.	O	O

How	WRB	O	O
the	DT	O	O
actions	NNS	O	O
of	IN	O	O
dopaminergic	JJ	O	O
drugs	NNS	O	O
produce	VBP	O	O
side	NN	O	O
effects	NNS	O	O
and	CC	O	O
how	WRB	O	O
these	DT	O	O
side	JJ	O	O
effects	NNS	O	O
should	MD	O	O
be	VB	O	O
managed	VBN	O	O
are	VBP	O	O
discussed	VBN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

N-Acetylglucosamine-1-phosphodiester	JJ	O	B-enzyme
alpha-N-Acetylglucosaminidase	NN	O	I-enzyme
(	(	O	O
EC	NNP	O	B-enzyme
3.1.4.45	CD	O	I-enzyme
;	:	O	O
phosphodiester	JJR	O	B-enzyme
alpha-GlcNAcase	NN	O	I-enzyme
)	)	O	O
catalyzes	VBZ	O	O
the	DT	O	O
second	JJ	O	O
step	NN	O	O
in	IN	O	O
the	DT	O	O
synthesis	NN	O	O
of	IN	O	O
the	DT	O	O
mannose	JJ	O	B-PRODUCT-OF
6-phosphate	JJ	O	I-PRODUCT-OF
determinant	NN	O	O
required	VBN	O	O
for	IN	O	O
efficient	JJ	O	O
intracellular	JJ	O	O
targeting	NN	O	O
of	IN	O	O
newly	RB	O	O
synthesized	VBN	O	O
lysosomal	JJ	O	O
hydrolases	NNS	O	O
to	TO	O	O
the	DT	O	O
lysosome	NN	O	O
.	.	O	O

A	DT	O	O
partially	RB	O	O
purified	JJ	O	O
preparation	NN	O	O
of	IN	O	O
phosphodiester	JJ	O	O
alpha-GlcNAcase	NN	O	O
from	IN	O	O
bovine	NN	O	O
pancreas	NN	O	O
was	VBD	O	O
used	VBN	O	O
to	TO	O	O
generate	VB	O	O
a	DT	O	O
panel	NN	O	O
of	IN	O	O
murine	JJ	O	O
monoclonal	JJ	O	O
antibodies	NNS	O	O
.	.	O	O

The	DT	O	O
anti-phosphodiester	JJ	O	O
alpha-GlcNAcase	JJ	O	O
monoclonal	JJ	O	O
antibody	NN	O	O
UC1	NNP	O	O
was	VBD	O	O
coupled	VBN	O	O
to	TO	O	O
a	DT	O	O
solid	JJ	O	O
support	NN	O	O
and	CC	O	O
used	VBN	O	O
to	TO	O	O
immunopurify	VB	O	O
the	DT	O	O
bovine	NN	O	O
liver	NN	O	O
enzyme	VBP	O	O
670,000-fold	JJ	O	O
in	IN	O	O
two	CD	O	O
steps	NNS	O	O
to	TO	O	O
apparent	JJ	O	O
homogeneity	NN	O	O
with	IN	O	O
an	DT	O	O
overall	JJ	O	O
yield	NN	O	O
of	IN	O	O
14	CD	O	O
%	NN	O	O
.	.	O	O

The	DT	O	O
purified	JJ	O	O
phosphodiester	NN	O	B-enzyme
alpha-GlcNAcase	NN	O	I-enzyme
has	VBZ	O	O
a	DT	O	O
specific	JJ	O	O
activity	NN	O	O
of	IN	O	O
498	CD	O	O
micromol	NN	O	O
of	IN	O	O
[	$	O	B-SUBSTRATE
3H	CD	O	O
]	JJ	O	O
GlcNAc-alpha-phosphomannose-alpha-methyl	NNP	O	O
cleaved	VBD	O	O
per	IN	O	O
h	NN	O	O
per	IN	O	O
mg	NN	O	O
of	IN	O	O
protein	NN	O	O
using	VBG	O	O
0.5	CD	O	O
mM	JJ	O	O
[	$	O	B-SUBSTRATE
3H	CD	O	O
]	JJ	O	O
GlcNAc-alpha-phosphomannose-alpha-methyl	NNP	O	O
as	IN	O	O
substrate	NN	O	O
.	.	O	O

The	DT	O	O
subunit	NN	O	O
structure	NN	O	O
of	IN	O	O
the	DT	O	O
enzyme	NN	O	O
was	VBD	O	O
determined	VBN	O	O
using	VBG	O	O
a	DT	O	O
combination	NN	O	O
of	IN	O	O
analytical	JJ	O	O
gel	NN	O	O
filtration	NN	O	O
chromatography	NN	O	O
,	,	O	O
SDS-polyacrylamide	NNP	O	O
gel	NN	O	O
electrophoresis	NN	O	O
,	,	O	O
and	CC	O	O
amino-terminal	JJ	O	O
sequencing	NN	O	O
.	.	O	O

The	DT	O	O
data	NN	O	O
indicate	NN	O	O
that	WDT	O	O
bovine	VBP	O	O
phosphodiester	JJR	O	O
alpha-GlcNAcase	NN	O	O
is	VBZ	O	O
a	DT	O	O
272,000-Da	JJ	O	O
complex	NN	O	O
of	IN	O	O
four	CD	O	O
identical	JJ	O	O
68,000-Da	CD	O	O
glycoprotein	NN	O	O
subunits	NNS	O	O
arranged	VBN	O	O
as	IN	O	O
two	CD	O	O
disulfide-linked	JJ	O	O
homodimers	NNS	O	O
.	.	O	O

A	DT	O	O
soluble	JJ	O	O
form	NN	O	O
of	IN	O	O
the	DT	O	O
enzyme	NN	O	O
,	,	O	O
isolated	VBN	O	O
from	IN	O	O
fetal	JJ	O	O
bovine	NN	O	O
serum	NN	O	O
,	,	O	O
showed	VBD	O	O
the	DT	O	O
same	JJ	O	O
subunit	NN	O	O
structure	NN	O	O
.	.	O	O

Both	DT	O	O
forms	NNS	O	O
of	IN	O	O
the	DT	O	O
enzyme	NN	O	O
reacted	VBD	O	O
with	IN	O	O
a	DT	O	O
rabbit	NN	O	O
antibody	NN	O	O
raised	VBD	O	O
to	TO	O	O
the	DT	O	O
amino-terminal	JJ	O	O
peptide	NN	O	O
of	IN	O	O
the	DT	O	O
liver	NN	O	O
enzyme	NN	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
phosphodiester	NN	O	O
alpha-GlcNAcase	NN	O	O
is	VBZ	O	O
a	DT	O	O
type	NN	O	O
I	PRP	O	O
membrane-spanning	JJ	O	O
glycoprotein	NN	O	O
with	IN	O	O
its	PRP$	O	O
amino	NN	O	O
terminus	NN	O	O
in	IN	O	O
the	DT	O	O
lumen	NNS	O	O
of	IN	O	O
the	DT	O	O
Golgi	NNP	O	O
apparatus	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Repeated	VBN	O	O
stress	NN	O	O
triggers	VBZ	O	O
a	DT	O	O
wide	JJ	O	O
range	NN	O	O
of	IN	O	O
adaptive	JJ	O	O
changes	NNS	O	O
in	IN	O	O
the	DT	O	O
central	JJ	O	O
nervous	JJ	O	O
system	NN	O	O
including	VBG	O	O
the	DT	O	O
elevation	NN	O	O
of	IN	O	O
serotonin	NN	O	O
(	(	O	O
5-HT	JJ	O	O
)	)	O	O
metabolism	NN	O	O
and	CC	O	O
an	DT	O	O
increased	VBN	O	O
susceptibility	NN	O	O
to	TO	O	O
affective	JJ	O	O
disorders	NNS	O	O
.	.	O	O

To	TO	O	O
begin	VB	O	O
to	TO	O	O
examine	VB	O	O
whether	IN	O	O
these	DT	O	O
changes	NNS	O	O
are	VBP	O	O
mediated	VBN	O	O
by	IN	O	O
alterations	NNS	O	O
in	IN	O	O
gene	NN	O	O
expression	NN	O	O
for	IN	O	O
tryptophan	JJ	O	B-enzyme
hydroxylase	NN	O	I-enzyme
(	(	O	O
TPH	NNP	O	B-enzyme
)	)	O	O
,	,	O	O
the	DT	O	O
rate-limiting	JJ	O	O
enzyme	NN	O	O
in	IN	O	O
5-HT	JJ	O	B-PRODUCT-OF
biosynthesis	NN	O	O
,	,	O	O
we	PRP	O	O
quantitated	VBD	O	O
its	PRP$	O	O
mRNA	NN	O	O
levels	NNS	O	O
by	IN	O	O
competitive	JJ	O	O
reverse	NN	O	O
transcription-polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
(	(	O	O
RT-PCR	NNP	O	O
)	)	O	O
.	.	O	O

Repeated	VBN	O	O
immobilization	NN	O	O
stress	NN	O	O
(	(	O	O
2	CD	O	O
h	NN	O	O
,	,	O	O
7	CD	O	O
days	NNS	O	O
)	)	O	O
elicited	VBD	O	O
a	DT	O	O
six-	JJ	O	O
or	CC	O	O
ten-fold	JJ	O	O
rise	NN	O	O
in	IN	O	O
TPH	NNP	O	O
mRNA	NN	O	O
in	IN	O	O
median	JJ	O	O
raphe	NN	O	O
nucleus	NN	O	O
(	(	O	O
MRN	NNP	O	O
)	)	O	O
and	CC	O	O
dorsal	JJ	O	O
raphe	NN	O	O
nucleus	NN	O	O
(	(	O	O
DRN	NNP	O	O
)	)	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
without	IN	O	O
significantly	RB	O	O
altering	VBG	O	O
TPH	NNP	O	O
mRNA	NN	O	O
levels	NNS	O	O
in	IN	O	O
the	DT	O	O
pineal	NN	O	O
gland	NN	O	O
.	.	O	O

In	IN	O	O
contrast	NN	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
little	JJ	O	O
change	NN	O	O
in	IN	O	O
mRNA	NN	O	O
levels	NNS	O	O
for	IN	O	O
GTP	NNP	O	B-enzyme
cyclohydrolase	NN	O	I-enzyme
I	PRP	O	O
(	(	O	O
GTPCH	NNP	O	B-enzyme
)	)	O	O
,	,	O	O
the	DT	O	O
rate	NN	O	O
limiting	VBG	O	O
enzyme	NN	O	O
in	IN	O	O
synthesis	NN	O	O
of	IN	O	O
the	DT	O	O
tetrahydrobiopterin	NN	O	B-PRODUCT-OF
(	(	O	O
BH4	NNP	O	B-PRODUCT-OF
)	)	O	O
,	,	O	O
the	DT	O	O
obligate	NN	O	O
cofactor	NN	O	O
for	IN	O	O
TPH	NNP	O	O
.	.	O	O

This	DT	O	O
is	VBZ	O	O
the	DT	O	O
first	JJ	O	O
study	NN	O	O
to	TO	O	O
reveal	VB	O	O
stress-elicited	JJ	O	O
activation	NN	O	O
of	IN	O	O
TPH	NNP	O	O
gene	NN	O	O
expression	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

The	DT	O	O
acute	JJ	O	O
toxicity	NN	O	O
of	IN	O	O
organophosphorus	NN	O	O
(	(	O	O
OP	NNP	O	O
)	)	O	O
compounds	VBZ	O	O
in	IN	O	O
mammals	NNS	O	O
is	VBZ	O	O
due	JJ	O	O
to	TO	O	O
their	PRP$	O	O
irreversible	JJ	O	O
inhibition	NN	O	O
of	IN	O	O
acetylcholinesterase	NN	O	B-enzyme
(	(	O	O
AChE	NNP	O	B-enzyme
)	)	O	O
in	IN	O	O
the	DT	O	O
nervous	JJ	O	O
system	NN	O	O
,	,	O	O
which	WDT	O	O
leads	VBZ	O	O
to	TO	O	O
increased	VBN	O	O
synaptic	JJ	O	O
acetylcholine	NN	O	B-SUBSTRATE
levels	NNS	O	O
.	.	O	O

The	DT	O	O
protective	JJ	O	O
actions	NNS	O	O
of	IN	O	O
intravenously	RB	O	O
(	(	O	O
i.v	JJ	O	O
.	.	O	O
)	)	O	O

administered	VBN	O	O
pyridostigmine	NN	O	O
,	,	O	O
physostigmine	NN	O	O
,	,	O	O
eptastigmine	NN	O	O
,	,	O	O
and	CC	O	O
an	DT	O	O
organophosphate	JJ	O	O
hydrolase	NN	O	O
,	,	O	O
phosphotriesterase	NN	O	O
,	,	O	O
in	IN	O	O
acute	JJ	O	O
sarin	JJ	O	O
intoxication	NN	O	O
were	VBD	O	O
studied	VBN	O	O
in	IN	O	O
mice	NN	O	O
.	.	O	O

The	DT	O	O
acute	NN	O	O
intragastric	NN	O	O
(	(	O	O
i.g	JJ	O	O
.	.	O	O
)	)	O	O

toxicity	NN	O	O
(	(	O	O
LD50	NNP	O	O
)	)	O	O
of	IN	O	O
sarin	NN	O	O
with	IN	O	O
and	CC	O	O
without	IN	O	O
the	DT	O	O
pretreatments	NNS	O	O
was	VBD	O	O
tested	VBN	O	O
by	IN	O	O
the	DT	O	O
up-and-down	JJ	O	O
method	NN	O	O
.	.	O	O

The	DT	O	O
mice	NN	O	O
received	VBD	O	O
pyridostigmine	NN	O	O
(	(	O	O
0.06	CD	O	O
mg/kg	NN	O	O
body	NN	O	O
weight	NN	O	O
)	)	O	O
,	,	O	O
physostigmine	NN	O	O
(	(	O	O
0.09	CD	O	O
mg/kg	NN	O	O
body	NN	O	O
weight	NN	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
physostigmine	NN	O	O
derivative	JJ	O	O
eptastigmine	NN	O	O
(	(	O	O
0.90	CD	O	O
mg/kg	NN	O	O
body	NN	O	O
weight	NN	O	O
)	)	O	O
or	CC	O	O
phosphotriesterase	NN	O	O
(	(	O	O
104	CD	O	O
U/g	NNP	O	O
,	,	O	O
10.7	CD	O	O
microg/g	NN	O	O
body	NN	O	O
weight	VBD	O	O
)	)	O	O
10	CD	O	O
min	NN	O	O
prior	RB	O	O
to	TO	O	O
the	DT	O	O
i.g	NN	O	O
.	.	O	O

administration	NN	O	O
of	IN	O	O
sarin	NN	O	O
.	.	O	O

Physostigmine	NN	O	O
was	VBD	O	O
also	RB	O	O
administered	VBN	O	O
with	IN	O	O
phosphotriesterase	NN	O	O
.	.	O	O

Phosphotriesterase	NNP	O	O
was	VBD	O	O
the	DT	O	O
most	RBS	O	O
effective	JJ	O	O
antidote	NN	O	O
in	IN	O	O
sarin	JJ	O	O
intoxication	NN	O	O
.	.	O	O

The	DT	O	O
LD50	NNP	O	O
value	NN	O	O
for	IN	O	O
sarin	NN	O	O
increased	VBD	O	O
3.4-fold	JJ	O	O
in	IN	O	O
mice	NN	O	O
receiving	VBG	O	O
phosphotriesterase	NN	O	O
.	.	O	O

Physostigmine	NN	O	O
was	VBD	O	O
the	DT	O	O
most	RBS	O	O
effective	JJ	O	O
carbamate	NN	O	O
in	IN	O	O
sarin	JJ	O	O
exposure	NN	O	O
.	.	O	O

The	DT	O	O
protective	JJ	O	O
ratios	NNS	O	O
of	IN	O	O
physostigmine	NN	O	O
and	CC	O	O
pyridostigmine	NN	O	O
were	VBD	O	O
1.5-	JJ	O	O
and	CC	O	O
1.2-1.3-fold	JJ	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Eptastigmine	NN	O	O
did	VBD	O	O
not	RB	O	O
give	VB	O	O
any	DT	O	O
protection	NN	O	O
against	IN	O	O
sarin	JJ	O	O
toxicity	NN	O	O
.	.	O	O

Both	DT	O	O
the	DT	O	O
phosphotriesterase	NN	O	O
and	CC	O	O
physostigmine	NN	O	O
treatments	NNS	O	O
protected	VBD	O	O
the	DT	O	O
brain	NN	O	O
AChE	NNP	O	O
activities	NNS	O	O
measured	VBD	O	O
24	CD	O	O
h	NN	O	O
after	IN	O	O
sarin	JJ	O	O
exposure	NN	O	O
.	.	O	O

In	IN	O	O
phosphotriesterase	NN	O	O
and	CC	O	O
physostigmine-treated	JJ	O	O
mice	NN	O	O
,	,	O	O
a	DT	O	O
4-	JJ	O	O
and	CC	O	O
2-fold	JJ	O	O
higher	JJR	O	O
sarin	NN	O	O
dose	NN	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
was	VBD	O	O
needed	VBN	O	O
to	TO	O	O
cause	VB	O	O
a	DT	O	O
50	CD	O	O
%	NN	O	O
inhibition	NN	O	O
of	IN	O	O
brain	NN	O	O
AChE	NNP	O	O
activity	NN	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
the	DT	O	O
combination	NN	O	O
of	IN	O	O
phosphotriesterase-physostigmine	NN	O	O
increased	VBD	O	O
the	DT	O	O
LD50	NNP	O	O
value	NN	O	O
for	IN	O	O
sarin	JJ	O	O
4.3-fold	JJ	O	O
.	.	O	O

The	DT	O	O
animals	NNS	O	O
pretreated	VBN	O	O
with	IN	O	O
phosphotriesterase-ephysostigmine	JJ	O	O
tolerated	VBD	O	O
four	CD	O	O
times	NNS	O	O
the	DT	O	O
lethal	NN	O	O
dose	NN	O	O
in	IN	O	O
control	NN	O	O
animals	NNS	O	O
,	,	O	O
furthermore	VBP	O	O
their	PRP$	O	O
survival	JJ	O	O
time	NN	O	O
was	VBD	O	O
2-3	JJ	O	O
h	NN	O	O
in	IN	O	O
comparison	NN	O	O
to	TO	O	O
20	CD	O	O
min	NN	O	O
in	IN	O	O
controls	NNS	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
phosphotriesterase	NN	O	O
and	CC	O	O
physostigmine	NN	O	O
were	VBD	O	O
the	DT	O	O
most	RBS	O	O
effective	JJ	O	O
treatments	NNS	O	O
against	IN	O	O
sarin	JJ	O	O
intoxication	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
eptastigmine	VBP	O	O
did	VBD	O	O
not	RB	O	O
provide	VB	O	O
any	DT	O	O
protection	NN	O	O
against	IN	O	O
sarin	JJ	O	O
toxicity	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Kinetic	JJ	O	O
studies	NNS	O	O
of	IN	O	O
tetrameric	JJ	O	O
recombinant	JJ	O	O
human	JJ	O	O
tyrosine	NN	O	O
hydroxylase	NN	O	O
isoform	NN	O	O
1	CD	O	O
(	(	O	O
hTH1	NN	O	O
)	)	O	O
have	VBP	O	O
revealed	VBN	O	O
properties	NNS	O	O
so	RB	O	O
far	RB	O	O
not	RB	O	O
reported	VBN	O	O
for	IN	O	O
this	DT	O	O
enzyme	NN	O	O
.	.	O	O

Firstly	RB	O	O
,	,	O	O
with	IN	O	O
the	DT	O	O
natural	JJ	O	O
cofactor	NN	O	O
(	(	O	O
6R	CD	O	O
)	)	O	O
-Lerythro-5,6,7	NN	O	O
,	,	O	O
8-tetrahydrobiopterin	JJ	O	O
(	(	O	O
H4biopterin	NNP	O	O
)	)	O	O
a	DT	O	O
time-dependent	JJ	O	O
change	NN	O	O
(	(	O	O
burst	NN	O	O
)	)	O	O
in	IN	O	O
enzyme	NN	O	O
activity	NN	O	O
was	VBD	O	O
observed	VBN	O	O
,	,	O	O
with	IN	O	O
a	DT	O	O
half-time	NN	O	O
of	IN	O	O
about	IN	O	O
20	CD	O	O
s	NN	O	O
for	IN	O	O
the	DT	O	O
kinetic	JJ	O	O
transient	NN	O	O
.	.	O	O

Secondly	RB	O	O
,	,	O	O
nonhyperbolic	JJ	O	O
saturation	NN	O	O
behaviour	NN	O	O
was	VBD	O	O
found	VBN	O	O
for	IN	O	O
H4biopterin	NNP	O	O
with	IN	O	O
a	DT	O	O
pronounced	JJ	O	O
negative	JJ	O	O
cooperativity	NN	O	O
(	(	O	O
0.39	CD	O	O
<	NN	O	O
h	NN	O	O
<	VBZ	O	O
0.58	CD	O	O
;	:	O	O
[	NNP	O	O
S	NNP	O	O
]	VBD	O	O
0.5	CD	O	O
=	JJ	O	O
24	CD	O	O
+/-	JJ	O	O
4	CD	O	O
microM	NN	O	O
)	)	O	O
.	.	O	O

On	IN	O	O
phosphorylation	NN	O	O
of	IN	O	O
Ser40	NNP	O	B-SUBSTRATE
by	IN	O	O
protein	NN	O	B-enzyme
kinase	NN	O	I-enzyme
A	NNP	O	O
,	,	O	O
the	DT	O	O
affinity	NN	O	O
for	IN	O	O
H4biopterin	NNP	O	O
increased	VBD	O	O
(	(	O	O
[	JJ	O	O
S	NNP	O	O
]	NNP	O	O
0.5	CD	O	O
=	VBD	O	O
11	CD	O	O
+/-	JJ	O	O
2	CD	O	O
microM	NN	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
negative	JJ	O	O
cooperativity	NN	O	O
was	VBD	O	O
amplified	VBN	O	O
(	(	O	O
h	JJ	O	O
=	$	O	O
0.27	CD	O	O
+/-	JJ	O	O
0.03	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
dimeric	JJ	O	O
C-terminal	JJ	O	O
deletion	NN	O	O
mutant	NN	O	O
(	(	O	O
Delta473-528	NNP	O	O
)	)	O	O
of	IN	O	O
hTH1	NN	O	O
also	RB	O	O
showed	VBD	O	O
negative	JJ	O	O
cooperativity	NN	O	O
of	IN	O	O
H4biopterin	NNP	O	O
binding	NN	O	O
(	(	O	O
h	JJ	O	O
=	NNP	O	O
0.4	CD	O	O
)	)	O	O
.	.	O	O

Cooperativity	NN	O	O
was	VBD	O	O
not	RB	O	O
observed	VBN	O	O
with	IN	O	O
the	DT	O	O
cofactor	NN	O	O
analogues	VBZ	O	O
6-methyl-5,6,7,8-tetrahydropterin	JJ	O	O
(	(	O	O
h	JJ	O	O
=	$	O	O
0.9	CD	O	O
+/-	JJ	O	O
0.1	CD	O	O
;	:	O	O
Km	NNP	O	O
=	VBD	O	O
62.7	CD	O	O
+/-	JJ	O	O
5.7	CD	O	O
microM	NN	O	O
)	)	O	O
and	CC	O	O
3-methyl-5,6,7	JJ	O	O
,	,	O	O
8-tetrahydropterin	JJ	O	O
(	(	O	O
H43-methyl-pterin	NNP	O	O
)	)	O	O
(	(	O	O
h	JJ	O	O
=	$	O	O
1.0	CD	O	O
+/-	JJ	O	O
0.1	CD	O	O
;	:	O	O
Km	NNP	O	O
=	VBD	O	O
687	CD	O	O
+/-	JJ	O	O
50	CD	O	O
microM	NN	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
1	CD	O	O
mM	JJ	O	O
H43-methyl-pterin	NNP	O	O
,	,	O	O
used	VBD	O	O
as	IN	O	O
a	DT	O	O
competitive	JJ	O	O
cofactor	NN	O	O
analogue	NN	O	O
to	TO	O	O
BH4	NNP	O	O
,	,	O	O
hyperbolic	JJ	O	O
saturation	NN	O	O
curves	NNS	O	O
were	VBD	O	O
also	RB	O	O
found	VBN	O	O
for	IN	O	O
H4biopterin	NNP	O	O
(	(	O	O
h	JJ	O	O
=	NNP	O	O
1.0	CD	O	O
)	)	O	O
,	,	O	O
thus	RB	O	O
confirming	VBG	O	O
the	DT	O	O
genuine	JJ	O	O
nature	NN	O	O
of	IN	O	O
the	DT	O	O
kinetic	JJ	O	O
negative	JJ	O	O
cooperativity	NN	O	O
.	.	O	O

This	DT	O	O
cooperativity	NN	O	O
was	VBD	O	O
confirmed	VBN	O	O
by	IN	O	O
real-time	NN	O	O
biospecific	NN	O	O
interaction	NN	O	O
analysis	NN	O	O
by	IN	O	O
surface	NN	O	O
plasmon	NN	O	O
resonance	NN	O	O
detection	NN	O	O
.	.	O	O

The	DT	O	O
equilibrium	NN	O	O
binding	NN	O	O
of	IN	O	O
H4biopterin	NNP	O	O
to	TO	O	O
the	DT	O	O
immobilized	JJ	O	O
iron-free	JJ	O	O
apoenzyme	NN	O	O
results	NNS	O	O
in	IN	O	O
a	DT	O	O
saturable	JJ	O	O
positive	JJ	O	O
resonance	NN	O	O
unit	NN	O	O
(	(	O	O
DeltaRU	NNP	O	O
)	)	O	O
response	NN	O	O
with	IN	O	O
negative	JJ	O	O
cooperativity	NN	O	O
(	(	O	O
h	JJ	O	O
=	NNP	O	O
0.52-0.56	NN	O	O
)	)	O	O
.	.	O	O

Infrared	NNP	O	O
spectroscopic	NN	O	O
studies	NNS	O	O
revealed	VBD	O	O
a	DT	O	O
reduced	VBN	O	O
thermal	JJ	O	O
stability	NN	O	O
both	DT	O	O
of	IN	O	O
the	DT	O	O
apo-and	JJ	O	O
the	DT	O	O
holo-hTH1	NN	O	O
on	IN	O	O
binding	NN	O	O
of	IN	O	O
H4biopterin	NNP	O	O
and	CC	O	O
Lerythro-dihydrobiopterin	NNP	O	O
(	(	O	O
H2biopterin	NNP	O	O
)	)	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
the	DT	O	O
ligand-bound	JJ	O	O
forms	NNS	O	O
of	IN	O	O
the	DT	O	O
enzyme	NN	O	O
also	RB	O	O
showed	VBD	O	O
a	DT	O	O
decreased	JJ	O	O
resistance	NN	O	O
to	TO	O	O
limited	VBN	O	O
tryptic	JJ	O	O
proteolysis	NN	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
the	DT	O	O
binding	NN	O	O
of	IN	O	O
H4biopterin	NNP	O	O
at	IN	O	O
the	DT	O	O
active	JJ	O	O
site	NN	O	O
induces	VBZ	O	O
a	DT	O	O
destabilizing	JJ	O	O
conformational	JJ	O	O
change	NN	O	O
in	IN	O	O
the	DT	O	O
enzyme	NN	O	O
which	WDT	O	O
could	MD	O	O
be	VB	O	O
related	VBN	O	O
to	TO	O	O
the	DT	O	O
observed	JJ	O	O
negative	JJ	O	O
cooperativity	NN	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
our	PRP$	O	O
studies	NNS	O	O
provide	VBP	O	O
new	JJ	O	O
insight	NN	O	O
into	IN	O	O
the	DT	O	O
regulation	NN	O	O
of	IN	O	O
TH	NNP	O	O
by	IN	O	O
the	DT	O	O
concentration	NN	O	O
of	IN	O	O
H4biopterin	NNP	O	O
which	WDT	O	O
may	MD	O	O
have	VB	O	O
significant	JJ	O	O
implications	NNS	O	O
for	IN	O	O
the	DT	O	O
physiological	JJ	O	O
regulation	NN	O	O
of	IN	O	O
catecholamine	JJ	O	O
biosynthesis	NN	O	O
in	IN	O	O
neuroendocrine	JJ	O	O
cells	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

The	DT	O	O
specific	JJ	O	O
enzymatic	JJ	O	O
activity	NN	O	O
of	IN	O	O
four	CD	O	O
different	JJ	O	O
aminopeptidases	NNS	O	O
(	(	O	O
aminopeptidase	NN	O	O
N	NNP	O	O
,	,	O	O
leucine	JJ	O	O
aminopeptidase	NN	O	O
,	,	O	O
aminopeptidase	VB	O	O
A	NNP	O	O
and	CC	O	O
aminopeptidase	NN	O	O
B	NNP	O	O
)	)	O	O
in	IN	O	O
vaginal	JJ	O	O
homogenates	NNS	O	O
from	IN	O	O
rabbit	NN	O	O
,	,	O	O
rat	NN	O	O
,	,	O	O
guinea-pig	NN	O	O
,	,	O	O
sheep	NN	O	O
and	CC	O	O
humans	NNS	O	O
was	VBD	O	O
compared	VBN	O	O
.	.	O	O

The	DT	O	O
purpose	NN	O	O
of	IN	O	O
the	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
find	VB	O	O
an	DT	O	O
appropriate	JJ	O	O
animal	NN	O	O
model	NN	O	O
that	WDT	O	O
can	MD	O	O
be	VB	O	O
used	VBN	O	O
in	IN	O	O
degradation	NN	O	O
studies	NNS	O	O
of	IN	O	O
protein	NN	O	O
and	CC	O	O
peptide	NN	O	O
drugs	NNS	O	O
.	.	O	O

Different	JJ	O	O
substrates	NNS	O	O
were	VBD	O	O
used	VBN	O	O
as	IN	O	O
the	DT	O	O
relative	JJ	O	O
specific	NN	O	O
substrates	NNS	O	O
for	IN	O	O
the	DT	O	O
determination	NN	O	O
of	IN	O	O
aminopeptidase	JJ	O	O
enzymatic	JJ	O	O
activity	NN	O	O
:	:	O	O
4-methoxy-2-naphthylamide	JJ	O	B-SUBSTRATE
of	IN	O	O
L-alanine	NNP	O	B-SUBSTRATE
for	IN	O	O
aminopeptidase	NN	O	B-enzyme
N	NNP	O	I-enzyme
,	,	O	O
4-methoxy-2-naphthylamide	CD	O	B-SUBSTRATE
of	IN	O	O
L-leucine	NNP	O	B-SUBSTRATE
for	IN	O	O
leucine	JJ	O	B-enzyme
aminopeptidase	NN	O	I-enzyme
,	,	O	O
4-methoxy-2-naphthylamide	CD	O	B-SUBSTRATE
of	IN	O	O
L-glutamic	JJ	O	B-SUBSTRATE
acid	NN	O	I-SUBSTRATE
for	IN	O	O
aminopeptidase	NN	O	B-enzyme
A	DT	O	I-enzyme
and	CC	O	O
4-methoxy-2-naphthylamide	CD	O	B-SUBSTRATE
of	IN	O	O
L-arginine	NNP	O	B-SUBSTRATE
for	IN	O	O
aminopeptidase	NN	O	B-enzyme
B	NNP	O	I-enzyme
.	.	O	O

The	DT	O	O
vaginal	JJ	O	O
aminopeptidase	NN	O	O
enzymatic	JJ	O	O
activity	NN	O	O
of	IN	O	O
different	JJ	O	O
species	NNS	O	O
was	VBD	O	O
determined	VBN	O	O
spectrofluorometrically	RB	O	O
.	.	O	O

The	DT	O	O
inhibition	NN	O	O
of	IN	O	O
aminopeptidase	NN	O	O
activity	NN	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
bestatin	NN	O	O
and	CC	O	O
puromycin	NN	O	O
inhibitors	NNS	O	O
was	VBD	O	O
also	RB	O	O
investigated	VBN	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
showed	VBD	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
aminopeptidase	JJ	O	O
enzymatic	JJ	O	O
activity	NN	O	O
in	IN	O	O
all	DT	O	O
vaginal	JJ	O	O
homogenates	NNS	O	O
in	IN	O	O
the	DT	O	O
order	NN	O	O
:	:	O	O
sheep	JJ	O	O
>	IN	O	O
guinea-pig	JJ	O	O
>	NNP	O	O
rabbit	NN	O	O
>	NN	O	O
or	CC	O	O
=	JJ	O	O
human	JJ	O	O
>	NN	O	O
or	CC	O	O
=	JJ	O	O
rat	NN	O	O
.	.	O	O

Based	VBN	O	O
on	IN	O	O
the	DT	O	O
results	NNS	O	O
of	IN	O	O
the	DT	O	O
hydrolysis	NN	O	O
and	CC	O	O
inhibition	NN	O	O
of	IN	O	O
the	DT	O	O
4-methoxy-2-naphthylamide	JJ	O	O
substrates	NNS	O	O
,	,	O	O
it	PRP	O	O
was	VBD	O	O
difficult	JJ	O	O
to	TO	O	O
have	VB	O	O
an	DT	O	O
exact	JJ	O	O
decision	NN	O	O
on	IN	O	O
the	DT	O	O
aminopeptidase	NN	O	O
type	NN	O	O
in	IN	O	O
the	DT	O	O
vaginal	JJ	O	O
homogenates	NNS	O	O
from	IN	O	O
the	DT	O	O
species	NNS	O	O
studied	VBN	O	O
.	.	O	O

It	PRP	O	O
was	VBD	O	O
found	VBN	O	O
that	IN	O	O
the	DT	O	O
aminopeptidase	NN	O	O
activity	NN	O	O
in	IN	O	O
rat	NN	O	O
,	,	O	O
rabbit	NN	O	O
and	CC	O	O
humans	NNS	O	O
was	VBD	O	O
not	RB	O	O
statistically	RB	O	O
different	JJ	O	O
.	.	O	O

Therefore	RB	O	O
,	,	O	O
we	PRP	O	O
suggest	VBP	O	O
that	IN	O	O
rats	NNS	O	O
and	CC	O	O
rabbits	NNS	O	O
could	MD	O	O
be	VB	O	O
used	VBN	O	O
as	IN	O	O
model	NN	O	O
animals	NNS	O	O
for	IN	O	O
vaginal	JJ	O	O
enzymatic	JJ	O	O
activity	NN	O	O
studies	NNS	O	O
and	CC	O	O
for	IN	O	O
determination	NN	O	O
of	IN	O	O
the	DT	O	O
degradation	NN	O	O
of	IN	O	O
protein	NN	O	O
and	CC	O	O
peptide	NN	O	O
drugs	NNS	O	O
in	IN	O	O
the	DT	O	O
vagina	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Administration	NN	O	O
of	IN	O	O
a	DT	O	O
high-dose	JJ	O	O
regimen	NN	O	O
of	IN	O	O
methamphetamine	NN	O	O
(	(	O	O
METH	NNP	O	O
)	)	O	O
rapidly	RB	O	O
and	CC	O	O
profoundly	RB	O	O
decreases	VBZ	O	O
plasmalemmal	JJ	O	O
and	CC	O	O
vesicular	JJ	O	O
dopamine	NN	O	O
(	(	O	O
DA	NNP	O	O
)	)	O	O
transport	NN	O	O
in	IN	O	O
the	DT	O	O
striatum	NN	O	O
,	,	O	O
as	IN	O	O
assessed	VBN	O	O
in	IN	O	O
synaptosomes	NNS	O	O
and	CC	O	O
purified	JJ	O	O
vesicles	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

To	TO	O	O
determine	VB	O	O
whether	IN	O	O
these	DT	O	O
responses	NNS	O	O
were	VBD	O	O
common	JJ	O	O
to	TO	O	O
other	JJ	O	O
amphetamines	NNS	O	O
of	IN	O	O
abuse	NN	O	O
,	,	O	O
effects	NNS	O	O
of	IN	O	O
methylenedioxymethamphetamine	NN	O	O
(	(	O	O
MDMA	NNP	O	O
)	)	O	O
on	IN	O	O
the	DT	O	O
plasmalemmal	JJ	O	O
DA	NNP	O	O
transporter	NN	O	O
(	(	O	O
DAT	NNP	O	O
)	)	O	O
and	CC	O	O
vesicular	JJ	O	O
monoamine	NN	O	O
transporter-2	NN	O	O
(	(	O	O
VMAT-2	NNP	O	O
)	)	O	O
were	VBD	O	O
assessed	VBN	O	O
.	.	O	O

Similar	JJ	O	O
to	TO	O	O
effects	NNS	O	O
of	IN	O	O
METH	NNP	O	O
reported	VBD	O	O
previously	RB	O	O
,	,	O	O
multiple	JJ	O	O
high-dose	JJ	O	O
MDMA	NNP	O	O
administrations	NNS	O	O
rapidly	RB	O	O
(	(	O	O
within	IN	O	O
1	CD	O	O
h	NN	O	O
)	)	O	O
decreased	VBD	O	O
plasmalemmal	JJ	O	O
DA	NNP	O	O
uptake	NN	O	O
,	,	O	O
as	IN	O	O
assessed	JJ	O	O
ex	NN	O	O
vivo	NN	O	O
in	IN	O	O
synaptosomes	NNS	O	O
prepared	VBN	O	O
from	IN	O	O
treated	JJ	O	O
rats	NNS	O	O
.	.	O	O

Unlike	IN	O	O
effects	NNS	O	O
of	IN	O	O
multiple	JJ	O	O
METH	NNP	O	O
injections	NNS	O	O
,	,	O	O
this	DT	O	O
deficit	NN	O	O
was	VBD	O	O
reversed	VBN	O	O
completely	RB	O	O
24	CD	O	O
h	NNS	O	O
after	IN	O	O
drug	NN	O	O
treatment	NN	O	O
.	.	O	O

Also	RB	O	O
in	IN	O	O
contrast	NN	O	O
to	TO	O	O
effects	NNS	O	O
of	IN	O	O
multiple	JJ	O	O
METH	NNP	O	O
injections	NNS	O	O
,	,	O	O
1	CD	O	O
)	)	O	O
MDMA	NNP	O	O
caused	VBD	O	O
little	JJ	O	O
or	CC	O	O
no	DT	O	O
decrease	NN	O	O
in	IN	O	O
binding	NN	O	O
of	IN	O	O
the	DT	O	O
DAT	NNP	O	B-enzyme
ligand	NN	O	O
WIN35428	NNP	O	O
,	,	O	O
and	CC	O	O
2	CD	O	O
)	)	O	O
neither	DT	O	O
prevention	NN	O	O
of	IN	O	O
hyperthermia	NN	O	O
nor	CC	O	O
prior	JJ	O	O
depletion	NN	O	O
of	IN	O	O
DA	NNP	O	B-SUBSTRATE
prevented	VBD	O	O
the	DT	O	O
MDMA-induced	NNP	O	O
reduction	NN	O	O
in	IN	O	O
plasmalemmal	JJ	O	O
DA	NNP	O	B-SUBSTRATE
transport	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
a	DT	O	O
role	NN	O	O
for	IN	O	O
phosphorylation	NN	O	O
was	VBD	O	O
suggested	VBN	O	O
because	IN	O	O
pretreatment	NN	O	O
with	IN	O	O
protein	JJ	O	O
kinase	NN	O	O
C	NNP	O	O
inhibitors	NNS	O	O
attenuated	VBD	O	O
the	DT	O	O
deficit	NN	O	O
caused	VBN	O	O
by	IN	O	O
MDMA	NNP	O	O
in	IN	O	O
an	DT	O	O
in	IN	O	O
vitro	NN	O	O
model	NN	O	O
system	NN	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
to	TO	O	O
affecting	VBG	O	O
DAT	NNP	O	B-enzyme
function	NN	O	O
,	,	O	O
MDMA	NNP	O	O
rapidly	RB	O	O
decreased	VBD	O	O
vesicular	JJ	O	O
DA	NNP	O	B-SUBSTRATE
transport	NN	O	O
as	IN	O	O
assessed	VBN	O	O
in	IN	O	O
striatal	JJ	O	O
vesicles	NNS	O	O
prepared	VBN	O	O
from	IN	O	O
treated	JJ	O	O
rats	NNS	O	O
.	.	O	O

Unlike	IN	O	O
effects	NNS	O	O
of	IN	O	O
multiple	JJ	O	O
METH	NNP	O	O
injections	NNS	O	O
reported	VBD	O	O
previously	RB	O	O
,	,	O	O
this	DT	O	O
decrease	NN	O	O
partially	RB	O	O
recovered	VBN	O	O
by	IN	O	O
24	CD	O	O
h	NNS	O	O
after	IN	O	O
drug	NN	O	O
treatment	NN	O	O
.	.	O	O

Taken	VBN	O	O
together	RB	O	O
,	,	O	O
these	DT	O	O
results	NNS	O	O
reveal	VBP	O	O
several	JJ	O	O
differences	NNS	O	O
between	IN	O	O
effects	NNS	O	O
of	IN	O	O
MDMA	NNP	O	O
and	CC	O	O
previously	RB	O	O
reported	VBD	O	O
METH	NNP	O	O
on	IN	O	O
DAT	NNP	O	O
and	CC	O	O
VMAT-2	NNP	O	O
;	:	O	O
differences	NNS	O	O
that	WDT	O	O
may	MD	O	O
underlie	VB	O	O
the	DT	O	O
dissimilar	JJ	O	O
neurotoxic	NN	O	O
profile	NN	O	O
of	IN	O	O
these	DT	O	O
agents	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Ever	RB	O	O
since	IN	O	O
the	DT	O	O
discovery	NN	O	O
that	WDT	O	O
(	(	O	O
6R	CD	O	O
)	)	O	O
-5,6,7,8-tetrahydro-L-biopterin	NN	O	O
(	(	O	O
BH4	NNP	O	O
)	)	O	O
is	VBZ	O	O
a	DT	O	O
cofactor	NN	O	O
of	IN	O	O
NOS	NNP	O	O
,	,	O	O
its	PRP$	O	O
function	NN	O	O
has	VBZ	O	O
been	VBN	O	O
the	DT	O	O
object	NN	O	O
of	IN	O	O
intense	JJ	O	O
research	NN	O	O
and	CC	O	O
occasional	JJ	O	O
controversy	NN	O	O
.	.	O	O

Only	RB	O	O
in	IN	O	O
the	DT	O	O
last	JJ	O	O
couple	NN	O	O
of	IN	O	O
years	NNS	O	O
a	DT	O	O
consensus	NN	O	O
has	VBZ	O	O
been	VBN	O	O
reached	VBN	O	O
on	IN	O	O
what	WDT	O	O
constitutes	VBZ	O	O
the	DT	O	O
main	JJ	O	O
role	NN	O	O
of	IN	O	O
BH4	NNP	O	O
in	IN	O	O
NO	NNP	O	O
synthesis	NN	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
review	NN	O	O
we	PRP	O	O
aim	VBP	O	O
to	TO	O	O
provide	VB	O	O
an	DT	O	O
outline	NN	O	O
of	IN	O	O
the	DT	O	O
various	JJ	O	O
ways	NNS	O	O
in	IN	O	O
which	WDT	O	O
BH4	NNP	O	O
affects	VBZ	O	O
NOS	NNP	O	O
catalysis	NN	O	O
.	.	O	O

First	RB	O	O
we	PRP	O	O
give	VBP	O	O
a	DT	O	O
brief	JJ	O	O
general	JJ	O	O
description	NN	O	O
of	IN	O	O
the	DT	O	O
structure	NN	O	O
and	CC	O	O
catalytic	JJ	O	O
mechanism	NN	O	O
of	IN	O	O
NOS	NNP	O	O
,	,	O	O
with	IN	O	O
special	JJ	O	O
emphasis	NN	O	O
on	IN	O	O
those	DT	O	O
aspects	NNS	O	O
of	IN	O	O
catalysis	NN	O	O
that	WDT	O	O
are	VBP	O	O
actively	RB	O	O
debated	VBN	O	O
,	,	O	O
and	CC	O	O
that	DT	O	O
directly	RB	O	O
or	CC	O	O
indirectly	RB	O	O
involve	VB	O	O
BH4	NNP	O	O
.	.	O	O

Foremost	NNP	O	O
among	IN	O	O
those	DT	O	O
issues	NNS	O	O
is	VBZ	O	O
uncoupled	JJ	O	O
catalysis	NN	O	O
,	,	O	O
i.e	NN	O	O
.	.	O	O

the	DT	O	O
NOS-catalyzed	JJ	O	O
oxidation	NN	O	O
of	IN	O	O
NADPH	NNP	O	O
in	IN	O	O
the	DT	O	O
absence	NN	O	O
of	IN	O	O
substrate	NN	O	O
or	CC	O	O
pterin	NN	O	O
that	WDT	O	O
does	VBZ	O	O
not	RB	O	O
result	VB	O	O
in	IN	O	O
NO	DT	O	O
production	NN	O	O
.	.	O	O

We	PRP	O	O
also	RB	O	O
shortly	RB	O	O
discuss	VBZ	O	O
the	DT	O	O
ongoing	JJ	O	O
debate	NN	O	O
on	IN	O	O
whether	IN	O	O
NO	NNP	O	B-PRODUCT-OF
is	VBZ	O	O
the	DT	O	O
actual	JJ	O	O
reaction	NN	O	O
product	NN	O	O
of	IN	O	O
NOS	NNP	O	B-enzyme
catalysis	NN	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
the	DT	O	O
phenomenon	NN	O	O
of	IN	O	O
NO-mediated	JJ	O	O
autoinhibition	NN	O	O
.	.	O	O

We	PRP	O	O
describe	VBP	O	O
the	DT	O	O
function	NN	O	O
of	IN	O	O
BH4	NNP	O	O
in	IN	O	O
aromatic	JJ	O	O
amino	NN	O	O
acid	NN	O	O
hydroxylation	NN	O	O
,	,	O	O
and	CC	O	O
discuss	VB	O	O
the	DT	O	O
allosteric	NN	O	O
and	CC	O	O
structural	JJ	O	O
effects	NNS	O	O
that	WDT	O	O
BH4	NNP	O	O
exerts	VBZ	O	O
on	IN	O	O
NOS	NNP	O	O
.	.	O	O

Next	IN	O	O
we	PRP	O	O
turn	VBP	O	O
our	PRP$	O	O
attention	NN	O	O
to	TO	O	O
what	WP	O	O
is	VBZ	O	O
now	RB	O	O
becoming	VBG	O	O
accepted	VBN	O	O
as	IN	O	O
the	DT	O	O
central	JJ	O	O
function	NN	O	O
of	IN	O	O
BH4	NNP	O	O
:	:	O	O
its	PRP$	O	O
capacity	NN	O	O
to	TO	O	O
act	VB	O	O
as	IN	O	O
a	DT	O	O
1-electron	JJ	O	O
donor	NN	O	O
during	IN	O	O
reductive	JJ	O	O
activation	NN	O	O
of	IN	O	O
the	DT	O	O
oxyferrous	JJ	O	O
complex	NN	O	O
of	IN	O	O
the	DT	O	O
heme	NN	O	O
.	.	O	O

Finally	RB	O	O
,	,	O	O
we	PRP	O	O
illustrate	VBP	O	O
how	WRB	O	O
BH4	NNP	O	O
might	MD	O	O
transform	VB	O	O
the	DT	O	O
NOS	NNP	O	O
dimer	NN	O	O
into	IN	O	O
an	DT	O	O
efficient	JJ	O	O
S-nitrosoglutathione	JJ	O	O
synthase	NN	O	O
,	,	O	O
and	CC	O	O
briefly	VB	O	O
touch	NN	O	O
on	IN	O	O
some	DT	O	O
more	RBR	O	O
speculative	JJ	O	O
aspects	NNS	O	O
of	IN	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
BH4	NNP	O	O
in	IN	O	O
NO	NNP	O	O
synthesis	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

BACKGROUND	NNP	O	O
AND	CC	O	O
AIMS	NNP	O	O
:	:	O	O
Glutamic	NNP	O	B-enzyme
acid	NN	O	I-enzyme
decarboxylase	NN	O	O
(	(	O	O
GAD	NNP	O	B-enzyme
,	,	O	O
EC	NNP	O	B-enzyme
4.1.1.15	CD	O	I-enzyme
)	)	O	O
catalyses	VBZ	O	O
the	DT	O	O
conversion	NN	O	O
of	IN	O	O
glutamate	NN	O	B-SUBSTRATE
to	TO	O	O
gamma-aminobutyric	JJ	O	B-PRODUCT-OF
acid	NN	O	I-PRODUCT-OF
(	(	O	O
GABA	NNP	O	B-PRODUCT-OF
)	)	O	O
.	.	O	O

The	DT	O	O
65	CD	O	O
kDa	NN	O	O
isoform	NN	O	O
,	,	O	O
GAD65	NNP	O	O
is	VBZ	O	O
a	DT	O	O
potent	JJ	O	O
autoantigen	NN	O	O
in	IN	O	O
type	NN	O	O
1	CD	O	O
diabetes	NNS	O	O
,	,	O	O
whereas	NNS	O	O
GAD67	NNP	O	O
is	VBZ	O	O
not	RB	O	O
.	.	O	O

A	DT	O	O
hybrid	JJ	O	O
cDNA	NN	O	O
was	VBD	O	O
created	VBN	O	O
by	IN	O	O
fusing	VBG	O	O
a	DT	O	O
human	JJ	O	O
cDNA	NN	O	O
for	IN	O	O
amino	JJ	O	O
acids	NNS	O	O
1-101	CD	O	O
of	IN	O	O
GAD67	NNP	O	O
to	TO	O	O
a	DT	O	O
human	JJ	O	O
cDNA	NN	O	O
for	IN	O	O
amino	JJ	O	O
acids	NNS	O	O
96-585	CD	O	O
of	IN	O	O
GAD65	NNP	O	O
;	:	O	O
the	DT	O	O
recombinant	NN	O	O
(	(	O	O
r	NN	O	O
)	)	O	O
protein	NN	O	O
was	VBD	O	O
expressed	VBN	O	O
in	IN	O	O
yeast	NN	O	O
and	CC	O	O
was	VBD	O	O
shown	VBN	O	O
to	TO	O	O
have	VB	O	O
equivalent	JJ	O	O
immunoreactivity	NN	O	O
to	TO	O	O
mammalian	JJ	O	O
brain	NN	O	O
GAD	NNP	O	O
with	IN	O	O
diabetes	NNS	O	O
sera	NNS	O	O
.	.	O	O

We	PRP	O	O
here	RB	O	O
report	VBP	O	O
on	IN	O	O
enzymatic	JJ	O	O
and	CC	O	O
molecular	JJ	O	O
properties	NNS	O	O
of	IN	O	O
rGAD67/65	NN	O	O
.	.	O	O

METHODS	NN	O	O
:	:	O	O
Studies	NNS	O	O
were	VBD	O	O
performed	VBN	O	O
on	IN	O	O
enzymatic	JJ	O	O
activity	NN	O	O
of	IN	O	O
rGAD67/65	NN	O	O
by	IN	O	O
production	NN	O	O
of	IN	O	O
3H-GABA	JJ	O	O
from	IN	O	O
3H-glutamate	JJ	O	O
,	,	O	O
enzyme	JJ	O	O
kinetics	NNS	O	O
,	,	O	O
binding	VBG	O	O
to	TO	O	O
the	DT	O	O
enzyme	NN	O	O
cofactor	NN	O	O
pyridoxal	NN	O	O
phosphate	NN	O	O
(	(	O	O
PLP	NNP	O	O
)	)	O	O
,	,	O	O
stability	NN	O	O
according	VBG	O	O
to	TO	O	O
differences	NNS	O	O
in	IN	O	O
pH	NN	O	O
,	,	O	O
temperature	NN	O	O
and	CC	O	O
duration	NN	O	O
of	IN	O	O
storage	NN	O	O
,	,	O	O
and	CC	O	O
antigenic	JJ	O	O
reactivity	NN	O	O
with	IN	O	O
various	JJ	O	O
GAD-specific	JJ	O	O
antisera	NN	O	O
.	.	O	O

RESULTS	NN	O	O
:	:	O	O
The	DT	O	O
properties	NNS	O	O
of	IN	O	O
rGAD67/65	NN	O	O
were	VBD	O	O
compared	VBN	O	O
with	IN	O	O
published	VBN	O	O
data	NNS	O	O
for	IN	O	O
mammalian	JJ	O	O
brain	NN	O	O
GAD	NNP	O	O
(	(	O	O
brackets	NNS	O	O
)	)	O	O
.	.	O	O

These	DT	O	O
included	VBD	O	O
a	DT	O	O
specific	JJ	O	O
enzyme	NN	O	O
activity	NN	O	O
of	IN	O	O
22.7	CD	O	O
(	(	O	O
16.7	CD	O	O
)	)	O	O
nKat	NN	O	O
,	,	O	O
optimal	JJ	O	O
pH	NN	O	O
for	IN	O	O
enzymatic	JJ	O	O
activity	NN	O	O
7.4	CD	O	O
(	(	O	O
6.8	CD	O	O
)	)	O	O
,	,	O	O
K	NNP	O	O
(	(	O	O
m	NN	O	O
)	)	O	O
of	IN	O	O
1.3	CD	O	O
(	(	O	O
1.3	CD	O	O
)	)	O	O
mM	NN	O	O
,	,	O	O
efficient	JJ	O	O
non-covalent	JJ	O	O
binding	NN	O	O
to	TO	O	O
the	DT	O	O
cofactor	NN	O	O
PLP	NNP	O	O
,	,	O	O
and	CC	O	O
high	JJ	O	O
autoantigenic	JJ	O	O
potency	NN	O	O
.	.	O	O

The	DT	O	O
stability	NN	O	O
of	IN	O	O
rGAD67/65	NN	O	O
was	VBD	O	O
optimal	JJ	O	O
over	IN	O	O
3	CD	O	O
months	NNS	O	O
at	IN	O	O
-80	NNP	O	O
degrees	NNS	O	O
C	NNP	O	O
,	,	O	O
or	CC	O	O
in	IN	O	O
lyophilized	JJ	O	O
form	NN	O	O
at	IN	O	O
-20	NNP	O	O
degrees	NNS	O	O
C.	NNP	O	O
CONCLUSIONS	NNP	O	O
:	:	O	O
Hybrid	NNP	O	O
rGAD67/65	NN	O	O
has	VBZ	O	O
enzymatic	JJ	O	O
and	CC	O	O
other	JJ	O	O
properties	NNS	O	O
similar	JJ	O	O
to	TO	O	O
those	DT	O	O
of	IN	O	O
the	DT	O	O
mixed	JJ	O	O
isoforms	NNS	O	O
of	IN	O	O
GAD	NNP	O	O
in	IN	O	O
preparations	NNS	O	O
from	IN	O	O
mammalian	JJ	O	O
brain	NN	O	O
as	IN	O	O
described	NN	O	O
elsewhere	RB	O	O
,	,	O	O
in	IN	O	O
addition	NN	O	O
to	TO	O	O
its	PRP$	O	O
previously	RB	O	O
described	VBN	O	O
similar	JJ	O	O
immunoreactivity	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

We	PRP	O	O
have	VBP	O	O
earlier	RBR	O	O
demonstrated	VBN	O	O
that	IN	O	O
dopamine	NN	O	O
stimulates	VBZ	O	O
the	DT	O	O
liberation	NN	O	O
of	IN	O	O
the	DT	O	O
prostaglandin	NN	O	O
E	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
(	(	O	O
PGE	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
)	)	O	O
precursor	NN	O	O
,	,	O	O
arachidonic	JJ	O	O
acid	NN	O	O
,	,	O	O
in	IN	O	O
Chinese	JJ	O	O
hamster	NN	O	O
ovary	JJ	O	O
cells	NNS	O	O
transfected	VBN	O	O
with	IN	O	O
the	DT	O	O
rat	NN	O	O
dopamine	NN	O	O
D	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
receptor	NN	O	O
(	(	O	O
long	JJ	O	O
isoform	NN	O	O
)	)	O	O
,	,	O	O
also	RB	O	O
without	IN	O	O
concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
a	DT	O	O
Ca	NNP	O	O
(	(	O	O
2+	CD	O	O
)	)	O	O
-releasing	VBG	O	O
agent	JJ	O	O
[	NNP	O	O
Nilsson	NNP	O	O
et	FW	O	O
al.	NN	O	O
,	,	O	O
Br	NNP	O	O
J	NNP	O	O
Pharmacol	NNP	O	O
1998	CD	O	O
;	:	O	O
124:1651-8	JJ	O	O
]	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
present	JJ	O	O
report	NN	O	O
,	,	O	O
we	PRP	O	O
show	VBP	O	O
that	DT	O	O
dopamine	NN	O	O
,	,	O	O
under	IN	O	O
the	DT	O	O
same	JJ	O	O
conditions	NNS	O	O
,	,	O	O
also	RB	O	O
induces	VBZ	O	O
a	DT	O	O
concentration-dependent	JJ	O	O
increase	NN	O	O
in	IN	O	O
the	DT	O	O
production	NN	O	O
of	IN	O	O
PGE	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
,	,	O	O
with	IN	O	O
a	DT	O	O
maximal	JJ	O	O
effect	NN	O	O
of	IN	O	O
235	CD	O	O
%	NN	O	O
at	IN	O	O
approximately	RB	O	O
100	CD	O	O
microM	NNS	O	O
,	,	O	O
and	CC	O	O
with	IN	O	O
an	DT	O	O
EC	NNP	O	O
(	(	O	O
50	CD	O	O
)	)	O	O
of	IN	O	O
794	CD	O	O
nM	NNS	O	O
.	.	O	O

The	DT	O	O
effect	NN	O	O
was	VBD	O	O
counteracted	VBN	O	O
by	IN	O	O
the	DT	O	O
D	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
antagonist	NN	O	O
eticlopride	NN	O	O
,	,	O	O
pertussis	NN	O	O
toxin	NN	O	O
,	,	O	O
the	DT	O	O
inhibitor	NN	O	O
of	IN	O	O
intracellular	JJ	O	O
Ca	NNP	O	O
(	(	O	O
2+	CD	O	O
)	)	O	O
release	NN	O	O
TMB-8	NNP	O	O
,	,	O	O
incubation	NN	O	O
in	IN	O	O
Ca	NNP	O	O
(	(	O	O
2+	CD	O	O
)	)	O	O
-free	CD	O	O
experimental	JJ	O	O
medium	NN	O	O
,	,	O	O
and	CC	O	O
PKC	NNP	O	O
desensitization	NN	O	O
obtained	VBN	O	O
by	IN	O	O
chronic	JJ	O	O
pretreatment	NN	O	O
with	IN	O	O
the	DT	O	O
phorbol	NN	O	O
ester	NN	O	O
TPA	NNP	O	O
.	.	O	O

It	PRP	O	O
was	VBD	O	O
also	RB	O	O
antagonized	VBN	O	O
by	IN	O	O
the	DT	O	O
non-specific	JJ	O	O
cyclooxygenase	NN	O	O
(	(	O	O
COX	NNP	O	O
)	)	O	O
inhibitor	NN	O	O
,	,	O	O
indomethacin	NN	O	O
,	,	O	O
and	CC	O	O
by	IN	O	O
the	DT	O	O
selective	JJ	O	O
COX-2	NNP	O	O
inhibitor	NN	O	O
,	,	O	O
NS-398	NNP	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
by	IN	O	O
the	DT	O	O
specific	JJ	O	O
COX-1	NNP	O	O
inhibitor	NN	O	O
,	,	O	O
valeryl	JJ	O	O
salicylate	NN	O	O
.	.	O	O

Both	DT	O	O
the	DT	O	O
non-specific	JJ	O	O
phospholipase	NN	O	O
A	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
inhibitor	NN	O	O
,	,	O	O
quinacrine	NN	O	O
,	,	O	O
and	CC	O	O
an	DT	O	O
inhibitor	NN	O	O
of	IN	O	O
cPLA	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
and	CC	O	O
iPLA	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
,	,	O	O
AACOF3	NNP	O	O
,	,	O	O
counteracted	VBD	O	O
the	DT	O	O
effect	NN	O	O
;	:	O	O
in	IN	O	O
contrast	NN	O	O
,	,	O	O
a	DT	O	O
selective	JJ	O	O
iPLA	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
inhibitor	NN	O	O
,	,	O	O
BEL	NNP	O	O
,	,	O	O
and	CC	O	O
a	DT	O	O
selective	JJ	O	O
sPLA	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
inhibitor	NN	O	O
,	,	O	O
TAPC	NNP	O	O
,	,	O	O
were	VBD	O	O
ineffective	JJ	O	O
.	.	O	O

No	DT	O	O
effects	NNS	O	O
of	IN	O	O
dopamine	NN	O	O
were	VBD	O	O
obtained	VBN	O	O
in	IN	O	O
control	NN	O	O
cells	NNS	O	O
mock-transfected	JJ	O	O
with	IN	O	O
the	DT	O	O
p3C	NN	O	O
vector	NN	O	O
only	RB	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
reinforce	VBP	O	O
previous	JJ	O	O
assumptions	NNS	O	O
that	IN	O	O
dopamine	NN	O	O
may	MD	O	O
interact	VB	O	O
with	IN	O	O
eicosanoid	JJ	O	O
metabolism	NN	O	O
by	IN	O	O
means	NNS	O	O
of	IN	O	O
D	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
receptor	NN	O	O
activation	NN	O	O
,	,	O	O
and	CC	O	O
implicate	VB	O	O
an	DT	O	O
involvement	NN	O	O
of	IN	O	O
cPLA	NN	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
and	CC	O	O
COX-2	NNP	O	O
in	IN	O	O
this	DT	O	O
effect	NN	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
suggested	VBN	O	O
that	IN	O	O
measurement	NN	O	O
of	IN	O	O
dopamine-induced	JJ	O	O
PGE	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
production	NN	O	O
may	MD	O	O
serve	VB	O	O
as	IN	O	O
a	DT	O	O
convenient	JJ	O	O
way	NN	O	O
to	TO	O	O
study	VB	O	O
D	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
receptor	NN	O	O
function	NN	O	O
in	IN	O	O
vitro	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Iron-sulphur	NNP	O	O
(	(	O	O
[	JJ	O	O
Fe-S	NNP	O	O
]	NNP	O	O
)	)	O	O
clusters	NNS	O	O
are	VBP	O	O
simple	JJ	O	O
inorganic	JJ	O	O
prosthetic	JJ	O	O
groups	NNS	O	O
that	WDT	O	O
are	VBP	O	O
contained	VBN	O	O
in	IN	O	O
a	DT	O	O
variety	NN	O	O
of	IN	O	O
proteins	NNS	O	O
having	VBG	O	O
functions	NNS	O	O
related	VBN	O	O
to	TO	O	O
electron	VB	O	O
transfer	NN	O	O
,	,	O	O
gene	NN	O	O
regulation	NN	O	O
,	,	O	O
environmental	JJ	O	O
sensing	NN	O	O
and	CC	O	O
substrate	JJ	O	O
activation	NN	O	O
.	.	O	O

In	IN	O	O
spite	NN	O	O
of	IN	O	O
their	PRP$	O	O
simple	JJ	O	O
structures	NNS	O	O
,	,	O	O
biological	JJ	O	O
[	CD	O	O
Fe-S	JJ	O	O
]	NN	O	O
clusters	NNS	O	O
are	VBP	O	O
not	RB	O	O
formed	VBN	O	O
spontaneously	RB	O	O
.	.	O	O

Rather	RB	O	O
,	,	O	O
a	DT	O	O
consortium	NN	O	O
of	IN	O	O
highly	RB	O	O
conserved	JJ	O	O
proteins	NNS	O	O
is	VBZ	O	O
required	VBN	O	O
for	IN	O	O
both	DT	O	O
the	DT	O	O
formation	NN	O	O
of	IN	O	O
[	JJ	O	O
Fe-S	NNP	O	O
]	NN	O	O
clusters	NNS	O	O
and	CC	O	O
their	PRP$	O	O
insertion	NN	O	O
into	IN	O	O
various	JJ	O	O
protein	JJ	O	O
partners	NNS	O	O
.	.	O	O

Among	IN	O	O
the	DT	O	O
[	NNP	O	O
Fe-S	NNP	O	O
]	NNP	O	O
cluster	NN	O	O
biosynthetic	JJ	O	O
proteins	NNS	O	O
are	VBP	O	O
included	VBN	O	O
a	DT	O	O
pyridoxal	JJ	O	O
phosphate-dependent	JJ	O	O
enzyme	NN	O	O
(	(	O	O
NifS	NNP	O	B-enzyme
)	)	O	O
that	WDT	O	O
is	VBZ	O	O
involved	VBN	O	O
in	IN	O	O
the	DT	O	O
activation	NN	O	O
of	IN	O	O
sulphur	NN	O	O
from	IN	O	O
l-cysteine	JJ	O	B-SUBSTRATE
,	,	O	O
and	CC	O	O
a	DT	O	O
molecular	JJ	O	O
scaffold	NN	O	O
protein	NN	O	O
(	(	O	O
NifU	NNP	O	O
)	)	O	O
upon	IN	O	O
which	WDT	O	O
[	NNP	O	O
Fe-S	NNP	O	O
]	NNP	O	O
cluster	NN	O	O
precursors	NNS	O	O
are	VBP	O	O
formed	VBN	O	O
.	.	O	O

The	DT	O	O
formation	NN	O	O
or	CC	O	O
transfer	NN	O	O
of	IN	O	O
[	JJ	O	O
Fe-S	NNP	O	O
]	NN	O	O
clusters	NNS	O	O
appears	VBZ	O	O
to	TO	O	O
require	VB	O	O
an	DT	O	O
electron-transfer	JJ	O	O
step	NN	O	O
.	.	O	O

Another	DT	O	O
complexity	NN	O	O
is	VBZ	O	O
that	IN	O	O
molecular	JJ	O	O
chaperones	NNS	O	O
homologous	JJ	O	O
to	TO	O	O
DnaJ	NNP	O	O
and	CC	O	O
DnaK	NNP	O	O
are	VBP	O	O
involved	VBN	O	O
in	IN	O	O
some	DT	O	O
aspect	NN	O	O
of	IN	O	O
the	DT	O	O
maturation	NN	O	O
of	IN	O	O
[	JJ	O	O
Fe-S	NNP	O	O
]	NNP	O	O
-cluster-containing	VBG	O	O
proteins	NNS	O	O
.	.	O	O

It	PRP	O	O
appears	VBZ	O	O
that	IN	O	O
the	DT	O	O
basic	JJ	O	O
biochemical	JJ	O	O
features	NNS	O	O
of	IN	O	O
[	JJ	O	O
Fe-S	NNP	O	O
]	NNP	O	O
cluster	NN	O	O
formation	NN	O	O
are	VBP	O	O
strongly	RB	O	O
conserved	VBN	O	O
in	IN	O	O
Nature	NNP	O	O
,	,	O	O
since	IN	O	O
organisms	NNS	O	O
from	IN	O	O
all	DT	O	O
three	CD	O	O
life	NN	O	O
Kingdoms	NNP	O	O
contain	VBP	O	O
the	DT	O	O
same	JJ	O	O
consortium	NN	O	O
of	IN	O	O
homologous	JJ	O	O
proteins	NNS	O	O
required	VBN	O	O
for	IN	O	O
[	JJ	O	O
Fe-S	NNP	O	O
]	NNP	O	O
cluster	NN	O	O
formation	NN	O	O
that	WDT	O	O
were	VBD	O	O
discovered	VBN	O	O
in	IN	O	O
the	DT	O	O
eubacteria	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

We	PRP	O	O
previously	RB	O	O
isolated	VBD	O	O
a	DT	O	O
mutant	NN	O	O
which	WDT	O	O
showed	VBD	O	O
a	DT	O	O
high	JJ	O	O
tolerance	NN	O	O
to	TO	O	O
freezing	VBG	O	O
that	IN	O	O
correlated	VBN	O	O
with	IN	O	O
higher	JJR	O	O
levels	NNS	O	O
of	IN	O	O
intracellular	JJ	O	O
L-proline	NNP	O	O
derived	VBD	O	O
from	IN	O	O
L-proline	NNP	O	O
analogue-resistant	JJ	O	O
mutants	NNS	O	O
.	.	O	O

The	DT	O	O
mutation	NN	O	O
responsible	JJ	O	O
for	IN	O	O
the	DT	O	O
analogue	NN	O	O
resistance	NN	O	O
and	CC	O	O
L-proline	JJ	O	O
accumulation	NN	O	O
was	VBD	O	O
a	DT	O	O
single	JJ	O	O
nuclear	JJ	O	O
dominant	JJ	O	O
mutation	NN	O	O
.	.	O	O

By	IN	O	O
introducing	VBG	O	O
the	DT	O	O
mutant-derived	JJ	O	O
genomic	JJ	O	O
library	NN	O	O
into	IN	O	O
a	DT	O	O
non-L-proline-utilizing	JJ	O	O
strain	NN	O	O
,	,	O	O
the	DT	O	O
mutant	NN	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
carry	VB	O	O
an	DT	O	O
allele	NN	O	O
of	IN	O	O
the	DT	O	O
wild-type	JJ	O	O
PRO1	NNP	O	O
gene	NN	O	O
encoding	VBG	O	O
gamma-glutamyl	JJ	O	O
kinase	NN	O	O
,	,	O	O
which	WDT	O	O
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
single	JJ	O	O
amino	NN	O	O
acid	JJ	O	O
replacement	NN	O	O
;	:	O	O
Asp	NNP	O	O
(	(	O	O
GAC	NNP	O	O
)	)	O	O
at	IN	O	O
position	NN	O	O
154	CD	O	O
was	VBD	O	O
replaced	VBN	O	O
by	IN	O	O
Asn	NNP	O	O
(	(	O	O
AAC	NNP	O	O
)	)	O	O
.	.	O	O

Interestingly	RB	O	O
,	,	O	O
the	DT	O	O
allele	NN	O	O
of	IN	O	O
PRO1	NNP	O	O
was	VBD	O	O
shown	VBN	O	O
to	TO	O	O
enhance	VB	O	O
the	DT	O	O
activities	NNS	O	O
of	IN	O	O
gamma-glutamyl	JJ	O	B-enzyme
kinase	NN	O	I-enzyme
and	CC	O	O
gamma-glutamyl	JJ	O	B-enzyme
phosphate	NN	O	I-enzyme
reductase	NN	O	O
,	,	O	O
both	DT	O	O
of	IN	O	O
which	WDT	O	O
catalyze	VBP	O	O
the	DT	O	O
first	JJ	O	O
two	CD	O	O
steps	NNS	O	O
of	IN	O	O
L-proline	JJ	O	B-PRODUCT-OF
synthesis	NN	O	O
from	IN	O	O
L-glutamate	NNP	O	B-SUBSTRATE
and	CC	O	O
which	WDT	O	O
together	RB	O	O
may	MD	O	O
form	VB	O	O
a	DT	O	O
complex	JJ	O	O
in	IN	O	O
vivo	NN	O	O
.	.	O	O

When	WRB	O	O
cultured	VBN	O	O
in	IN	O	O
liquid	NN	O	O
minimal	JJ	O	O
medium	NN	O	O
,	,	O	O
yeast	NN	O	O
cells	NNS	O	O
expressing	VBG	O	O
the	DT	O	O
mutated	VBN	O	O
gamma-glutamyl	JJ	O	B-enzyme
kinase	NN	O	I-enzyme
were	VBD	O	O
found	VBN	O	O
to	TO	O	O
accumulate	VB	O	O
intracellular	JJ	O	O
L-proline	NNP	O	B-PRODUCT-OF
and	CC	O	O
showed	VBD	O	O
a	DT	O	O
prominent	JJ	O	O
increase	NN	O	O
in	IN	O	O
cell	NN	O	O
viability	NN	O	O
after	IN	O	O
freezing	VBG	O	O
at	IN	O	O
-20	NNP	O	O
degrees	NNS	O	O
C	NNP	O	O
compared	VBN	O	O
to	TO	O	O
the	DT	O	O
viability	NN	O	O
of	IN	O	O
cells	NNS	O	O
harboring	VBG	O	O
the	DT	O	O
wild-type	JJ	O	O
PRO1	NNP	O	O
gene	NN	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
the	DT	O	O
altered	JJ	O	O
gamma-glutamyl	JJ	O	B-enzyme
kinase	NN	O	I-enzyme
results	NNS	O	O
in	IN	O	O
stabilization	NN	O	O
of	IN	O	O
the	DT	O	O
complex	NN	O	O
or	CC	O	O
has	VBZ	O	O
an	DT	O	O
indirect	JJ	O	O
effect	NN	O	O
on	IN	O	O
gamma-glutamyl	JJ	O	B-enzyme
phosphate	JJ	O	I-enzyme
reductase	NN	O	O
activity	NN	O	O
,	,	O	O
which	WDT	O	O
leads	VBZ	O	O
to	TO	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
L-proline	JJ	O	B-PRODUCT-OF
production	NN	O	O
in	IN	O	O
Saccharomyces	NNP	O	O
cerevisiae	NN	O	O
.	.	O	O

The	DT	O	O
approach	NN	O	O
described	VBD	O	O
in	IN	O	O
this	DT	O	O
paper	NN	O	O
could	MD	O	O
be	VB	O	O
a	DT	O	O
practical	JJ	O	O
method	NN	O	O
for	IN	O	O
breeding	VBG	O	O
novel	JJ	O	O
freeze-tolerant	JJ	O	O
yeast	NN	O	O
strains	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

D-Serine	NN	O	O
was	VBD	O	O
previously	RB	O	O
identified	VBN	O	O
in	IN	O	O
mammalian	JJ	O	O
brain	NN	O	O
and	CC	O	O
was	VBD	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
a	DT	O	O
co-agonist	NN	O	O
at	IN	O	O
the	DT	O	O
'glycine	NNP	O	O
'	POS	O	O
site	NN	O	O
of	IN	O	O
the	DT	O	O
N-methyl-D-aspartate	NNP	O	O
(	(	O	O
NMDA	NNP	O	O
)	)	O	O
-type	NN	O	O
receptors	NNS	O	O
.	.	O	O

Racemization	NN	O	O
of	IN	O	O
serine	NN	O	B-SUBSTRATE
is	VBZ	O	O
catalyzed	VBN	O	O
by	IN	O	O
serine	JJ	O	B-enzyme
racemase	NN	O	I-enzyme
,	,	O	O
a	DT	O	O
pyridoxal	JJ	O	O
5'-phosphate-dependent	JJ	O	O
enzyme	NN	O	O
expressed	VBN	O	O
mainly	RB	O	O
in	IN	O	O
brain	NN	O	O
and	CC	O	O
liver	NN	O	O
.	.	O	O

NMDA	NNP	O	O
receptor	NN	O	O
overactivation	NN	O	O
has	VBZ	O	O
been	VBN	O	O
implicated	VBN	O	O
in	IN	O	O
a	DT	O	O
number	NN	O	O
of	IN	O	O
pathological	JJ	O	O
conditions	NNS	O	O
and	CC	O	O
inhibitors	NNS	O	O
of	IN	O	O
serine	JJ	O	O
racemase	NN	O	O
are	VBP	O	O
thus	RB	O	O
potentially	RB	O	O
interesting	JJ	O	O
targets	NNS	O	O
for	IN	O	O
therapy	NN	O	O
.	.	O	O

We	PRP	O	O
expressed	VBD	O	O
recombinant	JJ	O	O
mouse	NN	O	O
serine	NN	O	O
racemase	NN	O	O
in	IN	O	O
insect	JJ	O	O
cells	NNS	O	O
and	CC	O	O
purified	VBD	O	O
it	PRP	O	O
to	TO	O	O
near	IN	O	O
homogeneity	NN	O	O
.	.	O	O

The	DT	O	O
enzyme	NN	O	O
is	VBZ	O	O
a	DT	O	O
non-covalent	JJ	O	O
homodimer	NN	O	O
in	IN	O	O
solution	NN	O	O
and	CC	O	O
requires	VBZ	O	O
divalent	JJ	O	O
cations	NNS	O	O
Mg	NNP	O	O
(	(	O	O
2+	CD	O	O
)	)	O	O
,	,	O	O
Ca	NNP	O	O
(	(	O	O
2+	CD	O	O
)	)	O	O
or	CC	O	O
Mn	NNP	O	O
(	(	O	O
2+	CD	O	O
)	)	O	O
for	IN	O	O
activity	NN	O	O
but	CC	O	O
not	RB	O	O
for	IN	O	O
dimerization	NN	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
to	TO	O	O
the	DT	O	O
racemization	NN	O	O
it	PRP	O	O
also	RB	O	O
catalyzes	VBZ	O	O
specific	JJ	O	O
elimination	NN	O	O
of	IN	O	O
L-Ser	NNP	O	O
to	TO	O	O
pyruvate	VB	O	O
.	.	O	O

D-Serine	NNP	O	O
is	VBZ	O	O
eliminated	VBN	O	O
much	RB	O	O
less	RBR	O	O
efficiently	RB	O	O
.	.	O	O

Both	DT	O	O
L-serine	NNP	O	O
racemization	NN	O	O
and	CC	O	O
elimination	NN	O	O
activities	NNS	O	O
of	IN	O	O
serine	JJ	O	O
racemase	NN	O	O
are	VBP	O	O
of	IN	O	O
comparable	JJ	O	O
magnitude	NN	O	O
,	,	O	O
display	NN	O	O
alkaline	NN	O	O
pH	NN	O	O
optimum	NN	O	O
and	CC	O	O
are	VBP	O	O
negligible	JJ	O	O
below	IN	O	O
pH	NN	O	O
6.5	CD	O	O
.	.	O	O

-DOCSTART- -X- -X- O

The	DT	O	O
treatment	NN	O	O
of	IN	O	O
erectile	JJ	O	O
dysfunction	NN	O	O
(	(	O	O
ED	NNP	O	O
)	)	O	O
has	VBZ	O	O
been	VBN	O	O
revolutionised	VBN	O	O
by	IN	O	O
new	JJ	O	O
agents	NNS	O	O
to	TO	O	O
inhibit	VB	O	O
the	DT	O	O
enzyme	NN	O	O
PDE5	NNP	O	O
.	.	O	O

The	DT	O	O
scientific	JJ	O	O
basis	NN	O	O
of	IN	O	O
this	DT	O	O
treatment	NN	O	O
of	IN	O	O
ED	NNP	O	O
includes	VBZ	O	O
relaxation	NN	O	O
of	IN	O	O
the	DT	O	O
corpus	NN	O	O
cavernosum	NN	O	O
smooth	JJ	O	O
muscle	NN	O	O
tissue	NN	O	O
by	IN	O	O
inhibition	NN	O	O
of	IN	O	O
PDE5	NNP	O	B-enzyme
that	IN	O	O
breaks	VBZ	O	O
down	RB	O	O
cGMP	NN	O	B-SUBSTRATE
,	,	O	O
the	DT	O	O
key	JJ	O	O
pathway	NN	O	O
for	IN	O	O
the	DT	O	O
production	NN	O	O
of	IN	O	O
erectile	JJ	O	O
function	NN	O	O
in	IN	O	O
humans	NNS	O	O
.	.	O	O

Many	JJ	O	O
clinical	JJ	O	O
studies	NNS	O	O
,	,	O	O
both	DT	O	O
pre-	JJ	O	O
and	CC	O	O
post-marketing	JJ	O	O
,	,	O	O
have	VBP	O	O
demonstrated	VBN	O	O
the	DT	O	O
clinical	JJ	O	O
efficacy	NN	O	O
and	CC	O	O
safety	NN	O	O
of	IN	O	O
sildenafil	NN	O	O
(	(	O	O
Viagra	NNP	O	O
,	,	O	O
Pfizer	NNP	O	O
)	)	O	O
-	:	O	O
the	DT	O	O
first	JJ	O	O
approved	VBD	O	O
selective	JJ	O	O
PDE	NNP	O	O
inhibitor	NN	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
ED	NNP	O	O
.	.	O	O

Sildenafil	NNP	O	O
is	VBZ	O	O
inhibitory	NN	O	O
of	IN	O	O
PDE5	NNP	O	O
at	IN	O	O
a	DT	O	O
rate	NN	O	O
tenfold	NN	O	O
higher	JJR	O	O
than	IN	O	O
for	IN	O	O
the	DT	O	O
next	JJ	O	O
PDE	NNP	O	O
(	(	O	O
PDE6	NNP	O	O
)	)	O	O
,	,	O	O
which	WDT	O	O
produces	VBZ	O	O
visual	JJ	O	O
changes	NNS	O	O
through	IN	O	O
the	DT	O	O
retinal	JJ	O	O
rods	NNS	O	O
.	.	O	O

Its	PRP$	O	O
clinical	JJ	O	O
effectiveness	NN	O	O
has	VBZ	O	O
been	VBN	O	O
well	RB	O	O
documented	VBN	O	O
in	IN	O	O
the	DT	O	O
majority	NN	O	O
of	IN	O	O
men	NNS	O	O
with	IN	O	O
ED	NNP	O	O
irrespective	NN	O	O
of	IN	O	O
aetiology	NN	O	O
.	.	O	O

The	DT	O	O
aetiology	NN	O	O
of	IN	O	O
ED	NNP	O	O
,	,	O	O
also	RB	O	O
,	,	O	O
does	VBZ	O	O
not	RB	O	O
appear	VB	O	O
to	TO	O	O
effect	NN	O	O
the	DT	O	O
function	NN	O	O
of	IN	O	O
sildenafil	NN	O	O
in	IN	O	O
relaxing	VBG	O	O
corpus	NN	O	O
cavernosum	NN	O	O
smooth	JJ	O	O
muscle	NN	O	O
tissue	NN	O	O
.	.	O	O

Adverse	JJ	O	O
events	NNS	O	O
are	VBP	O	O
usually	RB	O	O
associated	VBN	O	O
with	IN	O	O
the	DT	O	O
vascular	JJ	O	O
changes	NNS	O	O
from	IN	O	O
PDE5	NNP	O	O
inhibition	NN	O	O
.	.	O	O

These	DT	O	O
include	VBP	O	O
headache	NN	O	O
and	CC	O	O
flushing	NN	O	O
.	.	O	O

Each	DT	O	O
of	IN	O	O
these	DT	O	O
adverse	JJ	O	O
events	NNS	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
declines	NNS	O	O
with	IN	O	O
medication	NN	O	O
use	NN	O	O
.	.	O	O

With	IN	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
sildenafil	NN	O	O
,	,	O	O
it	PRP	O	O
has	VBZ	O	O
been	VBN	O	O
clearly	RB	O	O
,	,	O	O
clinically	RB	O	O
demonstrated	VBD	O	O
that	IN	O	O
the	DT	O	O
selective	JJ	O	O
inhibition	NN	O	O
of	IN	O	O
PDE5	NNP	O	O
is	VBZ	O	O
an	DT	O	O
appropriate	JJ	O	O
,	,	O	O
effective	JJ	O	O
,	,	O	O
safe	JJ	O	O
method	NN	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
ED	NNP	O	O
of	IN	O	O
all	DT	O	O
aetiologies	NNS	O	O
and	CC	O	O
severities	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Serine	NNP	O	O
(	(	O	O
Ser	NNP	O	O
)	)	O	O
biosynthesis	NN	O	O
in	IN	O	O
C	NNP	O	O
(	(	O	O
3	CD	O	O
)	)	O	O
plants	NNS	O	O
can	MD	O	O
occur	VB	O	O
via	IN	O	O
several	JJ	O	O
pathways	NNS	O	O
.	.	O	O

One	CD	O	O
major	JJ	O	O
route	NN	O	O
involves	VBZ	O	O
the	DT	O	O
tetrahydrofolate	NN	O	O
(	(	O	O
THF	NNP	O	O
)	)	O	O
-dependent	NN	O	O
activities	NNS	O	O
of	IN	O	O
the	DT	O	O
glycine	JJ	O	B-enzyme
decarboxylase	NN	O	I-enzyme
complex	NN	O	O
(	(	O	O
GDC	NNP	O	B-enzyme
,	,	O	O
EC	NNP	O	B-enzyme
2.1.1.10	CD	O	I-enzyme
)	)	O	O
and	CC	O	O
serine	JJ	O	B-enzyme
hydroxymethyltransferase	NN	O	I-enzyme
(	(	O	O
SHMT	NNP	O	B-enzyme
,	,	O	O
EC	NNP	O	B-enzyme
2.1.2.1	CD	O	I-enzyme
)	)	O	O
with	IN	O	O
glycine	NN	O	B-SUBSTRATE
(	(	O	O
Gly	NNP	O	B-SUBSTRATE
)	)	O	O
as	IN	O	O
one-carbon	NN	O	O
(	(	O	O
1-C	JJ	O	O
)	)	O	O
source	NN	O	O
.	.	O	O

An	DT	O	O
alternative	JJ	O	O
THF-dependent	JJ	O	O
pathway	NN	O	O
involves	VBZ	O	O
the	DT	O	O
C1-THF	NNP	O	B-enzyme
synthase/SHMT	NN	O	O
activities	NNS	O	O
with	IN	O	O
formate	NN	O	B-SUBSTRATE
as	IN	O	O
1-C	JJ	O	O
source	NN	O	O
.	.	O	O

Here	RB	O	O
,	,	O	O
we	PRP	O	O
have	VBP	O	O
investigated	VBN	O	O
aspects	NNS	O	O
of	IN	O	O
the	DT	O	O
regulation	NN	O	O
of	IN	O	O
these	DT	O	O
two	CD	O	O
folate-mediated	JJ	O	O
pathways	NNS	O	O
in	IN	O	O
Arabidopsis	NNP	O	O
thaliana	NN	O	O
(	(	O	O
L.	NNP	O	O
)	)	O	O
Heynh	NNP	O	O
.	.	O	O

Columbia	NNP	O	O
using	VBG	O	O
two	CD	O	O
approaches	NNS	O	O
.	.	O	O

Firstly	RB	O	O
,	,	O	O
transgenic	JJ	O	O
plants	NNS	O	O
overexpressing	VBG	O	O
formate	JJ	O	B-enzyme
dehydrogenase	NN	O	I-enzyme
(	(	O	O
FDH	NNP	O	B-enzyme
,	,	O	O
EC	NNP	O	B-enzyme
1.2.1.2	CD	O	I-enzyme
)	)	O	O
were	VBD	O	O
used	VBN	O	O
to	TO	O	O
continue	VB	O	O
our	PRP$	O	O
previous	JJ	O	O
studies	NNS	O	O
on	IN	O	O
the	DT	O	O
function	NN	O	O
of	IN	O	O
FDH	NNP	O	B-enzyme
in	IN	O	O
formate	JJ	O	B-SUBSTRATE
metabolism	NN	O	O
.	.	O	O

The	DT	O	O
formate	JJ	O	O
pool	NN	O	O
size	NN	O	O
was	VBD	O	O
approximately	RB	O	O
73	CD	O	O
nmol	NNS	O	O
(	(	O	O
g	JJ	O	O
FW	NNP	O	O
)	)	O	O
(	(	O	O
-1	NN	O	O
)	)	O	O
in	IN	O	O
wild	JJ	O	O
type	NN	O	O
(	(	O	O
WT	NNP	O	O
)	)	O	O
Arabidopsis	NN	O	O
plants	NNS	O	O
;	:	O	O
three	CD	O	O
independent	JJ	O	O
transgenic	JJ	O	O
lines	NNS	O	O
had	VBD	O	O
similar-sized	JJ	O	O
pools	NNS	O	O
of	IN	O	O
formate	NN	O	O
.	.	O	O

Transgenic	JJ	O	O
plants	NNS	O	O
produced	VBN	O	O
more	JJR	O	O
(	(	O	O
13	CD	O	O
)	)	O	O
CO	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
from	IN	O	O
supplied	VBN	O	O
[	NNP	O	O
(	(	O	O
13	CD	O	O
)	)	O	O
C	NNP	O	O
]	NNP	O	O
formate	NN	O	O
than	IN	O	O
did	VBD	O	O
WT	JJ	O	O
plants	NNS	O	O
but	CC	O	O
were	VBD	O	O
not	RB	O	O
significantly	RB	O	O
different	JJ	O	O
from	IN	O	O
WT	JJ	O	O
plants	NNS	O	O
in	IN	O	O
their	PRP$	O	O
synthesis	NN	O	O
of	IN	O	O
Ser	NNP	O	O
.	.	O	O

We	PRP	O	O
concluded	VBD	O	O
that	IN	O	O
FDH	NNP	O	O
has	VBZ	O	O
no	DT	O	O
direct	JJ	O	O
role	NN	O	O
in	IN	O	O
the	DT	O	O
regulation	NN	O	O
of	IN	O	O
the	DT	O	O
above	JJ	O	O
two	CD	O	O
pathways	NNS	O	O
of	IN	O	O
Ser	NNP	O	O
synthesis	NN	O	O
;	:	O	O
the	DT	O	O
breakdown	NN	O	O
of	IN	O	O
formate	NN	O	B-SUBSTRATE
to	TO	O	O
CO	NNP	O	B-PRODUCT-OF
(	(	O	O
2	CD	O	O
)	)	O	O
by	IN	O	O
the	DT	O	O
FDH	NNP	O	B-enzyme
reaction	NN	O	O
is	VBZ	O	O
the	DT	O	O
primary	JJ	O	O
and	CC	O	O
preferred	JJ	O	O
fate	NN	O	O
of	IN	O	O
the	DT	O	O
organic	JJ	O	O
acid	NN	O	O
in	IN	O	O
Arabidopsis	NNP	O	O
.	.	O	O

The	DT	O	O
ratio	NN	O	O
between	IN	O	O
the	DT	O	O
GDC/SHMT	NNP	O	O
and	CC	O	O
C1-THF	NNP	O	B-enzyme
synthase/SHMT	NNP	O	O
pathways	NNS	O	O
of	IN	O	O
Ser	NNP	O	B-PRODUCT-OF
synthesis	NN	O	O
from	IN	O	O
[	JJ	O	B-SUBSTRATE
alpha-	NN	O	O
(	(	O	O
13	CD	O	O
)	)	O	O
C	NNP	O	O
]	NNP	O	O
Gly	NNP	O	O
and	CC	O	O
[	NNP	O	B-SUBSTRATE
(	(	O	O
13	CD	O	O
)	)	O	O
C	NNP	O	O
]	NNP	O	O
formate	NN	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
in	IN	O	O
Arabidopsis	NNP	O	O
shoots	NNS	O	O
was	VBD	O	O
21	CD	O	O
:	:	O	O
1	CD	O	O
;	:	O	O
in	IN	O	O
roots	NNS	O	O
,	,	O	O
9	CD	O	O
:	:	O	O
1	CD	O	O
.	.	O	O

In	IN	O	O
shoots	NNS	O	O
,	,	O	O
therefore	RB	O	O
,	,	O	O
the	DT	O	O
pathway	NN	O	O
from	IN	O	O
formate	NN	O	O
plays	NNS	O	O
only	RB	O	O
a	DT	O	O
small	JJ	O	O
role	NN	O	O
in	IN	O	O
Ser	NNP	O	O
synthesis	NN	O	O
;	:	O	O
in	IN	O	O
the	DT	O	O
case	NN	O	O
of	IN	O	O
roots	NNS	O	O
,	,	O	O
results	NNS	O	O
indicated	VBD	O	O
that	IN	O	O
the	DT	O	O
9	CD	O	O
:	:	O	O
1	CD	O	O
ratio	NN	O	O
was	VBD	O	O
as	IN	O	O
a	DT	O	O
result	NN	O	O
of	IN	O	O
greater	JJR	O	O
fluxes	NNS	O	O
of	IN	O	O
(	(	O	O
13	CD	O	O
)	)	O	O
C	NNP	O	O
through	IN	O	O
both	DT	O	O
pathways	NNS	O	O
together	RB	O	O
with	IN	O	O
a	DT	O	O
relatively	RB	O	O
higher	JJR	O	O
contribution	NN	O	O
from	IN	O	O
the	DT	O	O
C1-THF	NNP	O	O
synthase/SHMT	NN	O	O
route	NN	O	O
than	IN	O	O
in	IN	O	O
shoots	NNS	O	O
.	.	O	O

We	PRP	O	O
also	RB	O	O
examined	VBD	O	O
the	DT	O	O
synthesis	NN	O	O
of	IN	O	O
Ser	NNP	O	O
in	IN	O	O
a	DT	O	O
GDC-deficient	JJ	O	O
mutant	NN	O	O
of	IN	O	O
Arabidopsis	NNP	O	O
(	(	O	O
glyD	NN	O	O
)	)	O	O
where	WRB	O	O
the	DT	O	O
GDC/SHMT	NNP	O	O
pathway	NN	O	O
was	VBD	O	O
impaired	VBN	O	O
.	.	O	O

Compared	VBN	O	O
with	IN	O	O
WT	NNP	O	O
,	,	O	O
glyD	NN	O	O
plants	NNS	O	O
accumulated	VBD	O	O
5-fold	CD	O	O
more	JJR	O	O
Gly	NNP	O	O
than	IN	O	O
WT	NNP	O	O
after	IN	O	O
supplying	VBG	O	O
[	JJ	O	O
alpha-	JJ	O	O
(	(	O	O
13	CD	O	O
)	)	O	O
C	NNP	O	O
]	NNP	O	O
Gly	NNP	O	O
for	IN	O	O
24	CD	O	O
h	NN	O	O
;	:	O	O
the	DT	O	O
accumulation	NN	O	O
of	IN	O	O
Ser	NNP	O	O
from	IN	O	O
[	NNP	O	O
alpha-	NN	O	O
(	(	O	O
13	CD	O	O
)	)	O	O
C	NNP	O	O
]	NNP	O	O
Gly	NNP	O	O
was	VBD	O	O
reduced	VBN	O	O
by	IN	O	O
25	CD	O	O
%	NN	O	O
in	IN	O	O
the	DT	O	O
same	JJ	O	O
time	NN	O	O
period	NN	O	O
.	.	O	O

On	IN	O	O
the	DT	O	O
other	JJ	O	O
hand	NN	O	O
,	,	O	O
the	DT	O	O
accumulation	NN	O	O
of	IN	O	O
Ser	NNP	O	B-PRODUCT-OF
through	IN	O	O
the	DT	O	O
C1-THF	NNP	O	O
synthase/SHMT	NN	O	O
pathway	NN	O	O
in	IN	O	O
glyD	NN	O	O
plants	NNS	O	O
was	VBD	O	O
2.5-fold	JJ	O	O
greater	JJR	O	O
than	IN	O	O
that	DT	O	O
in	IN	O	O
WT	NNP	O	O
plants	NNS	O	O
.	.	O	O

Our	PRP$	O	O
experiments	NNS	O	O
confirmed	VBD	O	O
that	IN	O	O
the	DT	O	O
GDC/SHMT	NNP	O	O
and	CC	O	O
C1-THF	NNP	O	O
synthase/SHMT	NN	O	O
pathways	NNS	O	O
normally	RB	O	O
operate	VBP	O	O
independently	RB	O	O
in	IN	O	O
Arabidopsis	NN	O	O
plants	NNS	O	O
but	CC	O	O
that	DT	O	O
when	WRB	O	O
the	DT	O	O
primary	JJ	O	O
GDC/SHMT	NNP	O	O
pathway	NN	O	O
is	VBZ	O	O
impaired	VBN	O	O
the	DT	O	O
alternative	JJ	O	O
C1-THF	NNP	O	O
synthase/SHMT	NN	O	O
pathway	NN	O	O
can	MD	O	O
partially	RB	O	O
compensate	VB	O	O
for	IN	O	O
deficiencies	NNS	O	O
in	IN	O	O
the	DT	O	O
synthesis	NN	O	O
of	IN	O	O
Ser	NNP	O	O
.	.	O	O

-DOCSTART- -X- -X- O

BACKGROUND	NNP	O	O
&	CC	O	O
AIMS	NNP	O	O
:	:	O	O
Of	IN	O	O
the	DT	O	O
2	CD	O	O
genes	NNS	O	O
(	(	O	O
MAT1A	NNP	O	B-enzyme
,	,	O	O
MAT2A	NNP	O	B-enzyme
)	)	O	O
encoding	VBG	O	O
methionine	JJ	O	B-enzyme
adenosyltransferase	NN	O	I-enzyme
,	,	O	O
the	DT	O	O
enzyme	NN	O	O
that	WDT	O	O
synthesizes	VBZ	O	O
S-adenosylmethionine	NNP	O	B-PRODUCT-OF
,	,	O	O
MAT1A	NNP	O	B-enzyme
,	,	O	O
is	VBZ	O	O
expressed	VBN	O	O
in	IN	O	O
liver	NN	O	O
,	,	O	O
whereas	JJ	O	O
MAT2A	NNP	O	O
is	VBZ	O	O
expressed	VBN	O	O
in	IN	O	O
extrahepatic	JJ	O	O
tissues	NNS	O	O
.	.	O	O

In	IN	O	O
liver	NN	O	O
,	,	O	O
MAT2A	NNP	O	O
expression	NN	O	O
associates	NNS	O	O
with	IN	O	O
growth	NN	O	O
,	,	O	O
dedifferentiation	NN	O	O
,	,	O	O
and	CC	O	O
cancer	NN	O	O
.	.	O	O

Here	RB	O	O
,	,	O	O
we	PRP	O	O
identified	VBD	O	O
the	DT	O	O
beta	NN	O	O
subunit	NN	O	O
as	IN	O	O
a	DT	O	O
regulator	NN	O	O
of	IN	O	O
proliferation	NN	O	O
in	IN	O	O
human	JJ	O	O
hepatoma	NN	O	O
cell	NN	O	O
lines	NNS	O	O
.	.	O	O

The	DT	O	O
beta	NN	O	O
subunit	NN	O	O
has	VBZ	O	O
been	VBN	O	O
cloned	VBN	O	O
and	CC	O	O
shown	VBN	O	O
to	TO	O	O
lower	VB	O	O
the	DT	O	O
K	NNP	O	O
(	(	O	O
m	NN	O	O
)	)	O	O
of	IN	O	O
methionine	NN	O	B-enzyme
adenosyltransferase	NN	O	I-enzyme
II	NNP	O	O
alpha2	NN	O	O
(	(	O	O
the	DT	O	O
MAT2A	NNP	O	B-enzyme
product	NN	O	O
)	)	O	O
for	IN	O	O
methionine	NN	O	B-SUBSTRATE
and	CC	O	O
to	TO	O	O
render	VB	O	O
the	DT	O	O
enzyme	NN	O	O
more	RBR	O	O
susceptible	JJ	O	O
to	TO	O	O
S-adenosylmethionine	JJ	O	O
inhibition	NN	O	O
.	.	O	O

METHODS	NN	O	O
:	:	O	O
Methionine	NNP	O	O
adenosyltransferase	NN	O	O
II	NNP	O	O
alpha2	NN	O	O
and	CC	O	O
beta	NN	O	O
subunit	NN	O	O
expression	NN	O	O
was	VBD	O	O
analyzed	VBN	O	O
in	IN	O	O
human	JJ	O	O
and	CC	O	O
rat	VB	O	O
liver	NN	O	O
and	CC	O	O
hepatoma	NN	O	O
cell	NN	O	O
lines	NNS	O	O
and	CC	O	O
their	PRP$	O	O
interaction	NN	O	O
studied	VBN	O	O
in	IN	O	O
HuH7	NNP	O	O
cells	NNS	O	O
.	.	O	O

beta	NN	O	O
Subunit	NNP	O	O
expression	NN	O	O
was	VBD	O	O
up-	JJ	O	O
and	CC	O	O
down-regulated	JJ	O	O
in	IN	O	O
human	JJ	O	O
hepatoma	NN	O	O
cell	NN	O	O
lines	NNS	O	O
and	CC	O	O
the	DT	O	O
effect	NN	O	O
on	IN	O	O
DNA	NNP	O	O
synthesis	NN	O	O
determined	VBD	O	O
.	.	O	O

RESULTS	NNS	O	O
:	:	O	O
We	PRP	O	O
found	VBD	O	O
that	IN	O	O
beta	NN	O	O
subunit	NN	O	O
is	VBZ	O	O
expressed	VBN	O	O
in	IN	O	O
rat	NN	O	O
extrahepatic	JJ	O	O
tissues	NNS	O	O
but	CC	O	O
not	RB	O	O
in	IN	O	O
normal	JJ	O	O
liver	NN	O	O
.	.	O	O

In	IN	O	O
human	JJ	O	O
liver	NN	O	O
,	,	O	O
beta	NN	O	O
subunit	NN	O	O
expression	NN	O	O
associates	VBZ	O	O
with	IN	O	O
cirrhosis	NN	O	O
and	CC	O	O
hepatoma	NN	O	O
.	.	O	O

beta	NN	O	O
Subunit	NNP	O	O
is	VBZ	O	O
expressed	VBN	O	O
in	IN	O	O
most	JJS	O	O
(	(	O	O
HepG2	NNP	O	O
,	,	O	O
PLC	NNP	O	O
,	,	O	O
and	CC	O	O
Hep3B	NNP	O	O
)	)	O	O
but	CC	O	O
not	RB	O	O
all	DT	O	O
(	(	O	O
HuH7	NNP	O	O
)	)	O	O
hepatoma	NN	O	O
cell	NN	O	O
lines	NNS	O	O
.	.	O	O

Transfection	NN	O	O
of	IN	O	O
beta	NN	O	O
subunit	NN	O	O
reduced	VBD	O	O
S-adenosylmethionine	NNP	O	O
content	NN	O	O
and	CC	O	O
stimulated	VBD	O	O
DNA	NNP	O	O
synthesis	NN	O	O
in	IN	O	O
HuH7	NNP	O	O
cells	NNS	O	O
,	,	O	O
whereas	IN	O	O
down-regulation	NN	O	O
of	IN	O	O
beta	NN	O	O
subunit	NN	O	O
expression	NN	O	O
diminished	VBD	O	O
DNA	NNP	O	O
synthesis	NN	O	O
in	IN	O	O
HepG2	NNP	O	O
.	.	O	O

The	DT	O	O
interaction	NN	O	O
between	IN	O	O
methionine	NN	O	O
adenosyltransferase	NN	O	O
II	NNP	O	O
alpha2	NN	O	O
and	CC	O	O
beta	NN	O	O
subunit	NN	O	O
was	VBD	O	O
demonstrated	VBN	O	O
in	IN	O	O
HuH7	NNP	O	O
cells	NNS	O	O
.	.	O	O

CONCLUSIONS	NN	O	O
:	:	O	O
Our	PRP$	O	O
findings	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
beta	NN	O	O
subunit	NN	O	O
associates	VBZ	O	O
with	IN	O	O
cirrhosis	NN	O	O
and	CC	O	O
cancer	NN	O	O
providing	VBG	O	O
a	DT	O	O
proliferative	JJ	O	O
advantage	NN	O	O
in	IN	O	O
hepatoma	NN	O	O
cells	NNS	O	O
through	IN	O	O
its	PRP$	O	O
interaction	NN	O	O
with	IN	O	O
methionine	JJ	O	O
adenosyltransferase	NN	O	O
II	NNP	O	O
alpha2	NN	O	O
and	CC	O	O
down-regulation	NN	O	O
of	IN	O	O
S-adenosylmethionine	NNP	O	O
levels	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

The	DT	O	O
YLR205c	NNP	O	O
gene	NN	O	O
of	IN	O	O
Saccharomyces	NNS	O	O
cerevisiae	NN	O	O
does	VBZ	O	O
not	RB	O	O
show	VB	O	O
significant	JJ	O	O
sequence	NN	O	O
identity	NN	O	O
to	TO	O	O
any	DT	O	O
known	VBN	O	O
gene	NN	O	O
,	,	O	O
except	IN	O	O
for	IN	O	O
heme	NN	O	O
oxygenase	NN	O	O
(	(	O	O
22	CD	O	O
%	NN	O	O
to	TO	O	O
human	JJ	O	O
HO-1	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
YLR205	NNP	O	O
ORF	NNP	O	O
was	VBD	O	O
cloned	VBN	O	O
and	CC	O	O
overexpressed	VBN	O	O
in	IN	O	O
both	DT	O	O
Escherichia	NNP	O	O
coli	NN	O	O
and	CC	O	O
S.	NNP	O	O
cerevisiae	NN	O	O
.	.	O	O

Both	DT	O	O
expression	NN	O	O
systems	NNS	O	O
yielded	VBD	O	O
proteins	NNS	O	O
that	WDT	O	O
bound	VBP	O	O
heme	DT	O	O
tightly	RB	O	O
.	.	O	O

The	DT	O	O
isolated	JJ	O	O
YLR205c	NNP	O	O
protein	NN	O	O
underwent	JJ	O	O
reduction	NN	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
either	DT	O	O
NADPH-cytochrome	NNP	O	O
P450	NNP	O	O
reductase	NN	O	O
or	CC	O	O
NADH-putidaredoxin-putidaredoxin	JJ	O	O
reductase	NN	O	O
but	CC	O	O
did	VBD	O	O
not	RB	O	O
exhibit	VB	O	O
heme	JJ	O	O
oxygenase	NN	O	O
activity	NN	O	O
.	.	O	O

The	DT	O	O
protein	NN	O	O
exhibited	VBD	O	O
modest	JJ	O	O
H	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
O	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
-dependent	NN	O	O
peroxidase	NN	O	B-enzyme
activities	NNS	O	O
with	IN	O	O
guaiacol	NN	O	B-SUBSTRATE
,	,	O	O
potassium	NN	O	B-SUBSTRATE
iodide	NN	O	I-SUBSTRATE
,	,	O	O
and	CC	O	O
2,2	CD	O	B-SUBSTRATE
(	(	O	O
'	POS	O	O
)	)	O	O
-azino-bis	NN	O	O
(	(	O	O
3-ethylbenzothiazoline-6-sulfonic	JJ	O	O
acid	NN	O	I-SUBSTRATE
(	(	O	O
ABTS	NNP	O	B-SUBSTRATE
)	)	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
YLR205c	NNP	O	O
codes	VBZ	O	O
for	IN	O	O
a	DT	O	O
hemoprotein	NN	O	O
of	IN	O	O
unknown	JJ	O	O
physiological	JJ	O	O
function	NN	O	O
that	IN	O	O
exhibits	VBZ	O	O
peroxidase	NN	O	O
activity	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

The	DT	O	O
discovery	NN	O	O
of	IN	O	O
an	DT	O	O
inducible	JJ	O	O
oxidase	NN	O	B-enzyme
whose	WP$	O	O
apparent	JJ	O	O
substrate	NN	O	O
preference	NN	O	O
is	VBZ	O	O
spermine	JJ	O	B-SUBSTRATE
indicates	NNS	O	O
that	IN	O	O
polyamine	JJ	O	O
catabolism	NN	O	O
is	VBZ	O	O
more	RBR	O	O
complex	JJ	O	O
than	IN	O	O
that	DT	O	O
originally	RB	O	O
proposed	VBN	O	O
.	.	O	O

To	TO	O	O
facilitate	VB	O	O
the	DT	O	O
study	NN	O	O
of	IN	O	O
this	DT	O	O
enzyme	NN	O	O
,	,	O	O
the	DT	O	O
purification	NN	O	O
and	CC	O	O
characterization	NN	O	O
of	IN	O	O
the	DT	O	O
recombinant	JJ	O	O
human	JJ	O	O
PAOh1/SMO	NNP	O	O
polyamine	NN	O	O
oxidase	NN	O	O
are	VBP	O	O
reported	VBN	O	O
.	.	O	O

Purified	NNP	O	O
PAOh1/SMO	NNP	O	O
oxidizes	VBZ	O	O
both	DT	O	O
spermine	NN	O	B-SUBSTRATE
(	(	O	O
K	NNP	O	O
(	(	O	O
m	NN	O	O
)	)	O	O
=1.6	NN	O	O
microM	NN	O	O
)	)	O	O
and	CC	O	O
N	NNP	O	B-SUBSTRATE
(	(	O	O
1	CD	O	O
)	)	O	O
-acetylspermine	NN	O	O
(	(	O	O
K	NNP	O	O
(	(	O	O
m	NN	O	O
)	)	O	O
=51	NN	O	O
microM	NN	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
does	VBZ	O	O
not	RB	O	O
oxidize	VB	O	O
spermidine	NN	O	O
.	.	O	O

The	DT	O	O
purified	JJ	O	O
human	JJ	O	O
enzyme	NN	O	O
also	RB	O	O
does	VBZ	O	O
not	RB	O	O
oxidize	VB	O	O
eight	CD	O	O
representative	JJ	O	O
antitumor	NN	O	O
polyamine	NN	O	O
analogues	NNS	O	O
;	:	O	O
however	RB	O	O
,	,	O	O
specific	JJ	O	O
oligamine	NN	O	O
analogues	NNS	O	O
were	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
potent	JJ	O	O
inhibitors	NNS	O	O
of	IN	O	O
the	DT	O	O
oxidation	NN	O	O
of	IN	O	O
spermine	NN	O	B-SUBSTRATE
by	IN	O	O
PAOh1/SMO	NNP	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
of	IN	O	O
these	DT	O	O
studies	NNS	O	O
are	VBP	O	O
consistent	JJ	O	O
with	IN	O	O
the	DT	O	O
hypothesis	NN	O	O
that	WDT	O	O
PAOh1/SMO	NNP	O	O
represents	VBZ	O	O
a	DT	O	O
new	JJ	O	O
addition	NN	O	O
to	TO	O	O
the	DT	O	O
polyamine	NN	O	O
metabolic	JJ	O	O
pathway	NN	O	O
that	WDT	O	O
may	MD	O	O
represent	VB	O	O
a	DT	O	O
new	JJ	O	O
target	NN	O	O
for	IN	O	O
antineoplastic	JJ	O	O
drug	NN	O	O
development	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Ames	NNS	O	O
dwarf	JJ	O	O
mice	NN	O	O
(	(	O	O
df/df	NN	O	O
)	)	O	O
are	VBP	O	O
deficient	JJ	O	O
in	IN	O	O
growth	NN	O	O
hormone	NN	O	O
,	,	O	O
prolactin	NN	O	O
,	,	O	O
and	CC	O	O
thyroid-stimulating	JJ	O	O
hormone	NN	O	O
and	CC	O	O
live	VBP	O	O
significantly	RB	O	O
longer	JJR	O	O
than	IN	O	O
their	PRP$	O	O
normal	JJ	O	O
siblings	NNS	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
current	JJ	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
found	VBD	O	O
that	IN	O	O
the	DT	O	O
hormone	NN	O	O
deficiencies	NNS	O	O
affect	VBP	O	O
methionine	JJ	O	O
metabolism	NN	O	O
.	.	O	O

We	PRP	O	O
previously	RB	O	O
reported	VBD	O	O
that	IN	O	O
the	DT	O	O
dwarf	JJ	O	O
mice	NN	O	O
exhibit	NN	O	O
enzyme	JJ	O	O
activities	NNS	O	O
and	CC	O	O
levels	NNS	O	O
that	IN	O	O
combat	NN	O	O
oxidative	JJ	O	O
stress	NN	O	O
more	RBR	O	O
efficiently	RB	O	O
than	IN	O	O
those	DT	O	O
of	IN	O	O
normal	JJ	O	O
mice	NN	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
methionine	NN	O	O
or	CC	O	O
metabolites	NNS	O	O
of	IN	O	O
methionine	NN	O	O
are	VBP	O	O
involved	VBN	O	O
in	IN	O	O
antioxidative	JJ	O	O
processes	NNS	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
we	PRP	O	O
performed	VBD	O	O
an	DT	O	O
experiment	NN	O	O
that	WDT	O	O
compared	VBN	O	O
various	JJ	O	O
parameters	NNS	O	O
of	IN	O	O
methionine	JJ	O	O
metabolism	NN	O	O
between	IN	O	O
18-month	JJ	O	O
old	JJ	O	O
male	NN	O	O
dwarf	NN	O	O
(	(	O	O
N=6	NNP	O	O
)	)	O	O
and	CC	O	O
wild	JJ	O	O
type	NN	O	O
(	(	O	O
N=5	NNP	O	O
)	)	O	O
mice	NN	O	O
.	.	O	O

The	DT	O	O
specific	JJ	O	O
activity	NN	O	O
of	IN	O	O
liver	NN	O	O
methionine	NN	O	O
adenosyltransferase	NN	O	O
(	(	O	O
MAT	NNP	O	O
)	)	O	O
was	VBD	O	O
significantly	RB	O	O
elevated	VBN	O	O
(	(	O	O
205	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0.0001	CD	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
dwarf	NN	O	O
mice	NN	O	O
,	,	O	O
as	IN	O	O
were	VBD	O	O
cystathionine	JJ	O	O
synthase	NN	O	O
(	(	O	O
50	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
,	,	O	O
cystathionase	NN	O	O
(	(	O	O
83	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
glycine	VB	O	O
N-methyltransferase	NNP	O	O
(	(	O	O
GNMT	NNP	O	O
,	,	O	O
91	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
activities	NNS	O	O
.	.	O	O

Even	RB	O	O
though	IN	O	O
the	DT	O	O
activities	NNS	O	O
of	IN	O	O
MAT	NNP	O	B-enzyme
and	CC	O	O
GNMT	NNP	O	B-enzyme
were	VBD	O	O
elevated	VBN	O	O
,	,	O	O
the	DT	O	O
concentration	NN	O	O
of	IN	O	O
liver	JJ	O	O
S-adenosylmethionine	NNP	O	B-SUBSTRATE
was	VBD	O	O
decreased	VBN	O	O
(	(	O	O
24	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
and	CC	O	O
S-adenosylhomocysteine	NNP	O	B-PRODUCT-OF
increased	VBD	O	O
(	(	O	O
113	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0.001	CD	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
dwarf	NN	O	O
mice	NN	O	O
.	.	O	O

These	DT	O	O
data	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
dwarf	NN	O	O
mice	NN	O	O
,	,	O	O
compared	VBN	O	O
to	TO	O	O
wild	VB	O	O
type	JJ	O	O
mice	NN	O	O
,	,	O	O
have	VBP	O	O
a	DT	O	O
markedly	RB	O	O
different	JJ	O	O
metabolism	NN	O	O
of	IN	O	O
methionine	NN	O	O
.	.	O	O

Altered	NNP	O	O
methionine	NN	O	O
metabolism	NN	O	O
may	MD	O	O
partially	RB	O	O
explain	VB	O	O
earlier	JJR	O	O
reports	NNS	O	O
indicating	VBG	O	O
less	RBR	O	O
oxidative	JJ	O	O
damage	NN	O	O
to	TO	O	O
proteins	NNS	O	O
in	IN	O	O
dwarf	JJ	O	O
mice	NN	O	O
.	.	O	O

Taken	VBN	O	O
together	RB	O	O
,	,	O	O
the	DT	O	O
data	NN	O	O
suggest	NN	O	O
that	IN	O	O
methionine	JJ	O	O
metabolism	NN	O	O
may	MD	O	O
play	VB	O	O
a	DT	O	O
role	NN	O	O
in	IN	O	O
oxidative	JJ	O	O
defense	NN	O	O
in	IN	O	O
the	DT	O	O
dwarf	NN	O	O
mouse	NN	O	O
and	CC	O	O
should	MD	O	O
be	VB	O	O
studied	VBN	O	O
as	IN	O	O
a	DT	O	O
potential	JJ	O	O
mechanism	NN	O	O
of	IN	O	O
extended	JJ	O	O
lifespan	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Kynurenic	NNP	O	O
acid	NN	O	O
(	(	O	O
KA	NNP	O	O
)	)	O	O
is	VBZ	O	O
an	DT	O	O
endogenous	JJ	O	O
glutamate	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
at	IN	O	O
the	DT	O	O
level	NN	O	O
of	IN	O	O
the	DT	O	O
different	JJ	O	O
ionotropic	NN	O	O
glutamate	NN	O	O
receptors	NNS	O	O
.	.	O	O

One	CD	O	O
of	IN	O	O
the	DT	O	O
enzymes	NNS	O	O
responsible	JJ	O	O
for	IN	O	O
the	DT	O	O
production	NN	O	O
of	IN	O	O
KA	NNP	O	B-PRODUCT-OF
,	,	O	O
kynurenine	JJ	O	B-enzyme
aminotransferase	NN	O	I-enzyme
I	PRP	O	O
(	(	O	O
KATI	NNP	O	B-enzyme
)	)	O	O
,	,	O	O
also	RB	O	O
catalyses	VBZ	O	O
the	DT	O	O
reversible	JJ	O	O
transamination	NN	O	O
of	IN	O	O
glutamine	NN	O	B-SUBSTRATE
to	TO	O	O
oxoglutaramic	VB	O	B-PRODUCT-OF
acid	NN	O	I-PRODUCT-OF
(	(	O	O
GTK	NNP	O	B-enzyme
,	,	O	O
EC	NNP	O	B-enzyme
2.6.1.15	CD	O	I-enzyme
)	)	O	O
.	.	O	O

The	DT	O	O
enzyme	NN	O	O
exists	VBZ	O	O
in	IN	O	O
a	DT	O	O
cytosolic	NN	O	O
and	CC	O	O
in	IN	O	O
a	DT	O	O
mitochondrial	JJ	O	O
form	NN	O	O
because	IN	O	O
of	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
two	CD	O	O
different	JJ	O	O
KATI	NNP	O	O
mRNAs	NN	O	O
coding	VBG	O	O
for	IN	O	O
a	DT	O	O
protein	NN	O	O
respectively	RB	O	O
with	IN	O	O
and	CC	O	O
without	IN	O	O
leader	NN	O	O
sequence	NN	O	O
targeting	VBG	O	O
the	DT	O	O
protein	NN	O	O
into	IN	O	O
mitochondria	NNS	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
cloned	VBN	O	O
from	IN	O	O
a	DT	O	O
phage	NN	O	O
library	NN	O	O
of	IN	O	O
rat	NN	O	O
kidney	NN	O	O
cDNA	VB	O	O
four	CD	O	O
new	JJ	O	O
KATI	NNP	O	O
cDNAs	NN	O	O
containing	VBG	O	O
different	JJ	O	O
5	CD	O	O
'	POS	O	O
untranslated	JJ	O	O
regions	NNS	O	O
(	(	O	O
UTRs	NNP	O	O
)	)	O	O
.	.	O	O

One	CD	O	O
of	IN	O	O
the	DT	O	O
transcripts	NNS	O	O
(	(	O	O
+14KATI	NNP	O	O
cDNA	NN	O	O
)	)	O	O
contains	VBZ	O	O
an	DT	O	O
alternative	JJ	O	O
site	NN	O	O
of	IN	O	O
initiation	NN	O	O
of	IN	O	O
translation	NN	O	O
.	.	O	O

The	DT	O	O
tissue	NN	O	O
distribution	NN	O	O
of	IN	O	O
the	DT	O	O
different	JJ	O	O
transcripts	NNS	O	O
was	VBD	O	O
studied	VBN	O	O
by	IN	O	O
RT-PCR	NNP	O	O
.	.	O	O

The	DT	O	O
study	NN	O	O
demonstrated	VBD	O	O
that	IN	O	O
several	JJ	O	O
KATI	NNP	O	O
mRNAs	NN	O	O
are	VBP	O	O
constitutively	RB	O	O
expressed	VBN	O	O
in	IN	O	O
ubiquitous	JJ	O	O
manner	NN	O	O
,	,	O	O
while	IN	O	O
+14KATI	JJ	O	O
mRNA	NN	O	O
is	VBZ	O	O
present	JJ	O	O
only	RB	O	O
in	IN	O	O
kidney	NN	O	O
.	.	O	O

The	DT	O	O
translational	JJ	O	O
efficiency	NN	O	O
of	IN	O	O
the	DT	O	O
different	JJ	O	O
transcripts	NNS	O	O
was	VBD	O	O
studied	VBN	O	O
in	IN	O	O
vitro	NN	O	O
and	CC	O	O
enzymatic	JJ	O	O
activities	NNS	O	O
were	VBD	O	O
measured	VBN	O	O
in	IN	O	O
transiently	RB	O	O
transfected	VBN	O	O
Cos-1	NNP	O	O
cells	NNS	O	O
.	.	O	O

Each	DT	O	O
KATI	NNP	O	O
mRNA	NN	O	O
exhibits	VBZ	O	O
a	DT	O	O
different	JJ	O	O
in	IN	O	O
vitro	JJ	O	O
translational	JJ	O	O
efficiency	NN	O	O
,	,	O	O
which	WDT	O	O
corresponds	VBZ	O	O
to	TO	O	O
different	JJ	O	O
levels	NNS	O	O
of	IN	O	O
KAT	NNP	O	O
enzymatic	JJ	O	O
activity	NN	O	O
in	IN	O	O
transfected	JJ	O	O
cells	NNS	O	O
.	.	O	O

Both	DT	O	O
findings	NNS	O	O
correlate	NN	O	O
with	IN	O	O
the	DT	O	O
predicted	JJ	O	O
accessibility	NN	O	O
of	IN	O	O
the	DT	O	O
ribosomal	JJ	O	O
binding	NN	O	O
sites	NNS	O	O
of	IN	O	O
the	DT	O	O
different	JJ	O	O
mRNAs	NN	O	O
.	.	O	O

The	DT	O	O
structure	NN	O	O
of	IN	O	O
the	DT	O	O
rat	NN	O	O
KATI/GTK	NNP	O	O
gene	NN	O	O
was	VBD	O	O
also	RB	O	O
studied	VBN	O	O
.	.	O	O

The	DT	O	O
expression	NN	O	O
of	IN	O	O
several	JJ	O	O
KATI	NNP	O	O
mRNAs	NN	O	O
with	IN	O	O
different	JJ	O	O
5'UTRs	CD	O	O
represents	VBZ	O	O
an	DT	O	O
interesting	JJ	O	O
example	NN	O	O
of	IN	O	O
transcriptional/translational	JJ	O	O
control	NN	O	O
on	IN	O	O
the	DT	O	O
expression	NN	O	O
of	IN	O	O
pyridoxal	NN	O	O
phosphate	NN	O	O
(	(	O	O
PLP	NNP	O	O
)	)	O	O
-dependent	NN	O	O
aminotransferases	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

We	PRP	O	O
examined	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
inhibition	NN	O	O
of	IN	O	O
Na+/H+	NNP	O	O
exchange	NN	O	O
(	(	O	O
NHE	NNP	O	O
)	)	O	O
on	IN	O	O
duodenal	JJ	O	O
bicarbonate	NN	O	O
secretion	NN	O	O
(	(	O	O
DBS	NNP	O	O
)	)	O	O
in	IN	O	O
rats	NNS	O	O
to	TO	O	O
further	JJ	O	O
understand	NN	O	O
DBS	NNP	O	O
regulation	NN	O	O
.	.	O	O

DBS	NNP	O	O
was	VBD	O	O
measured	VBN	O	O
by	IN	O	O
using	VBG	O	O
the	DT	O	O
pH-stat	JJ	O	O
method	NN	O	O
and	CC	O	O
by	IN	O	O
using	VBG	O	O
CO2-sensitive	JJ	O	O
electrodes	NNS	O	O
.	.	O	O

5-	JJ	O	O
(	(	O	O
N	NNP	O	O
,	,	O	O
N-dimethyl	NNP	O	O
)	)	O	O
-amiloride	NNP	O	O
(	(	O	O
50	CD	O	O
microM	NN	O	O
;	:	O	O
DMA	NNP	O	O
)	)	O	O
,	,	O	O
a	DT	O	O
concentration	NN	O	O
that	WDT	O	O
selectively	RB	O	O
inhibits	VBZ	O	O
the	DT	O	O
NHE	NNP	O	O
isoforms	NNS	O	O
NHE1	NNP	O	O
and	CC	O	O
NHE2	NNP	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
NHE3	NNP	O	O
,	,	O	O
did	VBD	O	O
not	RB	O	O
affect	VB	O	O
DBS	NNP	O	O
.	.	O	O

Nevertheless	RB	O	O
,	,	O	O
3	CD	O	O
mM	NN	O	O
DMA	NNP	O	O
,	,	O	O
a	DT	O	O
higher	JJR	O	O
concentration	NN	O	O
that	IN	O	O
inhibits	VBZ	O	O
NHE1	NNP	O	O
,	,	O	O
NHE2	NNP	O	O
,	,	O	O
and	CC	O	O
NHE3	NNP	O	O
,	,	O	O
significantly	RB	O	O
increased	VBD	O	O
DBS	NNP	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
S1611	NNP	O	O
and	CC	O	O
S3226	NNP	O	O
,	,	O	O
both	DT	O	O
specific	JJ	O	O
inhibitors	NNS	O	O
of	IN	O	O
NHE3	NNP	O	O
only	RB	O	O
,	,	O	O
or	CC	O	O
perfusion	NN	O	O
with	IN	O	O
Na+-free	JJ	O	O
solutions	NNS	O	O
,	,	O	O
dose	RB	O	O
dependently	RB	O	O
increased	VBN	O	O
DBS	NNP	O	O
,	,	O	O
as	IN	O	O
measured	VBN	O	O
by	IN	O	O
pH-stat	JJ	O	O
and	CC	O	O
CO2-sensitive	JJ	O	O
electrode	NN	O	O
,	,	O	O
without	IN	O	O
affecting	VBG	O	O
intracellular	JJ	O	O
pH	NN	O	O
.	.	O	O

Coperfusion	NN	O	O
with	IN	O	O
0.1	CD	O	O
microM	NNS	O	O
indomethacin	NN	O	O
,	,	O	O
0.5	CD	O	O
mM	NN	O	O
DIDS	NNP	O	O
,	,	O	O
or	CC	O	O
1	CD	O	O
mM	NNS	O	O
methazolamide	RB	O	O
did	VBD	O	O
not	RB	O	O
affect	VB	O	O
S3226-induced	NNP	O	O
DBS	NNP	O	O
.	.	O	O

Nevertheless	RB	O	O
,	,	O	O
coperfusion	NN	O	O
with	IN	O	O
0.1	CD	O	O
and	CC	O	O
0.3	CD	O	O
mM	NNS	O	O
5-nitro-2-	JJ	O	O
(	(	O	O
3-phenylpropylamino	JJ	O	O
)	)	O	O
benzoic	NN	O	O
acid	NN	O	O
,	,	O	O
which	WDT	O	O
inhibits	VBZ	O	O
the	DT	O	O
cystic	JJ	O	O
fibrosis	NN	O	O
transmembrane	NN	O	O
conductor	NN	O	O
regulator	NN	O	O
(	(	O	O
CFTR	NNP	O	O
)	)	O	O
,	,	O	O
dose	RB	O	O
dependently	RB	O	O
inhibited	VBN	O	O
S3226-induced	NNP	O	O
DBS	NNP	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
only	RB	O	O
specific	JJ	O	O
apical	JJ	O	O
NHE3	NNP	O	O
inhibition	NN	O	O
increased	VBD	O	O
DBS	NNP	O	O
,	,	O	O
whereas	JJ	O	O
prostaglandin	NN	O	O
synthesis	NN	O	O
,	,	O	O
Na+-HCO3-	NNP	O	O
cotransporter	NN	O	O
activation	NN	O	O
,	,	O	O
or	CC	O	O
intracellular	JJ	O	O
HCO3-	JJ	O	O
formation	NN	O	O
by	IN	O	O
carbonic	JJ	O	B-enzyme
anhydrase	NN	O	I-enzyme
was	VBD	O	O
not	RB	O	O
involved	VBN	O	O
.	.	O	O

Because	IN	O	O
NHE3	NNP	O	O
inhibition-increased	JJ	O	O
DBS	NNP	O	O
was	VBD	O	O
inhibited	VBN	O	O
by	IN	O	O
an	DT	O	O
anion	NN	O	O
channel	NN	O	O
inhibitor	NN	O	O
and	CC	O	O
because	RB	O	O
reciprocal	JJ	O	O
CFTR	NNP	O	O
regulation	NN	O	O
has	VBZ	O	O
been	VBN	O	O
previously	RB	O	O
shown	VBN	O	O
between	IN	O	O
NHE3	NNP	O	O
and	CC	O	O
apical	JJ	O	O
membrane	NN	O	O
anion	NN	O	O
transporters	NNS	O	O
,	,	O	O
we	PRP	O	O
speculate	VBP	O	O
that	IN	O	O
NHE3	NNP	O	O
inhibition	NN	O	O
increased	VBD	O	O
DBS	NNP	O	O
by	IN	O	O
altering	VBG	O	O
anion	NN	O	O
transporter	NN	O	O
function	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Cells	NNS	O	O
respond	NN	O	O
to	TO	O	O
physiological	JJ	O	O
stress	NN	O	O
by	IN	O	O
phosphorylating	VBG	O	O
the	DT	O	O
alpha	JJ	O	O
subunit	NN	O	O
of	IN	O	O
the	DT	O	O
translation	NN	O	O
initiation	NN	O	O
factor	NN	O	O
eIF2	NN	O	O
.	.	O	O

This	DT	O	O
adaptive	JJ	O	O
response	NN	O	O
inhibits	NNS	O	O
protein	VBP	O	O
synthesis	NN	O	O
and	CC	O	O
up-regulates	JJ	O	O
genes	NNS	O	O
essential	JJ	O	O
for	IN	O	O
cell	NN	O	O
survival	NN	O	O
.	.	O	O

Cat-1	NNP	O	B-enzyme
,	,	O	O
the	DT	O	O
transporter	NN	O	O
for	IN	O	O
the	DT	O	O
essential	JJ	O	O
amino	NN	O	B-SUBSTRATE
acids	NNS	O	I-SUBSTRATE
,	,	O	O
arginine	NN	O	B-SUBSTRATE
and	CC	O	O
lysine	NN	O	B-SUBSTRATE
,	,	O	O
is	VBZ	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
up-regulated	JJ	O	O
genes	NNS	O	O
.	.	O	O

We	PRP	O	O
previously	RB	O	O
showed	VBD	O	O
that	IN	O	O
stress	NN	O	O
increases	NNS	O	O
cat-1	JJ	O	O
expression	NN	O	O
by	IN	O	O
coordinated	JJ	O	O
stabilization	NN	O	O
of	IN	O	O
the	DT	O	O
mRNA	NN	O	O
and	CC	O	O
increased	VBD	O	O
mRNA	NN	O	O
translation	NN	O	O
.	.	O	O

This	DT	O	O
induction	NN	O	O
is	VBZ	O	O
triggered	VBN	O	O
by	IN	O	O
amino	NN	O	O
acid	NN	O	O
depletion	NN	O	O
and	CC	O	O
the	DT	O	O
unfolded	JJ	O	O
protein	NN	O	O
response	NN	O	O
(	(	O	O
UPR	NNP	O	O
)	)	O	O
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
caused	VBN	O	O
by	IN	O	O
unfolded	JJ	O	O
proteins	NNS	O	O
in	IN	O	O
the	DT	O	O
endoplasmic	JJ	O	O
reticulum	NN	O	O
.	.	O	O

We	PRP	O	O
show	VBP	O	O
here	RB	O	O
that	IN	O	O
cat-1	JJ	O	O
gene	NN	O	O
transcription	NN	O	O
is	VBZ	O	O
also	RB	O	O
increased	VBN	O	O
by	IN	O	O
cellular	JJ	O	O
stress	NN	O	O
.	.	O	O

Our	PRP$	O	O
studies	NNS	O	O
demonstrate	VBP	O	O
that	IN	O	O
the	DT	O	O
cat-1	JJ	O	O
gene	NN	O	O
promoter/regulatory	JJ	O	O
region	NN	O	O
is	VBZ	O	O
TATA-less	JJ	O	O
and	CC	O	O
is	VBZ	O	O
located	VBN	O	O
in	IN	O	O
a	DT	O	O
region	NN	O	O
that	WDT	O	O
includes	VBZ	O	O
94	CD	O	O
bases	NNS	O	O
of	IN	O	O
the	DT	O	O
first	JJ	O	O
exon	NN	O	O
.	.	O	O

Transcription	NN	O	O
from	IN	O	O
this	DT	O	O
promoter	NN	O	O
is	VBZ	O	O
stimulated	VBN	O	O
8-fold	JJ	O	O
by	IN	O	O
cellular	JJ	O	O
stress	NN	O	O
.	.	O	O

An	DT	O	O
amino	NN	O	O
acid	NN	O	O
response	NN	O	O
element	NN	O	O
within	IN	O	O
the	DT	O	O
first	JJ	O	O
exon	NN	O	O
is	VBZ	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
required	VBN	O	O
for	IN	O	O
the	DT	O	O
response	NN	O	O
to	TO	O	O
amino	VB	O	O
acid	JJ	O	O
depletion	NN	O	O
but	CC	O	O
not	RB	O	O
to	TO	O	O
the	DT	O	O
UPR	NNP	O	O
.	.	O	O

The	DT	O	O
stimulation	NN	O	O
of	IN	O	O
transcription	NN	O	O
by	IN	O	O
amino	NN	O	O
acid	NN	O	O
depletion	NN	O	O
requires	VBZ	O	O
activation	NN	O	O
of	IN	O	O
GCN2	NNP	O	O
kinase	NNP	O	O
,	,	O	O
which	WDT	O	O
phosphorylates	VBZ	O	O
eIF2alpha	NN	O	O
.	.	O	O

This	DT	O	O
phosphorylation	NN	O	O
also	RB	O	O
induces	VBZ	O	O
translation	NN	O	O
of	IN	O	O
the	DT	O	O
cat-1	JJ	O	O
mRNA	NN	O	O
,	,	O	O
demonstrating	VBG	O	O
that	IN	O	O
stress-induced	JJ	O	O
transcriptional	JJ	O	O
and	CC	O	O
translational	JJ	O	O
control	NN	O	O
of	IN	O	O
cat-1	NN	O	O
are	VBP	O	O
downstream	JJ	O	O
targets	NNS	O	O
of	IN	O	O
a	DT	O	O
signaling	VBG	O	O
pathway	NN	O	O
initiating	VBG	O	O
with	IN	O	O
eIF2alpha	JJ	O	O
phosphorylation	NN	O	O
.	.	O	O

Our	PRP$	O	O
studies	NNS	O	O
show	VBP	O	O
that	IN	O	O
the	DT	O	O
increase	NN	O	O
in	IN	O	O
cat-1	JJ	O	O
gene	NN	O	O
expression	NN	O	O
by	IN	O	O
cellular	JJ	O	O
stress	NN	O	O
involves	VBZ	O	O
at	IN	O	O
least	JJS	O	O
three	CD	O	O
types	NNS	O	O
of	IN	O	O
coordinate	NN	O	O
regulation	NN	O	O
:	:	O	O
regulation	NN	O	O
of	IN	O	O
transcription	NN	O	O
,	,	O	O
regulation	NN	O	O
of	IN	O	O
mRNA	NN	O	O
stability	NN	O	O
,	,	O	O
and	CC	O	O
regulation	NN	O	O
of	IN	O	O
mRNA	JJ	O	O
translation	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

CPT	NN	O	B-enzyme
I	PRP	O	I-enzyme
(	(	O	O
carnitine	JJ	O	B-enzyme
palmitoyltransferase	NN	O	I-enzyme
I	PRP	O	O
)	)	O	O
catalyses	VBZ	O	O
the	DT	O	O
conversion	NN	O	O
of	IN	O	O
palmitoyl-CoA	NN	O	B-SUBSTRATE
into	IN	O	O
palmitoylcarnitine	NN	O	B-PRODUCT-OF
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
L-carnitine	NNP	O	O
,	,	O	O
facilitating	VBG	O	O
the	DT	O	O
entry	NN	O	O
of	IN	O	O
fatty	JJ	O	O
acids	NNS	O	O
into	IN	O	O
mitochondria	NN	O	O
.	.	O	O

We	PRP	O	O
propose	VBP	O	O
a	DT	O	O
3-D	JJ	O	O
(	(	O	O
three-dimensional	JJ	O	O
)	)	O	O
structural	JJ	O	O
model	NN	O	O
for	IN	O	O
L-CPT	NNP	O	O
I	PRP	O	O
(	(	O	O
liver	IN	O	O
CPT	NNP	O	O
I	PRP	O	O
)	)	O	O
,	,	O	O
based	VBN	O	O
on	IN	O	O
the	DT	O	O
similarity	NN	O	O
of	IN	O	O
this	DT	O	O
enzyme	NN	O	O
to	TO	O	O
the	DT	O	O
recently	RB	O	O
crystallized	VBN	O	O
mouse	NN	O	O
carnitine	NN	O	O
acetyltransferase	NN	O	O
.	.	O	O

The	DT	O	O
model	NN	O	O
includes	VBZ	O	O
607	CD	O	O
of	IN	O	O
the	DT	O	O
773	CD	O	O
amino	JJ	O	O
acids	NNS	O	O
of	IN	O	O
L-CPT	NNP	O	O
I	PRP	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
positions	NNS	O	O
of	IN	O	O
carnitine	NN	O	O
,	,	O	O
CoA	NNP	O	O
and	CC	O	O
the	DT	O	O
palmitoyl	NN	O	O
group	NN	O	O
were	VBD	O	O
assigned	VBN	O	O
by	IN	O	O
superposition	NN	O	O
and	CC	O	O
docking	VBG	O	O
analysis	NN	O	O
.	.	O	O

Functional	JJ	O	O
analysis	NN	O	O
of	IN	O	O
this	DT	O	O
3-D	JJ	O	O
model	NN	O	O
included	VBD	O	O
the	DT	O	O
mutagenesis	NN	O	O
of	IN	O	O
several	JJ	O	O
amino	JJ	O	O
acids	NNS	O	O
in	IN	O	O
order	NN	O	O
to	TO	O	O
identify	VB	O	O
putative	JJ	O	O
catalytic	JJ	O	O
residues	NNS	O	O
.	.	O	O

Mutants	NNS	O	O
D477A	NNP	O	O
,	,	O	O
D567A	NNP	O	O
and	CC	O	O
E590D	NNP	O	O
showed	VBD	O	O
reduced	JJ	O	O
L-CPT	NNP	O	O
I	PRP	O	O
activity	NN	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
individual	JJ	O	O
mutation	NN	O	O
of	IN	O	O
amino	JJ	O	O
acids	NNS	O	O
forming	VBG	O	O
the	DT	O	O
conserved	VBN	O	O
Ser685-Thr686-Ser687	NNP	O	O
motif	NN	O	O
abolished	VBD	O	O
enzyme	JJ	O	O
activity	NN	O	O
in	IN	O	O
mutants	NNS	O	O
T686A	NNP	O	O
and	CC	O	O
S687A	NNP	O	O
and	CC	O	O
altered	VBN	O	O
K	NNP	O	O
(	(	O	O
m	NN	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
catalytic	JJ	O	O
efficiency	NN	O	O
for	IN	O	O
carnitine	NN	O	O
in	IN	O	O
mutant	JJ	O	O
S685A	NNP	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
the	DT	O	O
catalytic	JJ	O	O
residues	NNS	O	O
are	VBP	O	O
His473	NNP	O	O
and	CC	O	O
Asp477	NNP	O	O
,	,	O	O
while	IN	O	O
Ser687	NNP	O	O
probably	RB	O	O
stabilizes	VBZ	O	O
the	DT	O	O
transition	NN	O	O
state	NN	O	O
.	.	O	O

Several	JJ	O	O
conserved	VBD	O	O
lysines	NNS	O	O
,	,	O	O
i.e	NN	O	O
.	.	O	O

Lys455	NNP	O	O
,	,	O	O
Lys505	NNP	O	O
,	,	O	O
Lys560	NNP	O	O
and	CC	O	O
Lys561	NNP	O	O
,	,	O	O
were	VBD	O	O
also	RB	O	O
mutated	VBN	O	O
.	.	O	O

Only	RB	O	O
mutants	NNS	O	O
K455A	NNP	O	O
and	CC	O	O
K560A	NNP	O	O
showed	VBD	O	O
decreases	NNS	O	O
in	IN	O	O
activity	NN	O	O
of	IN	O	O
50	CD	O	O
%	NN	O	O
.	.	O	O

The	DT	O	O
model	NN	O	O
rationalizes	VBZ	O	O
the	DT	O	O
finding	NN	O	O
of	IN	O	O
nine	CD	O	O
natural	JJ	O	O
mutations	NNS	O	O
in	IN	O	O
patients	NNS	O	O
with	IN	O	O
hereditary	JJ	O	O
L-CPT	NNP	O	O
I	PRP	O	O
deficiencies	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Phosphatidylserine	NNP	O	B-PRODUCT-OF
(	(	O	O
PtdSer	NNP	O	O
)	)	O	O
is	VBZ	O	O
made	VBN	O	O
in	IN	O	O
mammalian	JJ	O	O
cells	NNS	O	O
by	IN	O	O
two	CD	O	O
PtdSer	NNP	O	B-enzyme
synthases	NNS	O	I-enzyme
,	,	O	O
PSS1	NNP	O	B-enzyme
and	CC	O	O
PSS2	NNP	O	B-enzyme
.	.	O	O

In	IN	O	O
the	DT	O	O
plasma	NN	O	O
membrane	NN	O	O
PtdSer	NNP	O	O
is	VBZ	O	O
normally	RB	O	O
localized	VBN	O	O
on	IN	O	O
the	DT	O	O
inner	JJ	O	O
leaflet	NN	O	O
but	CC	O	O
undergoes	JJ	O	O
transbilayer	JJ	O	O
movement	NN	O	O
during	IN	O	O
apoptosis	NN	O	O
and	CC	O	O
becomes	NNS	O	O
exposed	VBN	O	O
on	IN	O	O
the	DT	O	O
cell	NN	O	O
surface	NN	O	O
.	.	O	O

We	PRP	O	O
induced	VBD	O	O
apoptosis	NN	O	O
with	IN	O	O
staurosporine	NN	O	O
in	IN	O	O
four	CD	O	O
Chinese	JJ	O	O
hamster	NN	O	O
ovary	JJ	O	O
(	(	O	O
CHO	NNP	O	O
)	)	O	O
cell	NN	O	O
lines	NNS	O	O
that	WDT	O	O
are	VBP	O	O
deficient	JJ	O	O
in	IN	O	O
PSS1	NNP	O	O
and/or	NN	O	O
PSS2	NNP	O	O
to	TO	O	O
determine	VB	O	O
if	IN	O	O
PtdSer	NNP	O	O
generated	VBN	O	O
by	IN	O	O
either	DT	O	O
of	IN	O	O
these	DT	O	O
enzymes	NNS	O	O
is	VBZ	O	O
required	VBN	O	O
for	IN	O	O
externalization	NN	O	O
on	IN	O	O
the	DT	O	O
cell	NN	O	O
surface	NN	O	O
during	IN	O	O
apoptosis	NN	O	O
.	.	O	O

The	DT	O	O
onset	NN	O	O
of	IN	O	O
apoptosis	NN	O	O
was	VBD	O	O
confirmed	VBN	O	O
by	IN	O	O
the	DT	O	O
appearance	NN	O	O
of	IN	O	O
morphological	JJ	O	O
changes	NNS	O	O
and	CC	O	O
DNA	NNP	O	O
fragmentation	NN	O	O
while	IN	O	O
the	DT	O	O
plasma	NN	O	O
membrane	NN	O	O
remained	VBD	O	O
largely	RB	O	O
intact	JJ	O	O
.	.	O	O

In	IN	O	O
all	DT	O	O
cell	NN	O	O
lines	NNS	O	O
,	,	O	O
regardless	RB	O	O
of	IN	O	O
their	PRP$	O	O
content	NN	O	O
of	IN	O	O
PSS1	NNP	O	O
and/or	NN	O	O
PSS2	NNP	O	O
,	,	O	O
apoptosis	NN	O	O
occurred	VBD	O	O
to	TO	O	O
approximately	RB	O	O
the	DT	O	O
same	JJ	O	O
extent	NN	O	O
,	,	O	O
and	CC	O	O
within	IN	O	O
approximately	RB	O	O
the	DT	O	O
same	JJ	O	O
time	NN	O	O
frame	NN	O	O
,	,	O	O
as	IN	O	O
in	IN	O	O
parental	JJ	O	O
CHO-K1	NNP	O	O
cells	NNS	O	O
.	.	O	O

The	DT	O	O
exposure	NN	O	O
of	IN	O	O
PtdSer	NNP	O	O
on	IN	O	O
the	DT	O	O
cell	NN	O	O
surface	NN	O	O
was	VBD	O	O
assessed	VBN	O	O
by	IN	O	O
annexin	NN	O	O
V	NNP	O	O
labeling	NN	O	O
and	CC	O	O
flow	JJ	O	O
cytometry	NN	O	O
.	.	O	O

Cells	NNS	O	O
that	WDT	O	O
were	VBD	O	O
deficient	VBN	O	O
in	IN	O	O
either	DT	O	O
PSS1	NNP	O	O
or	CC	O	O
PSS2	NNP	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
cells	NNS	O	O
that	WDT	O	O
were	VBD	O	O
deficient	VBN	O	O
in	IN	O	O
both	DT	O	O
PSS1	NNP	O	O
and	CC	O	O
PSS2	NNP	O	O
,	,	O	O
externalized	VBD	O	O
normal	JJ	O	O
amounts	NNS	O	O
of	IN	O	O
PtdSer	NNP	O	O
.	.	O	O

Our	PRP$	O	O
study	NN	O	O
demonstrates	VBZ	O	O
,	,	O	O
that	DT	O	O
reduction	NN	O	O
of	IN	O	O
in	IN	O	O
vitro	JJ	O	O
serine-exchange	JJ	O	O
activity	NN	O	O
,	,	O	O
even	RB	O	O
by	IN	O	O
97	CD	O	O
%	NN	O	O
,	,	O	O
does	VBZ	O	O
not	RB	O	O
restrict	VB	O	O
the	DT	O	O
externalization	NN	O	O
of	IN	O	O
PtdSer	NNP	O	O
during	IN	O	O
apoptosis	NN	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
a	DT	O	O
normal	JJ	O	O
level	NN	O	O
of	IN	O	O
expression	NN	O	O
of	IN	O	O
PSS1	NNP	O	B-enzyme
and/or	NN	O	O
PSS2	NNP	O	B-enzyme
is	VBZ	O	O
not	RB	O	O
required	VBN	O	O
for	IN	O	O
generating	VBG	O	O
the	DT	O	O
pool	NN	O	O
of	IN	O	O
PtdSer	NNP	O	B-PRODUCT-OF
externalized	VBD	O	O
during	IN	O	O
apoptosis	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Voltage-gated	JJ	O	B-enzyme
sodium	NN	O	I-enzyme
(	(	O	O
Na	NNP	O	B-SUBSTRATE
)	)	O	O
channels	NNS	O	O
are	VBP	O	O
a	DT	O	O
critical	JJ	O	O
component	NN	O	O
of	IN	O	O
electrically	RB	O	O
excitable	JJ	O	O
cells	NNS	O	O
.	.	O	O

Phenytoin	NNP	O	O
(	(	O	O
diphenylhydantoin	NN	O	O
,	,	O	O
DPH	NNP	O	O
)	)	O	O
is	VBZ	O	O
an	DT	O	O
established	JJ	O	O
sodium	NN	O	B-enzyme
channel	NN	O	I-enzyme
blocker	NN	O	O
and	CC	O	O
is	VBZ	O	O
a	DT	O	O
useful	JJ	O	O
anticonvulsant	NN	O	O
and	CC	O	O
class	NN	O	O
1b	CD	O	O
antiarrhythmic	JJ	O	O
,	,	O	O
and	CC	O	O
has	VBZ	O	O
been	VBN	O	O
effectively	RB	O	O
used	VBN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
neuropathic	JJ	O	O
pain	NN	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
have	VBP	O	O
synthesized	VBN	O	O
novel	JJ	O	O
alpha-hydroxyphenylamide	JJ	O	O
analogues	NNS	O	O
of	IN	O	O
diphenylhydantoin	NN	O	O
and	CC	O	O
examined	VBD	O	O
their	PRP$	O	O
ability	NN	O	O
to	TO	O	O
inhibit	VB	O	O
human	JJ	O	B-enzyme
Na	NNP	O	I-enzyme
(	(	O	I-enzyme
V	NNP	O	I-enzyme
)	)	O	I-enzyme
1.5	CD	O	I-enzyme
sodium	NN	O	B-enzyme
channels	NNS	O	I-enzyme
expressed	VBN	O	O
in	IN	O	O
Chinese	JJ	O	O
Hamster	NNP	O	O
Ovary	NNP	O	O
(	(	O	O
CHO-K1	NNP	O	O
)	)	O	O
cells	NNS	O	O
.	.	O	O

Phenyl	NNP	O	O
ring	VBG	O	O
substitutions	NNS	O	O
were	VBD	O	O
examined	VBN	O	O
including	VBG	O	O
para-methyl	JJ	O	O
,	,	O	O
para-fluoro	JJ	O	O
,	,	O	O
para-chloro	JJ	O	O
,	,	O	O
ortho-chloro	JJ	O	O
and	CC	O	O
meta-chloro	JJ	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
found	VBN	O	O
that	IN	O	O
phenyl	JJ	O	O
ring	VBG	O	O
substitutions	NNS	O	O
with	IN	O	O
electron	NN	O	O
withdrawing	VBG	O	O
properties	NNS	O	O
resulted	VBN	O	O
in	IN	O	O
compounds	NNS	O	O
with	IN	O	O
greater	JJR	O	O
activity	NN	O	O
.	.	O	O

In	IN	O	O
comparison	NN	O	O
to	TO	O	O
diphenylhydantoin	VB	O	O
,	,	O	O
the	DT	O	O
novel	JJ	O	O
chloro-substituted	JJ	O	O
alpha-hydroxyphenylamide	JJ	O	O
compounds	NNS	O	O
produced	VBD	O	O
as	RB	O	O
much	JJ	O	O
as	IN	O	O
a	DT	O	O
20-fold	JJ	O	O
greater	JJR	O	O
tonic	JJ	O	O
and	CC	O	O
frequency-dependent	JJ	O	O
blockade	NN	O	O
of	IN	O	O
Na	NNP	O	O
(	(	O	O
V	NNP	O	O
)	)	O	O
1.5	CD	O	O
channels	NNS	O	O
with	IN	O	O
an	DT	O	O
IC	NNP	O	O
(	(	O	O
50	CD	O	O
)	)	O	O
value	NN	O	O
of	IN	O	O
14.5	CD	O	O
microM	NN	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
the	DT	O	O
chloro-substitutions	NNS	O	O
have	VBP	O	O
position	NN	O	O
specific	JJ	O	O
state	NN	O	O
dependent	JJ	O	O
blocking	NN	O	O
properties	NNS	O	O
.	.	O	O

The	DT	O	O
ortho-	JJ	O	O
,	,	O	O
meta-	JJ	O	O
and	CC	O	O
para-chloro	JJ	O	O
substitutions	NNS	O	O
have	VBP	O	O
an	DT	O	O
8-	JJ	O	O
,	,	O	O
13-	JJ	O	O
and	CC	O	O
3-fold	JJ	O	O
increased	JJ	O	O
affinity	NN	O	O
for	IN	O	O
the	DT	O	O
inactivated	JJ	O	O
state	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Molecular	JJ	O	O
modeling	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
these	DT	O	O
differences	NNS	O	O
in	IN	O	O
affinity	NN	O	O
are	VBP	O	O
due	JJ	O	O
to	TO	O	O
a	DT	O	O
direct	JJ	O	O
interaction	NN	O	O
with	IN	O	O
the	DT	O	O
receptor	NN	O	O
.	.	O	O

Comparing	VBG	O	O
models	NNS	O	O
of	IN	O	O
diphenylhydantoin	NN	O	O
to	TO	O	O
the	DT	O	O
novel	JJ	O	O
alpha-hydroxyphenlyamide	JJ	O	O
compound	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
the	DT	O	O
increased	VBN	O	O
activity	NN	O	O
may	MD	O	O
be	VB	O	O
due	JJ	O	O
to	TO	O	O
an	DT	O	O
optimized	VBN	O	O
phenyl	NN	O	O
ring	VBG	O	O
position	NN	O	O
and	CC	O	O
increased	VBD	O	O
molecular	JJ	O	O
volume	NN	O	O
.	.	O	O

This	DT	O	O
information	NN	O	O
may	MD	O	O
be	VB	O	O
useful	JJ	O	O
in	IN	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
more	RBR	O	O
potent	JJ	O	O
sodium	NN	O	B-enzyme
channel	NN	O	I-enzyme
blockers	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Scavenger	NNP	O	O
receptor	NN	O	O
class	NN	O	O
B	NNP	O	O
type	NN	O	O
I	PRP	O	O
(	(	O	O
SR-BI	NNP	O	O
)	)	O	O
and	CC	O	O
ABCA1	NNP	O	O
are	VBP	O	O
structurally	RB	O	O
dissimilar	JJ	O	O
cell	NN	O	O
surface	NN	O	O
proteins	VBZ	O	O
that	IN	O	O
play	NN	O	O
key	JJ	O	O
roles	NNS	O	O
in	IN	O	O
HDL	NNP	O	O
metabolism	NN	O	O
.	.	O	O

SR-BI	NNP	O	B-enzyme
is	VBZ	O	O
a	DT	O	O
receptor	NN	O	O
that	WDT	O	O
binds	VBZ	O	O
HDL	NNP	O	O
with	IN	O	O
high	JJ	O	O
affinity	NN	O	O
and	CC	O	O
mediates	VBZ	O	O
both	DT	O	O
the	DT	O	O
selective	JJ	O	O
lipid	JJ	O	O
uptake	NN	O	O
of	IN	O	O
cholesteryl	NN	O	B-SUBSTRATE
esters	NNS	O	I-SUBSTRATE
from	IN	O	O
lipid-rich	JJ	O	O
HDL	NNP	O	O
to	TO	O	O
cells	NNS	O	O
and	CC	O	O
the	DT	O	O
efflux	NN	O	O
of	IN	O	O
unesterified	JJ	O	O
cholesterol	NN	O	B-SUBSTRATE
from	IN	O	O
cells	NNS	O	O
to	TO	O	O
HDL	NNP	O	O
.	.	O	O

ABCA1	NNP	O	B-enzyme
mediates	VBZ	O	O
the	DT	O	O
efflux	NN	O	O
of	IN	O	O
unesterified	JJ	O	O
cholesterol	NN	O	B-SUBSTRATE
and	CC	O	O
phospholipids	NNS	O	O
from	IN	O	O
cells	NNS	O	O
to	TO	O	O
lipid-poor	JJ	O	O
apolipoprotein	JJ	O	O
A-I	NNP	O	O
(	(	O	O
apoA-I	JJ	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
activities	NNS	O	O
of	IN	O	O
ABCA1	NNP	O	O
and	CC	O	O
other	JJ	O	O
ATP	NNP	O	O
binding	VBG	O	O
cassette	NN	O	O
superfamily	JJ	O	O
members	NNS	O	O
are	VBP	O	O
inhibited	VBN	O	O
by	IN	O	O
the	DT	O	O
drug	NN	O	O
glyburide	NN	O	O
,	,	O	O
and	CC	O	O
SR-BI-mediated	NNP	O	O
lipid	JJ	O	O
transport	NN	O	O
is	VBZ	O	O
blocked	VBN	O	O
by	IN	O	O
small	JJ	O	O
molecule	NN	O	O
inhibitors	NNS	O	O
called	VBD	O	O
BLTs	NNP	O	O
.	.	O	O

Here	RB	O	O
,	,	O	O
we	PRP	O	O
show	VBP	O	O
that	IN	O	O
one	CD	O	O
BLT	NNP	O	O
,	,	O	O
[	NNP	O	O
1-	CD	O	O
(	(	O	O
2-methoxy-phenyl	CD	O	O
)	)	O	O
-3-naphthalen-2-yl-urea	NN	O	O
]	NN	O	O
(	(	O	O
BLT-4	NNP	O	O
)	)	O	O
,	,	O	O
blocked	VBD	O	O
ABCA1-mediated	JJ	O	O
cholesterol	NN	O	B-SUBSTRATE
efflux	NN	O	O
to	TO	O	O
lipid-poor	JJ	O	O
apoA-I	NN	O	O
at	IN	O	O
a	DT	O	O
potency	NN	O	O
similar	JJ	O	O
to	TO	O	O
that	DT	O	O
for	IN	O	O
its	PRP$	O	O
inhibition	NN	O	O
of	IN	O	O
SR-BI	NNP	O	O
(	(	O	O
IC	NNP	O	O
(	(	O	O
50	CD	O	O
)	)	O	O
approximately	RB	O	O
55-60	JJ	O	O
microM	NN	O	O
)	)	O	O
.	.	O	O

Reciprocally	RB	O	O
,	,	O	O
glyburide	JJ	O	O
blocked	VBD	O	O
SR-BI-mediated	JJ	O	O
selective	JJ	O	O
lipid	JJ	O	O
uptake	NN	O	O
and	CC	O	O
efflux	NN	O	O
at	IN	O	O
a	DT	O	O
potency	NN	O	O
similar	JJ	O	O
to	TO	O	O
that	DT	O	O
for	IN	O	O
its	PRP$	O	O
inhibition	NN	O	O
of	IN	O	O
ABCA1	NNP	O	O
(	(	O	O
IC	NNP	O	O
(	(	O	O
50	CD	O	O
)	)	O	O
approximately	RB	O	O
275-300	JJ	O	O
microM	NN	O	O
)	)	O	O
.	.	O	O

As	IN	O	O
is	VBZ	O	O
the	DT	O	O
case	NN	O	O
with	IN	O	O
BLTs	NNP	O	O
,	,	O	O
glyburide	NN	O	O
increased	VBD	O	O
the	DT	O	O
apparent	JJ	O	O
affinity	NN	O	O
of	IN	O	O
HDL	NNP	O	O
binding	VBG	O	O
to	TO	O	O
SR-BI	NNP	O	O
.	.	O	O

The	DT	O	O
reciprocal	JJ	O	O
inhibition	NN	O	O
of	IN	O	O
SR-BI	NNP	O	O
and	CC	O	O
ABCA1	NNP	O	O
by	IN	O	O
BLT-4	NNP	O	O
and	CC	O	O
glyburide	NN	O	O
raises	VBZ	O	O
the	DT	O	O
possibility	NN	O	O
that	IN	O	O
these	DT	O	O
proteins	NNS	O	O
may	MD	O	O
share	NN	O	O
similar	JJ	O	O
or	CC	O	O
common	JJ	O	O
steps	NNS	O	O
in	IN	O	O
their	PRP$	O	O
mechanisms	NNS	O	O
of	IN	O	O
lipid	JJ	O	O
transport	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

PURPOSE	NN	O	O
:	:	O	O
The	DT	O	O
fluoropyrimidine	NN	O	B-SUBSTRATE
carbamate	NN	O	I-SUBSTRATE
(	(	O	O
capecitabine	NN	O	B-SUBSTRATE
)	)	O	O
is	VBZ	O	O
converted	VBN	O	O
to	TO	O	O
5-fluorouracil	JJ	O	B-PRODUCT-OF
(	(	O	O
5-FU	JJ	O	B-PRODUCT-OF
)	)	O	O
by	IN	O	O
thymidine	NN	O	B-enzyme
phosphorylase	NN	O	I-enzyme
(	(	O	O
TP	NNP	O	B-enzyme
)	)	O	O
inside	IN	O	O
target	NN	O	O
tissues	NNS	O	O
.	.	O	O

5-FU	JJ	O	O
interferes	NNS	O	O
with	IN	O	O
DNA	NNP	O	O
synthesis	NN	O	O
by	IN	O	O
blocking	VBG	O	O
thymidylate	JJ	O	O
synthase	NN	O	O
(	(	O	O
TS	NNP	O	O
)	)	O	O
but	CC	O	O
is	VBZ	O	O
inactivated	VBN	O	O
by	IN	O	O
dihydropyrimidine	JJ	O	O
dehydrogenase	NN	O	O
(	(	O	O
DPD	NNP	O	O
)	)	O	O
.	.	O	O

Favorable	JJ	O	O
enzyme	NN	O	O
profiles	NNS	O	O
(	(	O	O
high	JJ	O	O
TP	NNP	O	B-enzyme
and	CC	O	O
low	JJ	O	O
DPD	NNP	O	B-enzyme
)	)	O	O
generate	VBP	O	O
high	JJ	O	O
intratumor	NN	O	O
levels	NNS	O	O
of	IN	O	O
5-FU	JJ	O	B-PRODUCT-OF
that	WDT	O	O
are	VBP	O	O
effective	JJ	O	O
against	IN	O	O
many	JJ	O	O
tumors	NNS	O	O
,	,	O	O
especially	RB	O	O
those	DT	O	O
with	IN	O	O
low	JJ	O	O
TS	NNP	O	O
.	.	O	O

Capecitabine	NNP	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
tested	VBN	O	O
against	IN	O	O
thyroid	NN	O	O
cancers	NNS	O	O
,	,	O	O
and	CC	O	O
it	PRP	O	O
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
to	TO	O	O
what	WP	O	O
extent	NN	O	O
thyroid	NN	O	O
cancers	NNS	O	O
express	VBP	O	O
TP	NNP	O	O
,	,	O	O
TS	NNP	O	O
or	CC	O	O
DPD	NNP	O	O
.	.	O	O

METHODS	NN	O	O
:	:	O	O
To	TO	O	O
test	VB	O	O
this	DT	O	O
,	,	O	O
we	PRP	O	O
determined	VBD	O	O
TP	NNP	O	O
,	,	O	O
TS	NNP	O	O
and	CC	O	O
DPD	NNP	O	O
in	IN	O	O
19	CD	O	O
thyroid	JJ	O	O
cancers	NNS	O	O
from	IN	O	O
young	JJ	O	O
patients	NNS	O	O
(	(	O	O
14	CD	O	O
papillary	NN	O	O
,	,	O	O
4	CD	O	O
follicular	NN	O	O
,	,	O	O
1	CD	O	O
medullary	NN	O	O
)	)	O	O
by	IN	O	O
immunohistochemistry	NN	O	O
.	.	O	O

After	IN	O	O
approval	NN	O	O
by	IN	O	O
the	DT	O	O
Human	NNP	O	O
Use	NNP	O	O
Committee	NNP	O	O
,	,	O	O
the	DT	O	O
intensity	NN	O	O
of	IN	O	O
TP	NNP	O	O
,	,	O	O
TS	NNP	O	O
,	,	O	O
and	CC	O	O
DPD	NNP	O	O
staining	NN	O	O
was	VBD	O	O
determined	VBN	O	O
by	IN	O	O
two	CD	O	O
independent	JJ	O	O
examiners	NNS	O	O
and	CC	O	O
graded	VBD	O	O
(	(	O	O
absent=0	NN	O	O
to	TO	O	O
intense=3	VB	O	O
)	)	O	O
with	IN	O	O
>	$	O	O
90	CD	O	O
%	NN	O	O
concordance	NN	O	O
.	.	O	O

RESULTS	NN	O	O
:	:	O	O
TS	NNP	O	O
was	VBD	O	O
detected	VBN	O	O
in	IN	O	O
7/19	CD	O	O
cancers	NNS	O	O
(	(	O	O
37	CD	O	O
%	NN	O	O
)	)	O	O
,	,	O	O
TP	NNP	O	O
in	IN	O	O
14/19	CD	O	O
cancers	NNS	O	O
(	(	O	O
74	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
DPD	NNP	O	O
in	IN	O	O
14/19	CD	O	O
cancers	NNS	O	O
(	(	O	O
74	CD	O	O
%	NN	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
six	CD	O	O
tumors	NNS	O	O
,	,	O	O
TP	NNP	O	O
was	VBD	O	O
more	RBR	O	O
intense	JJ	O	O
that	IN	O	O
DPD	NNP	O	O
,	,	O	O
suggesting	VBG	O	O
capecitabine	JJ	O	O
sensitivity	NN	O	O
.	.	O	O

Only	RB	O	O
five	CD	O	O
tumors	NNS	O	O
failed	VBD	O	O
to	TO	O	O
express	VB	O	O
TP	NNP	O	O
but	CC	O	O
four	CD	O	O
of	IN	O	O
these	DT	O	O
expressed	VBN	O	O
DPD	NNP	O	O
,	,	O	O
suggesting	VBG	O	O
capecitabine	NN	O	O
resistance	NN	O	O
.	.	O	O

Overall	JJ	O	O
,	,	O	O
6/19	CD	O	O
tumors	NNS	O	O
(	(	O	O
32	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
total	NN	O	O
)	)	O	O
had	VBD	O	O
a	DT	O	O
favorable	JJ	O	O
expression	NN	O	O
profile	NN	O	O
,	,	O	O
and	CC	O	O
all	DT	O	O
of	IN	O	O
them	PRP	O	O
were	VBD	O	O
papillary	JJ	O	O
cancers	NNS	O	O
.	.	O	O

CONCLUSIONS	NN	O	O
:	:	O	O
We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
the	DT	O	O
majority	NN	O	O
of	IN	O	O
differentiated	JJ	O	O
thyroid	NN	O	O
cancers	NNS	O	O
(	(	O	O
74	CD	O	O
%	NN	O	O
)	)	O	O
express	NN	O	O
TP	NNP	O	O
and	CC	O	O
low	JJ	O	O
levels	NNS	O	O
of	IN	O	O
TS	NNP	O	O
(	(	O	O
63	CD	O	O
%	NN	O	O
undetectable	JJ	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
support	VBD	O	O
the	DT	O	O
hypothesis	NN	O	O
that	IN	O	O
capecitabine	NN	O	O
is	VBZ	O	O
activated	VBN	O	O
in	IN	O	O
the	DT	O	O
majority	NN	O	O
of	IN	O	O
differentiated	JJ	O	O
thyroid	NN	O	O
cancers	NNS	O	O
and	CC	O	O
that	DT	O	O
32	CD	O	O
%	NN	O	O
have	VBP	O	O
favorable	JJ	O	O
expression	NN	O	O
of	IN	O	O
all	DT	O	O
three	CD	O	O
enzymes	NNS	O	O
(	(	O	O
TP	NNP	O	O
,	,	O	O
TS	NNP	O	O
,	,	O	O
and	CC	O	O
DPD	NNP	O	O
)	)	O	O
.	.	O	O

-DOCSTART- -X- -X- O

The	DT	O	O
uptake	NN	O	O
,	,	O	O
biosynthesis	NN	O	O
and	CC	O	O
catabolism	NN	O	O
of	IN	O	O
polyamines	NNS	O	O
in	IN	O	O
the	DT	O	O
microsporidian	JJ	O	O
parasite	NN	O	O
Encephalitozoon	NNP	O	O
cuniculi	NN	O	O
are	VBP	O	O
detailed	VBN	O	O
with	IN	O	O
reference	NN	O	O
to	TO	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
oligoamine	NN	O	O
and	CC	O	O
arylamine	JJ	O	O
analogues	NNS	O	O
of	IN	O	O
polyamines	NNS	O	O
.	.	O	O

Enc	NNP	O	O
.	.	O	O

cuniculi	NN	O	O
,	,	O	O
an	DT	O	O
intracellular	JJ	O	O
parasite	NN	O	O
of	IN	O	O
mammalian	JJ	O	O
cells	NNS	O	O
,	,	O	O
has	VBZ	O	O
both	DT	O	O
biosynthetic	JJ	O	O
and	CC	O	O
catabolic	JJ	O	O
enzymes	NNS	O	O
of	IN	O	O
polyamine	NN	O	O
metabolism	NN	O	O
,	,	O	O
as	IN	O	O
demonstrated	VBN	O	O
in	IN	O	O
cell-free	JJ	O	O
extracts	NNS	O	O
of	IN	O	O
mature	NN	O	O
spores	NNS	O	O
.	.	O	O

The	DT	O	O
uptake	NN	O	O
of	IN	O	O
polyamines	NNS	O	O
was	VBD	O	O
measured	VBN	O	O
in	IN	O	O
immature	NN	O	O
,	,	O	O
pre-emergent	JJ	O	O
spores	NNS	O	O
isolated	VBN	O	O
from	IN	O	O
host	NN	O	O
cells	NNS	O	O
by	IN	O	O
Percoll	NNP	O	O
gradient	NN	O	O
.	.	O	O

Spermine	NNP	O	O
was	VBD	O	O
rapidly	RB	O	O
taken	VBN	O	O
up	RP	O	O
and	CC	O	O
metabolized	VBN	O	O
to	TO	O	O
spermidine	VB	O	O
and	CC	O	O
an	DT	O	O
unknown	JJ	O	O
,	,	O	O
possibly	RB	O	O
acetamidopropanal	JJ	O	O
,	,	O	O
by	IN	O	O
spermidine/spermine	JJ	O	O
N	NNP	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
-acetyltransferase	NN	O	O
(	(	O	O
SSAT	NNP	O	O
)	)	O	O
and	CC	O	O
polyamine	JJ	O	O
oxidase	NN	O	O
(	(	O	O
PAO	NNP	O	O
)	)	O	O
.	.	O	O

Most	JJS	O	O
of	IN	O	O
the	DT	O	O
spermidine	NN	O	O
and	CC	O	O
the	DT	O	O
unknown	JJ	O	O
product	NN	O	O
were	VBD	O	O
found	VBN	O	O
in	IN	O	O
the	DT	O	O
cell	NN	O	O
incubation	NN	O	O
medium	NN	O	O
,	,	O	O
indicating	VBG	O	O
they	PRP	O	O
were	VBD	O	O
released	VBN	O	O
from	IN	O	O
the	DT	O	O
cell	NN	O	O
.	.	O	O

bis	NN	O	O
(	(	O	O
Ethyl	NNP	O	O
)	)	O	O
oligoamine	VBP	O	O
analogues	NNS	O	O
of	IN	O	O
polyamines	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
SL-11144	NNP	O	O
and	CC	O	O
SL-11158	NNP	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
arylamine	NN	O	O
analogues	NNS	O	O
[	VBP	O	O
BW-1	NNP	O	O
,	,	O	O
a	DT	O	O
bis	NN	O	O
(	(	O	O
phenylbenzyl	NN	O	O
)	)	O	O
3-7-3	CD	O	O
analogue	NN	O	O
]	NN	O	O
blocked	VBD	O	O
uptake	JJ	O	O
and	CC	O	O
interconversion	NN	O	O
of	IN	O	O
spermine	NN	O	O
at	IN	O	O
micromolar	JJ	O	O
levels	NNS	O	O
and	CC	O	O
,	,	O	O
in	IN	O	O
the	DT	O	O
case	NN	O	O
of	IN	O	O
BW-1	NNP	O	B-SUBSTRATE
,	,	O	O
acted	VBD	O	O
as	IN	O	O
substrate	NN	O	O
for	IN	O	O
PAO	NNP	O	B-enzyme
.	.	O	O

The	DT	O	O
Enc	NNP	O	O
.	.	O	O

cuniculi	NNS	O	O
PAO	NNP	O	O
activity	NN	O	O
differed	VBD	O	O
from	IN	O	O
that	DT	O	O
found	VBN	O	O
in	IN	O	O
mammalian	JJ	O	O
cells	NNS	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
pH	VB	O	O
optimum	JJ	O	O
,	,	O	O
substrate	JJ	O	O
specificity	NN	O	O
and	CC	O	O
sensitivity	NN	O	O
to	TO	O	O
known	VB	O	O
PAO	NNP	O	O
inhibitors	NNS	O	O
.	.	O	O

SL-11158	NNP	O	O
inhibited	JJ	O	O
SSAT	NNP	O	O
activity	NN	O	O
with	IN	O	O
a	DT	O	O
mixed	JJ	O	O
type	NN	O	O
of	IN	O	O
inhibition	NN	O	O
in	IN	O	O
which	WDT	O	O
the	DT	O	O
analogue	NN	O	O
had	VBD	O	O
a	DT	O	O
70-fold	JJ	O	O
higher	JJR	O	O
affinity	NN	O	O
for	IN	O	O
the	DT	O	O
enzyme	NN	O	O
than	IN	O	O
the	DT	O	O
natural	JJ	O	O
substrate	NN	O	O
,	,	O	O
spermine	NN	O	O
.	.	O	O

The	DT	O	O
interest	NN	O	O
in	IN	O	O
Enc	NNP	O	O
.	.	O	O

cuniculi	NNS	O	O
polyamine	VBP	O	O
metabolism	NN	O	O
and	CC	O	O
the	DT	O	O
biochemical	JJ	O	O
effects	NNS	O	O
of	IN	O	O
these	DT	O	O
polyamine	NN	O	O
analogues	NNS	O	O
is	VBZ	O	O
warranted	VBN	O	O
since	IN	O	O
they	PRP	O	O
cure	VBP	O	O
model	JJ	O	O
infections	NNS	O	O
of	IN	O	O
Enc	NNP	O	O
.	.	O	O

cuniculi	NN	O	O
in	IN	O	O
mice	NN	O	O
and	CC	O	O
are	VBP	O	O
potential	JJ	O	O
candidates	NNS	O	O
for	IN	O	O
human	JJ	O	O
clinical	JJ	O	O
trials	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

In	IN	O	O
this	DT	O	O
work	NN	O	O
,	,	O	O
we	PRP	O	O
report	VBP	O	O
that	IN	O	O
the	DT	O	O
recombinant	JJ	O	O
glutathione	NN	O	O
S-transferase	NNP	O	O
(	(	O	O
GST	NNP	O	O
)	)	O	O
-human	VBD	O	O
L-glutamic	JJ	O	O
acid	JJ	O	O
decarboxylase	NN	O	O
(	(	O	O
HGAD	NNP	O	O
)	)	O	O
isoforms	NNS	O	O
,	,	O	O
65-kDa	JJ	O	O
L-glutamic	JJ	O	O
acid	NN	O	O
decarboxylase	NN	O	O
(	(	O	O
GAD	NNP	O	O
)	)	O	O
(	(	O	O
GST-HGAD65	NNP	O	O
)	)	O	O
fusion	NN	O	O
protein	NN	O	O
or	CC	O	O
free	JJ	O	O
truncated	VBN	O	O
HGAD65	NNP	O	O
,	,	O	O
were	VBD	O	O
activated	VBN	O	O
by	IN	O	O
apocalmodulin	NN	O	O
(	(	O	O
ApoCaM	NNP	O	O
)	)	O	O
to	TO	O	O
an	DT	O	O
extent	NN	O	O
of	IN	O	O
60	CD	O	O
%	NN	O	O
.	.	O	O

Both	DT	O	O
truncated	VBD	O	O
forms	NNS	O	O
of	IN	O	O
GAD67	NNP	O	O
(	(	O	O
tGAD67	NN	O	O
)	)	O	O
,	,	O	O
HGAD67	NNP	O	O
(	(	O	O
Delta1-70	NNP	O	O
)	)	O	O
and	CC	O	O
HGAD67	NNP	O	O
(	(	O	O
Delta1-90	NNP	O	O
)	)	O	O
,	,	O	O
were	VBD	O	O
markedly	RB	O	O
activated	VBN	O	O
by	IN	O	O
ApoCaM	NNP	O	O
to	TO	O	O
an	DT	O	O
extent	NN	O	O
of	IN	O	O
141	CD	O	O
and	CC	O	O
85	CD	O	O
%	NN	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
while	IN	O	O
GST-HGAD67	NNP	O	O
was	VBD	O	O
not	RB	O	O
significantly	RB	O	O
affected	VBN	O	O
.	.	O	O

The	DT	O	O
activation	NN	O	O
appears	VBZ	O	O
to	TO	O	O
be	VB	O	O
due	JJ	O	O
to	TO	O	O
an	DT	O	O
increase	NN	O	O
of	IN	O	O
GAD	NNP	O	O
affinity	NN	O	O
for	IN	O	O
its	PRP$	O	O
cofactor	NN	O	O
,	,	O	O
pyridoxal	JJ	O	O
phosphate	NN	O	O
(	(	O	O
PLP	NNP	O	O
)	)	O	O
.	.	O	O

This	DT	O	O
conclusion	NN	O	O
is	VBZ	O	O
based	VBN	O	O
on	IN	O	O
the	DT	O	O
following	JJ	O	O
observations	NNS	O	O
.	.	O	O

Firstly	RB	O	O
,	,	O	O
the	DT	O	O
V	NNP	O	O
(	(	O	O
max	NN	O	O
)	)	O	O
of	IN	O	O
GAD	NNP	O	B-enzyme
was	VBD	O	O
increased	VBN	O	O
when	WRB	O	O
ApoCaM	NNP	O	O
was	VBD	O	O
present	JJ	O	O
whereas	IN	O	O
the	DT	O	O
affinity	NN	O	O
for	IN	O	O
the	DT	O	O
substrate	NN	O	O
,	,	O	O
glutamate	NN	O	B-SUBSTRATE
,	,	O	O
was	VBD	O	O
not	RB	O	O
affected	VBN	O	O
.	.	O	O

Secondly	RB	O	O
,	,	O	O
the	DT	O	O
affinity	NN	O	O
of	IN	O	O
GAD	NNP	O	O
for	IN	O	O
PLP	NNP	O	O
was	VBD	O	O
increased	VBN	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
ApoCaM	NNP	O	O
.	.	O	O

Thirdly	RB	O	O
,	,	O	O
results	NNS	O	O
from	IN	O	O
calmodulin-agarose	JJ	O	O
affinity	NN	O	O
column	NN	O	O
chromatography	NN	O	O
studies	NNS	O	O
indicated	VBD	O	O
a	DT	O	O
direct	JJ	O	O
interaction	NN	O	O
or	CC	O	O
binding	NN	O	O
between	IN	O	O
ApoCaM	NNP	O	O
and	CC	O	O
GAD	NNP	O	O
.	.	O	O

Fourthly	RB	O	O
,	,	O	O
ApoCaM	NNP	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
copurified	VBN	O	O
with	IN	O	O
GAD65/GAD67	NNP	O	O
by	IN	O	O
anti-GAD65/67	JJ	O	O
immunoaffinity	NN	O	O
column	NN	O	O
using	VBG	O	O
rat	NN	O	O
brain	NN	O	O
extract	NN	O	O
.	.	O	O

Hence	RB	O	O
,	,	O	O
it	PRP	O	O
is	VBZ	O	O
proposed	VBN	O	O
that	IN	O	O
a	DT	O	O
conformational	JJ	O	O
change	NN	O	O
is	VBZ	O	O
induced	VBN	O	O
when	WRB	O	O
ApoCaM	NNP	O	O
interacts	VBZ	O	O
with	IN	O	O
GAD65	NNP	O	O
or	CC	O	O
tGAD67	NN	O	O
,	,	O	O
resulting	VBG	O	O
in	IN	O	O
an	DT	O	O
increase	NN	O	O
of	IN	O	O
GAD	NNP	O	O
affinity	NN	O	O
for	IN	O	O
PLP	NNP	O	O
and	CC	O	O
the	DT	O	O
activation	NN	O	O
of	IN	O	O
GAD	NNP	O	O
.	.	O	O

The	DT	O	O
physiological	JJ	O	O
significance	NN	O	O
of	IN	O	O
the	DT	O	O
interaction	NN	O	O
between	IN	O	O
GAD	NNP	O	O
and	CC	O	O
ApoCaM	NNP	O	O
is	VBZ	O	O
discussed	VBN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

L-serine	JJ	O	B-enzyme
dehydratase	NN	O	I-enzyme
(	(	O	O
SDH	NNP	O	B-enzyme
)	)	O	O
,	,	O	O
a	DT	O	O
member	NN	O	O
of	IN	O	O
the	DT	O	O
beta-family	NN	O	O
of	IN	O	O
pyridoxal	JJ	O	O
phosphate-dependent	NN	O	O
(	(	O	O
PLP	NNP	O	O
)	)	O	O
enzymes	VBZ	O	O
,	,	O	O
catalyzes	VBZ	O	O
the	DT	O	O
deamination	NN	O	O
of	IN	O	O
L-serine	NNP	O	B-SUBSTRATE
and	CC	O	O
L-threonine	NNP	O	B-SUBSTRATE
to	TO	O	O
yield	VB	O	O
pyruvate	NN	O	B-PRODUCT-OF
or	CC	O	O
2-oxobutyrate	JJ	O	B-PRODUCT-OF
.	.	O	O

The	DT	O	O
crystal	JJ	O	O
structure	NN	O	O
of	IN	O	O
L-serine	JJ	O	O
dehydratase	NN	O	O
from	IN	O	O
human	JJ	O	O
liver	NN	O	O
(	(	O	O
hSDH	NN	O	O
)	)	O	O
has	VBZ	O	O
been	VBN	O	O
solved	VBN	O	O
at	IN	O	O
2.5	CD	O	O
A-resolution	NN	O	O
by	IN	O	O
molecular	JJ	O	O
replacement	NN	O	O
.	.	O	O

The	DT	O	O
structure	NN	O	O
is	VBZ	O	O
a	DT	O	O
homodimer	NN	O	O
and	CC	O	O
reveals	VBZ	O	O
a	DT	O	O
fold	JJ	O	O
typical	JJ	O	O
for	IN	O	O
beta-family	JJ	O	O
PLP-dependent	JJ	O	O
enzymes	NNS	O	O
.	.	O	O

Each	DT	O	O
monomer	NN	O	O
serves	VBZ	O	O
as	IN	O	O
an	DT	O	O
active	JJ	O	O
unit	NN	O	O
and	CC	O	O
is	VBZ	O	O
subdivided	VBN	O	O
into	IN	O	O
two	CD	O	O
distinct	JJ	O	O
domains	NNS	O	O
:	:	O	O
a	DT	O	O
small	JJ	O	O
domain	NN	O	O
and	CC	O	O
a	DT	O	O
PLP-binding	JJ	O	O
domain	NN	O	O
that	WDT	O	O
covalently	RB	O	O
anchors	VBZ	O	O
the	DT	O	O
cofactor	NN	O	O
.	.	O	O

Both	DT	O	O
domains	VBZ	O	O
show	VBP	O	O
the	DT	O	O
typical	JJ	O	O
open	JJ	O	O
alpha/beta	NN	O	O
architecture	NN	O	O
of	IN	O	O
PLP	NNP	O	O
enzymes	NNS	O	O
.	.	O	O

Comparison	NN	O	O
with	IN	O	O
the	DT	O	O
rSDH-	JJ	O	O
(	(	O	O
PLP-OMS	NNP	O	O
)	)	O	O
holo-enzyme	NN	O	O
reveals	VBZ	O	O
a	DT	O	O
large	JJ	O	O
structural	JJ	O	O
difference	NN	O	O
in	IN	O	O
active	JJ	O	O
sites	NNS	O	O
caused	VBN	O	O
by	IN	O	O
the	DT	O	O
artifical	JJ	O	O
O-methylserine	NNP	O	O
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
the	DT	O	O
activity	NN	O	O
of	IN	O	O
hSDH-PLP	NN	O	O
was	VBD	O	O
assayed	VBN	O	O
and	CC	O	O
it	PRP	O	O
proved	VBD	O	O
to	TO	O	O
show	VB	O	O
catalytic	JJ	O	O
activity	NN	O	O
.	.	O	O

That	DT	O	O
suggests	VBZ	O	O
that	IN	O	O
the	DT	O	O
structure	NN	O	O
of	IN	O	O
hSDH-PLP	NN	O	O
is	VBZ	O	O
the	DT	O	O
first	JJ	O	O
structure	NN	O	O
of	IN	O	O
the	DT	O	O
active	JJ	O	O
natural	JJ	O	O
holo-SDH	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Beta-1,4-galactosyltransferase	NN	O	B-enzyme
I	PRP	O	I-enzyme
(	(	O	O
beta4Gal-T1	NN	O	B-enzyme
)	)	O	O
normally	RB	O	O
transfers	NNS	O	O
Gal	VBP	O	O
from	IN	O	O
UDP-Gal	NNP	O	B-SUBSTRATE
to	TO	O	O
GlcNAc	NNP	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
Mn	NNP	O	O
(	(	O	O
2+	CD	O	O
)	)	O	O
ion	NN	O	O
(	(	O	O
Gal-T	NNP	O	B-enzyme
activity	NN	O	O
)	)	O	O
and	CC	O	O
also	RB	O	O
transfers	NNS	O	O
Glc	VBP	O	O
from	IN	O	O
UDP-Glc	NNP	O	B-SUBSTRATE
to	TO	O	O
GlcNAc	NNP	O	O
(	(	O	O
Glc-T	NNP	O	B-enzyme
activity	NN	O	O
)	)	O	O
,	,	O	O
albeit	RB	O	O
at	IN	O	O
only	RB	O	O
0.3	CD	O	O
%	NN	O	O
efficiency	NN	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
alpha-lactalbumin	NN	O	O
(	(	O	O
LA	NNP	O	O
)	)	O	O
enhances	VBZ	O	O
this	DT	O	O
Glc-T	JJ	O	O
activity	NN	O	O
more	JJR	O	O
than	IN	O	O
25	CD	O	O
times	NNS	O	O
.	.	O	O

Comparison	NNP	O	O
of	IN	O	O
the	DT	O	O
crystal	JJ	O	O
structures	NNS	O	O
of	IN	O	O
UDP-Gal-	NNP	O	O
and	CC	O	O
UDP-Glc-bound	NNP	O	O
beta4Gal-T1	NN	O	O
reveals	NNS	O	O
that	IN	O	O
the	DT	O	O
O4	NNP	O	O
hydroxyl	NN	O	O
group	NN	O	O
in	IN	O	O
both	DT	O	O
Gal	NNP	O	O
and	CC	O	O
Glc	NNP	O	O
moieties	NNS	O	O
forms	VBZ	O	O
a	DT	O	O
hydrogen	NN	O	O
bond	NN	O	O
with	IN	O	O
the	DT	O	O
side	NN	O	O
chain	NN	O	O
carboxylate	NN	O	O
group	NN	O	O
of	IN	O	O
Glu317	NNP	O	O
.	.	O	O

The	DT	O	O
orientation	NN	O	O
of	IN	O	O
the	DT	O	O
O4	NNP	O	O
hydroxyl	NN	O	O
of	IN	O	O
glucose	JJ	O	O
causes	NNS	O	O
a	DT	O	O
steric	JJ	O	O
hindrance	NN	O	O
to	TO	O	O
the	DT	O	O
side	NN	O	O
chain	NN	O	O
carboxylate	NN	O	O
group	NN	O	O
of	IN	O	O
Glu317	NNP	O	O
,	,	O	O
accounting	NN	O	O
for	IN	O	O
the	DT	O	O
enzyme	NN	O	O
's	POS	O	O
low	JJ	O	O
Glc-T	JJ	O	O
activity	NN	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
show	VBP	O	O
that	DT	O	O
mutation	NN	O	O
of	IN	O	O
Arg228	NNP	O	O
,	,	O	O
a	DT	O	O
residue	NN	O	O
in	IN	O	O
the	DT	O	O
vicinity	NN	O	O
of	IN	O	O
Glu317	NNP	O	O
,	,	O	O
to	TO	O	O
lysine	VB	O	O
(	(	O	O
R228K-Gal-T1	NNP	O	O
)	)	O	O
results	NNS	O	O
in	IN	O	O
a	DT	O	O
15-fold	JJ	O	O
higher	JJR	O	O
Glc-T	JJ	O	O
activity	NN	O	O
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
further	RBR	O	O
enhanced	VBN	O	O
by	IN	O	O
LA	NNP	O	O
to	TO	O	O
nearly	RB	O	O
25	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
Gal-T	NNP	O	O
activity	NN	O	O
of	IN	O	O
the	DT	O	O
wild	JJ	O	O
type	NN	O	O
.	.	O	O

The	DT	O	O
kinetic	JJ	O	O
parameters	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
the	DT	O	O
main	JJ	O	O
effect	NN	O	O
of	IN	O	O
the	DT	O	O
mutation	NN	O	O
of	IN	O	O
Arg228	NNP	O	O
to	TO	O	O
lysine	VB	O	O
is	VBZ	O	O
on	IN	O	O
the	DT	O	O
k	NN	O	O
(	(	O	O
cat	NN	O	O
)	)	O	O
of	IN	O	O
Glc-T	NNP	O	O
,	,	O	O
which	WDT	O	O
increases	VBZ	O	O
3-4-fold	CD	O	O
,	,	O	O
both	DT	O	O
in	IN	O	O
the	DT	O	O
absence	NN	O	O
and	CC	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
LA	NNP	O	O
;	:	O	O
simultaneously	RB	O	O
,	,	O	O
the	DT	O	O
k	NN	O	O
(	(	O	O
cat	NN	O	O
)	)	O	O
for	IN	O	O
the	DT	O	O
Gal-T	NNP	O	O
reaction	NN	O	O
is	VBZ	O	O
reduced	VBN	O	O
30-fold	JJ	O	O
.	.	O	O

The	DT	O	O
crystal	JJ	O	O
structure	NN	O	O
of	IN	O	O
R228K-Gal-T1	NNP	O	O
complexed	NN	O	O
with	IN	O	O
LA	NNP	O	O
,	,	O	O
UDP-Gal	NNP	O	O
,	,	O	O
and	CC	O	O
Mn	NNP	O	O
(	(	O	O
2+	CD	O	O
)	)	O	O
determined	VBN	O	O
at	IN	O	O
1.9	CD	O	O
A	DT	O	O
resolution	NN	O	O
shows	VBZ	O	O
that	IN	O	O
the	DT	O	O
Asp318	NNP	O	O
side	NN	O	O
chain	NN	O	O
exhibits	VBZ	O	O
a	DT	O	O
minor	JJ	O	O
alternate	NN	O	O
conformation	NN	O	O
,	,	O	O
compared	VBN	O	O
to	TO	O	O
that	DT	O	O
in	IN	O	O
the	DT	O	O
wild	JJ	O	O
type	NN	O	O
.	.	O	O

This	DT	O	O
alternate	JJ	O	O
conformation	NN	O	O
now	RB	O	O
causes	VBZ	O	O
a	DT	O	O
steric	JJ	O	O
hindrance	NN	O	O
to	TO	O	O
the	DT	O	O
O4	NNP	O	O
hydroxyl	NN	O	O
group	NN	O	O
of	IN	O	O
the	DT	O	O
Gal	NNP	O	O
moiety	NN	O	O
of	IN	O	O
UDP-Gal	NNP	O	O
,	,	O	O
probably	RB	O	O
causing	VBG	O	O
the	DT	O	O
dissociation	NN	O	O
of	IN	O	O
UDP-Gal	NNP	O	O
and	CC	O	O
the	DT	O	O
reduced	VBN	O	O
k	NN	O	O
(	(	O	O
cat	NN	O	O
)	)	O	O
of	IN	O	O
the	DT	O	O
Gal-T	NNP	O	O
reaction	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

The	DT	O	O
purpose	NN	O	O
of	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
test	VB	O	O
our	PRP$	O	O
hypothesis	NN	O	O
that	IN	O	O
amiloride	NN	O	O
,	,	O	O
a	DT	O	O
specific	JJ	O	O
u-PA	JJ	O	O
inhibitor	NN	O	O
,	,	O	O
effectively	RB	O	O
decreases	VBZ	O	O
u-PA	JJ	O	O
activity	NN	O	O
in	IN	O	O
cornea	NN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
in	IN	O	O
tear	JJ	O	O
fluid	NN	O	O
and	CC	O	O
favourably	RB	O	O
affects	NNS	O	O
corneal	VBP	O	O
healing	VBG	O	O
.	.	O	O

Therefore	RB	O	O
,	,	O	O
comparative	JJ	O	O
histochemical	NN	O	O
and	CC	O	O
biochemical	JJ	O	O
studies	NNS	O	O
of	IN	O	O
u-PA	JJ	O	B-enzyme
and	CC	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
amiloride	NN	O	O
were	VBD	O	O
performed	VBN	O	O
on	IN	O	O
rabbit	NN	O	O
corneas	NNS	O	O
and	CC	O	O
tear	JJ	O	O
fluid	NN	O	O
using	VBG	O	O
the	DT	O	O
sensitive	JJ	O	O
fluorogenic	JJ	O	O
substrate	NN	O	O
Z-Gly-Gly-Arg-7-amino-4-trifluoromethylcoumarin	NNP	O	B-SUBSTRATE
.	.	O	O

Rabbit	NNP	O	O
eyes	NNS	O	O
were	VBD	O	O
repeatedly	RB	O	O
irradiated	VBN	O	O
with	IN	O	O
UVB	NNP	O	O
for	IN	O	O
9	CD	O	O
days	NNS	O	O
and	CC	O	O
during	IN	O	O
the	DT	O	O
irradiation	NN	O	O
topically	RB	O	O
treated	VBN	O	O
with	IN	O	O
amiloride	NN	O	O
(	(	O	O
1	CD	O	O
mg/ml	RB	O	O
saline	NN	O	O
)	)	O	O
or	CC	O	O
placebo	NN	O	O
(	(	O	O
saline	NN	O	O
)	)	O	O
(	(	O	O
dropwise	NN	O	O
,	,	O	O
5	CD	O	O
times	NNS	O	O
daily	RB	O	O
)	)	O	O
.	.	O	O

Results	NNS	O	O
show	VBP	O	O
that	IN	O	O
in	IN	O	O
placebo-treated	JJ	O	O
eyes	NNS	O	O
,	,	O	O
UVB	NNP	O	O
evoked	VBD	O	O
the	DT	O	O
appearance	NN	O	O
of	IN	O	O
u-PA	JJ	O	O
activity	NN	O	O
in	IN	O	O
cornea	NN	O	O
and	CC	O	O
tear	JJ	O	O
fluid	NN	O	O
in	IN	O	O
early	JJ	O	O
stages	NNS	O	O
of	IN	O	O
irradiation	NN	O	O
,	,	O	O
and	CC	O	O
u-PA	JJ	O	O
levels	NNS	O	O
increased	VBN	O	O
during	IN	O	O
irradiation	NN	O	O
.	.	O	O

Corneal	NNP	O	O
epithelium	NN	O	O
was	VBD	O	O
gradually	RB	O	O
lost	VBN	O	O
and	CC	O	O
remnants	NNS	O	O
of	IN	O	O
the	DT	O	O
epithelium	NN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
keratocytes	NNS	O	O
in	IN	O	O
the	DT	O	O
upper	JJ	O	O
part	NN	O	O
of	IN	O	O
corneal	NN	O	O
stroma	NN	O	O
showed	VBD	O	O
high	JJ	O	O
u-PA	JJ	O	O
activity	NN	O	O
.	.	O	O

Finally	RB	O	O
,	,	O	O
corneas	NNS	O	O
lost	VBD	O	O
their	PRP$	O	O
epithelium	NN	O	O
completely	RB	O	O
.	.	O	O

In	IN	O	O
corneal	JJ	O	O
stroma	NN	O	O
,	,	O	O
numerous	JJ	O	O
u-PA-containing	JJ	O	O
inflammatory	NN	O	O
cells	NNS	O	O
were	VBD	O	O
present	JJ	O	O
.	.	O	O

Corneas	NNS	O	O
were	VBD	O	O
vascularized	VBN	O	O
.	.	O	O

When	WRB	O	O
amiloride	NN	O	O
was	VBD	O	O
dropped	VBN	O	O
on	IN	O	O
the	DT	O	O
eye	NN	O	O
surface	NN	O	O
on	IN	O	O
the	DT	O	O
first	JJ	O	O
day	NN	O	O
of	IN	O	O
irradiation	NN	O	O
and	CC	O	O
subsequently	RB	O	O
daily	RB	O	O
until	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
experiment	NN	O	O
,	,	O	O
u-PA	JJ	O	O
activity	NN	O	O
in	IN	O	O
both	DT	O	O
cornea	NN	O	O
and	CC	O	O
tear	JJ	O	O
fluid	NN	O	O
was	VBD	O	O
strongly	RB	O	O
inhibited	VBN	O	O
.	.	O	O

Corneas	NNS	O	O
were	VBD	O	O
covered	VBN	O	O
with	IN	O	O
a	DT	O	O
continuous	JJ	O	O
epithelium	NN	O	O
until	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
the	DT	O	O
experiment	NN	O	O
.	.	O	O

The	DT	O	O
number	NN	O	O
of	IN	O	O
inflammatory	JJ	O	O
cells	NNS	O	O
was	VBD	O	O
significantly	RB	O	O
decreased	VBN	O	O
.	.	O	O

Corneal	NNP	O	O
vascularization	NN	O	O
was	VBD	O	O
reduced	VBN	O	O
by	IN	O	O
50	CD	O	O
%	NN	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
early	JJ	O	O
application	NN	O	O
of	IN	O	O
amiloride	NN	O	O
inhibited	VBN	O	O
u-PA	JJ	O	O
activity	NN	O	O
in	IN	O	O
UVB-irradiated	JJ	O	O
corneas	NNS	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
in	IN	O	O
tear	JJ	O	O
fluid	NN	O	O
and	CC	O	O
diminished	VBD	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
corneal	NN	O	O
pathology	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Spermidine/spermine	JJ	O	B-enzyme
N1-acetyltransferase	NNP	O	I-enzyme
(	(	O	O
SSAT	NNP	O	O
)	)	O	O
is	VBZ	O	O
a	DT	O	O
key	JJ	O	O
enzyme	NN	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
of	IN	O	O
polyamine	NN	O	B-PRODUCT-OF
levels	NNS	O	O
in	IN	O	O
human	JJ	O	O
cells	NNS	O	O
,	,	O	O
as	IN	O	O
acetylation	NN	O	O
of	IN	O	O
spermidine	NN	O	B-SUBSTRATE
and	CC	O	O
spermine	NN	O	B-SUBSTRATE
triggers	NNS	O	O
export	VBP	O	O
or	CC	O	O
degradation	NN	O	O
.	.	O	O

Increased	VBN	O	O
intracellular	JJ	O	O
polyamine	NN	O	O
levels	NNS	O	O
accompany	IN	O	O
several	JJ	O	O
types	NNS	O	O
of	IN	O	O
cancers	NNS	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
other	JJ	O	O
human	JJ	O	O
diseases	NNS	O	O
,	,	O	O
and	CC	O	O
compounds	VBZ	O	O
that	WDT	O	O
affect	VBP	O	O
the	DT	O	O
expression	NN	O	O
,	,	O	O
activity	NN	O	O
,	,	O	O
or	CC	O	O
stability	NN	O	O
of	IN	O	O
SSAT	NNP	O	O
are	VBP	O	O
being	VBG	O	O
explored	VBN	O	O
as	IN	O	O
potential	JJ	O	O
therapeutic	JJ	O	O
drugs	NNS	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
expressed	VBN	O	O
human	JJ	O	O
SSAT	NNP	O	O
from	IN	O	O
the	DT	O	O
cloned	VBN	O	O
cDNA	NN	O	O
in	IN	O	O
Escherichia	NNP	O	O
coli	NN	O	O
and	CC	O	O
have	VBP	O	O
determined	VBN	O	O
high-resolution	JJ	O	O
structures	NNS	O	O
of	IN	O	O
wild-type	JJ	O	O
and	CC	O	O
mutant	JJ	O	O
SSAT	NNP	O	O
,	,	O	O
as	IN	O	O
the	DT	O	O
free	JJ	O	O
dimer	NN	O	O
and	CC	O	O
in	IN	O	O
binary	JJ	O	O
and	CC	O	O
ternary	JJ	O	O
complexes	NNS	O	O
with	IN	O	O
CoA	NNP	O	O
,	,	O	O
acetyl-CoA	JJ	O	O
(	(	O	O
AcCoA	NNP	O	O
)	)	O	O
,	,	O	O
spermine	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
inhibitor	NN	O	O
N1	NNP	O	O
,	,	O	O
N11bis-	NNP	O	O
(	(	O	O
ethyl	NN	O	O
)	)	O	O
-norspermine	NN	O	O
(	(	O	O
BE-3-3-3	NNP	O	O
)	)	O	O
.	.	O	O

These	DT	O	O
structures	NNS	O	O
show	VBP	O	O
details	NNS	O	O
of	IN	O	O
binding	VBG	O	O
sites	NNS	O	O
for	IN	O	O
cofactor	NN	O	O
,	,	O	O
substrates	NNS	O	O
,	,	O	O
and	CC	O	O
inhibitor	NN	O	O
and	CC	O	O
provide	VB	O	O
a	DT	O	O
framework	NN	O	O
to	TO	O	O
understand	VB	O	O
enzymatic	JJ	O	O
activity	NN	O	O
,	,	O	O
mutations	NNS	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
action	NN	O	O
of	IN	O	O
potential	JJ	O	O
drugs	NNS	O	O
.	.	O	O

Two	CD	O	O
dimer	JJ	O	O
conformations	NNS	O	O
were	VBD	O	O
observed	VBN	O	O
:	:	O	O
a	DT	O	O
symmetric	JJ	O	O
form	NN	O	O
with	IN	O	O
two	CD	O	O
open	JJ	O	O
surface	NN	O	O
channels	NNS	O	O
capable	JJ	O	O
of	IN	O	O
binding	VBG	O	O
substrate	NN	O	O
or	CC	O	O
cofactor	NN	O	O
,	,	O	O
and	CC	O	O
an	DT	O	O
asymmetric	JJ	O	O
form	NN	O	O
in	IN	O	O
which	WDT	O	O
only	RB	O	O
one	CD	O	O
of	IN	O	O
the	DT	O	O
surface	NN	O	O
channels	NNS	O	O
appears	VBZ	O	O
capable	JJ	O	O
of	IN	O	O
binding	VBG	O	O
and	CC	O	O
acetylating	VBG	O	O
polyamines	NNS	O	O
.	.	O	O

SSAT	NNP	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
self-acetylate	JJ	O	O
lysine-26	NN	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
AcCoA	NNP	O	O
and	CC	O	O
absence	NN	O	O
of	IN	O	O
substrate	NN	O	O
,	,	O	O
a	DT	O	O
reaction	NN	O	O
apparently	RB	O	O
catalzyed	VBN	O	O
by	IN	O	O
AcCoA	NNP	O	O
bound	NN	O	O
in	IN	O	O
the	DT	O	O
second	JJ	O	O
channel	NN	O	O
of	IN	O	O
the	DT	O	O
asymmetric	JJ	O	O
dimer	NN	O	O
.	.	O	O

These	DT	O	O
unexpected	JJ	O	O
and	CC	O	O
intriguing	JJ	O	O
complexities	NNS	O	O
seem	VBP	O	O
likely	JJ	O	O
to	TO	O	O
have	VB	O	O
some	DT	O	O
as	IN	O	O
yet	RB	O	O
undefined	JJ	O	O
role	NN	O	O
in	IN	O	O
regulating	VBG	O	O
SSAT	NNP	O	B-enzyme
activity	NN	O	O
or	CC	O	O
stability	NN	O	O
as	IN	O	O
a	DT	O	O
part	NN	O	O
of	IN	O	O
polyamine	JJ	O	B-PRODUCT-OF
homeostasis	NN	O	O
.	.	O	O

Sequence	NNP	O	O
signatures	NNS	O	O
group	NN	O	O
SSAT	NNP	O	O
with	IN	O	O
proteins	NNS	O	O
that	WDT	O	O
appear	VBP	O	O
to	TO	O	O
have	VB	O	O
thialysine	JJ	O	O
Nepsilon-acetyltransferase	NNP	O	O
activity	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Excess	JJ	O	O
activation	NN	O	O
of	IN	O	O
glutamatergic	JJ	O	O
neurotransmission	NN	O	O
in	IN	O	O
the	DT	O	O
cerebral	JJ	O	O
cortex	NN	O	O
following	VBG	O	O
ethanol	NN	O	O
withdrawal	NN	O	O
is	VBZ	O	O
considered	VBN	O	O
to	TO	O	O
contribute	VB	O	O
to	TO	O	O
significant	JJ	O	O
behavioural	JJ	O	O
disturbances	NNS	O	O
,	,	O	O
and	CC	O	O
to	TO	O	O
alcohol	VB	O	O
craving	NN	O	O
.	.	O	O

Astrocytes	NNS	O	O
may	MD	O	O
play	VB	O	O
a	DT	O	O
role	NN	O	O
in	IN	O	O
these	DT	O	O
manifestations	NNS	O	O
because	IN	O	O
astrocytes	NNS	O	O
are	VBP	O	O
essential	JJ	O	O
in	IN	O	O
the	DT	O	O
regulation	NN	O	O
of	IN	O	O
released	VBN	O	O
glutamate	NN	O	B-SUBSTRATE
and	CC	O	O
its	PRP$	O	O
conversion	NN	O	O
to	TO	O	O
glutamine	VB	O	B-PRODUCT-OF
through	IN	O	O
the	DT	O	O
enzyme	JJ	O	O
glutamine	NN	O	B-enzyme
synthetase	NN	O	I-enzyme
(	(	O	O
GS	NNP	O	B-enzyme
)	)	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
it	PRP	O	O
is	VBZ	O	O
unclear	JJ	O	O
if	IN	O	O
withdrawal	NN	O	O
from	IN	O	O
free-choice	JJ	O	O
ethanol	NN	O	O
drinking	NN	O	O
causes	NNS	O	O
changes	NNS	O	O
in	IN	O	O
the	DT	O	O
numbers	NNS	O	O
of	IN	O	O
astrocytes	NNS	O	O
expressing	VBG	O	O
GS	NNP	O	O
or	CC	O	O
the	DT	O	O
cytoskeletal	JJ	O	O
protein	NN	O	O
of	IN	O	O
astrocytes	NNS	O	O
glial	JJ	O	O
fibrillary	JJ	O	O
acidic	NN	O	O
protein	NN	O	O
(	(	O	O
GFAP	NNP	O	O
)	)	O	O
.	.	O	O

Alcohol-preferring	NNP	O	O
(	(	O	O
P	NNP	O	O
)	)	O	O
rats	NNS	O	O
exposed	VBN	O	O
to	TO	O	O
free-choice	JJ	O	O
ethanol	NN	O	O
drinking	NN	O	O
were	VBD	O	O
either	RB	O	O
maintained	VBN	O	O
without	IN	O	O
forced	JJ	O	O
interruption	NN	O	O
of	IN	O	O
ethanol	NN	O	O
drinking	NN	O	O
,	,	O	O
subjected	VBN	O	O
to	TO	O	O
a	DT	O	O
3-day	JJ	O	O
withdrawal	NN	O	O
period	NN	O	O
at	IN	O	O
the	DT	O	O
end	NN	O	O
of	IN	O	O
2	CD	O	O
months	NNS	O	O
,	,	O	O
or	CC	O	O
subjected	VBN	O	O
to	TO	O	O
three	CD	O	O
3-day	JJ	O	O
withdrawal	NN	O	O
periods	NNS	O	O
along	IN	O	O
6	CD	O	O
months	NNS	O	O
.	.	O	O

At	IN	O	O
2	CD	O	O
months	NNS	O	O
,	,	O	O
P	NNP	O	O
rats	NNS	O	O
were	VBD	O	O
also	RB	O	O
compared	VBN	O	O
with	IN	O	O
alcohol-naive	JJ	O	O
alcohol	NN	O	O
non-preferring	JJ	O	O
rats	NNS	O	O
(	(	O	O
NP	NNP	O	O
)	)	O	O
rats	NNS	O	O
.	.	O	O

Packing	VBG	O	O
density	NN	O	O
of	IN	O	O
GS	NNP	O	O
and	CC	O	O
GFAP-immunoreactive	NNP	O	O
(	(	O	O
IR	NNP	O	O
)	)	O	O
astrocytes	VBZ	O	O
was	VBD	O	O
measured	VBN	O	O
in	IN	O	O
sections	NNS	O	O
from	IN	O	O
the	DT	O	O
prelimbic	JJ	O	O
cortex	NN	O	O
(	(	O	O
PLC	NNP	O	O
)	)	O	O
using	VBG	O	O
the	DT	O	O
optical	JJ	O	O
disector	NN	O	O
probe	NN	O	O
.	.	O	O

An	DT	O	O
alcohol	NN	O	O
deprivation	NN	O	O
effect	NN	O	O
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
P	NNP	O	O
rats	NNS	O	O
with	IN	O	O
withdrawals	NNS	O	O
during	IN	O	O
a	DT	O	O
6-month	JJ	O	O
ethanol	NN	O	O
drinking	NN	O	O
period	NN	O	O
.	.	O	O

Ethanol	NNP	O	O
withdrawal	NN	O	O
significantly	RB	O	O
increased	VBD	O	O
the	DT	O	O
packing	VBG	O	O
density	NN	O	O
of	IN	O	O
GS-	NNP	O	O
and	CC	O	O
GFAP-IR	NNP	O	O
astrocytes	NNS	O	O
in	IN	O	O
the	DT	O	O
PLC	NNP	O	O
of	IN	O	O
P	NNP	O	O
rats	NNS	O	O
as	IN	O	O
compared	VBN	O	O
with	IN	O	O
P	NNP	O	O
rats	NNS	O	O
with	IN	O	O
continuous	JJ	O	O
access	NN	O	O
to	TO	O	O
ethanol	VB	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
there	EX	O	O
was	VBD	O	O
a	DT	O	O
positive	JJ	O	O
correlation	NN	O	O
between	IN	O	O
the	DT	O	O
pre-withdrawal	JJ	O	O
ethanol	NN	O	O
consumption	NN	O	O
and	CC	O	O
the	DT	O	O
packing	VBG	O	O
density	NN	O	O
of	IN	O	O
GS-IR	NNP	O	O
astrocytes	NNS	O	O
.	.	O	O

The	DT	O	O
present	JJ	O	O
results	NNS	O	O
suggest	VBP	O	O
the	DT	O	O
involvement	NN	O	O
of	IN	O	O
astrocytes	NNS	O	O
in	IN	O	O
the	DT	O	O
regulation	NN	O	O
of	IN	O	O
the	DT	O	O
glutamatergic	JJ	O	O
activation	NN	O	O
associated	VBN	O	O
with	IN	O	O
withdrawal	NN	O	O
from	IN	O	O
free-choice	JJ	O	O
ethanol	NN	O	O
consumption	NN	O	O
and	CC	O	O
point	NN	O	O
to	TO	O	O
differential	JJ	O	O
adaptations	NNS	O	O
of	IN	O	O
GS	NNP	O	O
and	CC	O	O
GFAP	NNP	O	O
to	TO	O	O
prolonged	VB	O	O
alcohol	NN	O	O
drinking	NN	O	O
in	IN	O	O
the	DT	O	O
PLC	NNP	O	O
of	IN	O	O
P	NNP	O	O
rats	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

BACKGROUND	NN	O	O
:	:	O	O
There	EX	O	O
have	VBP	O	O
been	VBN	O	O
many	JJ	O	O
studies	NNS	O	O
of	IN	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
high-dose	JJ	O	O
supplementation	NN	O	O
of	IN	O	O
vitamin	NN	O	O
B6	NNP	O	O
on	IN	O	O
children	NNS	O	O
and	CC	O	O
adults	NNS	O	O
with	IN	O	O
autism	NN	O	O
,	,	O	O
with	IN	O	O
all	DT	O	O
but	CC	O	O
one	CD	O	O
reporting	NN	O	O
benefits	NNS	O	O
.	.	O	O

OBJECTIVE	NN	O	O
:	:	O	O
The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
biochemical	JJ	O	O
basis	NN	O	O
for	IN	O	O
vitamin	NN	O	O
B6	NNP	O	O
therapy	NN	O	O
by	IN	O	O
measuring	VBG	O	O
the	DT	O	O
level	NN	O	O
of	IN	O	O
total	JJ	O	O
vitamin	NN	O	O
B6	NNP	O	O
in	IN	O	O
the	DT	O	O
plasma	NN	O	O
of	IN	O	O
unsupplemented	JJ	O	O
children	NNS	O	O
with	IN	O	O
autism	NN	O	O
spectrum	NN	O	O
disorder	NN	O	O
compared	VBN	O	O
to	TO	O	O
unsupplemented	JJ	O	O
control	NN	O	O
subjects	NNS	O	O
.	.	O	O

PARTICIPANTS	NNS	O	O
:	:	O	O
Children	NN	O	O
with	IN	O	O
autism	NN	O	O
spectrum	NN	O	O
disorders	NNS	O	O
(	(	O	O
n	JJ	O	O
=	NN	O	O
35	CD	O	O
,	,	O	O
age	NN	O	O
3-9	CD	O	O
years	NNS	O	O
)	)	O	O
and	CC	O	O
unrelated	JJ	O	O
typical	JJ	O	O
children	NNS	O	O
(	(	O	O
n	JJ	O	O
=	NN	O	O
11	CD	O	O
,	,	O	O
age	NN	O	O
6-9	JJ	O	O
years	NNS	O	O
)	)	O	O
,	,	O	O
all	DT	O	O
from	IN	O	O
Arizona	NNP	O	O
,	,	O	O
were	VBD	O	O
studied	VBN	O	O
.	.	O	O

(	(	O	O
This	DT	O	O
includes	VBZ	O	O
the	DT	O	O
data	NN	O	O
from	IN	O	O
24	CD	O	O
children	NNS	O	O
with	IN	O	O
autism	NN	O	O
from	IN	O	O
our	PRP$	O	O
previous	JJ	O	O
study	NN	O	O
.	.	O	O
)	)	O	O

METHODOLOGY	NN	O	O
:	:	O	O
A	DT	O	O
microbiologic	JJ	O	O
assay	NN	O	O
was	VBD	O	O
used	VBN	O	O
to	TO	O	O
measure	VB	O	O
the	DT	O	O
level	NN	O	O
of	IN	O	O
total	JJ	O	O
vitamin	NN	O	O
B6	NNP	O	O
(	(	O	O
including	VBG	O	O
phosphorylated	VBN	O	O
and	CC	O	O
unphosphorylated	JJ	O	O
forms	NNS	O	O
)	)	O	O
,	,	O	O
in	IN	O	O
a	DT	O	O
blinded	JJ	O	O
fashion	NN	O	O
.	.	O	O

RESULTS	NN	O	O
:	:	O	O
Children	NNP	O	O
with	IN	O	O
autism	NN	O	O
had	VBD	O	O
a	DT	O	O
75	CD	O	O
%	NN	O	O
higher	JJR	O	O
level	NN	O	O
of	IN	O	O
total	JJ	O	O
vitamin	NN	O	O
B6	NNP	O	O
than	IN	O	O
the	DT	O	O
controls	NNS	O	O
(	(	O	O
medians	NNS	O	O
of	IN	O	O
56	CD	O	O
versus	NN	O	O
32	CD	O	O
ng/mL	NN	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
p	JJ	O	O
=	NNP	O	O
0.00002	CD	O	O
)	)	O	O
.	.	O	O

Most	JJS	O	O
of	IN	O	O
the	DT	O	O
autistic	JJ	O	O
children	NNS	O	O
(	(	O	O
77	CD	O	O
%	NN	O	O
)	)	O	O
had	VBD	O	O
levels	NNS	O	O
that	WDT	O	O
were	VBD	O	O
more	JJR	O	O
than	IN	O	O
2	CD	O	O
standard	JJ	O	O
deviations	NNS	O	O
above	IN	O	O
the	DT	O	O
median	JJ	O	O
value	NN	O	O
of	IN	O	O
the	DT	O	O
controls	NNS	O	O
.	.	O	O

The	DT	O	O
autistic	JJ	O	O
girls	NNS	O	O
(	(	O	O
n	JJ	O	O
=	NNP	O	O
5	CD	O	O
)	)	O	O
also	RB	O	O
had	VBD	O	O
elevated	VBN	O	O
levels	NNS	O	O
(	(	O	O
mean	NN	O	O
of	IN	O	O
54.6	CD	O	O
ng/mL	NNS	O	O
,	,	O	O
median	NN	O	O
of	IN	O	O
60	CD	O	O
ng/mL	NN	O	O
)	)	O	O
.	.	O	O

DISCUSSION	NN	O	O
:	:	O	O
These	DT	O	O
results	NNS	O	O
are	VBP	O	O
consistent	JJ	O	O
with	IN	O	O
previous	JJ	O	O
studies	NNS	O	O
that	WDT	O	O
found	VBD	O	O
that	IN	O	O
:	:	O	O
(	(	O	O
1	CD	O	O
)	)	O	O
pyridoxal	NN	O	O
kinase	NN	O	O
had	VBD	O	O
a	DT	O	O
very	RB	O	O
low	JJ	O	O
activity	NN	O	O
in	IN	O	O
children	NNS	O	O
with	IN	O	O
autism	NN	O	O
and	CC	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
pyridoxal	NN	O	O
5	CD	O	O
phosphate	NN	O	O
(	(	O	O
PLP	NNP	O	O
)	)	O	O
levels	NNS	O	O
are	VBP	O	O
unusually	RB	O	O
low	JJ	O	O
in	IN	O	O
children	NNS	O	O
with	IN	O	O
autism	NN	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
it	PRP	O	O
appears	VBZ	O	O
that	IN	O	O
the	DT	O	O
low	JJ	O	O
conversion	NN	O	O
of	IN	O	O
pyridoxal	NN	O	O
and	CC	O	O
pyridoxine	NN	O	O
to	TO	O	O
PLP	NNP	O	O
results	NNS	O	O
in	IN	O	O
low	JJ	O	O
levels	NNS	O	O
of	IN	O	O
PLP	NNP	O	O
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
the	DT	O	O
active	JJ	O	O
cofactor	NN	O	O
for	IN	O	O
113	CD	O	O
known	JJ	O	O
enzymatic	JJ	O	O
reactions	NNS	O	O
,	,	O	O
including	VBG	O	O
the	DT	O	O
formation	NN	O	O
of	IN	O	O
many	JJ	O	O
key	JJ	O	O
neurotransmitters	NNS	O	O
.	.	O	O

CONCLUSIONS	NN	O	O
:	:	O	O
Total	JJ	O	O
vitamin	NN	O	O
B6	NNP	O	O
is	VBZ	O	O
abnormally	RB	O	O
high	JJ	O	O
in	IN	O	O
autism	NN	O	O
,	,	O	O
consistent	JJ	O	O
with	IN	O	O
previous	JJ	O	O
reports	NNS	O	O
of	IN	O	O
an	DT	O	O
impaired	JJ	O	O
pyridoxal	NN	O	B-enzyme
kinase	NN	O	I-enzyme
for	IN	O	O
the	DT	O	O
conversion	NN	O	O
of	IN	O	O
pyridoxine	NN	O	B-SUBSTRATE
and	CC	O	O
pyridoxal	NN	O	B-SUBSTRATE
to	TO	O	O
PLP	NNP	O	B-PRODUCT-OF
.	.	O	O

This	DT	O	O
may	MD	O	O
explain	VB	O	O
the	DT	O	O
many	JJ	O	O
published	VBN	O	O
studies	NNS	O	O
of	IN	O	O
benefits	NNS	O	O
of	IN	O	O
high-dose	JJ	O	O
vitamin	NN	O	O
B6	NNP	O	O
supplementation	NN	O	O
in	IN	O	O
some	DT	O	O
children	NNS	O	O
and	CC	O	O
adults	NNS	O	O
with	IN	O	O
autism	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Dietary	NNP	O	O
soy	NN	O	O
protein	NN	O	O
isolate	NN	O	O
(	(	O	O
SPI	NNP	O	O
)	)	O	O
reduces	VBZ	O	O
hepatic	JJ	O	O
lipogenesis	NN	O	O
by	IN	O	O
suppressing	VBG	O	O
gene	NN	O	O
expression	NN	O	O
of	IN	O	O
lipogenic	JJ	O	O
enzymes	NNS	O	O
,	,	O	O
including	VBG	O	O
acetyl-CoA	JJ	O	O
carboxylase	NN	O	O
(	(	O	O
ACC	NNP	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
order	NN	O	O
to	TO	O	O
elucidate	VB	O	O
the	DT	O	O
mechanism	NN	O	O
of	IN	O	O
this	DT	O	O
regulation	NN	O	O
,	,	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
dietary	JJ	O	O
SPI	NNP	O	O
on	IN	O	O
promoter	NN	O	O
(	(	O	O
PI	NNP	O	O
and	CC	O	O
PII	NNP	O	O
)	)	O	O
specific	JJ	O	O
gene	NN	O	O
expression	NN	O	O
of	IN	O	O
ACC	NNP	O	O
alpha	NN	O	O
was	VBD	O	O
investigated	VBN	O	O
.	.	O	O

Rats	NNS	O	O
were	VBD	O	O
fed	VBN	O	O
experimental	JJ	O	O
diets	NNS	O	O
containing	VBG	O	O
SPI	NNP	O	O
or	CC	O	O
casein	NN	O	B-enzyme
as	IN	O	O
a	DT	O	O
nitrogen	NN	O	B-PRODUCT-OF
source	NN	O	O
.	.	O	O

SPI	NNP	O	O
feeding	NN	O	O
decreased	VBD	O	O
the	DT	O	O
hepatic	JJ	O	O
contents	NNS	O	O
of	IN	O	O
total	JJ	O	O
ACC	NNP	O	O
mRNA	NN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
triglyceride	NN	O	O
(	(	O	O
TG	NNP	O	O
)	)	O	O
content	NN	O	O
,	,	O	O
but	CC	O	O
dietary	JJ	O	O
SPI	NNP	O	O
affected	VBD	O	O
the	DT	O	O
amount	NN	O	O
of	IN	O	O
sterol-regulatory	JJ	O	O
element	NN	O	O
binding	VBG	O	O
protein	NN	O	O
(	(	O	O
SREBP	NNP	O	O
)	)	O	O
-1	VBP	O	O
mRNA	NN	O	O
and	CC	O	O
protein	VB	O	O
very	RB	O	O
little	JJ	O	O
.	.	O	O

The	DT	O	O
amount	NN	O	O
of	IN	O	O
ACC	NNP	O	O
mRNA	FW	O	O
transcribed	VBN	O	O
from	IN	O	O
PII	NNP	O	O
promoter	NN	O	O
containing	VBG	O	O
SRE	NNP	O	O
was	VBD	O	O
not	RB	O	O
significantly	RB	O	O
affected	VBN	O	O
by	IN	O	O
dietary	JJ	O	O
protein	NNS	O	O
,	,	O	O
while	IN	O	O
a	DT	O	O
significant	JJ	O	O
decrease	NN	O	O
in	IN	O	O
PI-generated	NNP	O	O
ACC	NNP	O	O
mRNA	FW	O	O
content	NN	O	O
was	VBD	O	O
observed	VBN	O	O
in	IN	O	O
rats	NNS	O	O
fed	VBP	O	O
the	DT	O	O
SPI	NNP	O	O
diet	NN	O	O
.	.	O	O

These	DT	O	O
data	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
SPI	NNP	O	O
feeding	VBG	O	O
decreased	VBD	O	O
the	DT	O	O
hepatic	JJ	O	O
contents	NNS	O	O
of	IN	O	O
ACC	NNP	O	O
alpha	FW	O	O
mRNA	NN	O	O
mainly	RB	O	O
by	IN	O	O
regulating	VBG	O	O
PI	NNP	O	O
promoter	NN	O	O
via	IN	O	O
a	DT	O	O
nuclear	JJ	O	O
factor	NN	O	O
(	(	O	O
s	NN	O	O
)	)	O	O
other	JJ	O	O
than	IN	O	O
SREBP-1	NNP	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Reduced	VBN	O	O
synthesis	NN	O	O
of	IN	O	O
nitric	JJ	O	B-PRODUCT-OF
oxide	NN	O	I-PRODUCT-OF
(	(	O	O
NO	NNP	O	B-PRODUCT-OF
)	)	O	O
contributes	VBZ	O	O
to	TO	O	O
the	DT	O	O
endothelial	JJ	O	O
dysfunction	NN	O	O
and	CC	O	O
may	MD	O	O
be	VB	O	O
related	VBN	O	O
to	TO	O	O
limited	JJ	O	O
availability	NN	O	O
of	IN	O	O
L-arginine	NNP	O	B-SUBSTRATE
,	,	O	O
the	DT	O	O
common	JJ	O	O
substrate	NN	O	O
of	IN	O	O
constitutive	JJ	O	B-enzyme
nitric-oxide	JJ	O	I-enzyme
synthase	NN	O	O
(	(	O	O
NOS	NNP	O	B-enzyme
)	)	O	O
and	CC	O	O
cytosolic	JJ	O	O
arginase	NN	O	B-enzyme
I	PRP	O	I-enzyme
and	CC	O	O
mitochondrial	JJ	O	B-enzyme
arginase	NN	O	I-enzyme
II	NNP	O	O
.	.	O	O

To	TO	O	O
determine	VB	O	O
whether	IN	O	O
arginases	NNS	O	B-enzyme
modulate	VBP	O	O
the	DT	O	O
endothelial	JJ	O	O
NO	NNP	O	B-PRODUCT-OF
synthesis	NN	O	O
,	,	O	O
we	PRP	O	O
investigated	VBD	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
the	DT	O	O
competitive	JJ	O	O
arginase	NN	O	O
inhibitor	NN	O	O
N	NNP	O	O
(	(	O	O
omega	PRP	O	O
)	)	O	O
-hydroxy-nor-L-arginine	NN	O	O
(	(	O	O
Nor-NOHA	NNP	O	O
)	)	O	O
on	IN	O	O
the	DT	O	O
activity	NN	O	O
of	IN	O	O
NOS	NNP	O	O
,	,	O	O
arginases	VBZ	O	O
,	,	O	O
and	CC	O	O
L-arginine	NNP	O	O
transporter	NN	O	O
and	CC	O	O
on	IN	O	O
NO	NNP	O	O
release	NN	O	O
at	IN	O	O
surface	NN	O	O
of	IN	O	O
human	JJ	O	O
umbilical	JJ	O	O
vein	NN	O	O
endothelial	JJ	O	O
cells	NNS	O	O
(	(	O	O
HUVECs	NNP	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
unstimulated	JJ	O	O
cells	NNS	O	O
,	,	O	O
Nor-NOHA	JJ	O	O
dose-dependently	RB	O	O
reduced	VBD	O	O
the	DT	O	O
arginase	NN	O	O
activity	NN	O	O
with	IN	O	O
maximal	JJ	O	O
inhibition	NN	O	O
at	IN	O	O
20	CD	O	O
microM	NN	O	O
.	.	O	O

When	WRB	O	O
HUVECs	NNP	O	O
were	VBD	O	O
stimulated	VBN	O	O
by	IN	O	O
thrombin	NN	O	O
without	IN	O	O
extracellular	JJ	O	O
L-arginine	JJ	O	O
,	,	O	O
Nor-NOHA	JJ	O	O
dose-dependently	RB	O	O
increased	VBD	O	O
the	DT	O	O
NOS	NNP	O	O
activity	NN	O	O
and	CC	O	O
the	DT	O	O
NO	NNP	O	O
release	NN	O	O
with	IN	O	O
maximal	JJ	O	O
effects	NNS	O	O
at	IN	O	O
20	CD	O	O
microM	NN	O	O
.	.	O	O

Extracellular	JJ	O	O
L-arginine	NNP	O	O
also	RB	O	O
dose-dependently	RB	O	O
increased	JJ	O	O
NO	NNP	O	O
release	NN	O	O
and	CC	O	O
arginase	NN	O	O
activity	NN	O	O
.	.	O	O

When	WRB	O	O
HUVECs	NNP	O	O
were	VBD	O	O
stimulated	VBN	O	O
by	IN	O	O
thrombin	NN	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
100	CD	O	O
microM	JJ	O	O
L-arginine	NNP	O	O
,	,	O	O
NOS	NNP	O	O
activity	NN	O	O
and	CC	O	O
NO	DT	O	O
release	NN	O	O
were	VBD	O	O
similar	JJ	O	O
in	IN	O	O
untreated	JJ	O	O
and	CC	O	O
Nor-NOHA-treated	JJ	O	O
cells	NNS	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
despite	IN	O	O
activation	NN	O	O
of	IN	O	O
L-arginine	NNP	O	O
uptake	NN	O	O
,	,	O	O
the	DT	O	O
inhibition	NN	O	O
of	IN	O	O
arginase	NN	O	O
activity	NN	O	O
by	IN	O	O
Nor-NOHA	NNP	O	O
was	VBD	O	O
still	RB	O	O
significant	JJ	O	O
.	.	O	O

The	DT	O	O
depletion	NN	O	O
of	IN	O	O
freely	RB	O	O
exchangeable	JJ	O	O
L-arginine	JJ	O	O
pools	NNS	O	O
with	IN	O	O
extracellular	JJ	O	O
L-lysine	NNP	O	O
did	VBD	O	O
not	RB	O	O
prevent	VB	O	O
Nor-NOHA	NNP	O	O
from	IN	O	O
increasing	VBG	O	O
the	DT	O	O
NO	NNP	O	O
release	NN	O	O
.	.	O	O

This	DT	O	O
indicates	VBZ	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
pools	NNS	O	O
,	,	O	O
which	WDT	O	O
are	VBP	O	O
accessible	JJ	O	O
to	TO	O	O
NOS	NNP	O	O
and	CC	O	O
arginase	NN	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
exchangeable	JJ	O	O
.	.	O	O

Interestingly	RB	O	O
,	,	O	O
the	DT	O	O
mitochondrial	JJ	O	O
arginase	NN	O	O
II	NNP	O	O
was	VBD	O	O
constitutively	RB	O	O
expressed	VBN	O	O
,	,	O	O
whereas	IN	O	O
the	DT	O	O
cytosolic	JJ	O	O
arginase	NN	O	O
I	PRP	O	O
was	VBD	O	O
barely	RB	O	O
detectable	JJ	O	O
in	IN	O	O
HUVECs	NNP	O	O
.	.	O	O

These	DT	O	O
data	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
endothelial	JJ	O	O
NO	NNP	O	B-PRODUCT-OF
synthesis	NN	O	O
depends	VBZ	O	O
on	IN	O	O
the	DT	O	O
activity	NN	O	O
of	IN	O	O
arginase	NN	O	B-enzyme
II	NNP	O	I-enzyme
in	IN	O	O
mitochondria	NN	O	O
and	CC	O	O
l-arginine	JJ	O	O
carriers	NNS	O	O
in	IN	O	O
cell	NN	O	O
membrane	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Density	NNP	O	O
functional	JJ	O	O
theory	NN	O	O
calculations	NNS	O	O
using	VBG	O	O
the	DT	O	O
hybrid	JJ	O	O
functional	JJ	O	O
B3LYP	NNP	O	O
have	VBP	O	O
been	VBN	O	O
performed	VBN	O	O
to	TO	O	O
study	VB	O	O
the	DT	O	O
methyl	NN	O	B-SUBSTRATE
transfer	NN	O	O
step	NN	O	O
in	IN	O	O
glycine	JJ	O	B-enzyme
N-methyltransferase	NNP	O	I-enzyme
(	(	O	O
GNMT	NNP	O	B-enzyme
)	)	O	O
.	.	O	O

This	DT	O	O
enzyme	NN	O	O
catalyzes	VBZ	O	O
the	DT	O	O
S-adenosyl-L-methionine	NNP	O	O
(	(	O	O
SAM	NNP	O	O
)	)	O	O
-dependent	NN	O	O
methylation	NN	O	O
of	IN	O	O
glycine	NN	O	O
to	TO	O	O
form	VB	O	O
sarcosine	NN	O	O
.	.	O	O

The	DT	O	O
starting	NN	O	O
point	NN	O	O
for	IN	O	O
the	DT	O	O
calculations	NNS	O	O
is	VBZ	O	O
the	DT	O	O
recent	JJ	O	O
X-ray	JJ	O	O
crystal	NN	O	O
structure	NN	O	O
of	IN	O	O
GNMT	NNP	O	B-enzyme
complexed	NN	O	O
with	IN	O	O
SAM	NNP	O	B-SUBSTRATE
and	CC	O	O
acetate	NN	O	O
.	.	O	O

Several	JJ	O	O
quantum	JJ	O	O
chemical	NN	O	O
models	NNS	O	O
with	IN	O	O
different	JJ	O	O
sizes	NNS	O	O
,	,	O	O
employing	VBG	O	O
up	RP	O	O
to	TO	O	O
98	CD	O	O
atoms	NNS	O	O
,	,	O	O
were	VBD	O	O
used	VBN	O	O
.	.	O	O

The	DT	O	O
calculations	NNS	O	O
demonstrate	VBP	O	O
that	IN	O	O
the	DT	O	O
suggested	JJ	O	O
mechanism	NN	O	O
,	,	O	O
where	WRB	O	O
the	DT	O	O
methyl	NN	O	O
group	NN	O	O
is	VBZ	O	O
transferred	VBN	O	O
in	IN	O	O
a	DT	O	O
single	JJ	O	O
S	NNP	O	O
(	(	O	O
N	NNP	O	O
)	)	O	O
2	CD	O	O
step	NN	O	O
,	,	O	O
is	VBZ	O	O
thermodynamically	RB	O	O
plausible	JJ	O	O
.	.	O	O

By	IN	O	O
adding	VBG	O	O
or	CC	O	O
eliminating	VBG	O	O
various	JJ	O	O
groups	NNS	O	O
at	IN	O	O
the	DT	O	O
active	JJ	O	O
site	NN	O	O
,	,	O	O
it	PRP	O	O
was	VBD	O	O
furthermore	RB	O	O
demonstrated	JJ	O	O
that	IN	O	O
hydrogen	NN	O	O
bonds	NNS	O	O
to	TO	O	O
the	DT	O	O
amino	NN	O	O
group	NN	O	O
of	IN	O	O
the	DT	O	O
glycine	NN	O	O
substrate	NN	O	O
lower	RBR	O	O
the	DT	O	O
reaction	NN	O	O
barrier	NN	O	O
,	,	O	O
while	IN	O	O
hydrogen	NN	O	O
bonds	NNS	O	O
to	TO	O	O
the	DT	O	O
carboxylate	NN	O	O
group	NN	O	O
raise	VB	O	O
the	DT	O	O
barrier	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Estrogens	NNS	O	B-PRODUCT-OF
are	VBP	O	O
biosynthesised	VBN	O	O
from	IN	O	O
androgens	NNS	O	B-SUBSTRATE
by	IN	O	O
the	DT	O	O
CYP450	NNP	O	B-enzyme
enzyme	NN	O	O
complex	NN	O	O
called	VBN	O	O
aromatase	NN	O	B-enzyme
.	.	O	O

Aromatase	NNP	O	O
is	VBZ	O	O
expressed	VBN	O	O
in	IN	O	O
the	DT	O	O
ovary	JJ	O	O
,	,	O	O
placenta	NN	O	O
,	,	O	O
brain	NN	O	O
,	,	O	O
bone	NN	O	O
,	,	O	O
adipose	JJ	O	O
tissue	NN	O	O
and	CC	O	O
breast	NN	O	O
tissue	NN	O	O
.	.	O	O

In	IN	O	O
breast	NN	O	O
cancer	NN	O	O
,	,	O	O
intratumoural	JJ	O	O
aromatase	NN	O	B-enzyme
is	VBZ	O	O
the	DT	O	O
source	NN	O	O
for	IN	O	O
local	JJ	O	O
estrogen	NN	O	B-PRODUCT-OF
production	NN	O	O
in	IN	O	O
the	DT	O	O
tissue	NN	O	O
.	.	O	O

Inhibition	NN	O	O
of	IN	O	O
aromatase	NN	O	O
is	VBZ	O	O
an	DT	O	O
important	JJ	O	O
approach	NN	O	O
for	IN	O	O
reducing	VBG	O	O
growth	NN	O	O
stimulatory	JJ	O	O
effects	NNS	O	O
of	IN	O	O
estrogens	NNS	O	O
in	IN	O	O
estrogen-dependent	JJ	O	O
breast	NN	O	O
cancer	NN	O	O
.	.	O	O

The	DT	O	O
potent	NN	O	O
and	CC	O	O
selective	JJ	O	O
third-generation	NN	O	O
aromatase	NN	O	O
inhibitors	NNS	O	O
anastrozole	VBP	O	O
,	,	O	O
letrozole	JJ	O	O
and	CC	O	O
exemestane	NN	O	O
were	VBD	O	O
introduced	VBN	O	O
to	TO	O	O
the	DT	O	O
market	NN	O	O
as	IN	O	O
endocrine	JJ	O	O
therapy	NN	O	O
in	IN	O	O
postmenopausal	NN	O	O
patients	NNS	O	O
failing	VBG	O	O
anti-estrogen	JJ	O	O
therapy	NN	O	O
alone	RB	O	O
,	,	O	O
or	CC	O	O
multiple	JJ	O	O
hormonal	JJ	O	O
therapies	NNS	O	O
.	.	O	O

Anastrozole	NNP	O	O
and	CC	O	O
letrozole	NN	O	O
are	VBP	O	O
both	DT	O	O
non-steroidal	JJ	O	O
aromatase	NN	O	O
inhibitors	NNS	O	O
that	WDT	O	O
compete	VBP	O	O
with	IN	O	O
the	DT	O	O
substrate	NN	O	O
for	IN	O	O
binding	VBG	O	O
to	TO	O	O
the	DT	O	O
enzyme	NN	O	O
active	JJ	O	O
site	NN	O	O
.	.	O	O

Exemestane	NNP	O	O
is	VBZ	O	O
a	DT	O	O
mechanism-based	JJ	O	O
steroidal	NN	O	O
inhibitor	NN	O	O
that	WDT	O	O
mimics	VBZ	O	O
the	DT	O	O
substrate	NN	O	O
,	,	O	O
is	VBZ	O	O
converted	VBN	O	O
by	IN	O	O
the	DT	O	O
enzyme	NN	O	O
to	TO	O	O
a	DT	O	O
reactive	JJ	O	O
intermediate	NN	O	O
,	,	O	O
and	CC	O	O
results	NNS	O	O
in	IN	O	O
inactivation	NN	O	O
of	IN	O	O
aromatase	NN	O	O
.	.	O	O

These	DT	O	O
third-generation	JJ	O	O
aromatase	NN	O	O
inhibitors	NNS	O	O
are	VBP	O	O
currently	RB	O	O
approved	VBN	O	O
as	IN	O	O
first-line	JJ	O	O
therapy	NN	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
postmenopausal	JJ	O	O
women	NNS	O	O
with	IN	O	O
metastatic	JJ	O	O
estrogen-dependent	JJ	O	O
breast	NN	O	O
cancer	NN	O	O
.	.	O	O

The	DT	O	O
use	NN	O	O
of	IN	O	O
an	DT	O	O
aromatase	NN	O	O
inhibitor	NN	O	O
as	IN	O	O
initial	JJ	O	O
therapy	NN	O	O
,	,	O	O
or	CC	O	O
after	IN	O	O
treatment	NN	O	O
with	IN	O	O
tamoxifen	NN	O	O
,	,	O	O
is	VBZ	O	O
now	RB	O	O
recommended	VBN	O	O
as	IN	O	O
adjuvant	JJ	O	O
hormonal	JJ	O	O
therapy	NN	O	O
for	IN	O	O
postmenopausal	JJ	O	O
women	NNS	O	O
with	IN	O	O
hormone-dependent	JJ	O	O
breast	NN	O	O
cancer	NN	O	O
.	.	O	O

Several	JJ	O	O
clinical	JJ	O	O
studies	NNS	O	O
of	IN	O	O
aromatase	NN	O	O
inhibitors	NNS	O	O
focus	VBP	O	O
on	IN	O	O
the	DT	O	O
use	NN	O	O
of	IN	O	O
these	DT	O	O
agents	NNS	O	O
in	IN	O	O
the	DT	O	O
adjuvant	JJ	O	O
setting	NN	O	O
,	,	O	O
for	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
early	JJ	O	O
breast	NN	O	O
cancer	NN	O	O
.	.	O	O

Recently	RB	O	O
published	VBN	O	O
results	NNS	O	O
show	VBP	O	O
improved	JJ	O	O
responses	NNS	O	O
with	IN	O	O
these	DT	O	O
agents	NNS	O	O
compared	VBN	O	O
with	IN	O	O
tamoxifen	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

BACKGROUND	NN	O	O
:	:	O	O
Histamine	NNP	O	B-PRODUCT-OF
synthesized	VBN	O	O
by	IN	O	O
histidine	JJ	O	B-enzyme
decarboxylase	NN	O	I-enzyme
(	(	O	O
HDC	NNP	O	B-enzyme
)	)	O	O
from	IN	O	O
L-histidine	NNP	O	B-SUBSTRATE
is	VBZ	O	O
a	DT	O	O
major	JJ	O	O
chemical	NN	O	O
mediator	NN	O	O
in	IN	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
nasal	NN	O	O
allergy	NN	O	O
which	WDT	O	O
is	VBZ	O	O
characterized	VBN	O	O
by	IN	O	O
nasal	JJ	O	O
hypersensitivity	NN	O	O
.	.	O	O

However	RB	O	O
the	DT	O	O
regulatory	JJ	O	O
mechanism	NN	O	O
of	IN	O	O
histamine	JJ	O	B-PRODUCT-OF
synthesis	NN	O	O
by	IN	O	O
HDC	NNP	O	B-enzyme
remains	VBZ	O	O
to	TO	O	O
be	VB	O	O
elucidated	VBN	O	O
.	.	O	O

The	DT	O	O
objectives	NNS	O	O
of	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
were	VBD	O	O
to	TO	O	O
examine	VB	O	O
the	DT	O	O
changes	NNS	O	O
of	IN	O	O
histamine	NN	O	O
content	NN	O	O
,	,	O	O
HDC	NNP	O	O
activity	NN	O	O
and	CC	O	O
HDC	NNP	O	O
mRNA	NNP	O	O
expression	NN	O	O
in	IN	O	O
the	DT	O	O
nasal	JJ	O	O
mucosa	NN	O	O
of	IN	O	O
allergy	JJ	O	O
model	NN	O	O
rats	NNS	O	O
sensitized	VBN	O	O
by	IN	O	O
the	DT	O	O
exposure	NN	O	O
to	TO	O	O
toluene	VB	O	O
diisocyanate	NN	O	O
(	(	O	O
TDI	NNP	O	O
)	)	O	O
and	CC	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
dexamethasone	NN	O	O
on	IN	O	O
the	DT	O	O
above	NN	O	O
mentioned	VBD	O	O
allergic	JJ	O	O
parameters	NNS	O	O
.	.	O	O

METHODS	NN	O	O
:	:	O	O
Rats	NNS	O	O
were	VBD	O	O
sensitized	VBN	O	O
and	CC	O	O
provocated	VBN	O	O
by	IN	O	O
TDI	NNP	O	O
and	CC	O	O
the	DT	O	O
nasal	JJ	O	O
allergy-like	JJ	O	O
behaviors	NNS	O	O
were	VBD	O	O
scored	VBN	O	O
during	IN	O	O
a	DT	O	O
10	CD	O	O
minute	NN	O	O
period	NN	O	O
after	IN	O	O
provocation	NN	O	O
.	.	O	O

Histamine	NNP	O	O
content	NN	O	O
and	CC	O	O
HDC	NNP	O	O
activity	NN	O	O
in	IN	O	O
the	DT	O	O
nasal	JJ	O	O
mucosa	NN	O	O
were	VBD	O	O
determined	VBN	O	O
using	VBG	O	O
fluorometric	JJ	O	O
high	JJ	O	O
performance	NN	O	O
liquid	NN	O	O
chromatography	NN	O	O
.	.	O	O

The	DT	O	O
expression	NN	O	O
of	IN	O	O
HDC	NNP	O	O
mRNA	NN	O	O
in	IN	O	O
nasal	JJ	O	O
mucosa	NN	O	O
was	VBD	O	O
determined	VBN	O	O
using	VBG	O	O
real-time	JJ	O	O
quantitative	JJ	O	O
reverse	NN	O	O
transcriptase-polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
(	(	O	O
RT-PCR	NNP	O	O
)	)	O	O
.	.	O	O

RESULTS	NN	O	O
:	:	O	O
In	IN	O	O
TDI-sensitized	NNP	O	O
rats	NNS	O	O
,	,	O	O
nasal	JJ	O	O
allergy-like	JJ	O	O
behaviors	NNS	O	O
such	JJ	O	O
as	IN	O	O
sneezing	NN	O	O
and	CC	O	O
watery	NN	O	O
rhinorrhea	NN	O	O
were	VBD	O	O
induced	VBN	O	O
.	.	O	O

Histamine	NNP	O	O
content	NN	O	O
,	,	O	O
HDC	NNP	O	O
activity	NN	O	O
and	CC	O	O
HDC	NNP	O	O
mRNA	NNP	O	O
expression	NN	O	O
in	IN	O	O
nasal	JJ	O	O
mucosa	NN	O	O
were	VBD	O	O
also	RB	O	O
significantly	RB	O	O
increased	VBN	O	O
after	IN	O	O
TDI	NNP	O	O
provocation	NN	O	O
.	.	O	O

Pretreatment	NN	O	O
with	IN	O	O
dexamethasone	NN	O	O
significantly	RB	O	O
suppressed	VBD	O	O
nasal	JJ	O	O
allergy-like	JJ	O	O
behaviors	NNS	O	O
,	,	O	O
up-regulation	NN	O	O
of	IN	O	O
histamine	NN	O	O
content	NN	O	O
,	,	O	O
HDC	NNP	O	O
activity	NN	O	O
and	CC	O	O
HDC	NNP	O	O
mRNA	NN	O	O
induced	VBN	O	O
by	IN	O	O
TDI	NNP	O	O
in	IN	O	O
TDI-sensitized	NNP	O	O
rats	NNS	O	O
.	.	O	O

CONCLUSIONS	NN	O	O
:	:	O	O
These	DT	O	O
findings	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
increased	VBD	O	O
synthesis	NN	O	O
of	IN	O	O
histamine	NN	O	B-PRODUCT-OF
through	IN	O	O
up-regulation	NN	O	O
of	IN	O	O
HDC	NNP	O	B-enzyme
gene	NN	O	O
expression	NN	O	O
and	CC	O	O
HDC	NNP	O	B-enzyme
activity	NN	O	O
in	IN	O	O
nasal	JJ	O	O
mucosa	NN	O	O
plays	VBZ	O	O
an	DT	O	O
important	JJ	O	O
role	NN	O	O
in	IN	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
nasal	JJ	O	O
hypersensitivity	NN	O	O
.	.	O	O

Repression	NN	O	O
of	IN	O	O
HDC	NNP	O	O
gene	NN	O	O
expression	NN	O	O
and	CC	O	O
HDC	NNP	O	O
activity	NN	O	O
by	IN	O	O
dexamethasone	NN	O	O
may	MD	O	O
underlie	VB	O	O
its	PRP$	O	O
therapeutic	JJ	O	O
effect	NN	O	O
in	IN	O	O
the	DT	O	O
treatment	NN	O	O
of	IN	O	O
allergy	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Homocysteine	NNP	O	O
(	(	O	O
Hcy	NNP	O	O
)	)	O	O
is	VBZ	O	O
thought	VBN	O	O
to	TO	O	O
play	VB	O	O
an	DT	O	O
important	JJ	O	O
role	NN	O	O
in	IN	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
osteoporosis	NN	O	O
and	CC	O	O
fracture	NN	O	O
.	.	O	O

Methionine	NNP	O	B-enzyme
synthase	NN	O	I-enzyme
reductase	NN	O	O
(	(	O	O
MTRR	NNP	O	B-enzyme
)	)	O	O
is	VBZ	O	O
an	DT	O	O
enzyme	NN	O	O
involved	VBN	O	O
in	IN	O	O
the	DT	O	O
conversion	NN	O	O
of	IN	O	O
Hcy	NNP	O	B-SUBSTRATE
to	TO	O	O
methionine	VB	O	B-PRODUCT-OF
.	.	O	O

We	PRP	O	O
hypothesized	VBD	O	O
that	IN	O	O
certain	JJ	O	O
genetic	JJ	O	O
polymorphisms	NNS	O	O
of	IN	O	O
MTRR	NNP	O	O
leading	VBG	O	O
to	TO	O	O
reduced	VB	O	O
enzyme	JJ	O	O
activity	NN	O	O
may	MD	O	O
cause	VB	O	O
hyperhomocysteinemia	NN	O	O
and	CC	O	O
affect	VB	O	O
bone	NN	O	O
metabolism	NN	O	O
.	.	O	O

We	PRP	O	O
therefore	RB	O	O
examined	VBD	O	O
the	DT	O	O
associations	NNS	O	O
of	IN	O	O
the	DT	O	O
A66G	NNP	O	O
and	CC	O	O
C524T	NNP	O	O
polymorphisms	NNS	O	O
of	IN	O	O
the	DT	O	O
MTRR	NNP	O	O
gene	NN	O	O
with	IN	O	O
bone	JJ	O	O
mineral	JJ	O	O
density	NN	O	O
(	(	O	O
BMD	NNP	O	O
)	)	O	O
and	CC	O	O
serum	JJ	O	O
osteocalcin	NN	O	O
levels	NNS	O	O
in	IN	O	O
postmenopausal	JJ	O	O
women	NNS	O	O
.	.	O	O

Although	IN	O	O
we	PRP	O	O
did	VBD	O	O
not	RB	O	O
detect	VB	O	O
any	DT	O	O
significant	JJ	O	O
associations	NNS	O	O
between	IN	O	O
MTRR	NNP	O	O
polymorphisms	NNS	O	O
and	CC	O	O
BMD	NNP	O	O
or	CC	O	O
serum	VB	O	O
osteocalcin	JJ	O	O
levels	NNS	O	O
,	,	O	O
we	PRP	O	O
found	VBD	O	O
that	IN	O	O
the	DT	O	O
66G/524C	CD	O	O
haplotype	NN	O	O
,	,	O	O
which	WDT	O	O
has	VBZ	O	O
reduced	VBN	O	O
enzyme	JJ	O	O
activity	NN	O	O
,	,	O	O
was	VBD	O	O
significantly	RB	O	O
associated	VBN	O	O
with	IN	O	O
serum	JJ	O	O
osteocalcin	NN	O	O
levels	NNS	O	O
in	IN	O	O
a	DT	O	O
gene-dose	JJ	O	O
dependent	NN	O	O
manner	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.002	CD	O	O
)	)	O	O
.	.	O	O

That	DT	O	O
is	VBZ	O	O
,	,	O	O
the	DT	O	O
highest	JJS	O	O
osteocalcin	NN	O	O
levels	NNS	O	O
(	(	O	O
34.5	CD	O	O
+/-	JJ	O	O
16.8	CD	O	O
ng/ml	NN	O	O
)	)	O	O
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
subjects	NNS	O	O
bearing	VBG	O	O
two	CD	O	O
copies	NNS	O	O
,	,	O	O
intermediate	JJ	O	O
osteocalcin	NN	O	O
levels	NNS	O	O
(	(	O	O
32.6	CD	O	O
+/-	JJ	O	O
14.4	CD	O	O
ng/ml	NN	O	O
)	)	O	O
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
subjects	NNS	O	O
bearing	VBG	O	O
one	CD	O	O
copy	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
lowest	JJS	O	O
levels	NNS	O	O
of	IN	O	O
osteocalcin	NN	O	O
(	(	O	O
28.8	CD	O	O
+/-	JJ	O	O
10.9	CD	O	O
ng/ml	NN	O	O
)	)	O	O
were	VBD	O	O
observed	VBN	O	O
in	IN	O	O
subjects	NNS	O	O
bearing	VBG	O	O
no	DT	O	O
copies	NNS	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
the	DT	O	O
66G/524C	CD	O	O
haplotype	NN	O	O
of	IN	O	O
the	DT	O	O
MTRR	NNP	O	O
gene	NN	O	O
affect	VBP	O	O
bone	NN	O	O
turn	NN	O	O
over	RP	O	O
rate	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Warfarin	NNP	O	O
is	VBZ	O	O
the	DT	O	O
most	RBS	O	O
widely	RB	O	O
prescribed	JJ	O	O
oral	JJ	O	O
anticoagulant	NN	O	O
,	,	O	O
but	CC	O	O
there	EX	O	O
is	VBZ	O	O
greater	JJR	O	O
than	IN	O	O
10-fold	JJ	O	O
interindividual	JJ	O	O
variability	NN	O	O
in	IN	O	O
the	DT	O	O
dose	NN	O	O
required	VBN	O	O
to	TO	O	O
attain	VB	O	O
a	DT	O	O
therapeutic	JJ	O	O
response	NN	O	O
.	.	O	O

Information	NN	O	O
from	IN	O	O
pharmacogenomics	NNS	O	O
,	,	O	O
the	DT	O	O
study	NN	O	O
of	IN	O	O
the	DT	O	O
interaction	NN	O	O
of	IN	O	O
an	DT	O	O
individual	NN	O	O
's	POS	O	O
genotype	NN	O	O
and	CC	O	O
drug	NN	O	O
response	NN	O	O
,	,	O	O
can	MD	O	O
help	VB	O	O
optimize	VB	O	O
drug	NN	O	O
efficacy	NN	O	O
while	IN	O	O
minimizing	VBG	O	O
adverse	JJ	O	O
drug	NN	O	O
reactions	NNS	O	O
.	.	O	O

Pharmacogenetic	JJ	O	O
analysis	NN	O	O
of	IN	O	O
two	CD	O	O
genes	NNS	O	O
,	,	O	O
the	DT	O	O
warfarin	NN	O	B-SUBSTRATE
metabolic	JJ	O	O
enzyme	NN	O	O
CYP2C9	NNP	O	B-enzyme
and	CC	O	O
warfarin	VB	O	O
target	NN	O	O
enzyme	NN	O	O
,	,	O	O
vitamin	FW	O	O
K	NNP	O	O
epoxide	IN	O	O
reductase	NN	O	O
complex	JJ	O	O
1	CD	O	O
VKORC1	NNP	O	O
,	,	O	O
confirmed	VBD	O	O
their	PRP$	O	O
influence	NN	O	O
on	IN	O	O
warfarin	NN	O	O
maintenance	NN	O	O
dose	NN	O	O
.	.	O	O

Possession	NN	O	O
of	IN	O	O
CYP2C9	NNP	O	B-enzyme
*	NNP	O	O
2	CD	O	O
or	CC	O	O
CYP2C9	NNP	O	B-enzyme
*	VBP	O	O
3	CD	O	O
variant	JJ	O	O
alleles	NNS	O	O
,	,	O	O
which	WDT	O	O
result	VBP	O	O
in	IN	O	O
decreased	JJ	O	O
enzyme	NN	O	O
activity	NN	O	O
,	,	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
significant	JJ	O	O
decrease	NN	O	O
in	IN	O	O
the	DT	O	O
mean	JJ	O	O
warfarin	NN	O	B-SUBSTRATE
dose	NN	O	O
.	.	O	O

Several	JJ	O	O
single	JJ	O	O
nucleotide	JJ	O	O
polymorphisms	NN	O	O
(	(	O	O
SNPs	NNP	O	O
)	)	O	O
in	IN	O	O
VKORC1	NNP	O	O
are	VBP	O	O
associated	VBN	O	O
with	IN	O	O
warfarin	NN	O	O
dose	NN	O	O
across	IN	O	O
the	DT	O	O
normal	JJ	O	O
dose	JJ	O	O
range	NN	O	O
.	.	O	O

Haplotypes	NNS	O	O
based	VBN	O	O
on	IN	O	O
these	DT	O	O
SNPs	NNP	O	O
explain	VBP	O	O
a	DT	O	O
large	JJ	O	O
fraction	NN	O	O
of	IN	O	O
the	DT	O	O
interindividual	JJ	O	O
variation	NN	O	O
in	IN	O	O
warfarin	NN	O	O
dose	NN	O	O
,	,	O	O
and	CC	O	O
VKORC1	NNP	O	O
has	VBZ	O	O
an	DT	O	O
approximately	RB	O	O
three-fold	JJ	O	O
greater	JJR	O	O
effect	NN	O	O
than	IN	O	O
CYP2C9	NNP	O	O
.	.	O	O

Algorithms	NNP	O	O
incorporating	VBG	O	O
genetic	JJ	O	O
(	(	O	O
CYP2C9	NNP	O	O
and	CC	O	O
VKORC1	NNP	O	O
)	)	O	O
,	,	O	O
demographic	JJ	O	O
,	,	O	O
and	CC	O	O
clinical	JJ	O	O
factors	NNS	O	O
to	TO	O	O
estimate	VB	O	O
the	DT	O	O
warfarin	NN	O	O
dosage	NN	O	O
,	,	O	O
could	MD	O	O
potentially	RB	O	O
minimize	VB	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
over	IN	O	O
dose	NN	O	O
during	IN	O	O
warfarin	JJ	O	O
induction	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Hepatocellular	JJ	O	O
carcinoma	NN	O	O
(	(	O	O
HCC	NNP	O	O
)	)	O	O
is	VBZ	O	O
believed	VBN	O	O
to	TO	O	O
be	VB	O	O
auxotrophic	JJ	O	O
for	IN	O	O
arginine	NN	O	O
through	IN	O	O
the	DT	O	O
lack	NN	O	O
of	IN	O	O
expression	NN	O	O
of	IN	O	O
argininosuccinate	JJ	O	O
synthetase	NN	O	O
(	(	O	O
ASS	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
successful	JJ	O	O
use	NN	O	O
of	IN	O	O
the	DT	O	O
arginine-depleting	JJ	O	O
enzyme	NN	O	O
arginine	NN	O	O
deiminase	NN	O	O
(	(	O	O
ADI	NNP	O	O
)	)	O	O
to	TO	O	O
treat	VB	O	O
ASS-deficient	JJ	O	O
tumors	NNS	O	O
has	VBZ	O	O
opened	VBN	O	O
up	RP	O	O
new	JJ	O	O
possibilities	NNS	O	O
for	IN	O	O
effective	JJ	O	O
cancer	NN	O	O
therapy	NN	O	O
.	.	O	O

Nevertheless	RB	O	O
,	,	O	O
many	JJ	O	O
ASS-positive	JJ	O	O
HCC	NNP	O	O
cell	NN	O	O
lines	NNS	O	O
are	VBP	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
resistant	JJ	O	O
to	TO	O	O
ADI	NNP	O	O
treatment	NN	O	O
,	,	O	O
although	IN	O	O
most	JJS	O	O
require	VBP	O	O
arginine	NN	O	O
for	IN	O	O
proliferation	NN	O	O
.	.	O	O

Thus	RB	O	O
far	RB	O	O
,	,	O	O
an	DT	O	O
arginine-depleting	JJ	O	O
enzyme	NN	O	O
for	IN	O	O
killing	VBG	O	O
ASS-positive	JJ	O	O
tumors	NNS	O	O
has	VBZ	O	O
not	RB	O	O
been	VBN	O	O
reported	VBN	O	O
.	.	O	O

Here	RB	O	O
,	,	O	O
we	PRP	O	O
provide	VBP	O	O
direct	JJ	O	O
evidence	NN	O	O
that	WDT	O	O
recombinant	JJ	O	O
human	JJ	O	O
arginase	NN	O	O
(	(	O	O
rhArg	NN	O	O
)	)	O	O
inhibits	VBZ	O	O
ASS-positive	JJ	O	O
HCCs	NNP	O	O
.	.	O	O

All	PDT	O	O
the	DT	O	O
five	CD	O	O
human	JJ	O	O
HCC	NNP	O	O
cell	NN	O	O
lines	NNS	O	O
we	PRP	O	O
used	VBD	O	O
were	VBD	O	O
sensitive	JJ	O	O
to	TO	O	O
rhArg	VB	O	O
but	CC	O	O
ADI	NNP	O	O
had	VBD	O	O
virtually	RB	O	O
no	RB	O	O
effect	NN	O	O
on	IN	O	O
these	DT	O	O
cells	NNS	O	O
.	.	O	O

They	PRP	O	O
all	DT	O	O
expressed	VBD	O	O
ASS	NNP	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
ornithine	JJ	O	B-enzyme
transcarbamylase	NN	O	I-enzyme
(	(	O	O
OTC	NNP	O	B-enzyme
)	)	O	O
,	,	O	O
the	DT	O	O
enzyme	NN	O	O
that	WDT	O	O
converts	VBZ	O	O
ornithine	NN	O	B-SUBSTRATE
,	,	O	O
the	DT	O	O
product	NN	O	O
of	IN	O	O
degradation	NN	O	O
of	IN	O	O
arginine	NN	O	B-SUBSTRATE
with	IN	O	O
rhArg	NN	O	B-enzyme
,	,	O	O
to	TO	O	O
citrulline	VB	O	B-PRODUCT-OF
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
converted	VBN	O	O
back	RB	O	O
to	TO	O	O
arginine	VB	O	B-SUBSTRATE
via	IN	O	O
ASS	NNP	O	B-enzyme
.	.	O	O

Transfection	NN	O	O
of	IN	O	O
HCC	NNP	O	O
cells	NNS	O	O
with	IN	O	O
OTC	NNP	O	O
resulted	VBD	O	O
in	IN	O	O
resistance	NN	O	O
to	TO	O	O
rhArg	VB	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
OTC	NNP	O	O
expression	VBP	O	O
alone	RB	O	O
may	MD	O	O
be	VB	O	O
sufficient	JJ	O	O
to	TO	O	O
induce	VB	O	O
rhArg	JJ	O	O
resistance	NN	O	O
in	IN	O	O
ASS-positive	JJ	O	O
HCC	NNP	O	O
cells	NNS	O	O
.	.	O	O

This	DT	O	O
surprising	JJ	O	O
correlation	NN	O	O
between	IN	O	O
the	DT	O	O
lack	NN	O	O
of	IN	O	O
OTC	NNP	O	O
expression	NN	O	O
and	CC	O	O
sensitivity	NN	O	O
of	IN	O	O
ASS-positive	JJ	O	O
HCC	NNP	O	O
cells	NNS	O	O
shows	VBZ	O	O
that	IN	O	O
OTC-deficient	NNP	O	O
HCCs	NNP	O	O
are	VBP	O	O
sensitive	JJ	O	O
to	TO	O	O
rhArg-mediated	JJ	O	O
arginine	JJ	O	B-SUBSTRATE
depletion	NN	O	O
.	.	O	O

Therefore	RB	O	O
,	,	O	O
pretreatment	JJ	O	O
tumor	NN	O	O
gene	NN	O	O
expression	NN	O	O
profiling	NN	O	O
of	IN	O	O
ASS	NNP	O	O
and	CC	O	O
OTC	NNP	O	O
could	MD	O	O
aid	VB	O	O
in	IN	O	O
predicting	VBG	O	O
tumor	NN	O	O
response	NN	O	O
to	TO	O	O
arginine	VB	O	B-SUBSTRATE
depletion	NN	O	O
with	IN	O	O
arginine-depleting	JJ	O	B-enzyme
enzymes	NNS	O	I-enzyme
.	.	O	O

We	PRP	O	O
have	VBP	O	O
also	RB	O	O
shown	VBN	O	O
that	IN	O	O
the	DT	O	O
rhArg	NN	O	O
native	JJ	O	O
enzyme	NN	O	O
and	CC	O	O
the	DT	O	O
pegylated	VBN	O	O
rhArg	NN	O	O
(	(	O	O
rhArg-peg	JJ	O	O
(	(	O	O
5,000mw	CD	O	O
)	)	O	O
)	)	O	O
gave	VBD	O	O
similar	JJ	O	O
anticancer	NN	O	O
efficacy	NN	O	O
in	IN	O	O
vitro	NN	O	O
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
the	DT	O	O
growth	NN	O	O
of	IN	O	O
the	DT	O	O
OTC-deficient	JJ	O	O
Hep3B	NNP	O	O
tumor	NN	O	O
cells	NNS	O	O
(	(	O	O
ASS-positive	JJ	O	O
and	CC	O	O
ADI-resistant	JJ	O	O
)	)	O	O
in	IN	O	O
mice	NN	O	O
was	VBD	O	O
inhibited	VBN	O	O
by	IN	O	O
treatment	NN	O	O
with	IN	O	O
rhArg-peg	NN	O	O
(	(	O	O
5,000mw	CD	O	O
)	)	O	O
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
active	JJ	O	O
alone	RB	O	O
and	CC	O	O
is	VBZ	O	O
synergistic	JJ	O	O
in	IN	O	O
combination	NN	O	O
with	IN	O	O
5-fluorouracil	JJ	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
our	PRP$	O	O
data	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
rhArg-peg	NN	O	O
(	(	O	O
5,000mw	CD	O	O
)	)	O	O
is	VBZ	O	O
a	DT	O	O
novel	JJ	O	O
agent	NN	O	O
for	IN	O	O
effective	JJ	O	O
cancer	NN	O	O
therapy	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Metabolism	NN	O	O
of	IN	O	O
vitamin	NN	O	O
A	NNP	O	O
,	,	O	O
all-trans-retinol	NN	O	O
,	,	O	O
leads	VBZ	O	O
to	TO	O	O
the	DT	O	O
formation	NN	O	O
of	IN	O	O
11-cis-retinaldehyde	JJ	O	O
,	,	O	O
the	DT	O	O
visual	JJ	O	O
chromophore	NN	O	O
,	,	O	O
and	CC	O	O
all-trans-retinoic	JJ	O	O
acid	NN	O	O
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
involved	VBN	O	O
in	IN	O	O
the	DT	O	O
regulation	NN	O	O
of	IN	O	O
gene	NN	O	O
expression	NN	O	O
through	IN	O	O
the	DT	O	O
retinoic	NN	O	O
acid	NN	O	O
receptor	NN	O	O
.	.	O	O

Enzymes	NNS	O	O
and	CC	O	O
binding	VBG	O	O
proteins	NNS	O	O
involved	VBN	O	O
in	IN	O	O
retinoid	JJ	O	O
metabolism	NN	O	O
are	VBP	O	O
highly	RB	O	O
conserved	VBN	O	O
across	IN	O	O
species	NNS	O	O
.	.	O	O

We	PRP	O	O
previously	RB	O	O
described	VBD	O	O
a	DT	O	O
novel	JJ	O	O
mammalian	JJ	O	O
enzyme	NN	O	O
that	WDT	O	O
saturates	VBZ	O	O
the	DT	O	O
13-14	JJ	O	O
double	JJ	O	O
bond	NN	O	O
of	IN	O	O
all-trans-retinol	NN	O	O
to	TO	O	O
produce	VB	O	O
all-trans-13,14-dihydroretinol	NN	O	O
,	,	O	O
which	WDT	O	O
then	RB	O	O
follows	VBZ	O	O
the	DT	O	O
same	JJ	O	O
metabolic	JJ	O	O
fate	NN	O	O
as	IN	O	O
that	DT	O	O
of	IN	O	O
all-trans-retinol	NN	O	O
.	.	O	O

Specifically	RB	O	O
,	,	O	O
all-trans-13,14-dihydroretinol	JJ	O	B-SUBSTRATE
is	VBZ	O	O
transiently	RB	O	O
oxidized	VBN	O	O
to	TO	O	O
all-trans-13,14-dihydroretinoic	JJ	O	O
acid	NN	O	O
before	IN	O	O
being	VBG	O	O
oxidized	VBN	O	O
further	RB	O	O
by	IN	O	O
Cyp26	NNP	O	B-enzyme
enzymes	NNS	O	O
.	.	O	O

Here	RB	O	O
,	,	O	O
we	PRP	O	O
report	VBP	O	O
the	DT	O	O
identification	NN	O	O
of	IN	O	O
two	CD	O	O
putative	JJ	O	O
RetSat	NNP	O	O
homologues	NNS	O	O
in	IN	O	O
zebrafish	NN	O	O
,	,	O	O
one	CD	O	O
of	IN	O	O
which	WDT	O	O
,	,	O	O
zebrafish	JJ	O	O
RetSat	NNP	O	O
A	NNP	O	O
(	(	O	O
zRetSat	IN	O	O
A	NNP	O	O
)	)	O	O
,	,	O	O
also	RB	O	O
had	VBD	O	O
retinol	JJ	O	O
saturase	NN	O	O
activity	NN	O	O
,	,	O	O
whereas	WP	O	O
zebrafish	JJ	O	O
RetSat	NNP	O	O
B	NNP	O	O
(	(	O	O
zRetSat	NNP	O	O
B	NNP	O	O
)	)	O	O
was	VBD	O	O
inactive	JJ	O	O
under	IN	O	O
similar	JJ	O	O
conditions	NNS	O	O
.	.	O	O

Unlike	IN	O	O
mouse	NN	O	O
RetSat	NNP	O	O
(	(	O	O
mRetSat	NN	O	O
)	)	O	O
,	,	O	O
zRetSat	VBZ	O	B-enzyme
A	NNP	O	I-enzyme
had	VBD	O	O
an	DT	O	O
altered	VBN	O	O
bond	NN	O	O
specificity	NN	O	O
saturating	VBG	O	O
either	CC	O	O
the	DT	O	O
13-14	JJ	O	O
or	CC	O	O
7-8	JJ	O	O
double	JJ	O	O
bonds	NNS	O	O
of	IN	O	O
all-trans-retinol	NN	O	B-SUBSTRATE
to	TO	O	O
produce	VB	O	O
either	DT	O	O
all-trans-13,14-dihydroretinol	JJ	O	B-PRODUCT-OF
or	CC	O	O
all-trans-7,8-dihydroretinol	JJ	O	B-PRODUCT-OF
,	,	O	O
respectively	RB	O	O
.	.	O	O

zRetSat	NN	O	B-enzyme
A	NNP	O	I-enzyme
also	RB	O	O
saturated	VBD	O	O
the	DT	O	O
13-14	JJ	O	O
or	CC	O	O
7-8	JJ	O	O
double	JJ	O	O
bonds	NNS	O	O
of	IN	O	O
all-trans-3,4-didehydroretinol	NN	O	B-SUBSTRATE
(	(	O	O
vitamin	JJ	O	B-SUBSTRATE
A2	NNP	O	I-SUBSTRATE
)	)	O	O
,	,	O	O
a	DT	O	O
second	JJ	O	O
endogenous	JJ	O	O
form	NN	O	O
of	IN	O	O
vitamin	NN	O	O
A	NNP	O	O
in	IN	O	O
zebrafish	NN	O	O
.	.	O	O

The	DT	O	O
dual	JJ	O	O
enzymatic	JJ	O	O
activity	NN	O	O
of	IN	O	O
zRetSat	NN	O	O
A	NNP	O	O
displays	VBZ	O	O
a	DT	O	O
newly	RB	O	O
acquired	VBN	O	O
specificity	NN	O	O
for	IN	O	O
the	DT	O	O
13-14	JJ	O	O
double	JJ	O	O
bond	NN	O	O
retained	VBD	O	O
in	IN	O	O
higher	JJR	O	O
vertebrates	NNS	O	O
and	CC	O	O
also	RB	O	O
the	DT	O	O
evolutionarily	RB	O	O
preserved	VBN	O	O
activity	NN	O	O
of	IN	O	O
bacterial	JJ	O	O
phytoene	NN	O	O
desaturases	NNS	O	O
and	CC	O	O
plant	NN	O	O
carotenoid	NN	O	O
isomerases	NNS	O	O
.	.	O	O

Expression	NN	O	O
of	IN	O	O
zRetSat	NN	O	O
A	NNP	O	O
was	VBD	O	O
restricted	VBN	O	O
to	TO	O	O
the	DT	O	O
liver	NN	O	O
and	CC	O	O
intestine	NN	O	O
of	IN	O	O
hatchlings	NNS	O	O
and	CC	O	O
adult	NN	O	O
zebrafish	NN	O	O
,	,	O	O
whereas	WP	O	O
zRetSat	NN	O	O
B	NNP	O	O
was	VBD	O	O
expressed	VBN	O	O
in	IN	O	O
the	DT	O	O
same	JJ	O	O
tissues	NNS	O	O
but	CC	O	O
at	IN	O	O
earlier	JJR	O	O
developmental	JJ	O	O
stages	NNS	O	O
.	.	O	O

Exogenous	JJ	O	O
all-trans-retinol	JJ	O	O
,	,	O	O
all-trans-13,14-dihydroretinol	JJ	O	O
,	,	O	O
or	CC	O	O
all-trans-7,8-dihydroretinol	NN	O	O
led	VBN	O	O
to	TO	O	O
the	DT	O	O
strong	JJ	O	O
induction	NN	O	O
of	IN	O	O
the	DT	O	O
expression	NN	O	O
of	IN	O	O
the	DT	O	O
retinoic	JJ	O	O
acid-metabolizing	JJ	O	O
enzyme	NN	O	O
,	,	O	O
Cyp26A1	NNP	O	O
,	,	O	O
arguing	VBG	O	O
for	IN	O	O
an	DT	O	O
active	JJ	O	O
signaling	NN	O	O
function	NN	O	O
of	IN	O	O
dihydroretinoid	NN	O	O
metabolites	NNS	O	O
in	IN	O	O
zebrafish	NN	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
point	NN	O	O
to	TO	O	O
a	DT	O	O
conserved	JJ	O	O
function	NN	O	O
but	CC	O	O
altered	JJ	O	O
specificity	NN	O	O
of	IN	O	O
RetSat	NNP	O	O
in	IN	O	O
vertebrates	NNS	O	O
,	,	O	O
leading	VBG	O	O
to	TO	O	O
the	DT	O	O
generation	NN	O	O
of	IN	O	O
various	JJ	O	O
dihydroretinoid	JJ	O	O
compounds	NNS	O	O
,	,	O	O
some	DT	O	O
of	IN	O	O
which	WDT	O	O
could	MD	O	O
have	VB	O	O
signaling	VBG	O	O
functions	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

The	DT	O	O
growing	VBG	O	O
use	NN	O	O
of	IN	O	O
N-acetylaspartate	NNP	O	O
as	IN	O	O
an	DT	O	O
indicator	NN	O	O
of	IN	O	O
neuronal	JJ	O	O
viability	NN	O	O
has	VBZ	O	O
fostered	VBN	O	O
interest	NN	O	O
in	IN	O	O
the	DT	O	O
biological	JJ	O	O
function	NN	O	O
(	(	O	O
s	JJ	O	O
)	)	O	O
of	IN	O	O
this	DT	O	O
unusual	JJ	O	O
amino	NN	O	O
acid	NN	O	O
derivative	NN	O	O
.	.	O	O

In	IN	O	O
considering	VBG	O	O
the	DT	O	O
various	JJ	O	O
physiological	JJ	O	O
roles	NNS	O	O
that	WDT	O	O
have	VBP	O	O
been	VBN	O	O
proposed	VBN	O	O
for	IN	O	O
this	DT	O	O
relatively	RB	O	O
abundant	JJ	O	O
molecule	NN	O	O
one	CD	O	O
is	VBZ	O	O
obliged	VBN	O	O
to	TO	O	O
take	VB	O	O
into	IN	O	O
account	NN	O	O
its	PRP$	O	O
unusual	JJ	O	O
metabolic	JJ	O	O
compartmentalization	NN	O	O
,	,	O	O
according	VBG	O	O
to	TO	O	O
which	WDT	O	O
synthesis	NN	O	O
and	CC	O	O
storage	NN	O	O
occur	NN	O	O
in	IN	O	O
the	DT	O	O
neuron	NN	O	O
and	CC	O	O
hydrolytic	JJ	O	O
cleavage	NN	O	O
in	IN	O	O
the	DT	O	O
oligodendrocyte	NN	O	O
.	.	O	O

The	DT	O	O
latter	JJ	O	O
reaction	NN	O	O
,	,	O	O
catalyzed	VBN	O	O
by	IN	O	O
aspartoacylase	NN	O	B-enzyme
(	(	O	O
ASPA	NNP	O	B-enzyme
)	)	O	O
,	,	O	O
produces	VBZ	O	O
acetyl	JJ	O	B-PRODUCT-OF
groups	NNS	O	O
plus	CC	O	O
aspartate	NN	O	B-PRODUCT-OF
and	CC	O	O
has	VBZ	O	O
been	VBN	O	O
proposed	VBN	O	O
to	TO	O	O
occur	VB	O	O
in	IN	O	O
both	DT	O	O
soluble	JJ	O	O
and	CC	O	O
membranous	JJ	O	O
subfractions	NNS	O	O
of	IN	O	O
white	JJ	O	O
matter	NN	O	O
.	.	O	O

Our	PRP$	O	O
study	NN	O	O
supports	NNS	O	O
such	JJ	O	O
bimodal	JJ	O	O
occurrence	NN	O	O
and	CC	O	O
we	PRP	O	O
now	RB	O	O
present	JJ	O	O
immunoblot	NN	O	O
,	,	O	O
proteomic	JJ	O	O
,	,	O	O
and	CC	O	O
biochemical	JJ	O	O
evidence	NN	O	O
that	IN	O	O
the	DT	O	O
membrane-bound	JJ	O	O
form	NN	O	O
of	IN	O	O
ASPA	NNP	O	O
is	VBZ	O	O
intrinsic	JJ	O	O
to	TO	O	O
purified	JJ	O	O
myelin	NN	O	O
membranes	NNS	O	O
.	.	O	O

This	DT	O	O
was	VBD	O	O
supported	VBN	O	O
by	IN	O	O
a	DT	O	O
novel	JJ	O	O
TLC-based	JJ	O	O
method	NN	O	O
for	IN	O	O
the	DT	O	O
assay	NN	O	O
of	IN	O	O
ASPA	NNP	O	O
.	.	O	O

That	DT	O	O
observation	NN	O	O
,	,	O	O
together	RB	O	O
with	IN	O	O
previous	JJ	O	O
demonstrations	NNS	O	O
of	IN	O	O
numerous	JJ	O	O
lipid-synthesizing	JJ	O	O
enzymes	NNS	O	O
in	IN	O	O
myelin	NN	O	O
,	,	O	O
suggests	VBZ	O	O
utilization	NN	O	O
of	IN	O	O
acetyl	NN	O	O
groups	NNS	O	O
liberated	VBN	O	O
by	IN	O	O
myelin-localized	JJ	O	O
ASPA	NNP	O	O
for	IN	O	O
lipid	JJ	O	O
synthesis	NN	O	O
within	IN	O	O
the	DT	O	O
myelin	JJ	O	O
sheath	NN	O	O
.	.	O	O

Such	JJ	O	O
synthesis	NN	O	O
might	MD	O	O
be	VB	O	O
selective	JJ	O	O
and	CC	O	O
could	MD	O	O
explain	VB	O	O
the	DT	O	O
deficit	NN	O	O
of	IN	O	O
myelin	NN	O	O
lipids	NNS	O	O
in	IN	O	O
animals	NNS	O	O
lacking	VBG	O	O
ASPA	NNP	O	O
.	.	O	O

-DOCSTART- -X- -X- O

BACKGROUND	NN	O	O
:	:	O	O
Delta	NNP	O	O
(	(	O	O
6	CD	O	O
)	)	O	O
-Desaturase	NN	O	O
(	(	O	O
FADS2	NNP	O	O
)	)	O	O
is	VBZ	O	O
the	DT	O	O
rate-limiting	JJ	O	O
step	NN	O	O
in	IN	O	O
the	DT	O	O
polyunsaturated	JJ	O	O
fatty	JJ	O	O
acid	NN	O	O
(	(	O	O
PUFA	NNP	O	O
)	)	O	O
biosynthetic	JJ	O	O
pathway	NN	O	O
.	.	O	O

OBJECTIVE	NN	O	O
:	:	O	O
The	DT	O	O
aim	NN	O	O
was	VBD	O	O
to	TO	O	O
test	VB	O	O
whether	IN	O	O
the	DT	O	O
common	JJ	O	O
deletion	NN	O	O
[	IN	O	O
T/-	NNP	O	O
]	NNP	O	O
in	IN	O	O
the	DT	O	O
promoter	NN	O	O
of	IN	O	O
FADS2	NNP	O	B-enzyme
affects	VBZ	O	O
the	DT	O	O
PUFA	NNP	O	B-PRODUCT-OF
biosynthetic	JJ	O	O
pathway	NN	O	O
and	CC	O	O
consequently	RB	O	O
modifies	VBZ	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
alpha-linolenic	JJ	O	B-SUBSTRATE
acid	NN	O	I-SUBSTRATE
(	(	O	O
ALA	NNP	O	B-SUBSTRATE
)	)	O	O
on	IN	O	O
myocardial	JJ	O	O
infarction	NN	O	O
(	(	O	O
MI	NNP	O	O
)	)	O	O
.	.	O	O

DESIGN	NN	O	O
:	:	O	O
Case	NN	O	O
subjects	NNS	O	O
(	(	O	O
n	JJ	O	O
=1694	NN	O	O
)	)	O	O
with	IN	O	O
a	DT	O	O
first	JJ	O	O
nonfatal	JJ	O	O
acute	NN	O	O
MI	NNP	O	O
were	VBD	O	O
matched	VBN	O	O
by	IN	O	O
age	NN	O	O
,	,	O	O
sex	NN	O	O
,	,	O	O
and	CC	O	O
area	NN	O	O
of	IN	O	O
residence	NN	O	O
to	TO	O	O
1694	CD	O	O
population-based	JJ	O	O
control	NN	O	O
subjects	VBZ	O	O
in	IN	O	O
Costa	NNP	O	O
Rica	NNP	O	O
.	.	O	O

PUFAs	NNP	O	O
were	VBD	O	O
quantified	VBN	O	O
by	IN	O	O
gas-liquid	JJ	O	O
chromatography	NN	O	O
from	IN	O	O
plasma	NN	O	O
and	CC	O	O
adipose	JJ	O	O
tissue	NN	O	O
samples	NNS	O	O
.	.	O	O

Least-squares	NNS	O	O
means	NNS	O	O
from	IN	O	O
generalized	VBN	O	O
linear	JJ	O	O
models	NNS	O	O
and	CC	O	O
odds	NNS	O	O
ratios	NNS	O	O
(	(	O	O
ORs	NNP	O	O
)	)	O	O
and	CC	O	O
95	CD	O	O
%	NN	O	O
CIs	NNP	O	O
from	IN	O	O
multiple	JJ	O	O
conditional	JJ	O	O
logistic	JJ	O	O
regression	NN	O	O
models	NNS	O	O
were	VBD	O	O
estimated	VBN	O	O
.	.	O	O

RESULTS	NN	O	O
:	:	O	O
The	DT	O	O
prevalence	NN	O	O
of	IN	O	O
the	DT	O	O
variant	JJ	O	O
T/-	NNP	O	O
allele	NN	O	O
was	VBD	O	O
48	CD	O	O
%	NN	O	O
.	.	O	O

Eicosapentaenoic	NNP	O	O
acid	NN	O	O
,	,	O	O
gamma-linolenic	JJ	O	O
acid	NN	O	O
,	,	O	O
and	CC	O	O
arachidonic	JJ	O	O
acid	NN	O	O
decreased	VBN	O	O
in	IN	O	O
adipose	JJ	O	O
tissue	NN	O	O
and	CC	O	O
plasma	NN	O	O
with	IN	O	O
increasing	VBG	O	O
number	NN	O	O
of	IN	O	O
copies	NNS	O	O
of	IN	O	O
the	DT	O	O
variant	JJ	O	O
allele	NN	O	O
with	IN	O	O
a	DT	O	O
monotonic	JJ	O	O
trend	NN	O	O
(	(	O	O
P	NNP	O	O
<	VBZ	O	O
0.05	CD	O	O
for	IN	O	O
all	DT	O	O
)	)	O	O
.	.	O	O

Fasting	VBG	O	O
plasma	NN	O	O
triacylglycerols	NNS	O	O
by	IN	O	O
genotype	NN	O	O
were	VBD	O	O
2.08	CD	O	O
mmol/L	NN	O	O
for	IN	O	O
TT	NNP	O	O
,	,	O	O
2.16	CD	O	O
mmol/L	NN	O	O
for	IN	O	O
T-	NNP	O	O
,	,	O	O
and	CC	O	O
2.26	CD	O	O
mmol/L	NN	O	O
for	IN	O	O
-	:	O	O
-	:	O	O
[	NN	O	O
ie	NN	O	O
,	,	O	O
homozygous	JJ	O	O
for	IN	O	O
the	DT	O	O
variant	NN	O	O
(	(	O	O
deletion	NN	O	O
)	)	O	O
allele	NN	O	O
]	NNP	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.03	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
FADS2	NNP	O	O
deletion	NN	O	O
was	VBD	O	O
not	RB	O	O
associated	VBN	O	O
with	IN	O	O
MI	NNP	O	O
and	CC	O	O
did	VBD	O	O
not	RB	O	O
significantly	RB	O	O
modify	VB	O	O
the	DT	O	O
association	NN	O	O
between	IN	O	O
adipose	JJ	O	O
tissue	NN	O	O
ALA	NNP	O	O
and	CC	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
MI	NNP	O	O
.	.	O	O

CONCLUSIONS	NN	O	O
:	:	O	O
The	DT	O	O
FADS2	NNP	O	O
deletion	NN	O	O
may	MD	O	O
prevent	VB	O	O
the	DT	O	O
conversion	NN	O	O
of	IN	O	O
ALA	NNP	O	O
into	IN	O	O
very-long-chain	JJ	O	O
PUFAs	NNP	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
this	DT	O	O
metabolic	JJ	O	O
effect	NN	O	O
is	VBZ	O	O
not	RB	O	O
translated	VBN	O	O
into	IN	O	O
an	DT	O	O
attenuated	VBN	O	O
risk	NN	O	O
between	IN	O	O
ALA	NNP	O	O
and	CC	O	O
MI	NNP	O	O
among	IN	O	O
carriers	NNS	O	O
of	IN	O	O
the	DT	O	O
variant	NN	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
possible	JJ	O	O
that	IN	O	O
,	,	O	O
at	IN	O	O
current	JJ	O	O
intakes	NNS	O	O
of	IN	O	O
ALA	NNP	O	O
,	,	O	O
any	DT	O	O
potential	JJ	O	O
defect	NN	O	O
in	IN	O	O
the	DT	O	O
transcription	NN	O	O
of	IN	O	O
the	DT	O	O
gene	NN	O	O
is	VBZ	O	O
masked	VBN	O	O
by	IN	O	O
the	DT	O	O
availability	NN	O	O
of	IN	O	O
substrate	NN	O	O
.	.	O	O

Further	JJ	O	O
research	NN	O	O
in	IN	O	O
populations	NNS	O	O
deficient	NN	O	O
in	IN	O	O
ALA	NNP	O	O
intake	NN	O	O
is	VBZ	O	O
warranted	VBN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

RATIONALE	NN	O	O
:	:	O	O
Recent	JJ	O	O
studies	NNS	O	O
provide	VBP	O	O
evidence	NN	O	O
for	IN	O	O
reduced	VBN	O	O
phosphodiesterase-4B	NN	O	O
(	(	O	O
PDE4B	NNP	O	O
)	)	O	O
as	IN	O	O
a	DT	O	O
genetic	JJ	O	O
susceptibility	NN	O	O
factor	NN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
suggesting	VBG	O	O
an	DT	O	O
association	NN	O	O
of	IN	O	O
several	JJ	O	O
single	JJ	O	O
nucleotide	JJ	O	O
polymorphisms	NN	O	O
(	(	O	O
SNPs	NNP	O	O
)	)	O	O
in	IN	O	O
PDE4B	NNP	O	O
that	WDT	O	O
are	VBP	O	O
associated	VBN	O	O
with	IN	O	O
an	DT	O	O
increased	JJ	O	O
incidence	NN	O	O
of	IN	O	O
schizophrenia	NN	O	O
.	.	O	O

OBJECTIVES	NN	O	O
:	:	O	O
The	DT	O	O
aim	NN	O	O
of	IN	O	O
the	DT	O	O
current	JJ	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
assess	VB	O	O
the	DT	O	O
activity	NN	O	O
of	IN	O	O
rolipram	NN	O	O
,	,	O	O
a	DT	O	O
nonsubtype-selective	JJ	O	O
PDE4	NNP	O	O
inhibitor	NN	O	O
,	,	O	O
in	IN	O	O
several	JJ	O	O
animal	JJ	O	O
models	NNS	O	O
predictive	IN	O	O
of	IN	O	O
antipsychotic-like	JJ	O	O
efficacy	NN	O	O
and	CC	O	O
side-effect	JJ	O	O
liability	NN	O	O
and	CC	O	O
to	TO	O	O
use	VB	O	O
PDE4B	NNP	O	O
wild-type	NN	O	O
and	CC	O	O
knockout	NN	O	O
mice	NN	O	O
to	TO	O	O
begin	VB	O	O
to	TO	O	O
understand	VB	O	O
the	DT	O	O
subtypes	NNS	O	O
involved	VBN	O	O
in	IN	O	O
the	DT	O	O
activity	NN	O	O
of	IN	O	O
rolipram	NN	O	O
.	.	O	O

RESULTS	NN	O	O
:	:	O	O
In	IN	O	O
rats	NNS	O	O
,	,	O	O
rolipram	NN	O	O
antagonized	VBD	O	O
both	DT	O	O
phencyclidine	JJ	O	O
hydrochloride-	NN	O	O
and	CC	O	O
D-amphetamine-induced	NNP	O	O
hyperactivity	NN	O	O
and	CC	O	O
inhibited	VBD	O	O
conditioned	VBN	O	O
avoidance	NN	O	O
responding	VBG	O	O
(	(	O	O
CAR	NNP	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
PDE4B	NNP	O	O
wild-type	JJ	O	O
mice	NN	O	O
,	,	O	O
rolipram	VB	O	O
dose-dependently	RB	O	O
suppressed	JJ	O	O
CAR	NNP	O	O
(	(	O	O
ED	NNP	O	O
(	(	O	O
50	CD	O	O
)	)	O	O
=	VBD	O	O
2.4	CD	O	O
mg/kg	NN	O	O
)	)	O	O
;	:	O	O
however	RB	O	O
,	,	O	O
in	IN	O	O
knockout	NN	O	O
mice	NN	O	O
,	,	O	O
their	PRP$	O	O
sensitivity	NN	O	O
to	TO	O	O
rolipram	VB	O	O
at	IN	O	O
the	DT	O	O
higher	JJR	O	O
doses	NNS	O	O
(	(	O	O
1.0	CD	O	O
and	CC	O	O
3.2	CD	O	O
mg/kg	NN	O	O
)	)	O	O
was	VBD	O	O
reduced	VBN	O	O
,	,	O	O
resulting	VBG	O	O
in	IN	O	O
a	DT	O	O
threefold	JJ	O	O
shift	NN	O	O
in	IN	O	O
the	DT	O	O
ED	NNP	O	O
(	(	O	O
50	CD	O	O
)	)	O	O
(	(	O	O
7.3	CD	O	O
mg/kg	NN	O	O
)	)	O	O
,	,	O	O
suggesting	VBG	O	O
PDE4B	NNP	O	O
is	VBZ	O	O
involved	VBN	O	O
,	,	O	O
at	IN	O	O
least	JJS	O	O
in	IN	O	O
part	NN	O	O
,	,	O	O
with	IN	O	O
the	DT	O	O
activity	NN	O	O
of	IN	O	O
rolipram	NN	O	O
.	.	O	O

Only	RB	O	O
the	DT	O	O
highest	JJS	O	O
dose	NN	O	O
of	IN	O	O
rolipram	NN	O	O
(	(	O	O
3.2	CD	O	O
mg/kg	NN	O	O
)	)	O	O
produced	VBD	O	O
a	DT	O	O
modest	JJ	O	O
but	CC	O	O
significant	JJ	O	O
degree	NN	O	O
of	IN	O	O
catalepsy	NN	O	O
.	.	O	O

CONCLUSIONS	NN	O	O
:	:	O	O
Rolipram	NNP	O	O
has	VBZ	O	O
a	DT	O	O
pharmacologic	NN	O	O
profile	NN	O	O
similar	JJ	O	O
to	TO	O	O
that	DT	O	O
of	IN	O	O
the	DT	O	O
atypical	JJ	O	O
antipsychotics	NNS	O	O
and	CC	O	O
has	VBZ	O	O
low	JJ	O	O
extrapyramidal	RB	O	O
symptom	NN	O	O
liability	NN	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
PDE4B	NNP	O	O
mediates	VBZ	O	O
the	DT	O	O
antipsychotic	JJ	O	O
effects	NNS	O	O
of	IN	O	O
rolipram	NN	O	O
in	IN	O	O
CAR	NNP	O	O
and	CC	O	O
that	IN	O	O
the	DT	O	O
PDE4B-regulated	NNP	O	O
cyclic	JJ	O	B-SUBSTRATE
adenosine	NN	O	I-SUBSTRATE
monophosphate	NN	O	O
signaling	VBG	O	O
pathway	NN	O	O
may	MD	O	O
play	VB	O	O
a	DT	O	O
role	NN	O	O
in	IN	O	O
the	DT	O	O
pathophysiology	NN	O	O
and	CC	O	O
pharmacotherapy	NN	O	O
of	IN	O	O
psychosis	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Hydrogen	NNP	O	B-PRODUCT-OF
sulphide	NN	O	I-PRODUCT-OF
(	(	O	O
H	NNP	O	B-PRODUCT-OF
(	(	O	O
2	CD	O	O
)	)	O	O
S	NNP	O	O
)	)	O	O
is	VBZ	O	O
synthesized	VBN	O	O
from	IN	O	O
L-cysteine	NNP	O	B-SUBSTRATE
via	IN	O	O
the	DT	O	O
action	NN	O	O
of	IN	O	O
cystathionine-gamma-lyase	NN	O	B-enzyme
(	(	O	O
CSE	NNP	O	B-enzyme
)	)	O	O
and	CC	O	O
cystathionine-beta-synthase	NN	O	B-enzyme
(	(	O	O
CBS	NNP	O	B-enzyme
)	)	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
earlier	JJR	O	O
shown	VBN	O	O
that	IN	O	O
H	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
S	NNP	O	O
acts	VBZ	O	O
as	IN	O	O
a	DT	O	O
mediator	NN	O	O
of	IN	O	O
inflammation	NN	O	O
.	.	O	O

However	RB	O	O
the	DT	O	O
mechanism	NN	O	O
remains	VBZ	O	O
unclear	JJ	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
investigated	VBD	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
H	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
S	NNP	O	O
and	CC	O	O
the	DT	O	O
expression	NN	O	O
of	IN	O	O
H	NNP	O	B-PRODUCT-OF
(	(	O	O
2	CD	O	O
)	)	O	O
S	NNP	O	O
synthesizing	VBG	O	O
enzymes	RB	O	O
,	,	O	O
CSE	NNP	O	B-enzyme
and	CC	O	O
CBS	NNP	O	B-enzyme
,	,	O	O
in	IN	O	O
isolated	JJ	O	O
mouse	NN	O	O
pancreatic	JJ	O	O
acini	NN	O	O
.	.	O	O

Pancreatic	JJ	O	O
acinar	NN	O	O
cells	NNS	O	O
from	IN	O	O
mice	NNS	O	O
were	VBD	O	O
incubated	VBN	O	O
with	IN	O	O
or	CC	O	O
without	IN	O	O
caerulein	NN	O	O
(	(	O	O
10	CD	O	O
(	(	O	O
-7	NN	O	O
)	)	O	O
M	NNP	O	O
for	IN	O	O
30	CD	O	O
and	CC	O	O
60	CD	O	O
min	NN	O	O
)	)	O	O
.	.	O	O

Caerulein	NNP	O	O
increased	VBD	O	O
the	DT	O	O
levels	NNS	O	O
of	IN	O	O
H	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
S	NNP	O	O
and	CC	O	O
CSE	NNP	O	O
mRNA	NNP	O	O
expression	NN	O	O
while	IN	O	O
CBS	NNP	O	O
mRNA	FW	O	O
expression	NN	O	O
was	VBD	O	O
decreased	VBN	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
cells	NNS	O	O
pre-treated	JJ	O	O
with	IN	O	O
DL-propargylglycine	NNP	O	O
(	(	O	O
PAG	NNP	O	O
,	,	O	O
3	CD	O	O
mM	NN	O	O
)	)	O	O
,	,	O	O
a	DT	O	O
CSE	NNP	O	O
inhibitor	NN	O	O
,	,	O	O
reduced	VBD	O	O
the	DT	O	O
formation	NN	O	O
of	IN	O	O
H	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
S	NN	O	O
in	IN	O	O
caerulein	NN	O	O
treated	VBD	O	O
cells	NNS	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
CSE	NNP	O	B-enzyme
may	MD	O	O
be	VB	O	O
the	DT	O	O
main	JJ	O	O
enzyme	NN	O	O
involved	VBN	O	O
in	IN	O	O
H	NNP	O	B-PRODUCT-OF
(	(	O	O
2	CD	O	O
)	)	O	O
S	NNP	O	O
formation	NN	O	O
in	IN	O	O
mouse	NN	O	O
acinar	NN	O	O
cells	NNS	O	O
.	.	O	O

Furthermore	RB	O	O
,	,	O	O
substance	NN	O	O
P	NNP	O	O
(	(	O	O
SP	NNP	O	O
)	)	O	O
concentration	NN	O	O
in	IN	O	O
the	DT	O	O
acini	NN	O	O
and	CC	O	O
expression	NN	O	O
of	IN	O	O
SP	NNP	O	O
gene	NN	O	O
(	(	O	O
preprotachykinin-A	JJ	O	O
,	,	O	O
PPT-A	NNP	O	O
)	)	O	O
and	CC	O	O
neurokinin-1	JJ	O	O
receptor	NN	O	O
(	(	O	O
NK-1R	NNP	O	O
)	)	O	O
,	,	O	O
the	DT	O	O
primary	JJ	O	O
receptor	NN	O	O
for	IN	O	O
SP	NNP	O	O
,	,	O	O
are	VBP	O	O
increased	VBN	O	O
in	IN	O	O
secretagogue	JJ	O	O
caerulein-treated	JJ	O	O
acinar	NN	O	O
cells	NNS	O	O
.	.	O	O

Inhibition	NN	O	O
of	IN	O	O
endogenous	JJ	O	O
production	NN	O	O
of	IN	O	O
H	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
S	NN	O	O
by	IN	O	O
PAG	NNP	O	O
significantly	RB	O	O
suppressed	VBD	O	O
SP	NNP	O	O
concentration	NN	O	O
,	,	O	O
PPT-A	NNP	O	O
expression	NN	O	O
and	CC	O	O
NK1-R	JJ	O	O
expression	NN	O	O
in	IN	O	O
the	DT	O	O
acini	NN	O	O
.	.	O	O

To	TO	O	O
determine	VB	O	O
whether	IN	O	O
H	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
S	NNP	O	O
itself	PRP	O	O
provoked	VBD	O	O
inflammation	NN	O	O
in	IN	O	O
acinar	NN	O	O
cells	NNS	O	O
,	,	O	O
the	DT	O	O
cells	NNS	O	O
were	VBD	O	O
treated	VBN	O	O
with	IN	O	O
H	NNP	O	O
(	(	O	O
2	CD	O	O
)	)	O	O
S	NNP	O	O
donor	JJ	O	O
drug	NN	O	O
,	,	O	O
sodium	NN	O	O
hydrosulphide	NN	O	O
(	(	O	O
NaHS	NNP	O	O
)	)	O	O
,	,	O	O
(	(	O	O
10	CD	O	O
,	,	O	O
50	CD	O	O
and	CC	O	O
100	CD	O	O
muM	NN	O	O
)	)	O	O
,	,	O	O
that	WDT	O	O
resulted	VBD	O	O
in	IN	O	O
a	DT	O	O
significant	JJ	O	O
increase	NN	O	O
in	IN	O	O
SP	NNP	O	O
concentration	NN	O	O
and	CC	O	O
expression	NN	O	O
of	IN	O	O
PPT-A	NNP	O	O
and	CC	O	O
NK1-R	NNP	O	O
in	IN	O	O
acinar	NN	O	O
cells	NNS	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
the	DT	O	O
pro-inflammatory	JJ	O	O
effect	NN	O	O
of	IN	O	O
H	NNP	O	B-PRODUCT-OF
(	(	O	O
2	CD	O	O
)	)	O	O
S	NN	O	O
may	MD	O	O
be	VB	O	O
mediated	VBN	O	O
by	IN	O	O
SP-NK-1R	NNP	O	O
related	JJ	O	O
pathway	NN	O	O
in	IN	O	O
mouse	NN	O	O
pancreatic	JJ	O	O
acinar	NN	O	O
cells	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

4-Hydroxynonenal	JJ	O	B-SUBSTRATE
(	(	O	O
4-HNE	JJ	O	B-SUBSTRATE
)	)	O	O
is	VBZ	O	O
a	DT	O	O
mutagenic	JJ	O	O
alpha	NN	O	B-SUBSTRATE
,	,	O	O
beta-unsaturated	JJ	O	O
aldehyde	NN	O	I-SUBSTRATE
produced	VBN	O	O
during	IN	O	O
oxidative	JJ	O	O
injury	NN	O	O
that	WDT	O	O
is	VBZ	O	O
conjugated	VBN	O	O
by	IN	O	O
several	JJ	O	O
glutathione	CD	O	B-enzyme
S-transferase	NNP	O	I-enzyme
(	(	O	O
GST	NNP	O	B-enzyme
)	)	O	O
isoforms	NNS	O	O
.	.	O	O

The	DT	O	O
alpha	JJ	O	O
class	NN	O	O
human	JJ	O	B-enzyme
GSTA4-4	NNP	O	I-enzyme
enzyme	NN	O	O
(	(	O	O
hGSTA4-4	NN	O	B-enzyme
)	)	O	O
has	VBZ	O	O
a	DT	O	O
particularly	RB	O	O
high	JJ	O	O
catalytic	JJ	O	O
efficiency	NN	O	O
toward	IN	O	O
4-HNE	JJ	O	B-SUBSTRATE
conjugation	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
hGST4-4	JJ	O	O
expression	NN	O	O
is	VBZ	O	O
low	JJ	O	O
in	IN	O	O
most	JJS	O	O
human	JJ	O	O
cells	NNS	O	O
and	CC	O	O
there	EX	O	O
are	VBP	O	O
other	JJ	O	O
aldehyde	IN	O	O
metabolizing	VBG	O	O
enzymes	NNS	O	O
that	WDT	O	O
detoxify	VBP	O	O
4-HNE	JJ	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
current	JJ	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
determined	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
over-expression	NN	O	O
of	IN	O	O
hGSTA4	NN	O	O
mRNA	NN	O	O
on	IN	O	O
the	DT	O	O
sensitivity	NN	O	O
of	IN	O	O
HepG2	NNP	O	O
cells	NNS	O	O
to	TO	O	O
4-HNE	JJ	O	O
injury	NN	O	O
.	.	O	O

HepG2	NNP	O	O
cells	NNS	O	O
transfected	VBD	O	O
with	IN	O	O
an	DT	O	O
hGSTA4	NN	O	O
vector	NN	O	O
construct	NN	O	O
exhibited	VBN	O	O
high	JJ	O	O
steady-state	JJ	O	O
hGSTA4	NN	O	O
mRNA	NN	O	O
,	,	O	O
high	JJ	O	O
GST-4-HNE	NNP	O	O
catalytic	JJ	O	O
activities	NNS	O	O
,	,	O	O
but	CC	O	O
lower	JJR	O	O
basal	NN	O	O
glutathione	NN	O	O
(	(	O	O
GSH	NNP	O	O
)	)	O	O
concentrations	NNS	O	O
relative	VBP	O	O
to	TO	O	O
insert-free	JJ	O	O
vector	NN	O	O
(	(	O	O
control	NN	O	O
)	)	O	O
cells	NNS	O	O
.	.	O	O

Exposure	NN	O	O
to	TO	O	O
4-HNE	JJ	O	O
elicited	VBN	O	O
an	DT	O	O
increase	NN	O	O
in	IN	O	O
GSH	NNP	O	O
concentrations	NNS	O	O
in	IN	O	O
the	DT	O	O
control	NN	O	O
and	CC	O	O
hGSTA4	NN	O	O
cells	NNS	O	O
,	,	O	O
although	IN	O	O
the	DT	O	O
dose-response	NN	O	O
of	IN	O	O
GSH	NNP	O	O
induction	NN	O	O
differed	VBD	O	O
among	IN	O	O
the	DT	O	O
two	CD	O	O
cell	NN	O	O
types	NNS	O	O
.	.	O	O

Specifically	RB	O	O
,	,	O	O
hGSTA4	NN	O	B-enzyme
cells	NNS	O	O
had	VBD	O	O
significantly	RB	O	O
higher	JJR	O	O
GSH	NNP	O	O
concentrations	NNS	O	O
when	WRB	O	O
exposed	VBN	O	O
to	TO	O	O
5-15	JJ	O	O
microM	JJ	O	O
4-HNE	JJ	O	B-SUBSTRATE
,	,	O	O
but	CC	O	O
not	RB	O	O
at	IN	O	O
20	CD	O	O
microM	JJ	O	O
4-HNE	CD	O	B-SUBSTRATE
,	,	O	O
suggesting	VBG	O	O
extensive	JJ	O	O
GSH	NNP	O	O
utilization	NN	O	O
at	IN	O	O
high	JJ	O	O
concentrations	NNS	O	O
of	IN	O	O
4-HNE	JJ	O	O
.	.	O	O

The	DT	O	O
hGSTA4	NN	O	O
cells	NNS	O	O
exhibited	VBD	O	O
a	DT	O	O
significant	JJ	O	O
growth	NN	O	O
advantage	NN	O	O
relative	JJ	O	O
to	TO	O	O
control	VB	O	O
cells	NNS	O	O
in	IN	O	O
the	DT	O	O
absence	NN	O	O
of	IN	O	O
4-HNE	JJ	O	O
,	,	O	O
and	CC	O	O
a	DT	O	O
trend	NN	O	O
towards	NNS	O	O
increased	VBD	O	O
growth	NN	O	O
at	IN	O	O
low	JJ	O	O
dose	NN	O	O
exposures	NNS	O	O
to	TO	O	O
4-HNE	JJ	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
hGSTA4	NN	O	O
cells	NNS	O	O
did	VBD	O	O
not	RB	O	O
exhibit	VB	O	O
a	DT	O	O
growth	NN	O	O
advantage	NN	O	O
relative	JJ	O	O
to	TO	O	O
control	VB	O	O
cells	NNS	O	O
at	IN	O	O
higher	JJR	O	O
4-HNE	JJ	O	O
exposures	NNS	O	O
associated	VBN	O	O
with	IN	O	O
increased	JJ	O	O
GSH	NNP	O	O
utilization	NN	O	O
.	.	O	O

As	IN	O	O
expected	VBN	O	O
,	,	O	O
the	DT	O	O
hGSTA4	NN	O	O
cells	NNS	O	O
showed	VBD	O	O
resistance	NN	O	O
to	TO	O	O
4-HNE	JJ	O	O
stimulated	JJ	O	O
lipid	JJ	O	O
peroxidation	NN	O	O
at	IN	O	O
all	DT	O	O
4-HNE	JJ	O	O
doses	NNS	O	O
.	.	O	O

In	IN	O	O
summary	JJ	O	O
,	,	O	O
our	PRP$	O	O
data	NNS	O	O
indicates	VBZ	O	O
that	IN	O	O
over-expression	NN	O	O
of	IN	O	O
hGSTA4	NN	O	O
at	IN	O	O
levels	NNS	O	O
conferring	VBG	O	O
high	JJ	O	O
GST-4-HNE	JJ	O	O
conjugating	NN	O	O
activity	NN	O	O
confers	VBZ	O	O
a	DT	O	O
partial	JJ	O	O
growth	NN	O	O
advantage	NN	O	O
to	TO	O	O
HepG2	NNP	O	O
cells	NNS	O	O
and	CC	O	O
protects	NNS	O	O
against	IN	O	O
4-HNE	JJ	O	O
oxidative	JJ	O	O
injury	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
loss	NN	O	O
of	IN	O	O
proliferative	JJ	O	O
capacity	NN	O	O
of	IN	O	O
hGSTA4	NN	O	B-enzyme
cells	NNS	O	O
challenged	VBN	O	O
with	IN	O	O
levels	NNS	O	O
of	IN	O	O
4-HNE	JJ	O	B-SUBSTRATE
associated	VBN	O	O
with	IN	O	O
severe	JJ	O	O
oxidative	JJ	O	O
stress	NN	O	O
indicates	VBZ	O	O
a	DT	O	O
role	NN	O	O
of	IN	O	O
other	JJ	O	O
aldehyde	JJ	O	O
metabolizing	VBG	O	O
enzymes	NNS	O	O
,	,	O	O
and/or	JJ	O	O
GSH-electrophile	NNP	O	O
transporter	NN	O	O
proteins	NNS	O	O
,	,	O	O
in	IN	O	O
providing	VBG	O	O
full	JJ	O	O
cellular	JJ	O	O
protection	NN	O	O
against	IN	O	O
4-HNE	JJ	O	O
toxicity	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

A	DT	O	O
pretreatment	NN	O	O
with	IN	O	O
20kPa	CD	O	O
CO2+20	NNP	O	O
kPa	NN	O	O
O2+60	NNP	O	O
kPa	VBZ	O	O
N2	NNP	O	O
for	IN	O	O
3	CD	O	O
days	NNS	O	O
proved	VBD	O	O
effective	JJ	O	O
in	IN	O	O
maintaining	VBG	O	O
the	DT	O	O
fruit	NN	O	O
quality	NN	O	O
and	CC	O	O
controlling	VBG	O	O
decay	NN	O	O
in	IN	O	O
table	JJ	O	O
grapes	NNS	O	O
(	(	O	O
Vitis	NNP	O	O
vinifera	NN	O	O
cv	NN	O	O
.	.	O	O

Cardinal	NNP	O	O
)	)	O	O
stored	VBD	O	O
at	IN	O	O
0	CD	O	O
degrees	NNS	O	O
C.	NNP	O	O
In	IN	O	O
the	DT	O	O
present	JJ	O	O
work	NN	O	O
,	,	O	O
we	PRP	O	O
analyzed	VBD	O	O
whether	IN	O	O
total	JJ	O	O
anthocyanin	NN	O	O
content	NN	O	O
,	,	O	O
the	DT	O	O
molecular	JJ	O	O
mechanism	NN	O	O
implicated	VBN	O	O
in	IN	O	O
their	PRP$	O	O
biosynthesis	NN	O	O
and	CC	O	O
antioxidant	JJ	O	O
activity	NN	O	O
is	VBZ	O	O
related	VBN	O	O
to	TO	O	O
the	DT	O	O
beneficial	JJ	O	O
effect	NN	O	O
of	IN	O	O
this	DT	O	O
gaseous	JJ	O	O
treatment	NN	O	O
.	.	O	O

We	PRP	O	O
isolated	VBD	O	O
partial	JJ	O	O
cDNAs	NN	O	O
that	WDT	O	O
codified	VBD	O	O
for	IN	O	O
enzymes	NNS	O	O
implicated	VBN	O	O
in	IN	O	O
the	DT	O	O
anthocyanin	JJ	O	B-PRODUCT-OF
biosynthesis	NN	O	O
such	JJ	O	O
as	IN	O	O
l-phenylalanine	JJ	O	B-enzyme
ammonia-lyase	NN	O	I-enzyme
(	(	O	O
PAL	NNP	O	B-enzyme
)	)	O	O
and	CC	O	O
chalcone	JJ	O	B-enzyme
synthase	NN	O	I-enzyme
(	(	O	O
CHS	NNP	O	B-enzyme
)	)	O	O
,	,	O	O
and	CC	O	O
an	DT	O	O
antioxidant	JJ	O	O
enzyme	NN	O	O
such	JJ	O	O
as	IN	O	O
ascorbate	JJ	O	B-enzyme
peroxidase	NN	O	I-enzyme
(	(	O	O
APX	NNP	O	B-enzyme
)	)	O	O
.	.	O	O

Low	JJ	O	O
temperatures	NNS	O	O
induced	VBD	O	O
an	DT	O	O
accumulation	NN	O	O
of	IN	O	O
total	JJ	O	O
anthocyanin	NN	O	O
content	NN	O	O
in	IN	O	O
the	DT	O	O
skin	NN	O	O
of	IN	O	O
both	DT	O	O
treated	VBN	O	O
and	CC	O	O
non-treated	JJ	O	O
grapes	NNS	O	O
,	,	O	O
although	IN	O	O
levels	NNS	O	O
were	VBD	O	O
lower	JJR	O	O
in	IN	O	O
CO2-treated	JJ	O	O
fruit	NN	O	O
.	.	O	O

By	IN	O	O
contrast	NN	O	O
,	,	O	O
antioxidant	JJ	O	O
activity	NN	O	O
decreased	VBD	O	O
during	IN	O	O
storage	NN	O	O
at	IN	O	O
0	CD	O	O
degrees	NNS	O	O
C	NNP	O	O
in	IN	O	O
non-treated	JJ	O	O
grapes	NNS	O	O
but	CC	O	O
did	VBD	O	O
not	RB	O	O
change	VB	O	O
in	IN	O	O
CO2-treated	JJ	O	O
grapes	NNS	O	O
.	.	O	O

The	DT	O	O
up-regulation	NN	O	O
of	IN	O	O
anthocyanin	JJ	O	O
biosynthesis	NN	O	O
gene	NN	O	O
expression	NN	O	O
and	CC	O	O
VcAPX	NNP	O	O
mRNA	VBP	O	O
observed	VBN	O	O
in	IN	O	O
non-treated	JJ	O	O
grape	NN	O	O
is	VBZ	O	O
not	RB	O	O
enhanced	VBN	O	O
in	IN	O	O
CO2-treated	NNP	O	O
grapes	NNS	O	O
,	,	O	O
which	WDT	O	O
presented	VBD	O	O
low	JJ	O	O
total	JJ	O	O
decay	NN	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
point	VBP	O	O
out	RP	O	O
the	DT	O	O
ability	NN	O	O
of	IN	O	O
CO2-treated	NNP	O	O
grapes	NNS	O	O
to	TO	O	O
prevent	VB	O	O
the	DT	O	O
generation	NN	O	O
of	IN	O	O
reactive	JJ	O	O
oxygen	NN	O	O
species	NNS	O	O
rather	RB	O	O
than	IN	O	O
their	PRP$	O	O
inactivation	NN	O	O
by	IN	O	O
means	NNS	O	O
of	IN	O	O
induction	NN	O	O
of	IN	O	O
studied	JJ	O	O
defense	NN	O	O
systems	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Indoleamine	JJ	O	B-enzyme
2,3-dioxygenase	JJ	O	I-enzyme
(	(	O	O
IDO	NNP	O	B-enzyme
)	)	O	O
,	,	O	O
a	DT	O	O
tryptophan	NN	O	B-SUBSTRATE
catabolizing	VBG	O	O
enzyme	NN	O	O
,	,	O	O
has	VBZ	O	O
been	VBN	O	O
implicated	VBN	O	O
in	IN	O	O
the	DT	O	O
pathogenesis	NN	O	O
of	IN	O	O
various	JJ	O	O
neurological	JJ	O	O
disorders	NNS	O	O
.	.	O	O

IDO	NNP	O	O
expression	NN	O	O
is	VBZ	O	O
induced	VBN	O	O
by	IN	O	O
IFN-gamma	NNP	O	O
and	CC	O	O
leads	VBZ	O	O
to	TO	O	O
neurotoxicity	NN	O	O
by	IN	O	O
generating	VBG	O	O
quinolinic	JJ	O	O
acid	NN	O	O
.	.	O	O

Additionally	RB	O	O
,	,	O	O
it	PRP	O	O
inhibits	VBZ	O	O
the	DT	O	O
immune	JJ	O	O
response	NN	O	O
through	IN	O	O
both	DT	O	O
tryptophan	JJ	O	O
depletion	NN	O	O
and	CC	O	O
generating	VBG	O	O
other	JJ	O	O
tryptophan	JJ	O	O
catabolites	NNS	O	O
.	.	O	O

IL-4	JJ	O	O
and	CC	O	O
IL-13	NNP	O	O
have	VBP	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
control	VB	O	O
IDO	NNP	O	O
expression	NN	O	O
by	IN	O	O
antagonizing	VBG	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
IFN-gamma	NNP	O	O
in	IN	O	O
different	JJ	O	O
cell	NN	O	O
types	NNS	O	O
.	.	O	O

Here	RB	O	O
,	,	O	O
we	PRP	O	O
investigated	VBD	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
these	DT	O	O
cytokines	NNS	O	O
on	IN	O	O
IDO	NNP	O	O
expression	NN	O	O
in	IN	O	O
microglia	NN	O	O
.	.	O	O

Interestingly	RB	O	O
,	,	O	O
we	PRP	O	O
observed	VBD	O	O
that	IN	O	O
both	DT	O	O
IL-4	NNP	O	O
and	CC	O	O
IL-13	NNP	O	O
greatly	RB	O	O
enhanced	VBD	O	O
IFN-gamma-induced	NNP	O	O
IDO	NNP	O	O
expression	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
tryptophanyl-tRNA	JJ	O	O
synthetase	NN	O	O
(	(	O	O
WRS	NNP	O	O
)	)	O	O
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
coinduced	VBN	O	O
with	IN	O	O
IDO	NNP	O	O
by	IN	O	O
IFN-gamma	NNP	O	O
,	,	O	O
is	VBZ	O	O
downregulated	VBN	O	O
by	IN	O	O
IL-4	NNP	O	O
and	CC	O	O
IL-13	NNP	O	O
.	.	O	O

The	DT	O	O
effect	NN	O	O
of	IN	O	O
IL-4	NNP	O	O
and	CC	O	O
IL-13	NNP	O	O
was	VBD	O	O
independent	JJ	O	O
of	IN	O	O
STAT-6	NNP	O	O
.	.	O	O

Modulation	NN	O	O
of	IN	O	O
IDO	NNP	O	O
but	CC	O	O
not	RB	O	O
WRS	NNP	O	O
was	VBD	O	O
eliminated	VBN	O	O
by	IN	O	O
inhibition	NN	O	O
of	IN	O	O
protein	JJ	O	O
phosphatase	NN	O	O
2A	CD	O	O
(	(	O	O
PP2A	NNP	O	O
)	)	O	O
activity	NN	O	O
.	.	O	O

The	DT	O	O
phosphatidylinositol	JJ	O	O
3-kinase	JJ	O	O
(	(	O	O
PI3K	NNP	O	O
)	)	O	O
pathway	RB	O	O
further	RBR	O	O
differentiated	VBD	O	O
the	DT	O	O
regulation	NN	O	O
of	IN	O	O
these	DT	O	O
two	CD	O	O
enzymes	NNS	O	O
,	,	O	O
as	IN	O	O
inhibiting	VBG	O	O
the	DT	O	O
PI3K	NNP	O	O
pathway	NN	O	O
eliminated	VBD	O	O
IFN-gamma	NNP	O	O
induction	NN	O	O
of	IN	O	O
IDO	NNP	O	O
,	,	O	O
whereas	NNS	O	O
such	JJ	O	O
inhibition	NN	O	O
greatly	RB	O	O
enhanced	VBD	O	O
WRS	NNP	O	O
expression	NN	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
show	VBP	O	O
discordance	NN	O	O
between	IN	O	O
modulations	NNS	O	O
of	IN	O	O
expression	NN	O	O
of	IN	O	O
two	CD	O	O
distinct	JJ	O	O
enzymes	NNS	O	O
utilizing	VBG	O	O
tryptophan	NN	O	O
as	IN	O	O
a	DT	O	O
common	JJ	O	O
substrate	NN	O	O
,	,	O	O
and	CC	O	O
raise	VB	O	O
the	DT	O	O
possibility	NN	O	O
of	IN	O	O
their	PRP$	O	O
involvement	NN	O	O
in	IN	O	O
regulating	VBG	O	O
immune	JJ	O	O
responses	NNS	O	O
in	IN	O	O
various	JJ	O	O
neurological	JJ	O	O
disorders	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

For	IN	O	O
more	JJR	O	O
than	IN	O	O
three	CD	O	O
decades	NNS	O	O
,	,	O	O
acetaminophen	NN	O	O
(	(	O	O
INN	NNP	O	O
,	,	O	O
paracetamol	NN	O	O
)	)	O	O
has	VBZ	O	O
been	VBN	O	O
claimed	VBN	O	O
to	TO	O	O
be	VB	O	O
devoid	NN	O	O
of	IN	O	O
significant	JJ	O	O
inhibition	NN	O	O
of	IN	O	O
peripheral	JJ	O	O
prostanoids	NNS	O	O
.	.	O	O

Meanwhile	RB	O	O
,	,	O	O
attempts	NNS	O	O
to	TO	O	O
explain	VB	O	O
its	PRP$	O	O
action	NN	O	O
by	IN	O	O
inhibition	NN	O	O
of	IN	O	O
a	DT	O	O
central	JJ	O	O
cyclooxygenase	NN	O	O
(	(	O	O
COX	NNP	O	O
)	)	O	O
-3	WDT	O	O
have	VBP	O	O
been	VBN	O	O
rejected	VBN	O	O
.	.	O	O

The	DT	O	O
fact	NN	O	O
that	IN	O	O
acetaminophen	JJ	O	O
acts	NNS	O	O
functionally	RB	O	O
as	IN	O	O
a	DT	O	O
selective	JJ	O	O
COX-2	NNP	O	O
inhibitor	NN	O	O
led	VBD	O	O
us	PRP	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
hypothesis	NN	O	O
of	IN	O	O
whether	IN	O	O
it	PRP	O	O
works	VBZ	O	O
via	IN	O	O
preferential	JJ	O	O
COX-2	NNP	O	O
blockade	NN	O	O
.	.	O	O

Ex	NNP	O	O
vivo	NN	O	O
COX	NNP	O	O
inhibition	NN	O	O
and	CC	O	O
pharmacokinetics	NNS	O	O
of	IN	O	O
acetaminophen	NN	O	O
were	VBD	O	O
assessed	VBN	O	O
in	IN	O	O
5	CD	O	O
volunteers	NNS	O	O
receiving	VBG	O	O
single	JJ	O	O
1000	CD	O	O
mg	NN	O	O
doses	VBZ	O	O
orally	RB	O	O
.	.	O	O

Coagulation-induced	NNP	O	O
thromboxane	NN	O	B-PRODUCT-OF
B	NNP	O	I-PRODUCT-OF
(	(	O	I-PRODUCT-OF
2	CD	O	I-PRODUCT-OF
)	)	O	I-PRODUCT-OF
and	CC	O	O
lipopolysaccharide-induced	JJ	O	O
prostaglandin	NN	O	B-PRODUCT-OF
E	NNP	O	I-PRODUCT-OF
(	(	O	I-PRODUCT-OF
2	CD	O	I-PRODUCT-OF
)	)	O	I-PRODUCT-OF
were	VBD	O	O
measured	VBN	O	O
ex	JJ	O	O
vivo	NN	O	O
and	CC	O	O
in	IN	O	O
vitro	NN	O	O
in	IN	O	O
human	JJ	O	O
whole	JJ	O	O
blood	NN	O	O
as	IN	O	O
indices	NNS	O	O
of	IN	O	O
COX-1	NNP	O	B-enzyme
and	CC	O	O
COX-2	NNP	O	B-enzyme
activity	NN	O	O
.	.	O	O

In	IN	O	O
vitro	NN	O	O
,	,	O	O
acetaminophen	RB	O	O
elicited	VBD	O	O
a	DT	O	O
4.4-fold	JJ	O	O
selectivity	NN	O	O
toward	IN	O	O
COX-2	NNP	O	O
inhibition	NN	O	O
(	(	O	O
IC	NNP	O	O
(	(	O	O
50	CD	O	O
)	)	O	O
=113.7	NN	O	O
micromol/L	NN	O	O
for	IN	O	O
COX-1	NNP	O	O
;	:	O	O
IC	NNP	O	O
(	(	O	O
50	CD	O	O
)	)	O	O
=25.8	NN	O	O
micromol/L	NN	O	O
for	IN	O	O
COX-2	NNP	O	O
)	)	O	O
.	.	O	O

Following	VBG	O	O
oral	JJ	O	O
administration	NN	O	O
of	IN	O	O
the	DT	O	O
drug	NN	O	O
,	,	O	O
maximal	JJ	O	O
ex	FW	O	O
vivo	FW	O	O
inhibitions	NNS	O	O
were	VBD	O	O
56	CD	O	O
%	NN	O	O
(	(	O	O
COX-1	NNP	O	O
)	)	O	O
and	CC	O	O
83	CD	O	O
%	NN	O	O
(	(	O	O
COX-2	NNP	O	O
)	)	O	O
.	.	O	O

Acetaminophen	NNP	O	O
plasma	NN	O	O
concentrations	NNS	O	O
remained	VBD	O	O
above	IN	O	O
the	DT	O	O
in	IN	O	O
vitro	NN	O	O
IC	NNP	O	O
(	(	O	O
50	CD	O	O
)	)	O	O
for	IN	O	O
COX-2	NNP	O	O
for	IN	O	O
at	IN	O	O
least	JJS	O	O
5	CD	O	O
h	JJ	O	O
postadministration	NN	O	O
.	.	O	O

Ex	NNP	O	O
vivo	NN	O	O
IC	NNP	O	O
(	(	O	O
50	CD	O	O
)	)	O	O
values	NNS	O	O
(	(	O	O
COX-1	JJ	O	O
:	:	O	O
105.2	CD	O	O
micromol/L	NN	O	O
;	:	O	O
COX-2	JJ	O	O
:	:	O	O
26.3	CD	O	O
micromol/L	NN	O	O
)	)	O	O
of	IN	O	O
acetaminophen	NN	O	O
compared	VBN	O	O
favorably	RB	O	O
with	IN	O	O
its	PRP$	O	O
in	IN	O	O
vitro	NN	O	O
IC	NNP	O	O
(	(	O	O
50	CD	O	O
)	)	O	O
values	NNS	O	O
.	.	O	O

In	IN	O	O
contrast	NN	O	O
to	TO	O	O
previous	JJ	O	O
concepts	NNS	O	O
,	,	O	O
acetaminophen	RB	O	O
inhibited	VBN	O	O
COX-2	NNP	O	O
by	IN	O	O
more	JJR	O	O
than	IN	O	O
80	CD	O	O
%	NN	O	O
,	,	O	O
i.e.	NN	O	O
,	,	O	O
to	TO	O	O
a	DT	O	O
degree	NN	O	O
comparable	JJ	O	O
to	TO	O	O
nonsteroidal	VB	O	O
antiinflammatory	NN	O	O
drugs	NNS	O	O
(	(	O	O
NSAIDs	NNP	O	O
)	)	O	O
and	CC	O	O
selective	JJ	O	O
COX-2	JJ	O	O
inhibitors	NNS	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
a	DT	O	O
>	JJ	O	O
95	CD	O	O
%	NN	O	O
COX-1	NNP	O	O
blockade	NN	O	O
relevant	NN	O	O
for	IN	O	O
suppression	NN	O	O
of	IN	O	O
platelet	NN	O	O
function	NN	O	O
was	VBD	O	O
not	RB	O	O
achieved	VBN	O	O
.	.	O	O

Our	PRP$	O	O
data	NNS	O	O
may	MD	O	O
explain	VB	O	O
acetaminophen	NN	O	O
's	POS	O	O
analgesic	JJ	O	O
and	CC	O	O
antiinflammatory	JJ	O	O
action	NN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
its	PRP$	O	O
superior	JJ	O	O
overall	JJ	O	O
gastrointestinal	JJ	O	O
safety	NN	O	O
profile	NN	O	O
compared	VBN	O	O
with	IN	O	O
NSAIDs	NNP	O	O
.	.	O	O

In	IN	O	O
view	NN	O	O
of	IN	O	O
its	PRP$	O	O
substantial	JJ	O	O
COX-2	JJ	O	O
inhibition	NN	O	O
,	,	O	O
recently	RB	O	O
defined	VBD	O	O
cardiovascular	JJ	O	O
warnings	NNS	O	O
for	IN	O	O
use	NN	O	O
of	IN	O	O
COX-2	JJ	O	O
inhibitors	NNS	O	O
should	MD	O	O
also	RB	O	O
be	VB	O	O
considered	VBN	O	O
for	IN	O	O
acetaminophen	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

The	DT	O	O
Na	NNP	O	B-enzyme
(	(	O	O
+	NNP	O	O
)	)	O	O
/Ca	NNP	O	O
(	(	O	O
2+	CD	O	O
)	)	O	O
exchanger	NN	O	I-enzyme
(	(	O	O
NCX	NNP	O	O
)	)	O	O
is	VBZ	O	O
a	DT	O	O
bidirectional	JJ	O	O
transporter	NN	O	O
that	WDT	O	O
normally	RB	O	O
extrudes	VBZ	O	O
Ca	NNP	O	B-SUBSTRATE
(	(	O	O
2+	CD	O	O
)	)	O	O
from	IN	O	O
the	DT	O	O
cell	NN	O	O
(	(	O	O
forward	RB	O	O
mode	NN	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
also	RB	O	O
brings	VBZ	O	O
Ca	NNP	O	B-SUBSTRATE
(	(	O	O
2+	CD	O	O
)	)	O	O
into	IN	O	O
the	DT	O	O
cell	NN	O	O
(	(	O	O
reverse	JJ	O	O
mode	NN	O	O
)	)	O	O
under	IN	O	O
special	JJ	O	O
conditions	NNS	O	O
such	JJ	O	O
as	IN	O	O
intracellular	JJ	O	O
Na	NNP	O	O
(	(	O	O
+	NNP	O	O
)	)	O	O
(	(	O	O
Na	NNP	O	O
(	(	O	O
+	NNP	O	O
)	)	O	O
(	(	O	O
i	NN	O	O
)	)	O	O
)	)	O	O
accumulation	NN	O	O
or	CC	O	O
membrane	NN	O	O
depolarization	NN	O	O
.	.	O	O

There	EX	O	O
are	VBP	O	O
three	CD	O	O
mammalian	JJ	O	O
NCX	NNP	O	O
isoforms	NNS	O	O
:	:	O	O
NCX1	NNP	O	O
is	VBZ	O	O
widely	RB	O	O
expressed	VBN	O	O
in	IN	O	O
the	DT	O	O
heart	NN	O	O
,	,	O	O
kidney	NN	O	O
,	,	O	O
brain	NN	O	O
,	,	O	O
blood	NN	O	O
vessels	NNS	O	O
,	,	O	O
and	CC	O	O
so	RB	O	O
on	IN	O	O
;	:	O	O
whereas	IN	O	O
the	DT	O	O
expression	NN	O	O
of	IN	O	O
NCX2	NNP	O	O
and	CC	O	O
NCX3	NNP	O	O
is	VBZ	O	O
limited	VBN	O	O
mainly	RB	O	O
to	TO	O	O
the	DT	O	O
brain	NN	O	O
and	CC	O	O
skeletal	JJ	O	O
muscle	NN	O	O
.	.	O	O

The	DT	O	O
pharmacology	NN	O	O
of	IN	O	O
NCX	NNP	O	O
inhibitors	NNS	O	O
has	VBZ	O	O
been	VBN	O	O
studied	VBN	O	O
extensively	RB	O	O
since	IN	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
KB-R7943	NNP	O	O
,	,	O	O
a	DT	O	O
prototype	NN	O	O
benzyloxyphenyl	NN	O	O
NCX	NNP	O	O
inhibitor	NN	O	O
,	,	O	O
in	IN	O	O
1996	CD	O	O
.	.	O	O

Currently	RB	O	O
,	,	O	O
experiments	NNS	O	O
are	VBP	O	O
actively	RB	O	O
progressing	VBG	O	O
with	IN	O	O
more	RBR	O	O
selective	JJ	O	O
inhibitors	NNS	O	O
:	:	O	O
SEA0400	NNP	O	O
,	,	O	O
SN-6	NNP	O	O
,	,	O	O
and	CC	O	O
YM-244769	NNP	O	O
.	.	O	O

Intriguingly	RB	O	O
,	,	O	O
the	DT	O	O
inhibitory	JJ	O	O
potency	NN	O	O
of	IN	O	O
benzyloxyphenyl	NN	O	O
NCX	NNP	O	O
inhibitors	NNS	O	O
is	VBZ	O	O
directly	RB	O	O
coupled	VBN	O	O
to	TO	O	O
the	DT	O	O
rate	NN	O	O
of	IN	O	O
Na	NNP	O	O
(	(	O	O
+	NNP	O	O
)	)	O	O
(	(	O	O
i	NN	O	O
)	)	O	O
-dependent	NN	O	O
inactivation	NN	O	O
.	.	O	O

Therefore	RB	O	O
,	,	O	O
the	DT	O	O
benzyloxyphenyl	NN	O	O
inhibitors	NNS	O	O
are	VBP	O	O
apparently	RB	O	O
dormant	JJ	O	O
during	IN	O	O
the	DT	O	O
forward	JJ	O	O
mode	NN	O	O
under	IN	O	O
normal	JJ	O	O
conditions	NNS	O	O
(	(	O	O
low	JJ	O	O
Na	NNP	O	O
(	(	O	O
+	NNP	O	O
)	)	O	O
(	(	O	O
i	NN	O	O
)	)	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
become	VBP	O	O
effective	JJ	O	O
during	IN	O	O
the	DT	O	O
reverse	NN	O	O
mode	NN	O	O
under	IN	O	O
pathological	JJ	O	O
conditions	NNS	O	O
(	(	O	O
high	JJ	O	O
Na	NNP	O	O
(	(	O	O
+	NNP	O	O
)	)	O	O
(	(	O	O
i	NN	O	O
)	)	O	O
)	)	O	O
.	.	O	O

This	DT	O	O
should	MD	O	O
be	VB	O	O
an	DT	O	O
ideal	JJ	O	O
profile	NN	O	O
for	IN	O	O
calcium	NN	O	O
regulators	NNS	O	O
against	IN	O	O
Na	NNP	O	O
(	(	O	O
+	NNP	O	O
)	)	O	O
(	(	O	O
i	NN	O	O
)	)	O	O
-related	VBD	O	O
diseases	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
ischemia/reperfusion	NN	O	O
injuries	NNS	O	O
,	,	O	O
salt-dependent	JJ	O	O
hypertension	NN	O	O
,	,	O	O
and	CC	O	O
digitalis	JJ	O	O
arrhythmia	NN	O	O
.	.	O	O

Existing	VBG	O	O
ion	NN	O	O
channel	NN	O	O
blockers	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
amiodarone	NN	O	O
,	,	O	O
dronedarone	NN	O	O
,	,	O	O
bepridil	NN	O	O
,	,	O	O
aprindine	NN	O	O
,	,	O	O
and	CC	O	O
cibenzoline	NN	O	O
,	,	O	O
have	VBP	O	O
been	VBN	O	O
found	VBN	O	O
to	TO	O	O
have	VB	O	O
an	DT	O	O
NCX	NNP	O	O
inhibitory	NN	O	O
action	NN	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
possible	JJ	O	O
that	IN	O	O
this	DT	O	O
property	NN	O	O
is	VBZ	O	O
partly	RB	O	O
responsible	JJ	O	O
for	IN	O	O
their	PRP$	O	O
antiarrhythmic	JJ	O	O
and	CC	O	O
cardioprotective	JJ	O	O
effects	NNS	O	O
.	.	O	O

This	DT	O	O
article	NN	O	O
presents	VBZ	O	O
the	DT	O	O
characteristics	NNS	O	O
of	IN	O	O
selective	JJ	O	O
and	CC	O	O
non-selective	JJ	O	O
NCX	NNP	O	O
inhibitors	NNS	O	O
and	CC	O	O
their	PRP$	O	O
therapeutic	JJ	O	O
potential	NN	O	O
as	IN	O	O
a	DT	O	O
new	JJ	O	O
calcium	NN	O	O
regulator	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Adenylosuccinate	NNP	O	B-enzyme
synthetase	NN	O	I-enzyme
(	(	O	O
AdSS	NNP	O	B-enzyme
)	)	O	O
catalyzes	VBZ	O	O
the	DT	O	O
Mg2+	NNP	O	B-SUBSTRATE
dependent	JJ	O	O
condensation	NN	O	O
of	IN	O	O
a	DT	O	O
molecule	NN	O	O
of	IN	O	O
IMP	NNP	O	O
with	IN	O	O
aspartate	NN	O	O
to	TO	O	O
form	VB	O	O
adenylosuccinate	NN	O	B-PRODUCT-OF
,	,	O	O
in	IN	O	O
a	DT	O	O
reaction	NN	O	O
driven	VBN	O	O
by	IN	O	O
the	DT	O	O
hydrolysis	NN	O	O
of	IN	O	O
GTP	NNP	O	O
to	TO	O	O
GDP	NNP	O	O
.	.	O	O

AdSS	NN	O	O
from	IN	O	O
the	DT	O	O
thermophilic	JJ	O	O
archaea	NN	O	O
,	,	O	O
Methanocaldococcus	NNP	O	O
jannaschii	NN	O	O
(	(	O	O
MjAdSS	NNP	O	O
)	)	O	O
is	VBZ	O	O
345	CD	O	O
amino	JJ	O	O
acids	NNS	O	O
long	RB	O	O
against	IN	O	O
an	DT	O	O
average	JJ	O	O
length	NN	O	O
of	IN	O	O
430-457	JJ	O	O
amino	NN	O	O
acids	NNS	O	O
for	IN	O	O
most	JJS	O	O
mesophilic	JJ	O	O
AdSS	NNP	O	O
.	.	O	O

This	DT	O	O
short	JJ	O	O
AdSS	NNP	O	O
has	VBZ	O	O
two	CD	O	O
large	JJ	O	O
deletions	NNS	O	O
that	WDT	O	O
map	VBP	O	O
to	TO	O	O
the	DT	O	O
middle	JJ	O	O
and	CC	O	O
C-terminus	NNP	O	O
of	IN	O	O
the	DT	O	O
protein	NN	O	O
.	.	O	O

This	DT	O	O
article	NN	O	O
discusses	VBZ	O	O
the	DT	O	O
detailed	JJ	O	O
kinetic	JJ	O	O
characterization	NN	O	O
of	IN	O	O
MjAdSS	NNP	O	O
.	.	O	O

Initial	JJ	O	O
velocity	NN	O	O
and	CC	O	O
product	NN	O	O
inhibition	NN	O	O
studies	NNS	O	O
,	,	O	O
carried	VBD	O	O
out	RP	O	O
at	IN	O	O
70	CD	O	O
degrees	NNS	O	O
C	NNP	O	O
,	,	O	O
suggest	VBP	O	O
a	DT	O	O
rapid	JJ	O	O
equilibrium	NN	O	O
random	NN	O	O
AB	NNP	O	O
steady-state	NN	O	O
ordered	VBD	O	O
C	NNP	O	O
kinetic	JJ	O	O
mechanism	NN	O	O
for	IN	O	O
the	DT	O	O
MjAdSS	NNP	O	O
catalyzed	VBN	O	O
reaction	NN	O	O
.	.	O	O

AdSS	NNP	O	O
are	VBP	O	O
known	VBN	O	O
to	TO	O	O
exhibit	VB	O	O
monomer-dimer	JJ	O	O
equilibrium	NN	O	O
with	IN	O	O
the	DT	O	O
dimer	NN	O	O
being	VBG	O	O
implicated	VBN	O	O
in	IN	O	O
catalysis	NN	O	O
.	.	O	O

In	IN	O	O
contrast	NN	O	O
,	,	O	O
our	PRP$	O	O
studies	NNS	O	O
show	VBP	O	O
that	IN	O	O
MjAdSS	NNP	O	O
is	VBZ	O	O
an	DT	O	O
equilibrium	JJ	O	O
mixture	NN	O	O
of	IN	O	O
dimers	NNS	O	O
and	CC	O	O
tetramers	NNS	O	O
with	IN	O	O
the	DT	O	O
tetramer	NN	O	O
being	VBG	O	O
the	DT	O	O
catalytically	RB	O	O
active	JJ	O	O
form	NN	O	O
.	.	O	O

The	DT	O	O
tetramer	NN	O	O
dissociates	VBZ	O	O
into	IN	O	O
dimers	NNS	O	O
with	IN	O	O
a	DT	O	O
minor	JJ	O	O
increase	NN	O	O
in	IN	O	O
ionic	JJ	O	O
strength	NN	O	O
of	IN	O	O
the	DT	O	O
buffer	NN	O	O
,	,	O	O
while	IN	O	O
the	DT	O	O
dimer	NN	O	O
is	VBZ	O	O
extremely	RB	O	O
stable	JJ	O	O
and	CC	O	O
does	VBZ	O	O
not	RB	O	O
dissociate	VB	O	O
even	RB	O	O
at	IN	O	O
1.2	CD	O	O
M	NNP	O	O
NaCl	NNP	O	O
.	.	O	O

Phosphate	NNP	O	O
,	,	O	O
a	DT	O	O
product	NN	O	O
of	IN	O	O
the	DT	O	O
reaction	NN	O	O
,	,	O	O
was	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
a	DT	O	O
potent	JJ	O	O
inhibitor	NN	O	O
of	IN	O	O
MjAdSS	NNP	O	O
showing	VBG	O	O
biphasic	JJ	O	O
inhibition	NN	O	O
of	IN	O	O
enzyme	JJ	O	O
activity	NN	O	O
.	.	O	O

The	DT	O	O
inhibition	NN	O	O
was	VBD	O	O
competitive	JJ	O	O
with	IN	O	O
IMP	NNP	O	O
and	CC	O	O
noncompetitive	JJ	O	O
with	IN	O	O
GTP	NNP	O	O
.	.	O	O

MjAdSS	NNP	O	O
,	,	O	O
like	IN	O	O
the	DT	O	O
mouse	NN	O	O
acidic	JJ	O	O
isozyme	NN	O	O
,	,	O	O
exhibits	VBZ	O	O
substrate	JJ	O	O
inhibition	NN	O	O
,	,	O	O
with	IN	O	O
IMP	NNP	O	O
inhibiting	VBG	O	O
enzyme	JJ	O	O
activity	NN	O	O
at	IN	O	O
subsaturating	VBG	O	O
GTP	NNP	O	O
concentrations	NNS	O	O
.	.	O	O

Regulation	NN	O	O
of	IN	O	O
enzyme	NN	O	O
activity	NN	O	O
by	IN	O	O
the	DT	O	O
glycolytic	JJ	O	O
intermediate	NN	O	O
,	,	O	O
fructose	RB	O	O
1,6	CD	O	O
bisphosphate	NN	O	O
,	,	O	O
was	VBD	O	O
also	RB	O	O
observed	VBN	O	O
with	IN	O	O
the	DT	O	O
inhibition	NN	O	O
being	VBG	O	O
competitive	JJ	O	O
with	IN	O	O
IMP	NNP	O	O
and	CC	O	O
noncompetitive	JJ	O	O
against	IN	O	O
GTP	NNP	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Risperidone	NN	O	B-SUBSTRATE
is	VBZ	O	O
metabolized	VBN	O	O
to	TO	O	O
its	PRP$	O	O
active	JJ	O	O
metabolite	NN	O	O
,	,	O	O
9-hydroxyrisperidone	CD	O	B-PRODUCT-OF
,	,	O	O
mainly	RB	O	O
by	IN	O	O
the	DT	O	O
cytochrome	NN	O	B-enzyme
P450	NNP	O	I-enzyme
enzymes	VBZ	O	O
CYP2D6	NNP	O	O
and	CC	O	O
3A4	CD	O	O
.	.	O	O

Its	PRP$	O	O
antipsychotic	JJ	O	O
effect	NN	O	O
is	VBZ	O	O
assumed	VBN	O	O
to	TO	O	O
be	VB	O	O
related	VBN	O	O
to	TO	O	O
the	DT	O	O
active	JJ	O	O
moiety	NN	O	O
,	,	O	O
that	WDT	O	O
is	VBZ	O	O
,	,	O	O
the	DT	O	O
sum	NN	O	O
of	IN	O	O
risperidone	NN	O	O
and	CC	O	O
9-hydroxyrisperidone	CD	O	O
.	.	O	O

Both	DT	O	O
risperidone	NN	O	B-SUBSTRATE
and	CC	O	O
9-hydroxyrisperidone	CD	O	B-SUBSTRATE
are	VBP	O	O
substrates	NNS	O	O
of	IN	O	O
P-glycoprotein	NNP	O	B-enzyme
(	(	O	O
P-gp	NNP	O	B-enzyme
)	)	O	O
,	,	O	O
a	DT	O	O
transport	NN	O	O
protein	NN	O	O
involved	VBN	O	O
in	IN	O	O
drug	NN	O	O
absorption	NN	O	O
,	,	O	O
distribution	NN	O	O
,	,	O	O
and	CC	O	O
elimination	NN	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
influence	NN	O	O
of	IN	O	O
polymorphisms	NN	O	O
in	IN	O	O
genes	NNS	O	O
encoding	VBG	O	O
CYP3A5	NNP	O	O
and	CC	O	O
P-gp	NNP	O	O
(	(	O	O
ABCB1	NNP	O	O
)	)	O	O
on	IN	O	O
the	DT	O	O
steady-state	JJ	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
risperidone	NN	O	O
,	,	O	O
9-hydroxyrisperidone	CD	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
active	JJ	O	O
moiety	NN	O	O
,	,	O	O
taking	VBG	O	O
CYP2D6	NNP	O	O
genotype	NN	O	O
status	NN	O	O
into	IN	O	O
account	NN	O	O
.	.	O	O

Forty-six	NNP	O	O
white	JJ	O	O
patients	NNS	O	O
with	IN	O	O
schizophrenia	NN	O	O
treated	VBN	O	O
with	IN	O	O
risperidone	NN	O	O
(	(	O	O
1-10	JJ	O	O
mg/d	NN	O	O
)	)	O	O
in	IN	O	O
monotherapy	NN	O	O
for	IN	O	O
4-6	JJ	O	O
weeks	NNS	O	O
were	VBD	O	O
genotyped	VBN	O	O
,	,	O	O
and	CC	O	O
their	PRP$	O	O
plasma	JJ	O	O
concentrations	NNS	O	O
of	IN	O	O
risperidone	NN	O	O
and	CC	O	O
9-hydroxyrisperidone	CD	O	O
were	VBD	O	O
measured	VBN	O	O
.	.	O	O

Dose-corrected	JJ	O	O
plasma	NN	O	O
concentrations	NNS	O	O
(	(	O	O
C/D	NNP	O	O
)	)	O	O
of	IN	O	O
risperidone	NN	O	O
,	,	O	O
9-hydroxyrisperidone	CD	O	O
,	,	O	O
and	CC	O	O
active	JJ	O	O
moiety	NN	O	O
showed	VBD	O	O
up	IN	O	O
to	TO	O	O
68-	JJ	O	O
,	,	O	O
9-	JJ	O	O
,	,	O	O
and	CC	O	O
10-fold	JJ	O	O
interindividual	JJ	O	O
variation	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Six	CD	O	O
patients	NNS	O	O
carried	VBD	O	O
1	CD	O	O
CYP3A5	NNP	O	O
*	VBD	O	O
1	CD	O	O
allele	NNS	O	O
and	CC	O	O
therefore	NN	O	O
were	VBD	O	O
likely	JJ	O	O
to	TO	O	O
express	VB	O	O
the	DT	O	O
CYP3A5	NNP	O	O
enzyme	NN	O	O
.	.	O	O

The	DT	O	O
CYP3A5	NNP	O	O
genotype	NN	O	O
did	VBD	O	O
not	RB	O	O
influence	VB	O	O
risperidone	NN	O	O
,	,	O	O
9-hydroxyrisperidone	CD	O	O
,	,	O	O
or	CC	O	O
active	JJ	O	O
moiety	NN	O	O
C/Ds	NNP	O	O
.	.	O	O

The	DT	O	O
CYP2D6	NNP	O	O
genotype	NN	O	O
in	IN	O	O
these	DT	O	O
46	CD	O	O
patients	NNS	O	O
was	VBD	O	O
again	RB	O	O
associated	VBN	O	O
with	IN	O	O
risperidone	NN	O	O
C/D	NNP	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.001	CD	O	O
)	)	O	O
but	CC	O	O
not	RB	O	O
with	IN	O	O
9-hydroxyrisperidone	CD	O	O
C/D	NNP	O	O
or	CC	O	O
active	JJ	O	O
moiety	NN	O	O
C/D	NNP	O	O
,	,	O	O
as	IN	O	O
previously	RB	O	O
shown	VBN	O	O
by	IN	O	O
our	PRP$	O	O
group	NN	O	O
in	IN	O	O
37	CD	O	O
of	IN	O	O
these	DT	O	O
patients	NNS	O	O
.	.	O	O

Patients	NNS	O	O
homozygous	JJ	O	O
for	IN	O	O
the	DT	O	O
ABCB1	NNP	O	O
3435T/2677T/1236T	CD	O	O
haplotype	NN	O	O
had	VBD	O	O
significantly	RB	O	O
lower	JJR	O	O
C/Ds	NNP	O	O
of	IN	O	O
9-hydroxyrisperidone	CD	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.026	CD	O	O
)	)	O	O
and	CC	O	O
active	JJ	O	O
moiety	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.028	CD	O	O
)	)	O	O
than	IN	O	O
patients	NNS	O	O
carrying	VBG	O	O
other	JJ	O	O
ABCB1	NNP	O	O
genotypes	NNS	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
our	PRP$	O	O
results	NNS	O	O
confirmed	VBD	O	O
the	DT	O	O
significant	JJ	O	O
effect	NN	O	O
of	IN	O	O
CYP2D6	NNP	O	O
genotype	NN	O	O
on	IN	O	O
the	DT	O	O
steady-state	JJ	O	O
plasma	NN	O	O
levels	NNS	O	O
of	IN	O	O
risperidone	NN	O	O
and	CC	O	O
showed	VBD	O	O
that	IN	O	O
ABCB1	NNP	O	O
polymorphisms	NNS	O	O
have	VBP	O	O
a	DT	O	O
moderate	JJ	O	O
effect	NN	O	O
on	IN	O	O
those	DT	O	O
of	IN	O	O
9-hydroxyrisperidone	CD	O	O
and	CC	O	O
the	DT	O	O
active	JJ	O	O
moiety	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

The	DT	O	O
neuronal	JJ	O	O
vesicular	JJ	O	O
monoamine	NN	O	O
transporter	NN	O	O
(	(	O	O
VMAT2	NNP	O	O
)	)	O	O
is	VBZ	O	O
the	DT	O	O
target	NN	O	O
molecule	NN	O	O
of	IN	O	O
action	NN	O	O
of	IN	O	O
some	DT	O	O
psychostimulants	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
methamphetamine	NN	O	O
and	CC	O	O
3,4-methylenedioxymethamphetamine	JJ	O	O
(	(	O	O
MDMA	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
present	JJ	O	O
study	NN	O	O
examined	VBD	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
antidepressants	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
selective	JJ	O	O
serotonin	NN	O	O
reuptake	NN	O	O
inhibitors	NNS	O	O
(	(	O	O
SSRIs	NNP	O	O
)	)	O	O
,	,	O	O
on	IN	O	O
VMAT2	NNP	O	B-enzyme
activity	NN	O	O
by	IN	O	O
measuring	VBG	O	O
adenosine	JJ	O	O
triphosphate-dependent	JJ	O	O
[	NN	O	B-SUBSTRATE
(	(	O	O
3	CD	O	O
)	)	O	O
H	NNP	O	O
]	NNP	O	O
dopamine	VB	O	O
uptake	NN	O	O
into	IN	O	O
synaptic	JJ	O	O
vesicles	NNS	O	O
prepared	VBN	O	O
from	IN	O	O
rat	NN	O	O
striatum	NN	O	O
.	.	O	O

SSRIs	NNP	O	O
,	,	O	O
fluoxetine	NN	O	O
,	,	O	O
paroxetine	NN	O	O
,	,	O	O
and	CC	O	O
fluvoxamine	NN	O	O
,	,	O	O
inhibited	VBD	O	O
vesicular	JJ	O	O
[	NNP	O	O
(	(	O	O
3	CD	O	O
)	)	O	O
H	NNP	O	O
]	NNP	O	O
dopamine	NN	O	O
uptake	NN	O	O
in	IN	O	O
vitro	NN	O	O
.	.	O	O

The	DT	O	O
rank	NN	O	O
order	NN	O	O
of	IN	O	O
potency	NN	O	O
was	VBD	O	O
reserpine	JJ	O	O
>	NNP	O	O
>	NNP	O	O
fluoxetine	NN	O	O
,	,	O	O
paroxetine	NN	O	O
>	NNP	O	O
fluvoxamine	NN	O	O
,	,	O	O
methamphetamine	NN	O	O
>	NNP	O	O
MDMA	NNP	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
kinetic	JJ	O	O
analysis	NN	O	O
revealed	VBD	O	O
that	IN	O	O
inhibition	NN	O	O
by	IN	O	O
reserpine	NN	O	O
,	,	O	O
a	DT	O	O
typical	JJ	O	O
VMAT2	NNP	O	B-enzyme
inhibitor	NN	O	O
,	,	O	O
was	VBD	O	O
uncompetitive	JJ	O	O
,	,	O	O
decreasing	VBG	O	O
maximum	JJ	O	O
velocity	NN	O	O
and	CC	O	O
affinity	NN	O	O
for	IN	O	O
dopamine	NN	O	B-SUBSTRATE
.	.	O	O

Inhibition	NN	O	O
by	IN	O	O
fluoxetine	NN	O	O
was	VBD	O	O
noncompetitive	JJ	O	O
,	,	O	O
only	RB	O	O
decreasing	VBG	O	O
maximum	JJ	O	O
velocity	NN	O	O
for	IN	O	O
dopamine	NN	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
fluoxetine	NN	O	O
inhibited	VBD	O	O
the	DT	O	O
activity	NN	O	O
of	IN	O	O
VMAT2	NNP	O	O
by	IN	O	O
a	DT	O	O
mechanism	NN	O	O
different	JJ	O	O
from	IN	O	O
that	DT	O	O
of	IN	O	O
reserpine	NN	O	O
and	CC	O	O
did	VBD	O	O
not	RB	O	O
directly	RB	O	O
interact	JJ	O	O
with	IN	O	O
the	DT	O	O
active	JJ	O	O
site	NN	O	O
of	IN	O	O
VMAT2	NNP	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Thymidine	JJ	O	B-enzyme
kinase-1	NN	O	I-enzyme
(	(	O	O
TK-1	NNP	O	B-enzyme
)	)	O	O
and	CC	O	O
thymidylate	JJ	O	B-enzyme
synthase	NN	O	I-enzyme
(	(	O	O
TS	NNP	O	B-enzyme
)	)	O	O
are	VBP	O	O
key	JJ	O	O
enzymes	NNS	O	O
for	IN	O	O
salvage	NN	O	O
and	CC	O	O
de	VB	O	O
novo	FW	O	O
pyrimidine	JJ	O	B-PRODUCT-OF
synthesis	NN	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Numerous	JJ	O	O
studies	NNS	O	O
have	VBP	O	O
suggested	VBN	O	O
that	IN	O	O
increased	VBD	O	O
TS	NNP	O	O
levels	NNS	O	O
are	VBP	O	O
associated	VBN	O	O
closely	RB	O	O
with	IN	O	O
resistance	NN	O	O
to	TO	O	O
fluoropyrimidine-based	JJ	O	O
chemotherapy	NN	O	O
.	.	O	O

TAS-102	NNP	O	B-SUBSTRATE
is	VBZ	O	O
a	DT	O	O
novel	JJ	O	O
drug	NN	O	O
containing	VBG	O	O
trifluorothymidine	NN	O	B-SUBSTRATE
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
phosphorylated	VBN	O	O
by	IN	O	O
TK-1	NNP	O	B-enzyme
to	TO	O	O
its	PRP$	O	O
active	JJ	O	O
monophosphated	VBN	O	O
form	NN	O	O
,	,	O	O
that	IN	O	O
in	IN	O	O
turn	NN	O	O
can	MD	O	O
inhibit	VB	O	O
TS	NNP	O	O
.	.	O	O

TAS-102	NNP	O	O
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
exhibit	VB	O	O
antitumor	JJ	O	O
activity	NN	O	O
in	IN	O	O
fluoropyrimidine-resistant	JJ	O	O
human	JJ	O	O
cancer	NN	O	O
cells	NNS	O	O
.	.	O	O

TAS-102	NNP	O	O
is	VBZ	O	O
currently	RB	O	O
undergoing	JJ	O	O
clinical	JJ	O	O
trials	NNS	O	O
for	IN	O	O
use	NN	O	O
in	IN	O	O
gastrointestinal	JJ	O	O
cancers	NNS	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
used	VBD	O	O
immunohistochemistry	NN	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
expression	NN	O	O
of	IN	O	O
TK-1	NNP	O	O
and	CC	O	O
TS	NNP	O	O
in	IN	O	O
various	JJ	O	O
types	NNS	O	O
of	IN	O	O
cancer	NN	O	O
.	.	O	O

TK-1	NNP	O	O
and	CC	O	O
TS	NNP	O	O
expression	NN	O	O
was	VBD	O	O
markedly	RB	O	O
different	JJ	O	O
between	IN	O	O
cancer	NN	O	O
types	NNS	O	O
.	.	O	O

High	JJ	O	O
TK-1	NNP	O	O
expression	NN	O	O
was	VBD	O	O
detected	VBN	O	O
prominently	RB	O	O
in	IN	O	O
gastrointestinal	JJ	O	O
adenocarcinomas	NN	O	O
and	CC	O	O
esophageal	NN	O	O
and	CC	O	O
uterine	JJ	O	O
squamous	JJ	O	O
cell	NN	O	O
carcinomas	NN	O	O
.	.	O	O

Gastrointestinal	NNP	O	O
adenocarcinomas	NN	O	O
and	CC	O	O
squamous	JJ	O	O
cell	NN	O	O
uterine	JJ	O	O
carcinomas	NN	O	O
were	VBD	O	O
often	RB	O	O
accompanied	VBN	O	O
by	IN	O	O
high	JJ	O	O
TS	NNP	O	B-enzyme
expression	NN	O	O
,	,	O	O
indicating	VBG	O	O
activation	NN	O	O
of	IN	O	O
pyrimidine	NN	O	B-PRODUCT-OF
synthesis	NN	O	O
through	IN	O	O
both	DT	O	O
the	DT	O	O
salvage	NN	O	O
and	CC	O	O
de	VB	O	O
novo	FW	O	O
pathways	NNS	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
led	VBD	O	O
us	PRP	O	O
to	TO	O	O
consider	VB	O	O
that	DT	O	O
TAS-102	NNP	O	O
may	MD	O	O
also	RB	O	O
be	VB	O	O
effective	JJ	O	O
for	IN	O	O
esophageal	NN	O	O
and	CC	O	O
uterine	JJ	O	O
squamous	JJ	O	O
cell	NN	O	O
carcinomas	NN	O	O
,	,	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
for	IN	O	O
gastrointestinal	JJ	O	O
adenocarcinomas	NN	O	O
,	,	O	O
even	RB	O	O
in	IN	O	O
fluoropyrimidine-resistant	JJ	O	O
cases	NNS	O	O
with	IN	O	O
high	JJ	O	O
TS	NNP	O	O
expression	NN	O	O
.	.	O	O

In	IN	O	O
contrast	NN	O	O
,	,	O	O
thyroid	JJ	O	O
papillary	JJ	O	O
carcinomas	NN	O	O
,	,	O	O
lung	NN	O	O
adenocarcinomas	NN	O	O
,	,	O	O
hepatocellular	JJ	O	O
carcinomas	NN	O	O
,	,	O	O
pancreatic	JJ	O	O
ductal	NN	O	O
carcinomas	NN	O	O
,	,	O	O
and	CC	O	O
renal	JJ	O	O
cell	NN	O	O
carcinomas	NN	O	O
,	,	O	O
which	WDT	O	O
exhibit	VBP	O	O
low	JJ	O	O
TK-1	NNP	O	O
expression	NN	O	O
,	,	O	O
may	MD	O	O
be	VB	O	O
resistant	JJ	O	O
to	TO	O	O
TAS-102	NNP	O	O
.	.	O	O

In	IN	O	O
non-small	JJ	O	O
cell	NN	O	O
lung	NN	O	O
cancers	NNS	O	O
,	,	O	O
high	JJ	O	O
TK-1	NNP	O	O
expression	NN	O	O
was	VBD	O	O
demonstrated	VBN	O	O
in	IN	O	O
squamous	JJ	O	O
cell	NN	O	O
carcinomas	NN	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
in	IN	O	O
adenocarcinomas	NN	O	O
.	.	O	O

This	DT	O	O
result	NN	O	O
suggests	VBZ	O	O
that	IN	O	O
TAS-102	NNP	O	O
efficacy	NN	O	O
and	CC	O	O
the	DT	O	O
pyrimidine	NN	O	O
synthetic	JJ	O	O
pathway	NN	O	O
may	MD	O	O
differ	VB	O	O
depending	VBG	O	O
on	IN	O	O
histological	JJ	O	O
type	NN	O	O
.	.	O	O

Our	PRP$	O	O
results	NNS	O	O
indicate	VBP	O	O
that	DT	O	O
administration	NN	O	O
of	IN	O	O
TAS-102	NNP	O	O
could	MD	O	O
be	VB	O	O
selected	VBN	O	O
on	IN	O	O
the	DT	O	O
basis	NN	O	O
of	IN	O	O
the	DT	O	O
immunohistochemical	JJ	O	O
evaluation	NN	O	O
of	IN	O	O
TK-1	NNP	O	O
and	CC	O	O
TS	NNP	O	O
.	.	O	O

-DOCSTART- -X- -X- O

BACKGROUND	NN	O	O
:	:	O	O
(	(	O	O
+/-	JJ	O	O
)	)	O	O
-Modafinil	NN	O	O
has	VBZ	O	O
piqued	VBN	O	O
interest	NN	O	O
as	IN	O	O
a	DT	O	O
treatment	NN	O	O
for	IN	O	O
attention-deficit/hyperactivity	NN	O	O
disorder	NN	O	O
and	CC	O	O
stimulant	JJ	O	O
dependence	NN	O	O
.	.	O	O

The	DT	O	O
R-enantiomer	NNP	O	O
of	IN	O	O
modafinil	NN	O	O
might	MD	O	O
have	VB	O	O
unique	JJ	O	O
pharmacological	JJ	O	O
properties	NNS	O	O
that	WDT	O	O
should	MD	O	O
be	VB	O	O
further	RB	O	O
investigated	VBN	O	O
.	.	O	O

METHODS	NN	O	O
:	:	O	O
(	(	O	O
+/-	JJ	O	O
)	)	O	O
-Modafinil	NN	O	O
and	CC	O	O
its	PRP$	O	O
R-	NNP	O	O
(	(	O	O
-	:	O	O
)	)	O	O
-	:	O	O
and	CC	O	O
S-	NNP	O	O
(	(	O	O
+	NNP	O	O
)	)	O	O
-enantiomers	NNS	O	O
were	VBD	O	O
synthesized	VBN	O	O
and	CC	O	O
tested	VBN	O	O
for	IN	O	O
inhibition	NN	O	O
of	IN	O	O
[	NNP	O	B-SUBSTRATE
(	(	O	O
3	CD	O	O
)	)	O	O
H	NNP	O	O
]	NNP	O	O
dopamine	NN	O	I-SUBSTRATE
(	(	O	O
DA	NNP	O	B-SUBSTRATE
)	)	O	O
uptake	NN	O	O
and	CC	O	O
[	NNP	O	O
(	(	O	O
3	CD	O	O
)	)	O	O
H	NNP	O	O
]	NNP	O	O
WIN	NNP	O	O
35428	CD	O	O
binding	NN	O	O
in	IN	O	O
human	JJ	O	B-enzyme
dopamine	NN	O	I-enzyme
transporter	NN	O	O
(	(	O	O
DAT	NNP	O	B-enzyme
)	)	O	O
wild-type	NN	O	O
and	CC	O	O
mutants	NNS	O	O
with	IN	O	O
altered	JJ	O	O
conformational	JJ	O	O
equilibria	NN	O	O
.	.	O	O

Data	NNS	O	O
were	VBD	O	O
compared	VBN	O	O
with	IN	O	O
cocaine	NN	O	O
and	CC	O	O
the	DT	O	O
atypical	JJ	O	O
DA	NNP	O	O
uptake	NN	O	O
inhibitor	NN	O	O
,	,	O	O
JHW	NNP	O	O
007	CD	O	O
.	.	O	O

R-	JJ	O	O
and	CC	O	O
S-modafinil	NNP	O	O
were	VBD	O	O
also	RB	O	O
evaluated	VBN	O	O
in	IN	O	O
microdialysis	NN	O	O
studies	NNS	O	O
in	IN	O	O
the	DT	O	O
mouse	NN	O	O
nucleus	NN	O	O
accumbens	VBZ	O	O
shell	NN	O	O
and	CC	O	O
in	IN	O	O
a	DT	O	O
cocaine	NN	O	O
discrimination	NN	O	O
procedure	NN	O	O
.	.	O	O

RESULTS	NN	O	O
:	:	O	O
(	(	O	O
+/-	NN	O	O
)	)	O	O
-	:	O	O
,	,	O	O
R-	NNP	O	O
,	,	O	O
and	CC	O	O
S-modafinil	NNP	O	O
bind	NN	O	O
to	TO	O	O
the	DT	O	O
DAT	NNP	O	B-enzyme
and	CC	O	O
inhibit	VB	O	O
DA	NNP	O	B-SUBSTRATE
uptake	NN	O	O
less	RBR	O	O
potently	RB	O	O
than	IN	O	O
cocaine	NN	O	O
,	,	O	O
with	IN	O	O
R-modafinil	NNP	O	O
having	VBG	O	O
approximately	RB	O	O
threefold	JJ	O	O
higher	JJR	O	O
affinity	NN	O	O
than	IN	O	O
its	PRP$	O	O
S-enantiomer	NNP	O	O
.	.	O	O

Molecular	JJ	O	O
docking	VBG	O	O
studies	NNS	O	O
revealed	VBD	O	O
subtle	JJ	O	O
differences	NNS	O	O
in	IN	O	O
binding	VBG	O	O
modes	NNS	O	O
for	IN	O	O
the	DT	O	O
enantiomers	NNS	O	O
.	.	O	O

R-modafinil	NNP	O	O
was	VBD	O	O
significantly	RB	O	O
less	JJR	O	O
potent	NN	O	O
in	IN	O	O
the	DT	O	O
DAT	NNP	O	O
Y156F	NNP	O	O
mutant	NN	O	O
compared	VBN	O	O
with	IN	O	O
wild-type	JJ	O	O
DAT	NNP	O	O
,	,	O	O
whereas	IN	O	O
S-modafinil	NNP	O	O
was	VBD	O	O
affected	VBN	O	O
less	RBR	O	O
.	.	O	O

Studies	NNS	O	O
with	IN	O	O
the	DT	O	O
Y335A	NNP	O	O
DAT	NNP	O	O
mutant	NN	O	O
showed	VBD	O	O
that	IN	O	O
the	DT	O	O
R-	NNP	O	O
and	CC	O	O
S-enantiomers	NNP	O	O
tolerated	VBD	O	O
the	DT	O	O
inward-facing	JJ	O	O
conformation	NN	O	O
better	RBR	O	O
than	IN	O	O
cocaine	NN	O	O
,	,	O	O
which	WDT	O	O
was	VBD	O	O
further	RBR	O	O
supported	VBN	O	O
by	IN	O	O
[	JJ	O	O
2-	JJ	O	O
(	(	O	O
trimethylammonium	NN	O	O
)	)	O	O
ethyl	NN	O	O
]	JJ	O	O
-methanethiosulfonate	NNP	O	O
reactivity	NN	O	O
on	IN	O	O
the	DT	O	O
DAT	NNP	O	O
E2C	NNP	O	O
I159C	NNP	O	O
.	.	O	O

Microdialysis	NNP	O	O
studies	NNS	O	O
demonstrated	VBD	O	O
that	IN	O	O
both	DT	O	O
R-	NNP	O	O
and	CC	O	O
S-modafinil	NNP	O	O
produced	VBD	O	O
increases	NNS	O	O
in	IN	O	O
extracellular	JJ	O	O
DA	NNP	O	O
concentrations	NNS	O	O
in	IN	O	O
the	DT	O	O
nucleus	NN	O	O
accumbens	VBZ	O	O
shell	RB	O	O
less	RBR	O	O
efficaciously	RB	O	O
than	IN	O	O
cocaine	NN	O	O
and	CC	O	O
with	IN	O	O
a	DT	O	O
longer	JJR	O	O
duration	NN	O	O
of	IN	O	O
action	NN	O	O
.	.	O	O

Both	DT	O	O
enantiomers	NNS	O	O
fully	RB	O	O
substituted	VBN	O	O
in	IN	O	O
mice	NN	O	O
trained	VBN	O	O
to	TO	O	O
discriminate	VB	O	O
cocaine	NN	O	O
from	IN	O	O
saline	NN	O	O
.	.	O	O

CONCLUSIONS	NN	O	O
:	:	O	O
R-modafinil	JJ	O	O
displays	NNS	O	O
an	DT	O	O
in	IN	O	O
vitro	NN	O	O
profile	NN	O	O
different	JJ	O	O
from	IN	O	O
cocaine	NN	O	O
.	.	O	O

Future	JJ	O	O
trials	NNS	O	O
with	IN	O	O
R-modafinil	NNP	O	O
as	IN	O	O
a	DT	O	O
substitute	NN	O	O
therapy	NN	O	O
with	IN	O	O
the	DT	O	O
potential	JJ	O	O
benefit	NN	O	O
of	IN	O	O
cognitive	JJ	O	O
enhancement	NN	O	O
for	IN	O	O
psychostimulant	JJ	O	O
addiction	NN	O	O
are	VBP	O	O
warranted	VBN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Aldo-keto	JJ	O	B-enzyme
reductases	NNS	O	I-enzyme
(	(	O	O
AKRs	NNP	O	B-enzyme
)	)	O	O
metabolize	VB	O	O
a	DT	O	O
wide	JJ	O	O
range	NN	O	O
of	IN	O	O
substrates	NNS	O	O
,	,	O	O
including	VBG	O	O
polycyclic	JJ	O	B-SUBSTRATE
aromatic	JJ	O	I-SUBSTRATE
hydrocarbons	NNS	O	O
(	(	O	O
PAHs	NNP	O	B-SUBSTRATE
)	)	O	O
,	,	O	O
generating	VBG	O	O
metabolites	NNS	O	O
(	(	O	O
o-quinones	NNS	O	B-SUBSTRATE
)	)	O	O
and	CC	O	O
reactive	JJ	O	O
oxygen	NN	O	B-PRODUCT-OF
species	NNS	O	O
(	(	O	O
ROS	NNP	O	O
)	)	O	O
,	,	O	O
which	WDT	O	O
are	VBP	O	O
capable	JJ	O	O
of	IN	O	O
initiating	VBG	O	O
and	CC	O	O
promoting	VBG	O	O
carcinogenesis	NN	O	O
.	.	O	O

Exposure	NN	O	O
to	TO	O	O
PAHs	NNP	O	O
,	,	O	O
their	PRP$	O	O
metabolites	NNS	O	O
,	,	O	O
and	CC	O	O
ROS	NNP	O	O
further	JJ	O	O
increase	NN	O	O
AKRs	NNP	O	O
isoform	NN	O	O
expression	NN	O	O
that	WDT	O	O
may	MD	O	O
amplify	VB	O	O
oxidative	JJ	O	O
damage	NN	O	O
.	.	O	O

Human	NNP	O	O
AKR	NNP	O	O
enzymes	NNS	O	O
are	VBP	O	O
highly	RB	O	O
polymorphic	JJ	O	O
,	,	O	O
and	CC	O	O
allelic	JJ	O	O
variants	NNS	O	O
may	MD	O	O
contribute	VB	O	O
to	TO	O	O
different	JJ	O	O
AKRs	NNP	O	O
expression	NN	O	O
in	IN	O	O
individuals	NNS	O	O
.	.	O	O

Despite	IN	O	O
the	DT	O	O
importance	NN	O	O
of	IN	O	O
AKRs	NNP	O	B-enzyme
in	IN	O	O
PAHs	NNP	O	B-SUBSTRATE
metabolism	NN	O	O
,	,	O	O
there	EX	O	O
are	VBP	O	O
no	DT	O	O
studies	NNS	O	O
that	WDT	O	O
evaluate	VBP	O	O
,	,	O	O
in	IN	O	O
general	JJ	O	O
human	JJ	O	O
populations	NNS	O	O
,	,	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
PAHs	NNP	O	O
on	IN	O	O
AKRs	NNP	O	O
expression	NN	O	O
in	IN	O	O
peripheral	JJ	O	O
blood	NN	O	O
lymphocytes	NNS	O	O
(	(	O	O
PBLs	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
aim	NN	O	O
of	IN	O	O
this	DT	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
determine	VB	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
tobacco	NN	O	O
smoke	NN	O	O
exposure	NN	O	O
,	,	O	O
and	CC	O	O
AKR1A1	NNP	O	O
*	NNP	O	O
2	CD	O	O
and	CC	O	O
AKR1C3	NNP	O	O
*	NNP	O	O
2	CD	O	O
polymorphisms	NNS	O	O
,	,	O	O
on	IN	O	O
AKR1A1	NNP	O	O
and	CC	O	O
AKR1C1-AKR1C3	NNP	O	O
messenger	NN	O	O
RNA	NNP	O	O
(	(	O	O
mRNA	NN	O	O
)	)	O	O
levels	NNS	O	O
in	IN	O	O
PBLs	NNP	O	O
from	IN	O	O
smokers	NNS	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
smoker	NN	O	O
group	NN	O	O
,	,	O	O
there	EX	O	O
is	VBZ	O	O
a	DT	O	O
statistically	RB	O	O
significant	JJ	O	O
positive	JJ	O	O
association	NN	O	O
between	IN	O	O
AKR1A1	NNP	O	O
,	,	O	O
AKR1C1	NNP	O	O
,	,	O	O
and	CC	O	O
AKR1C3	NNP	O	O
mRNA	NNP	O	O
induction	NN	O	O
and	CC	O	O
urine	JJ	O	O
cotinine	NN	O	O
levels	NNS	O	O
in	IN	O	O
individuals	NNS	O	O
with	IN	O	O
a	DT	O	O
body	NN	O	O
mass	NN	O	O
index	NN	O	O
(	(	O	O
BMI	NNP	O	O
)	)	O	O
less	JJR	O	O
than	IN	O	O
25	CD	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
AKR1A1	NNP	O	O
*	NNP	O	O
2	CD	O	O
and	CC	O	O
AKR1C3	NNP	O	O
*	NNP	O	O
2	CD	O	O
alleles	NNS	O	O
did	VBD	O	O
not	RB	O	O
influence	VB	O	O
AKR1A1	NNP	O	O
and	CC	O	O
AKR1C1-AKR1C3	NNP	O	O
mRNA	NN	O	O
levels	NNS	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
AKRs	NNP	O	O
induction	NN	O	O
by	IN	O	O
PAHs	NNP	O	O
in	IN	O	O
smokers	NNS	O	O
'	POS	O	O
PBLs	NNP	O	O
is	VBZ	O	O
associated	VBN	O	O
with	IN	O	O
BMI	NNP	O	O
;	:	O	O
therefore	RB	O	O
,	,	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
adipose	JJ	O	O
tissue	NN	O	O
accumulation	NN	O	O
in	IN	O	O
PAHs	NNP	O	O
'	POS	O	O
effects	NNS	O	O
needs	VBZ	O	O
further	JJ	O	O
investigation	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Thiazolidinediones	NNS	O	O
(	(	O	O
TZDs	NNP	O	O
)	)	O	O
are	VBP	O	O
insulin	JJ	O	O
sensitizers	NNS	O	O
used	VBN	O	O
for	IN	O	O
treatment	NN	O	O
of	IN	O	O
diabetes	NNS	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
previously	RB	O	O
reported	VBN	O	O
that	IN	O	O
TZDs	NNP	O	O
reduce	VB	O	O
estrogen	NN	O	B-PRODUCT-OF
synthesis	NN	O	O
by	IN	O	O
inhibiting	VBG	O	O
aromatase	NN	O	B-enzyme
activity	NN	O	O
in	IN	O	O
human	JJ	O	O
granulosa	NN	O	O
cells	NNS	O	O
(	(	O	O
HGC	NNP	O	O
)	)	O	O
.	.	O	O

Multiple	NNP	O	O
clinical	JJ	O	O
trials	NNS	O	O
demonstrated	VBD	O	O
that	IN	O	O
TZDs	NNP	O	O
increase	VB	O	O
the	DT	O	O
risk	NN	O	O
of	IN	O	O
fractures	NNS	O	O
in	IN	O	O
postmenopausal	JJ	O	O
women	NNS	O	O
with	IN	O	O
type	JJ	O	O
2	CD	O	O
diabetes	NNS	O	O
.	.	O	O

We	PRP	O	O
studied	VBD	O	O
mouse	NN	O	O
osteoblasts	NNS	O	O
alone	RB	O	O
or	CC	O	O
in	IN	O	O
a	DT	O	O
co-culture	NN	O	O
with	IN	O	O
HGC	NNP	O	O
to	TO	O	O
determine	VB	O	O
whether	IN	O	O
TZD	NNP	O	O
inhibition	NN	O	O
of	IN	O	O
aromatase	NN	O	O
plays	VBZ	O	O
a	DT	O	O
role	NN	O	O
in	IN	O	O
their	PRP$	O	O
effects	NNS	O	O
on	IN	O	O
bone	NN	O	O
metabolism	NN	O	O
.	.	O	O

Mouse	NN	O	O
osteoblasts	NNS	O	O
were	VBD	O	O
cultured	VBN	O	O
with	IN	O	O
and	CC	O	O
without	IN	O	O
HGC	NNP	O	O
,	,	O	O
and	CC	O	O
incubated	VBN	O	O
in	IN	O	O
a	DT	O	O
medium	NN	O	O
with	IN	O	O
or	CC	O	O
without	IN	O	O
testosterone	NN	O	O
,	,	O	O
pioglitazone	NN	O	O
or	CC	O	O
rosiglitazone	NN	O	O
.	.	O	O

Cell	NNP	O	O
growth	NN	O	O
,	,	O	O
oleic	JJ	O	O
acid	NN	O	O
uptake	NN	O	O
,	,	O	O
alkaline	JJ	O	O
phosphatase	NN	O	O
activity	NN	O	O
,	,	O	O
and	CC	O	O
osteocalcin	JJ	O	O
production	NN	O	O
were	VBD	O	O
measured	VBN	O	O
.	.	O	O

TZDs	NNP	O	O
inhibited	VBD	O	O
estradiol	JJ	O	O
production	NN	O	O
by	IN	O	O
up	IN	O	O
to	TO	O	O
84	CD	O	O
%	NN	O	O
in	IN	O	O
HGC/mouse	NNP	O	O
osteoblast	IN	O	O
co-cultures	NNS	O	O
.	.	O	O

TZDs	NNP	O	O
induced	VBD	O	O
mouse	IN	O	O
osteoblast	JJ	O	O
death	NN	O	O
and	CC	O	O
increased	VBD	O	O
oleic	JJ	O	O
acid	JJ	O	O
uptake	NN	O	O
.	.	O	O

TZDs	NNP	O	O
also	RB	O	O
inhibited	VBD	O	O
alkaline	JJ	O	O
phosphatase	NN	O	O
activity	NN	O	O
(	(	O	O
58-75	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0.046	CD	O	O
)	)	O	O
and	CC	O	O
osteocalcin	JJ	O	O
production	NN	O	O
(	(	O	O
52-75	CD	O	O
%	NN	O	O
,	,	O	O
p	NN	O	O
<	NNP	O	O
0.031	CD	O	O
)	)	O	O
.	.	O	O

For	IN	O	O
all	PDT	O	O
the	DT	O	O
parameters	NNS	O	O
,	,	O	O
there	EX	O	O
were	VBD	O	O
no	DT	O	O
significant	JJ	O	O
differences	NNS	O	O
between	IN	O	O
the	DT	O	O
osteoblast	JJ	O	O
cultures	NNS	O	O
alone	RB	O	O
and	CC	O	O
the	DT	O	O
HCG/osteoblast	NNP	O	O
co-cultures	NNS	O	O
.	.	O	O

TZD	NNP	O	O
effects	NNS	O	O
on	IN	O	O
osteoblast	JJ	O	O
viability	NN	O	O
,	,	O	O
oleic	JJ	O	O
acid	NN	O	O
uptake	NN	O	O
,	,	O	O
alkaline	JJ	O	O
phosphatase	NN	O	O
and	CC	O	O
osteocalcin	JJ	O	O
production	NN	O	O
are	VBP	O	O
independent	JJ	O	O
of	IN	O	O
their	PRP$	O	O
effects	NNS	O	O
on	IN	O	O
aromatase	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

A	DT	O	O
wide	JJ	O	O
variety	NN	O	O
of	IN	O	O
contaminants	NNS	O	O
are	VBP	O	O
ingested	VBN	O	O
through	IN	O	O
food	NN	O	O
,	,	O	O
among	IN	O	O
them	PRP	O	O
the	DT	O	O
pro-carcinogenic	JJ	O	O
polycyclic	JJ	O	O
aromatic	JJ	O	O
hydrocarbon	NN	O	O
benzo	NN	O	O
[	VBZ	O	O
a	DT	O	O
]	JJ	O	O
pyrene	NN	O	O
(	(	O	O
BP	NNP	O	O
)	)	O	O
that	WDT	O	O
is	VBZ	O	O
resorbed	VBN	O	O
and	CC	O	O
partially	RB	O	O
metabolized	VBN	O	O
in	IN	O	O
the	DT	O	O
enterocytes	NNS	O	O
of	IN	O	O
the	DT	O	O
small	JJ	O	O
intestine	NN	O	O
.	.	O	O

Previous	JJ	O	O
in	IN	O	O
vitro	JJ	O	O
studies	NNS	O	O
have	VBP	O	O
revealed	VBN	O	O
that	IN	O	O
BP	NNP	O	O
phenols	NNS	O	O
are	VBP	O	O
excreted	VBN	O	O
as	IN	O	O
Phase	NNP	O	O
II	NNP	O	O
metabolites	VBZ	O	O
including	VBG	O	O
glucuronides	NNS	O	O
and	CC	O	O
sulfates	NNS	O	O
.	.	O	O

This	DT	O	O
export	NN	O	O
is	VBZ	O	O
mediated	VBN	O	O
by	IN	O	O
the	DT	O	O
breast	NN	O	O
cancer	NN	O	O
resistance	NN	O	O
protein	NN	O	O
(	(	O	O
ABCG2	NNP	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
ultimate	JJ	O	O
carcinogenic	JJ	O	O
Phase	NN	O	O
I	PRP	O	O
BP	NNP	O	O
metabolite	RB	O	O
anti-BP-7,8-dihydrodiol-9,10-epoxide	NN	O	O
(	(	O	O
BPDE	NNP	O	O
)	)	O	O
can	MD	O	O
be	VB	O	O
detoxified	VBN	O	O
by	IN	O	O
glutathione	NN	O	B-PRODUCT-OF
conjugate	NN	O	O
formation	NN	O	O
catalyzed	VBN	O	O
by	IN	O	O
glutathione	NN	O	B-enzyme
S-transferases	NNS	O	I-enzyme
.	.	O	O

In	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
,	,	O	O
differentiated	VBN	O	O
human	JJ	O	O
intestinal	JJ	O	O
Caco-2	NNP	O	O
cells	NNS	O	O
were	VBD	O	O
used	VBN	O	O
as	IN	O	O
a	DT	O	O
model	NN	O	O
for	IN	O	O
the	DT	O	O
human	JJ	O	O
small	JJ	O	O
intestine	NN	O	O
to	TO	O	O
investigate	VB	O	O
the	DT	O	O
detoxification	NN	O	O
of	IN	O	O
BPDE	NNP	O	O
and	CC	O	O
excretion	NN	O	O
of	IN	O	O
stereoisomeric	JJ	O	O
glutathione	NN	O	O
conjugates	NNS	O	O
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
an	DT	O	O
inhibitor	NN	O	O
of	IN	O	O
the	DT	O	O
glutathione-cleaving	JJ	O	O
enzyme	JJ	O	O
gamma-glutamyl	JJ	O	O
transpeptidase	NN	O	O
at	IN	O	O
the	DT	O	O
cell	NN	O	O
surface	NN	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
the	DT	O	O
glutathione	NN	O	O
conjugates	NNS	O	O
of	IN	O	O
BPDE	NNP	O	O
are	VBP	O	O
formed	VBN	O	O
and	CC	O	O
excreted	VBN	O	O
mainly	RB	O	O
to	TO	O	O
the	DT	O	O
apical	JJ	O	O
and	CC	O	O
to	TO	O	O
a	DT	O	O
minor	JJ	O	O
extent	NN	O	O
to	TO	O	O
the	DT	O	O
basolateral	JJ	O	O
side	NN	O	O
of	IN	O	O
polarized	JJ	O	O
Caco-2	JJ	O	O
monolayers	NNS	O	O
.	.	O	O

Inhibition	NNP	O	O
studies	NNS	O	O
revealed	VBD	O	O
that	IN	O	O
the	DT	O	O
multidrug	JJ	O	B-enzyme
resistance-associated	JJ	O	I-enzyme
proteins	NNS	O	O
(	(	O	O
ABCCs	NNP	O	B-enzyme
)	)	O	O
are	VBP	O	O
involved	VBN	O	O
in	IN	O	O
the	DT	O	O
transport	NN	O	O
of	IN	O	O
BPDE	NNP	O	B-SUBSTRATE
glutathione	NN	O	I-SUBSTRATE
conjugates	NNS	O	O
.	.	O	O

Stable	JJ	O	O
ABCC1	NNP	O	B-enzyme
,	,	O	O
ABCC2	NNP	O	B-enzyme
and	CC	O	O
ABCC3	NNP	O	O
knockdown	NNP	O	O
cell	NN	O	O
lines	NNS	O	O
were	VBD	O	O
generated	VBN	O	O
,	,	O	O
thus	RB	O	O
making	VBG	O	O
it	PRP	O	O
possible	JJ	O	O
to	TO	O	O
demonstrate	VB	O	O
that	IN	O	O
ABCC1	NNP	O	B-enzyme
mediates	VBZ	O	O
the	DT	O	O
basolateral	JJ	O	O
and	CC	O	O
ABCC2	NNP	O	B-enzyme
the	DT	O	O
apical	JJ	O	O
excretion	NN	O	O
of	IN	O	O
BPDE	NNP	O	B-SUBSTRATE
glutathione	NN	O	I-SUBSTRATE
conjugates	NNS	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
the	DT	O	O
ultimate	JJ	O	O
carcinogen	NN	O	O
BPDE	NNP	O	O
is	VBZ	O	O
detoxified	VBN	O	O
via	IN	O	O
glutathione	NN	O	O
conjugation	NN	O	O
and	CC	O	O
subsequently	RB	O	O
excreted	VBN	O	O
by	IN	O	O
Caco-2	NNP	O	O
cells	NNS	O	O
in	IN	O	O
both	DT	O	O
apical	JJ	O	O
and	CC	O	O
basolateral	JJ	O	O
directions	NNS	O	O
.	.	O	O

This	DT	O	O
finding	NN	O	O
is	VBZ	O	O
equivalent	JJ	O	O
to	TO	O	O
a	DT	O	O
transport	NN	O	O
into	IN	O	O
feces	NNS	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
blood	NN	O	O
system	NN	O	O
in	IN	O	O
the	DT	O	O
in	IN	O	O
vivo	JJ	O	O
situation	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

The	DT	O	O
mitochondrial	JJ	O	B-enzyme
respiratory	NN	O	I-enzyme
chain	NN	O	O
complex	JJ	O	O
IV	NNP	O	O
(	(	O	O
cytochrome	JJ	O	B-enzyme
c	NN	O	I-enzyme
oxidase	NN	O	O
)	)	O	O
is	VBZ	O	O
a	DT	O	O
multi-subunit	JJ	O	O
enzyme	NN	O	O
that	IN	O	O
transfers	NNS	O	O
electrons	NNS	O	O
from	IN	O	O
cytochrome	JJ	O	O
c	NN	O	O
to	TO	O	O
molecular	JJ	O	O
oxygen	NN	O	B-SUBSTRATE
,	,	O	O
yielding	VBG	O	O
water	NN	O	O
.	.	O	O

Its	PRP$	O	O
biogenesis	NN	O	O
requires	VBZ	O	O
concerted	JJ	O	O
expression	NN	O	O
of	IN	O	O
mitochondria-	JJ	O	O
and	CC	O	O
nuclear-encoded	JJ	O	O
subunits	NNS	O	O
and	CC	O	O
assembly	NN	O	O
factors	NNS	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
report	NN	O	O
,	,	O	O
we	PRP	O	O
describe	VBP	O	O
a	DT	O	O
homozygous	JJ	O	O
missense	NN	O	O
mutation	NN	O	O
in	IN	O	O
FAM36A	NNP	O	O
from	IN	O	O
a	DT	O	O
patient	NN	O	O
who	WP	O	O
displays	VBZ	O	O
ataxia	NN	O	O
and	CC	O	O
muscle	NN	O	O
hypotonia	NN	O	O
.	.	O	O

The	DT	O	O
FAM36A	NNP	O	O
gene	NN	O	O
is	VBZ	O	O
a	DT	O	O
remote	JJ	O	O
,	,	O	O
putative	JJ	O	O
ortholog	NN	O	O
of	IN	O	O
the	DT	O	O
fungal	NN	O	O
complex	JJ	O	O
IV	NNP	O	O
assembly	NN	O	O
factor	NN	O	O
COX20	NNP	O	O
.	.	O	O

Messenger	NNP	O	O
RNA	NNP	O	O
(	(	O	O
mRNA	NN	O	O
)	)	O	O
and	CC	O	O
protein	JJ	O	O
co-expression	NN	O	O
analyses	NNS	O	O
support	VBP	O	O
the	DT	O	O
involvement	NN	O	O
of	IN	O	O
FAM36A	NNP	O	O
in	IN	O	O
complex	JJ	O	O
IV	NNP	O	O
function	NN	O	O
in	IN	O	O
mammals	NNS	O	O
.	.	O	O

The	DT	O	O
c.154A	NN	O	O
>	NNP	O	O
C	NNP	O	O
mutation	NN	O	O
in	IN	O	O
the	DT	O	O
FAM36A	NNP	O	O
gene	NN	O	O
,	,	O	O
a	DT	O	O
mutation	NN	O	O
that	WDT	O	O
is	VBZ	O	O
absent	JJ	O	O
in	IN	O	O
sequenced	JJ	O	O
exomes	NNS	O	O
,	,	O	O
leads	VBZ	O	O
to	TO	O	O
a	DT	O	O
reduced	VBN	O	O
activity	NN	O	O
and	CC	O	O
lower	JJR	O	O
levels	NNS	O	O
of	IN	O	O
complex	JJ	O	O
IV	NNP	O	O
and	CC	O	O
its	PRP$	O	O
protein	NN	O	O
subunits	NNS	O	O
.	.	O	O

The	DT	O	O
FAM36A	NNP	O	O
protein	NN	O	O
is	VBZ	O	O
nearly	RB	O	O
absent	JJ	O	O
in	IN	O	O
patient	NN	O	O
's	POS	O	O
fibroblasts	NNS	O	O
.	.	O	O

Cells	NNS	O	O
affected	VBN	O	O
by	IN	O	O
the	DT	O	O
mutation	NN	O	O
accumulate	NN	O	O
subassemblies	NNS	O	O
of	IN	O	O
complex	JJ	O	O
IV	NNP	O	O
that	WDT	O	O
contain	VBP	O	O
COX1	NNP	O	O
but	CC	O	O
are	VBP	O	O
almost	RB	O	O
devoid	JJ	O	O
of	IN	O	O
COX2	NNP	O	O
protein	NN	O	O
.	.	O	O

We	PRP	O	O
observe	VBP	O	O
co-purification	NN	O	O
of	IN	O	O
FAM36A	NNP	O	O
and	CC	O	O
COX2	NNP	O	O
proteins	NNS	O	O
,	,	O	O
supporting	VBG	O	O
that	IN	O	O
the	DT	O	O
FAM36A	NNP	O	O
defect	NN	O	O
hampers	VBZ	O	O
the	DT	O	O
early	JJ	O	O
step	NN	O	O
of	IN	O	O
complex	JJ	O	O
IV	NNP	O	O
assembly	NN	O	O
at	IN	O	O
the	DT	O	O
incorporation	NN	O	O
of	IN	O	O
the	DT	O	O
COX2	NNP	O	O
subunit	NN	O	O
.	.	O	O

Lentiviral	JJ	O	O
complementation	NN	O	O
of	IN	O	O
patient	NN	O	O
's	POS	O	O
fibroblasts	NNS	O	O
with	IN	O	O
wild-type	JJ	O	O
FAM36A	NNP	O	O
increases	VBZ	O	O
the	DT	O	O
complex	JJ	O	O
IV	NNP	O	O
activity	NN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
the	DT	O	O
amount	NN	O	O
of	IN	O	O
holocomplex	JJ	O	O
IV	NNP	O	O
and	CC	O	O
of	IN	O	O
individual	JJ	O	O
subunits	NNS	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
establish	VB	O	O
the	DT	O	O
function	NN	O	O
of	IN	O	O
the	DT	O	O
human	JJ	O	O
gene	NN	O	O
FAM36A/COX20	NNP	O	O
in	IN	O	O
complex	JJ	O	O
IV	NNP	O	O
assembly	NN	O	O
and	CC	O	O
support	VB	O	O
a	DT	O	O
causal	JJ	O	O
role	NN	O	O
of	IN	O	O
the	DT	O	O
gene	NN	O	O
in	IN	O	O
complex	JJ	O	O
IV	NNP	O	O
deficiency	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Phenformin	NNP	O	O
causes	VBZ	O	O
lactic	JJ	O	O
acidosis	NN	O	O
in	IN	O	O
clinical	JJ	O	O
situations	NNS	O	O
due	JJ	O	O
to	TO	O	O
inhibition	NN	O	O
of	IN	O	O
mitochondrial	JJ	O	O
respiratory	NN	O	O
chain	NN	O	O
complex	JJ	O	O
I	PRP	O	O
.	.	O	O

It	PRP	O	O
is	VBZ	O	O
reportedly	RB	O	O
taken	VBN	O	O
up	RP	O	O
by	IN	O	O
hepatocytes	NNS	O	O
and	CC	O	O
exhibits	VBZ	O	O
mitochondrial	JJ	O	O
toxicity	NN	O	O
in	IN	O	O
the	DT	O	O
liver	NN	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
uptake	NN	O	O
of	IN	O	O
phenformin	NN	O	O
and	CC	O	O
[	NNP	O	O
(	(	O	O
14	CD	O	O
)	)	O	O
C	NNP	O	O
]	NNP	O	O
tetraethylammonium	NN	O	O
(	(	O	O
TEA	NNP	O	O
)	)	O	O
and	CC	O	O
complex	JJ	O	O
I	PRP	O	O
inhibition	NN	O	O
by	IN	O	O
phenformin	NN	O	O
were	VBD	O	O
examined	VBN	O	O
in	IN	O	O
isolated	JJ	O	O
liver	NN	O	O
and	CC	O	O
heart	NN	O	O
mitochondria	NN	O	O
.	.	O	O

Uptake	NN	O	O
of	IN	O	O
phenformin	NN	O	O
into	IN	O	O
isolated	JJ	O	O
rat	NN	O	O
liver	NN	O	O
mitochondria	NN	O	O
was	VBD	O	O
higher	JJR	O	O
than	IN	O	O
that	DT	O	O
into	IN	O	O
heart	NN	O	O
mitochondria	NN	O	O
.	.	O	O

It	PRP	O	O
was	VBD	O	O
inhibited	VBN	O	O
by	IN	O	O
several	JJ	O	O
cat	NNS	O	O
ionic	JJ	O	O
compounds	NNS	O	O
,	,	O	O
which	WDT	O	O
suggests	VBZ	O	O
the	DT	O	O
involvement	NN	O	O
of	IN	O	O
multispecific	NN	O	O
transport	NN	O	O
system	NN	O	O
(	(	O	O
s	NN	O	O
)	)	O	O
.	.	O	O

Similar	JJ	O	O
characteristics	NNS	O	O
were	VBD	O	O
also	RB	O	O
observed	VBN	O	O
for	IN	O	O
uptake	NN	O	O
of	IN	O	O
TEA	NNP	O	O
;	:	O	O
however	RB	O	O
,	,	O	O
uptake	NN	O	O
of	IN	O	O
phenformin	NN	O	O
into	IN	O	O
mitochondria	NN	O	O
of	IN	O	O
organic	JJ	O	O
cation/carnitine	NN	O	O
transporter	NN	O	O
1	CD	O	O
(	(	O	O
OCTN1	NNP	O	O
)	)	O	O
knockout	NN	O	O
mice	NN	O	O
was	VBD	O	O
lower	JJR	O	O
than	IN	O	O
that	DT	O	O
in	IN	O	O
wild-type	JJ	O	O
mice	NN	O	O
,	,	O	O
whereas	JJ	O	O
uptake	NN	O	O
of	IN	O	O
TEA	NNP	O	O
was	VBD	O	O
comparable	JJ	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
strains	NNS	O	O
,	,	O	O
suggesting	VBG	O	O
the	DT	O	O
involvement	NN	O	O
of	IN	O	O
distinct	JJ	O	O
transport	NN	O	O
mechanisms	NNS	O	O
for	IN	O	O
these	DT	O	O
two	CD	O	O
cations	NNS	O	O
in	IN	O	O
mitochondria	NN	O	O
.	.	O	O

Inhibition	NN	O	O
by	IN	O	O
phenformin	NN	O	O
of	IN	O	O
oxygen	NN	O	O
consumption	NN	O	O
via	IN	O	O
complex	JJ	O	O
I	PRP	O	O
respiration	VBP	O	O
in	IN	O	O
isolated	JJ	O	O
rat	NN	O	O
liver	NN	O	O
mitochondria	NN	O	O
was	VBD	O	O
greater	JJR	O	O
than	IN	O	O
that	DT	O	O
in	IN	O	O
heart	NN	O	O
mitochondria	NN	O	O
,	,	O	O
whereas	JJ	O	O
inhibitory	JJ	O	O
effect	NN	O	O
of	IN	O	O
phenformin	NN	O	O
on	IN	O	O
complex	JJ	O	O
I	PRP	O	O
respiration	NN	O	O
was	VBD	O	O
similar	JJ	O	O
in	IN	O	O
inside-out	NN	O	O
structured	JJ	O	O
submitochondrial	JJ	O	O
particles	NNS	O	O
prepared	VBN	O	O
from	IN	O	O
rat	NN	O	O
livers	NNS	O	O
and	CC	O	O
hearts	NNS	O	O
.	.	O	O

Lactic	JJ	O	O
acidosis	NN	O	O
provoked	VBN	O	O
by	IN	O	O
iv	JJ	O	O
infusion	NN	O	O
of	IN	O	O
phenformin	NN	O	O
was	VBD	O	O
weaker	JJR	O	O
in	IN	O	O
octn1	NN	O	O
(	(	O	O
-/-	NNP	O	O
)	)	O	O
mice	NN	O	O
than	IN	O	O
that	DT	O	O
in	IN	O	O
wild-type	JJ	O	O
mice	NN	O	O
.	.	O	O

These	DT	O	O
observations	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
uptake	NN	O	O
of	IN	O	O
phenformin	NN	O	B-SUBSTRATE
into	IN	O	O
liver	JJ	O	O
mitochondria	NN	O	O
is	VBZ	O	O
at	IN	O	O
least	JJS	O	O
partly	RB	O	O
mediated	VBN	O	O
by	IN	O	O
OCTN1	NNP	O	B-enzyme
and	CC	O	O
functionally	RB	O	O
relevant	JJ	O	O
to	TO	O	O
its	PRP$	O	O
inhibition	NN	O	O
potential	NN	O	O
of	IN	O	O
complex	JJ	O	O
I	PRP	O	O
respiration	NN	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
was	VBD	O	O
,	,	O	O
thus	RB	O	O
,	,	O	O
the	DT	O	O
first	JJ	O	O
to	TO	O	O
demonstrate	VB	O	O
OCTN1-mediated	NNP	O	O
mitochondrial	JJ	O	O
transport	NN	O	O
and	CC	O	O
toxicity	NN	O	O
of	IN	O	O
biguanide	NN	O	O
in	IN	O	O
vivo	NN	O	O
in	IN	O	O
rodents	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Vertebrate	NNP	O	O
ALDH2	NNP	O	O
genes	NNS	O	O
encode	VBP	O	O
mitochondrial	JJ	O	O
enzymes	NNS	O	O
capable	JJ	O	O
of	IN	O	O
metabolizing	VBG	O	O
acetaldehyde	NN	O	O
and	CC	O	O
other	JJ	O	O
biological	JJ	O	O
aldehydes	NNS	O	O
in	IN	O	O
the	DT	O	O
body	NN	O	O
.	.	O	O

Mammalian	JJ	O	B-enzyme
ALDH1B1	NNP	O	I-enzyme
,	,	O	O
another	DT	O	O
mitochondrial	JJ	O	O
enzyme	NN	O	O
sharing	VBG	O	O
72	CD	O	O
%	NN	O	O
identity	NN	O	O
with	IN	O	O
ALDH2	NNP	O	B-enzyme
,	,	O	O
is	VBZ	O	O
also	RB	O	O
capable	JJ	O	O
of	IN	O	O
metabolizing	VBG	O	O
acetaldehyde	NN	O	B-SUBSTRATE
but	CC	O	O
has	VBZ	O	O
a	DT	O	O
tissue	NN	O	O
distribution	NN	O	O
and	CC	O	O
pattern	NN	O	O
of	IN	O	O
activity	NN	O	O
distinct	NN	O	O
from	IN	O	O
that	DT	O	O
of	IN	O	O
ALDH2	NNP	O	O
.	.	O	O

Bioinformatic	JJ	O	O
analyses	NNS	O	O
of	IN	O	O
several	JJ	O	O
vertebrate	NN	O	O
genomes	NNS	O	O
were	VBD	O	O
undertaken	JJ	O	O
using	VBG	O	O
known	VBN	O	O
ALDH2	NNP	O	O
and	CC	O	O
ALDH1B1	NNP	O	O
amino	NN	O	O
acid	NN	O	O
sequences	NNS	O	O
.	.	O	O

Phylogenetic	JJ	O	O
analysis	NN	O	O
of	IN	O	O
many	JJ	O	O
representative	JJ	O	O
vertebrate	NN	O	O
species	NNS	O	O
(	(	O	O
including	VBG	O	O
fish	NN	O	O
,	,	O	O
amphibians	NNS	O	O
,	,	O	O
birds	NNS	O	O
and	CC	O	O
mammals	NNS	O	O
)	)	O	O
indicated	VBD	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
ALDH1B1	NNP	O	O
in	IN	O	O
many	JJ	O	O
mammalian	JJ	O	O
species	NNS	O	O
and	CC	O	O
in	IN	O	O
frogs	NNS	O	O
(	(	O	O
Xenopus	NNP	O	O
tropicalis	NN	O	O
)	)	O	O
;	:	O	O
no	DT	O	O
evidence	NN	O	O
was	VBD	O	O
found	VBN	O	O
for	IN	O	O
ALDH1B1	NNP	O	O
in	IN	O	O
the	DT	O	O
genomes	NNS	O	O
of	IN	O	O
birds	NNS	O	O
,	,	O	O
reptiles	NNS	O	O
or	CC	O	O
fish	NN	O	O
.	.	O	O

Predicted	VBN	O	O
vertebrate	NN	O	O
ALDH2	NNP	O	O
and	CC	O	O
ALDH1B1	NNP	O	O
subunit	NN	O	O
sequences	NNS	O	O
and	CC	O	O
structures	NNS	O	O
were	VBD	O	O
highly	RB	O	O
conserved	VBN	O	O
,	,	O	O
including	VBG	O	O
residues	NNS	O	O
previously	RB	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
involved	VBN	O	O
in	IN	O	O
catalysis	NN	O	O
and	CC	O	O
coenzyme	NN	O	O
binding	NN	O	O
for	IN	O	O
human	JJ	O	O
ALDH2	NNP	O	O
.	.	O	O

Studies	NNS	O	O
of	IN	O	O
ALDH1B1	NNP	O	O
sequences	NNS	O	O
supported	VBD	O	O
the	DT	O	O
hypothesis	NN	O	O
that	IN	O	O
the	DT	O	O
ALDH1B1	NNP	O	O
gene	NN	O	O
originated	VBD	O	O
in	IN	O	O
early	JJ	O	O
vertebrates	NNS	O	O
from	IN	O	O
a	DT	O	O
retrotransposition	NN	O	O
of	IN	O	O
the	DT	O	O
vertebrate	NN	O	O
ALDH2	NNP	O	O
gene	NN	O	O
.	.	O	O

Given	VBN	O	O
the	DT	O	O
high	JJ	O	O
degree	NN	O	O
of	IN	O	O
similarity	NN	O	O
between	IN	O	O
ALDH2	NNP	O	O
and	CC	O	O
ALDH1B1	NNP	O	O
,	,	O	O
it	PRP	O	O
is	VBZ	O	O
surprising	JJ	O	O
that	IN	O	O
individuals	NNS	O	O
with	IN	O	O
an	DT	O	O
inactivating	VBG	O	O
mutation	NN	O	O
in	IN	O	O
ALDH2	NNP	O	O
(	(	O	O
ALDH2	NNP	O	O
*	NNP	O	O
2	CD	O	O
)	)	O	O
do	VBP	O	O
not	RB	O	O
exhibit	VB	O	O
a	DT	O	O
compensatory	JJ	O	O
increase	NN	O	O
in	IN	O	O
ALDH1B1	NNP	O	O
activity	NN	O	O
.	.	O	O

We	PRP	O	O
hypothesized	VBD	O	O
that	IN	O	O
the	DT	O	O
similarity	NN	O	O
between	IN	O	O
the	DT	O	O
two	CD	O	O
ALDHs	NNP	O	O
would	MD	O	O
allow	VB	O	O
for	IN	O	O
dominant	JJ	O	O
negative	JJ	O	O
heterotetramerization	NN	O	O
between	IN	O	O
the	DT	O	O
inactive	JJ	O	O
ALDH2	NNP	O	O
mutants	NNS	O	O
and	CC	O	O
ALDH1B1	NNP	O	O
.	.	O	O

Computational-based	JJ	O	O
molecular	JJ	O	O
modeling	NN	O	O
studies	NNS	O	O
examining	VBG	O	O
predicted	VBD	O	O
protein-protein	JJ	O	O
interactions	NNS	O	O
indicated	VBD	O	O
that	IN	O	O
heterotetramerization	NN	O	O
between	IN	O	O
ALDH2	NNP	O	O
and	CC	O	O
ALDH1B1	NNP	O	O
subunits	NNS	O	O
was	VBD	O	O
highly	RB	O	O
probable	JJ	O	O
and	CC	O	O
may	MD	O	O
partially	RB	O	O
explain	VB	O	O
a	DT	O	O
lack	NN	O	O
of	IN	O	O
compensation	NN	O	O
by	IN	O	O
ALDH1B1	NNP	O	O
in	IN	O	O
ALDH2	NNP	O	O
(	(	O	O
)	)	O	O
2	CD	O	O
individuals	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Aldose	JJ	O	B-enzyme
reductase	NN	O	I-enzyme
(	(	O	O
AR	NNP	O	B-enzyme
)	)	O	O
catalyzes	VBZ	O	O
the	DT	O	O
reduction	NN	O	O
of	IN	O	O
toxic	JJ	O	O
lipid	JJ	O	O
aldehydes	NNS	O	B-SUBSTRATE
to	TO	O	O
their	PRP$	O	O
alcohol	NN	O	B-PRODUCT-OF
products	NNS	O	O
and	CC	O	O
mediates	NNS	O	O
inflammatory	JJ	O	O
signals	NNS	O	O
triggered	VBN	O	O
by	IN	O	O
lipopolysaccharide	NN	O	O
(	(	O	O
LPS	NNP	O	O
)	)	O	O
.	.	O	O

Beta-glucogallin	NNP	O	O
(	(	O	O
BGG	NNP	O	O
)	)	O	O
,	,	O	O
a	DT	O	O
recently	RB	O	O
described	VBN	O	O
AR	NNP	O	O
inhibitor	NN	O	O
,	,	O	O
was	VBD	O	O
purified	VBN	O	O
from	IN	O	O
extracts	NNS	O	O
of	IN	O	O
the	DT	O	O
Indian	JJ	O	O
gooseberry	NN	O	O
(	(	O	O
Emblica	NNP	O	O
officinalis	RB	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
found	VBD	O	O
that	IN	O	O
BGG	NNP	O	O
showed	VBD	O	O
low	JJ	O	O
cytotoxicity	NN	O	O
in	IN	O	O
Raw264.7	NNP	O	O
murine	NN	O	O
macrophages	NNS	O	O
and	CC	O	O
effectively	RB	O	O
inhibited	JJ	O	O
AR	NNP	O	O
activity	NN	O	O
as	IN	O	O
measured	VBN	O	O
by	IN	O	O
a	DT	O	O
decrease	NN	O	O
in	IN	O	O
sorbitol	JJ	O	O
accumulation	NN	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
,	,	O	O
BGG-mediated	JJ	O	O
inhibition	NN	O	O
of	IN	O	O
AR	NNP	O	O
prevented	VBD	O	O
LPS-induced	NNP	O	O
activation	NN	O	O
of	IN	O	O
JNK	NNP	O	O
and	CC	O	O
p38	NN	O	O
and	CC	O	O
lowered	VBD	O	O
ROS	NNP	O	O
levels	NNS	O	O
,	,	O	O
which	WDT	O	O
could	MD	O	O
inhibit	VB	O	O
LPS-induced	JJ	O	O
apoptosis	NN	O	O
.	.	O	O

Uveitis	NN	O	O
is	VBZ	O	O
a	DT	O	O
disease	NN	O	O
of	IN	O	O
the	DT	O	O
eye	NN	O	O
associated	VBN	O	O
with	IN	O	O
chronic	JJ	O	O
inflammation	NN	O	O
.	.	O	O

In	IN	O	O
this	DT	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
also	RB	O	O
demonstrated	VBD	O	O
that	IN	O	O
treatment	NN	O	O
with	IN	O	O
BGG	NNP	O	O
decreased	VBD	O	O
the	DT	O	O
number	NN	O	O
of	IN	O	O
inflammatory	JJ	O	O
cells	NNS	O	O
that	WDT	O	O
infiltrate	VBP	O	O
the	DT	O	O
ocular	JJ	O	O
media	NNS	O	O
of	IN	O	O
mice	NN	O	O
with	IN	O	O
experimental	JJ	O	O
uveitis	NN	O	O
.	.	O	O

Accordingly	RB	O	O
,	,	O	O
these	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
BGG	NNP	O	O
is	VBZ	O	O
a	DT	O	O
potential	JJ	O	O
therapy	NN	O	O
for	IN	O	O
inflammatory	JJ	O	O
diseases	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Brain	NN	O	O
metastases	NNS	O	O
are	VBP	O	O
a	DT	O	O
common	JJ	O	O
cause	NN	O	O
of	IN	O	O
death	NN	O	O
in	IN	O	O
stage	NN	O	O
IV	NNP	O	O
metastatic	JJ	O	O
melanoma	NN	O	O
.	.	O	O

Dabrafenib	NNP	O	O
is	VBZ	O	O
a	DT	O	O
BRAF	NNP	O	O
(	(	O	O
gene	NN	O	O
encoding	VBG	O	O
serine/threonine-protein	JJ	O	O
kinase	NN	O	O
B-Raf	NNP	O	O
)	)	O	O
inhibitor	NN	O	O
that	WDT	O	O
has	VBZ	O	O
been	VBN	O	O
developed	VBN	O	O
to	TO	O	O
selectively	RB	O	O
target	VB	O	O
the	DT	O	O
valine	NN	O	O
600	CD	O	O
to	TO	O	O
glutamic	VB	O	O
acid	JJ	O	O
substitution	NN	O	O
(	(	O	O
BRAF	NNP	O	O
(	(	O	O
V600E	NNP	O	O
)	)	O	O
)	)	O	O
,	,	O	O
which	WDT	O	O
is	VBZ	O	O
commonly	RB	O	O
found	VBN	O	O
in	IN	O	O
metastatic	JJ	O	O
melanoma	NN	O	O
.	.	O	O

Clinical	JJ	O	O
trials	NNS	O	O
with	IN	O	O
dabrafenib	NNS	O	O
have	VBP	O	O
shown	VBN	O	O
encouraging	JJ	O	O
results	NNS	O	O
;	:	O	O
however	RB	O	O
,	,	O	O
the	DT	O	O
central	JJ	O	O
nervous	JJ	O	O
system	NN	O	O
distribution	NN	O	O
of	IN	O	O
dabrafenib	NN	O	O
remains	VBZ	O	O
unknown	JJ	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
the	DT	O	O
objective	NN	O	O
of	IN	O	O
the	DT	O	O
current	JJ	O	O
study	NN	O	O
was	VBD	O	O
to	TO	O	O
evaluate	VB	O	O
the	DT	O	O
brain	NN	O	O
distribution	NN	O	O
of	IN	O	O
dabrafenib	NN	O	O
in	IN	O	O
mice	NN	O	O
,	,	O	O
and	CC	O	O
to	TO	O	O
see	VB	O	O
whether	IN	O	O
active	JJ	O	O
efflux	NN	O	O
by	IN	O	O
P-glycoprotein	NNP	O	O
(	(	O	O
P-gp	NNP	O	O
)	)	O	O
and	CC	O	O
breast	NN	O	O
cancer	NN	O	O
resistance	NN	O	O
protein	NN	O	O
(	(	O	O
BCRP	NNP	O	O
)	)	O	O
restricts	VBZ	O	O
its	PRP$	O	O
delivery	NN	O	O
across	IN	O	O
the	DT	O	O
blood-brain	NN	O	O
barrier	NN	O	O
(	(	O	O
BBB	NNP	O	O
)	)	O	O
.	.	O	O

In	IN	O	O
vitro	JJ	O	O
accumulation	NN	O	O
studies	NNS	O	O
conducted	VBN	O	O
in	IN	O	O
Madin-Darby	NNP	O	O
canine	NN	O	O
kidney	NN	O	O
II	NNP	O	O
cells	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
dabrafenib	NN	O	B-SUBSTRATE
is	VBZ	O	O
an	DT	O	O
avid	JJ	O	O
substrate	NN	O	O
for	IN	O	O
both	DT	O	O
P-gp	NNP	O	B-enzyme
and	CC	O	O
BCRP	NNP	O	B-enzyme
.	.	O	O

Directional	NNP	O	O
flux	NN	O	O
studies	NNS	O	O
revealed	VBD	O	O
greater	JJR	O	O
transport	NN	O	O
in	IN	O	O
the	DT	O	O
basolateral	JJ	O	O
to	TO	O	O
apical	JJ	O	O
direction	NN	O	O
with	IN	O	O
corrected	VBN	O	O
efflux	NN	O	O
ratios	NNS	O	O
greater	JJR	O	O
than	IN	O	O
2	CD	O	O
for	IN	O	O
both	DT	O	O
P-gp	NNP	O	O
and	CC	O	O
Bcrp1	NNP	O	O
transfected	VBD	O	O
cell	NN	O	O
lines	NNS	O	O
.	.	O	O

In	IN	O	O
vivo	NN	O	O
,	,	O	O
the	DT	O	O
ratio	NN	O	O
of	IN	O	O
area	NN	O	O
under	IN	O	O
the	DT	O	O
concentration-time	JJ	O	O
curve	NN	O	O
(	(	O	O
AUC	NNP	O	O
)	)	O	O
(	(	O	O
brain	NN	O	O
)	)	O	O
to	TO	O	O
AUC	NNP	O	O
(	(	O	O
plasma	NN	O	O
)	)	O	O
(	(	O	O
K	NNP	O	O
(	(	O	O
p	NN	O	O
)	)	O	O
)	)	O	O
of	IN	O	O
dabrafenib	NN	O	O
after	IN	O	O
an	DT	O	O
i.v	NN	O	O
.	.	O	O

dose	NN	O	O
(	(	O	O
2.5	CD	O	O
mg/kg	NN	O	O
)	)	O	O
was	VBD	O	O
0.023	CD	O	O
,	,	O	O
which	WDT	O	O
increased	VBN	O	O
by	IN	O	O
18-fold	JJ	O	O
in	IN	O	O
Mdr1	NNP	O	O
a/b	NN	O	O
(	(	O	O
-/-	NNP	O	O
)	)	O	O
Bcrp1	NNP	O	O
(	(	O	O
-/-	NNP	O	O
)	)	O	O
mice	NN	O	O
to	TO	O	O
0.42	CD	O	O
.	.	O	O

Dabrafenib	NNP	O	O
plasma	NN	O	O
exposure	NN	O	O
was	VBD	O	O
2-fold	JJ	O	O
greater	JJR	O	O
in	IN	O	O
Mdr1	NNP	O	O
a/b	NN	O	O
(	(	O	O
-/-	NNP	O	O
)	)	O	O
Bcrp1	NNP	O	O
(	(	O	O
-/-	NNP	O	O
)	)	O	O
mice	NN	O	O
as	IN	O	O
compared	VBN	O	O
with	IN	O	O
wild-type	NN	O	O
with	IN	O	O
an	DT	O	O
oral	JJ	O	O
dose	NN	O	O
(	(	O	O
25	CD	O	O
mg/kg	NN	O	O
)	)	O	O
;	:	O	O
however	RB	O	O
,	,	O	O
the	DT	O	O
brain	NN	O	O
distribution	NN	O	O
was	VBD	O	O
increased	VBN	O	O
by	IN	O	O
~10-fold	JJ	O	O
with	IN	O	O
a	DT	O	O
resulting	VBG	O	O
K	NNP	O	O
(	(	O	O
p	NN	O	O
)	)	O	O
of	IN	O	O
0.25	CD	O	O
.	.	O	O

Further	RB	O	O
,	,	O	O
compared	VBN	O	O
with	IN	O	O
vemurafenib	NN	O	O
,	,	O	O
another	DT	O	O
BRAF	NNP	O	O
(	(	O	O
V600E	NNP	O	O
)	)	O	O
inhibitor	NN	O	O
,	,	O	O
dabrafenib	NN	O	O
showed	VBD	O	O
greater	JJR	O	O
brain	NN	O	O
penetration	NN	O	O
with	IN	O	O
a	DT	O	O
similar	JJ	O	O
dose	NN	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
the	DT	O	O
dabrafenib	NN	O	O
brain	NN	O	O
distribution	NN	O	O
is	VBZ	O	O
limited	VBN	O	O
in	IN	O	O
an	DT	O	O
intact	JJ	O	O
BBB	NNP	O	O
model	NN	O	O
,	,	O	O
and	CC	O	O
the	DT	O	O
data	NNS	O	O
presented	VBD	O	O
herein	NN	O	O
may	MD	O	O
have	VB	O	O
clinical	JJ	O	O
implications	NNS	O	O
in	IN	O	O
the	DT	O	O
prevention	NN	O	O
and	CC	O	O
treatment	NN	O	O
of	IN	O	O
melanoma	NN	O	O
brain	NN	O	O
metastases	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

During	IN	O	O
early	JJ	O	O
pregnancy	NN	O	O
in	IN	O	O
sheep	NN	O	O
,	,	O	O
the	DT	O	O
elongating	VBG	O	O
conceptus	NN	O	O
secretes	VBZ	O	O
interferon-tau	JJ	O	O
(	(	O	O
IFNT	NNP	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
conceptus	NN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
endometrial	JJ	O	O
epithelia	NN	O	O
produce	NN	O	O
prostaglandins	NNS	O	B-PRODUCT-OF
(	(	O	O
PG	NNP	O	O
)	)	O	O
via	IN	O	O
PG	NNP	O	B-enzyme
synthase	VBD	O	I-enzyme
2	CD	O	O
(	(	O	O
PTGS2	NNP	O	B-enzyme
)	)	O	O
and	CC	O	O
cortisol	JJ	O	B-PRODUCT-OF
via	IN	O	O
hydroxysteroid	NN	O	B-enzyme
(	(	O	I-enzyme
11-beta	JJ	O	I-enzyme
)	)	O	I-enzyme
dehydrogenase	NN	O	O
1	CD	O	O
(	(	O	O
HSD11B1	NNP	O	B-enzyme
)	)	O	O
.	.	O	O

Ovarian	JJ	O	O
progesterone	NN	O	O
induces	NNS	O	O
and	CC	O	O
PG	NNP	O	O
and	CC	O	O
IFNT	NNP	O	O
stimulates	VBZ	O	O
endometrial	JJ	O	O
HSD11B1	NNP	O	O
expression	NN	O	O
and	CC	O	O
keto-reductase	NN	O	O
activity	NN	O	O
as	RB	O	O
well	RB	O	O
as	IN	O	O
many	JJ	O	O
epithelial	JJ	O	O
genes	NNS	O	O
that	WDT	O	O
govern	VBP	O	O
trophectoderm	JJ	O	O
proliferation	NN	O	O
,	,	O	O
migration	NN	O	O
,	,	O	O
and	CC	O	O
attachment	NN	O	O
during	IN	O	O
elongation	NN	O	O
.	.	O	O

The	DT	O	O
primary	JJ	O	O
aim	NN	O	O
of	IN	O	O
these	DT	O	O
studies	NNS	O	O
was	VBD	O	O
to	TO	O	O
test	VB	O	O
the	DT	O	O
hypothesis	NN	O	O
that	IN	O	O
HSD11B1-derived	NNP	O	O
cortisol	NN	O	B-PRODUCT-OF
has	VBZ	O	O
a	DT	O	O
biological	JJ	O	O
role	NN	O	O
in	IN	O	O
endometrial	JJ	O	O
function	NN	O	O
and	CC	O	O
conceptus	NN	O	O
development	NN	O	O
during	IN	O	O
early	JJ	O	O
pregnancy	NN	O	O
in	IN	O	O
sheep	NN	O	O
.	.	O	O

In	IN	O	O
study	NN	O	O
1	CD	O	O
,	,	O	O
cyclic	JJ	O	O
ewes	FW	O	O
received	VBN	O	O
vehicle	NN	O	O
,	,	O	O
cortisol	NN	O	O
,	,	O	O
PF	NNP	O	O
915275	CD	O	O
(	(	O	O
PF	NNP	O	O
;	:	O	O
a	DT	O	O
selective	JJ	O	O
inhibitor	NN	O	O
of	IN	O	O
HSD11B1	NNP	O	O
)	)	O	O
,	,	O	O
cortisol	NN	O	O
and	CC	O	O
PF	NNP	O	O
,	,	O	O
meloxicam	NN	O	O
(	(	O	O
a	DT	O	O
selective	JJ	O	O
inhibitor	NN	O	O
of	IN	O	O
PTGS2	NNP	O	O
)	)	O	O
,	,	O	O
cortisol	NN	O	O
and	CC	O	O
meloxicam	NN	O	O
,	,	O	O
recombinant	JJ	O	O
ovine	NN	O	O
IFNT	NNP	O	O
,	,	O	O
or	CC	O	O
IFNT	NNP	O	O
and	CC	O	O
PF	NNP	O	O
into	IN	O	O
the	DT	O	O
uterus	JJ	O	O
from	IN	O	O
day	NN	O	O
10	CD	O	O
to	TO	O	O
day14	VB	O	O
after	IN	O	O
estrus	NN	O	O
.	.	O	O

Cortisol	NNP	O	O
and	CC	O	O
IFNT	NNP	O	O
stimulated	VBD	O	O
endometrial	JJ	O	O
HSD11B1	NNP	O	O
expression	NN	O	O
and	CC	O	O
activity	NN	O	O
,	,	O	O
increased	VBD	O	O
endometrial	JJ	O	O
PTGS2	NNP	O	O
activity	NN	O	O
and	CC	O	O
the	DT	O	O
amount	NN	O	O
of	IN	O	O
PG	NNP	O	O
in	IN	O	O
the	DT	O	O
uterine	JJ	O	O
lumen	NNS	O	O
,	,	O	O
and	CC	O	O
up-regulated	JJ	O	O
many	JJ	O	O
conceptus	NN	O	O
elongation-related	JJ	O	O
genes	NNS	O	O
in	IN	O	O
the	DT	O	O
endometrium	NN	O	O
.	.	O	O

Some	DT	O	O
effects	NNS	O	O
of	IN	O	O
cortisol	NN	O	O
and	CC	O	O
IFNT	NNP	O	O
were	VBD	O	O
mediated	VBN	O	O
by	IN	O	O
PTGS2-derived	NNP	O	O
PG	NNP	O	O
.	.	O	O

In	IN	O	O
study	NN	O	O
2	CD	O	O
,	,	O	O
bred	VBD	O	O
ewes	RB	O	O
received	VBN	O	O
PF	NNP	O	O
915275	CD	O	O
or	CC	O	O
recombinant	JJ	O	O
ovine	NN	O	O
IFNT	NNP	O	O
and	CC	O	O
into	IN	O	O
the	DT	O	O
uterus	JJ	O	O
from	IN	O	O
day	NN	O	O
10	CD	O	O
to	TO	O	O
day	NN	O	O
14	CD	O	O
after	IN	O	O
mating	NN	O	O
.	.	O	O

Inhibition	NN	O	O
of	IN	O	O
HSD11B1	NNP	O	O
activity	NN	O	O
in	IN	O	O
utero	NN	O	O
prevented	VBN	O	O
conceptus	NN	O	O
elongation	NN	O	O
,	,	O	O
whereas	WP	O	O
IFNT	NNP	O	O
rescued	VBD	O	O
conceptus	JJ	O	O
elongation	NN	O	O
in	IN	O	O
PF-infused	JJ	O	O
ewes	NN	O	O
.	.	O	O

These	DT	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
HSD11B1-derived	NNP	O	O
cortisol	NN	O	B-PRODUCT-OF
mediates	NNS	O	O
,	,	O	O
in	IN	O	O
part	NN	O	O
,	,	O	O
actions	NNS	O	O
of	IN	O	O
ovarian	JJ	O	O
progesterone	NN	O	O
and	CC	O	O
the	DT	O	O
conceptus	NN	O	O
on	IN	O	O
endometrial	JJ	O	O
function	NN	O	O
and	CC	O	O
support	VB	O	O
the	DT	O	O
hypothesis	NN	O	O
that	WDT	O	O
IFNT	NNP	O	O
,	,	O	O
PG	NNP	O	O
,	,	O	O
and	CC	O	O
cortisol	VB	O	O
coordinately	RB	O	O
regulate	JJ	O	O
endometrial	JJ	O	O
functions	NNS	O	O
important	JJ	O	O
for	IN	O	O
conceptus	JJ	O	O
elongation	NN	O	O
and	CC	O	O
implantation	NN	O	O
during	IN	O	O
early	JJ	O	O
pregnancy	NN	O	O
in	IN	O	O
sheep	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Water	NNP	O	O
and	CC	O	O
food	NN	O	O
are	VBP	O	O
the	DT	O	O
main	JJ	O	O
sources	NNS	O	O
of	IN	O	O
fluoride	JJ	O	O
exposure	NN	O	O
and	CC	O	O
therefore	VB	O	O
it	PRP	O	O
is	VBZ	O	O
necessary	JJ	O	O
to	TO	O	O
study	VB	O	O
intestinal	JJ	O	O
absorption	NN	O	O
in	IN	O	O
order	NN	O	O
to	TO	O	O
make	VB	O	O
a	DT	O	O
correct	JJ	O	O
evaluation	NN	O	O
of	IN	O	O
the	DT	O	O
risk/benefit	NN	O	O
associated	VBN	O	O
with	IN	O	O
exposure	NN	O	O
to	TO	O	O
fluoride	VB	O	O
.	.	O	O

The	DT	O	O
present	JJ	O	O
study	NN	O	O
characterizes	VBZ	O	O
intestinal	JJ	O	O
transport	NN	O	O
of	IN	O	O
fluoride	NN	O	O
,	,	O	O
using	VBG	O	O
the	DT	O	O
Caco-2	NNP	O	O
cell	NN	O	O
line	NN	O	O
as	IN	O	O
a	DT	O	O
model	NN	O	O
of	IN	O	O
the	DT	O	O
intestinal	JJ	O	O
epithelium	NN	O	O
,	,	O	O
and	CC	O	O
evaluates	VBZ	O	O
the	DT	O	O
coefficients	NNS	O	O
of	IN	O	O
apparent	JJ	O	O
permeability	NN	O	O
and	CC	O	O
intracellular	JJ	O	O
accumulation	NN	O	O
in	IN	O	O
various	JJ	O	O
conditions	NNS	O	O
(	(	O	O
pH	NN	O	O
,	,	O	O
temperature	NN	O	O
,	,	O	O
opening	NN	O	O
of	IN	O	O
cell	NN	O	O
junctions	NNS	O	O
,	,	O	O
presence	NN	O	O
of	IN	O	O
anions	NNS	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
fluoride	NN	O	O
is	VBZ	O	O
an	DT	O	O
element	NN	O	O
with	IN	O	O
moderate	JJ	O	O
absorption	NN	O	O
(	(	O	O
<	JJ	O	O
70	CD	O	O
%	NN	O	O
)	)	O	O
in	IN	O	O
both	DT	O	O
directions	NNS	O	O
(	(	O	O
absorptive	JJ	O	O
and	CC	O	O
secretory	NN	O	O
)	)	O	O
.	.	O	O

Both	DT	O	O
in	IN	O	O
absorption	NN	O	O
(	(	O	O
apical-basolateral	JJ	O	O
)	)	O	O
and	CC	O	O
in	IN	O	O
secretion	NN	O	O
(	(	O	O
basolateral-apical	JJ	O	O
)	)	O	O
there	EX	O	O
is	VBZ	O	O
transport	NN	O	O
by	IN	O	O
the	DT	O	O
paracellular	JJ	O	O
pathway	NN	O	O
,	,	O	O
which	WDT	O	O
may	MD	O	O
be	VB	O	O
considered	VBN	O	O
predominant	JJ	O	O
.	.	O	O

Absorption	NN	O	O
and	CC	O	O
secretion	NN	O	O
of	IN	O	O
fluoride	JJ	O	B-SUBSTRATE
increase	NN	O	O
at	IN	O	O
acid	JJ	O	O
pH	NN	O	O
levels	NNS	O	O
,	,	O	O
possibly	RB	O	O
because	IN	O	O
of	IN	O	O
its	PRP$	O	O
non-ionized	JJ	O	O
state	NN	O	O
at	IN	O	O
these	DT	O	O
pHs	NNS	O	O
and/or	VBP	O	O
because	IN	O	O
of	IN	O	O
participation	NN	O	O
of	IN	O	O
a	DT	O	O
F	NNP	O	B-enzyme
(	(	O	O
-	:	O	O
)	)	O	O
/H	NN	O	O
(	(	O	O
+	NNP	O	O
)	)	O	O
cotransporter	NN	O	I-enzyme
or	CC	O	O
a	DT	O	O
F	NNP	O	B-enzyme
(	(	O	O
-	:	O	O
)	)	O	O
/OH	NN	O	O
(	(	O	O
-	:	O	O
)	)	O	O
antiporter	NN	O	I-enzyme
.	.	O	O

The	DT	O	O
results	NNS	O	O
also	RB	O	O
suggest	VBP	O	O
transcellular	JJ	O	O
participation	NN	O	O
of	IN	O	O
mechanisms	NNS	O	O
involved	VBN	O	O
in	IN	O	O
transport	NN	O	O
of	IN	O	O
Cl	NNP	O	O
(	(	O	O
-	:	O	O
)	)	O	O
and	CC	O	O
of	IN	O	O
an	DT	O	O
active	JJ	O	O
transport	NN	O	O
in	IN	O	O
the	DT	O	O
secretory	JJ	O	O
direction	NN	O	O
.	.	O	O

The	DT	O	O
present	JJ	O	O
study	NN	O	O
extend	VBP	O	O
the	DT	O	O
knowledge	NN	O	O
on	IN	O	O
the	DT	O	O
cellular	JJ	O	O
transport	NN	O	O
of	IN	O	O
fluoride	NN	O	O
and	CC	O	O
provide	VB	O	O
the	DT	O	O
basis	NN	O	O
for	IN	O	O
future	JJ	O	O
studies	NNS	O	O
aimed	VBN	O	O
at	IN	O	O
identifying	VBG	O	O
potential	JJ	O	O
transporters	NNS	O	O
involved	VBN	O	O
in	IN	O	O
human	JJ	O	O
fluoride	JJ	O	O
absorption	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Our	PRP$	O	O
knowledge	NN	O	O
of	IN	O	O
how	WRB	O	O
androgens	JJ	O	O
influence	NN	O	O
the	DT	O	O
cardiovascular	NN	O	O
system	NN	O	O
is	VBZ	O	O
far	RB	O	O
from	IN	O	O
complete	JJ	O	O
,	,	O	O
and	CC	O	O
this	DT	O	O
lack	NN	O	O
of	IN	O	O
understanding	NN	O	O
is	VBZ	O	O
especially	RB	O	O
true	JJ	O	O
of	IN	O	O
how	WRB	O	O
androgens	JJ	O	O
affect	JJ	O	O
resistance	NN	O	O
vessels	NNS	O	O
.	.	O	O

Our	PRP$	O	O
aim	NN	O	O
was	VBD	O	O
to	TO	O	O
identify	VB	O	O
the	DT	O	O
signaling	VBG	O	O
mechanisms	NNS	O	O
stimulated	VBN	O	O
by	IN	O	O
testosterone	NN	O	O
(	(	O	O
TES	NNP	O	O
)	)	O	O
in	IN	O	O
microvascular	JJ	O	O
arteries	NNS	O	O
and	CC	O	O
to	TO	O	O
understand	VB	O	O
how	WRB	O	O
these	DT	O	O
mechanisms	NNS	O	O
mediate	VBP	O	O
TES-induced	JJ	O	O
vasodilation	NN	O	O
.	.	O	O

Mesenteric	JJ	O	O
microvessels	NNS	O	O
were	VBD	O	O
isolated	VBN	O	O
from	IN	O	O
male	JJ	O	O
Sprague-Dawley	JJ	O	O
rats	NNS	O	O
.	.	O	O

Tension	NN	O	O
studies	NNS	O	O
demonstrated	VBD	O	O
a	DT	O	O
rapid	JJ	O	O
,	,	O	O
concentration-dependent	JJ	O	O
,	,	O	O
vasodilatory	JJ	O	O
response	NN	O	O
to	TO	O	O
TES	VB	O	O
that	DT	O	O
did	VBD	O	O
not	RB	O	O
involve	VB	O	O
protein	NN	O	O
synthesis	NN	O	O
or	CC	O	O
aromatization	NN	O	O
to	TO	O	O
17beta-estradiol	CD	O	O
.	.	O	O

Dichlorofluorescein	NNP	O	O
fluorescence	NN	O	O
and	CC	O	O
nitrotyrosine	JJ	O	O
immunoblot	NN	O	O
experiments	NNS	O	O
indicated	VBD	O	O
that	IN	O	O
TES	NNP	O	O
stimulated	VBD	O	O
peroxynitrite	JJ	O	O
formation	NN	O	O
in	IN	O	O
microvessels	NNS	O	O
,	,	O	O
and	CC	O	O
functional	JJ	O	O
studies	NNS	O	O
demonstrated	VBD	O	O
that	IN	O	O
TES-induced	NNP	O	O
vasodilation	NN	O	O
was	VBD	O	O
inhibited	VBN	O	O
by	IN	O	O
scavenging	VBG	O	O
peroxynitrite	NN	O	O
.	.	O	O

As	IN	O	O
predicted	VBN	O	O
,	,	O	O
TES	NNP	O	O
enhanced	VBD	O	O
the	DT	O	O
production	NN	O	O
of	IN	O	O
both	DT	O	O
peroxynitrite	JJ	O	O
precursors	NNS	O	O
(	(	O	O
i.e.	FW	O	O
,	,	O	O
superoxide	NN	O	O
and	CC	O	O
nitic	JJ	O	O
oxide	NN	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
xanthine	JJ	O	B-enzyme
oxidase	NN	O	I-enzyme
was	VBD	O	O
identified	VBN	O	O
as	IN	O	O
the	DT	O	O
likely	JJ	O	O
source	NN	O	O
of	IN	O	O
TES-stimulated	NNP	O	O
superoxide	JJ	O	B-PRODUCT-OF
production	NN	O	O
.	.	O	O

Functional	NNP	O	O
and	CC	O	O
biochemical	JJ	O	O
studies	NNS	O	O
indicated	VBD	O	O
that	IN	O	O
TES	NNP	O	O
signaling	VBG	O	O
involved	JJ	O	O
activity	NN	O	O
of	IN	O	O
the	DT	O	O
phosphoinositide	NN	O	O
3	CD	O	O
(	(	O	O
PI3	NNP	O	O
)	)	O	O
kinase-protein	NN	O	O
kinase	NN	O	O
B	NNP	O	O
(	(	O	O
Akt	NNP	O	O
)	)	O	O
cascade	NN	O	O
initiated	VBN	O	O
by	IN	O	O
activation	NN	O	O
of	IN	O	O
the	DT	O	O
androgen	NN	O	O
receptor	NN	O	O
and	CC	O	O
culminated	VBN	O	O
in	IN	O	O
enhanced	JJ	O	O
production	NN	O	O
of	IN	O	O
cGMP	NN	O	O
and	CC	O	O
microvascular	JJ	O	O
vasodilation	NN	O	O
.	.	O	O

These	DT	O	O
findings	NNS	O	O
,	,	O	O
derived	VBN	O	O
from	IN	O	O
a	DT	O	O
variety	NN	O	O
of	IN	O	O
analytical	JJ	O	O
and	CC	O	O
functional	JJ	O	O
approaches	NNS	O	O
,	,	O	O
provide	VBP	O	O
evidence	NN	O	O
for	IN	O	O
a	DT	O	O
novel	JJ	O	O
nongenomic	JJ	O	O
signaling	NN	O	O
mechanism	NN	O	O
for	IN	O	O
androgen	JJ	O	O
action	NN	O	O
in	IN	O	O
the	DT	O	O
microvasculature	NN	O	O
:	:	O	O
TES-stimulated	JJ	O	O
vasodilation	NN	O	O
mediated	VBN	O	O
primarily	RB	O	O
by	IN	O	O
peroxynitrite	NN	O	B-PRODUCT-OF
formed	VBN	O	O
from	IN	O	O
xanthine	JJ	O	B-enzyme
oxidase-generated	JJ	O	O
superoxide	NN	O	B-PRODUCT-OF
and	CC	O	O
NO	NNP	O	B-PRODUCT-OF
.	.	O	O

This	DT	O	O
response	NN	O	O
was	VBD	O	O
associated	VBN	O	O
with	IN	O	O
activation	NN	O	O
of	IN	O	O
the	DT	O	O
PI3	NNP	O	O
kinase-Akt	JJ	O	O
signaling	VBG	O	O
cascade	NN	O	O
initiated	VBN	O	O
by	IN	O	O
activation	NN	O	O
of	IN	O	O
the	DT	O	O
androgen	NN	O	O
receptor	NN	O	O
.	.	O	O

We	PRP	O	O
propose	VBP	O	O
this	DT	O	O
mechanism	NN	O	O
could	MD	O	O
account	VB	O	O
for	IN	O	O
TES-stimulated	JJ	O	O
cGMP	NN	O	O
production	NN	O	O
in	IN	O	O
microvessels	NNS	O	O
and	CC	O	O
,	,	O	O
ultimately	RB	O	O
,	,	O	O
vasodilation	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Organic	JJ	O	O
anion	NN	O	O
transporting	VBG	O	O
polypeptides	NNS	O	O
(	(	O	O
OATPs	NNP	O	O
)	)	O	O
1B1	CD	O	O
and	CC	O	O
1B3	CD	O	O
are	VBP	O	O
transporters	NNS	O	O
that	WDT	O	O
are	VBP	O	O
expressed	VBN	O	O
selectively	RB	O	O
in	IN	O	O
human	JJ	O	O
hepatocytes	NNS	O	O
under	IN	O	O
normal	JJ	O	O
conditions	NNS	O	O
.	.	O	O

OATP1B3	NNP	O	O
is	VBZ	O	O
also	RB	O	O
expressed	VBN	O	O
in	IN	O	O
certain	JJ	O	O
cancers	NNS	O	O
.	.	O	O

Flavonoids	NNS	O	O
such	JJ	O	O
as	IN	O	O
green	JJ	O	O
tea	NN	O	O
catechins	NNS	O	O
and	CC	O	O
quercetin	NN	O	O
glycosides	NNS	O	O
have	VBP	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
modulate	VB	O	O
the	DT	O	O
function	NN	O	O
of	IN	O	O
some	DT	O	O
OATPs	NNP	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
,	,	O	O
the	DT	O	O
extent	NN	O	O
to	TO	O	O
which	WDT	O	O
six	CD	O	O
substituted	VBD	O	O
quercetin	NN	O	O
derivatives	NNS	O	O
(	(	O	O
1-6	JJ	O	O
)	)	O	O
affected	VBD	O	O
the	DT	O	O
function	NN	O	O
of	IN	O	O
OATP1B1	NNP	O	O
and	CC	O	O
OATP1B3	NNP	O	O
was	VBD	O	O
investigated	VBN	O	O
.	.	O	O

Uptake	NN	O	O
of	IN	O	O
the	DT	O	O
radiolabeled	JJ	O	O
model	NN	O	O
substrates	NNS	O	O
estradiol	VBP	O	B-SUBSTRATE
17beta-glucuronide	JJ	O	I-SUBSTRATE
,	,	O	O
estrone	JJ	O	B-SUBSTRATE
3-sulfate	JJ	O	I-SUBSTRATE
,	,	O	O
and	CC	O	O
dehydroepiandrosterone	NN	O	B-SUBSTRATE
sulfate	NN	O	I-SUBSTRATE
(	(	O	O
DHEAS	NNP	O	B-SUBSTRATE
)	)	O	O
was	VBD	O	O
determined	VBN	O	O
in	IN	O	O
the	DT	O	O
absence	NN	O	O
and	CC	O	O
presence	NN	O	O
of	IN	O	O
compounds	NNS	O	O
1-6	JJ	O	O
using	VBG	O	O
Chinese	JJ	O	O
hamster	NN	O	O
ovary	JJ	O	O
(	(	O	O
CHO	NNP	O	O
)	)	O	O
cells	NNS	O	O
stably	RB	O	O
expressing	VBG	O	O
either	CC	O	O
OATP1B1	NNP	O	B-enzyme
or	CC	O	O
OATP1B3	NNP	O	B-enzyme
.	.	O	O

Several	JJ	O	O
of	IN	O	O
compounds	NNS	O	O
1-6	JJ	O	O
inhibited	JJ	O	O
OATP-mediated	JJ	O	O
uptake	NN	O	O
of	IN	O	O
all	DT	O	O
three	CD	O	O
model	NN	O	O
substrates	NNS	O	O
,	,	O	O
suggesting	VBG	O	O
that	IN	O	O
they	PRP	O	O
could	MD	O	O
also	RB	O	O
be	VB	O	O
potential	JJ	O	O
substrates	NNS	O	O
.	.	O	O

Compound	$	O	O
6	CD	O	O
stimulated	VBN	O	O
OATP1B3-mediated	JJ	O	O
estradiol	JJ	O	B-SUBSTRATE
17beta-glucuronide	JJ	O	I-SUBSTRATE
uptake	NN	O	O
by	IN	O	O
increasing	VBG	O	O
the	DT	O	O
apparent	JJ	O	O
affinity	NN	O	O
of	IN	O	O
OATP1B3	NNP	O	B-enzyme
for	IN	O	O
its	PRP$	O	O
substrate	NN	O	O
.	.	O	O

Cytotoxicity	NNP	O	O
assays	NNS	O	O
demonstrated	VBD	O	O
that	IN	O	O
epigallocatechin	JJ	O	B-SUBSTRATE
3-O-gallate	JJ	O	I-SUBSTRATE
(	(	O	O
EGCG	NNP	O	B-SUBSTRATE
)	)	O	O
and	CC	O	O
most	JJS	O	O
of	IN	O	O
compounds	NNS	O	O
1-6	JJ	O	O
killed	VBN	O	O
preferentially	RB	O	O
OATP-expressing	NNP	O	O
CHO	NNP	O	O
cells	NNS	O	O
.	.	O	O

EGCG	NNP	O	O
,	,	O	O
1	CD	O	O
,	,	O	O
and	CC	O	O
3	CD	O	O
were	VBD	O	O
the	DT	O	O
most	RBS	O	O
potent	JJ	O	O
cytotoxic	NN	O	O
compounds	NNS	O	O
,	,	O	O
with	IN	O	O
EGCG	NNP	O	B-SUBSTRATE
and	CC	O	O
3	CD	O	O
selectively	RB	O	O
killing	VBG	O	O
OATP1B3-expressing	NNP	O	O
cells	NNS	O	O
.	.	O	O

Given	VBN	O	O
that	DT	O	O
OATP1B3	NNP	O	O
is	VBZ	O	O
expressed	VBN	O	O
in	IN	O	O
several	JJ	O	O
cancers	NNS	O	O
,	,	O	O
EGCG	NNP	O	O
and	CC	O	O
some	DT	O	O
of	IN	O	O
the	DT	O	O
quercetin	NN	O	O
derivatives	NNS	O	O
studied	VBD	O	O
might	MD	O	O
be	VB	O	O
promising	VBG	O	O
lead	JJ	O	O
compounds	NNS	O	O
for	IN	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
novel	JJ	O	O
anticancer	NN	O	O
drugs	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Type	$	O	B-enzyme
2	CD	O	I-enzyme
11beta-hydroxysteroid	JJ	O	O
dehydrogenase	NN	O	O
encoded	VBN	O	O
by	IN	O	O
the	DT	O	O
HSD11B2	NNP	O	B-enzyme
gene	NN	O	O
converts	NNS	O	O
cortisol	VBP	O	B-SUBSTRATE
to	TO	O	O
inactive	VB	O	O
cortisone	NN	O	B-PRODUCT-OF
,	,	O	O
and	CC	O	O
alteration	NN	O	O
in	IN	O	O
this	DT	O	O
enzymatic	JJ	O	O
activity	NN	O	O
might	MD	O	O
affect	VB	O	O
glucose	JJ	O	O
homeostasis	NN	O	O
by	IN	O	O
affecting	VBG	O	O
circulating	NN	O	O
levels	NNS	O	O
or	CC	O	O
tissue	NN	O	O
availability	NN	O	O
of	IN	O	O
glucocorticoids	NNS	O	O
.	.	O	O

We	PRP	O	O
investigated	VBD	O	O
the	DT	O	O
association	NN	O	O
of	IN	O	O
HSD11B2	NNP	O	O
variant	NN	O	O
with	IN	O	O
glucose	JJ	O	O
homeostasis	NN	O	O
.	.	O	O

Subjects	NNS	O	O
with	IN	O	O
normal	JJ	O	O
glucose	JJ	O	O
tolerance	NN	O	O
(	(	O	O
n=585	NN	O	O
)	)	O	O
,	,	O	O
impaired	VBD	O	O
glucose	JJ	O	O
tolerance	NN	O	O
(	(	O	O
n=202	JJ	O	O
)	)	O	O
and	CC	O	O
type	$	O	O
2	CD	O	O
diabetes	NNS	O	O
(	(	O	O
n=355	NN	O	O
)	)	O	O
were	VBD	O	O
genotyped	VBN	O	O
for	IN	O	O
a	DT	O	O
highly	RB	O	O
polymorphic	JJ	O	O
CA-repeat	NNP	O	O
polymorphism	NN	O	O
in	IN	O	O
the	DT	O	O
first	JJ	O	O
intron	NN	O	O
of	IN	O	O
HSD11B2	NNP	O	O
.	.	O	O

Allele	NNP	O	O
and	CC	O	O
genotype	JJ	O	O
frequencies	NNS	O	O
differed	VBD	O	O
between	IN	O	O
normal	JJ	O	O
and	CC	O	O
impaired	JJ	O	O
glucose	JJ	O	O
tolerance	NN	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.0014	CD	O	O
and	CC	O	O
0.0407	CD	O	O
,	,	O	O
respectively	RB	O	O
;	:	O	O
4DF	CD	O	O
)	)	O	O
or	CC	O	O
type	$	O	O
2	CD	O	O
diabetes	NNS	O	O
(	(	O	O
P	NNP	O	O
=	NNP	O	O
0.0053	CD	O	O
and	CC	O	O
0.0078	CD	O	O
)	)	O	O
,	,	O	O
with	IN	O	O
significant	JJ	O	O
linear	JJ	O	O
trends	NNS	O	O
between	IN	O	O
the	DT	O	O
repeat	NN	O	O
length	NN	O	O
and	CC	O	O
the	DT	O	O
phenotype	JJ	O	O
fraction	NN	O	O
.	.	O	O

In	IN	O	O
normal	JJ	O	O
subjects	NNS	O	O
,	,	O	O
total	JJ	O	O
CA-repeat	NNP	O	O
length	NN	O	O
was	VBD	O	O
negatively	RB	O	O
correlated	VBN	O	O
with	IN	O	O
fasting	JJ	O	O
insulin	NN	O	O
and	CC	O	O
HOMA-beta	NNP	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
subjects	VBZ	O	O
having	VBG	O	O
more	RBR	O	O
CA	JJ	O	O
repeats	NNS	O	O
are	VBP	O	O
susceptible	JJ	O	O
to	TO	O	O
developing	VBG	O	O
abnormal	JJ	O	O
glucose	NN	O	O
tolerance	NN	O	O
,	,	O	O
whereas	IN	O	O
normal	JJ	O	O
subjects	NNS	O	O
carrying	VBG	O	O
more	JJR	O	O
CA	JJ	O	O
repeats	NNS	O	O
appeared	VBD	O	O
to	TO	O	O
have	VB	O	O
frugal	JJ	O	O
characteristics	NNS	O	O
in	IN	O	O
insulin	NN	O	O
secretion	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Chronic	NNP	O	O
arsenic	JJ	O	O
ingestion	NN	O	O
predisposes	NNS	O	O
to	TO	O	O
vascular	JJ	O	O
disease	NN	O	O
,	,	O	O
but	CC	O	O
underlying	JJ	O	O
mechanisms	NNS	O	O
are	VBP	O	O
poorly	RB	O	O
understood	JJ	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
present	JJ	O	O
study	NN	O	O
we	PRP	O	O
have	VBP	O	O
analyzed	VBN	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
short-term	JJ	O	O
arsenite	JJ	O	O
exposure	NN	O	O
on	IN	O	O
vascular	JJ	O	O
function	NN	O	O
and	CC	O	O
endothelium-dependent	JJ	O	O
relaxation	NN	O	O
.	.	O	O

Endothelium-dependent	JJ	O	O
relaxations	NNS	O	O
,	,	O	O
nitric	JJ	O	O
oxide	NN	O	O
(	(	O	O
NO	NNP	O	O
)	)	O	O
and	CC	O	O
endothelium	$	O	O
derived	VBN	O	O
hyperpolarizing	VBG	O	O
factor	NN	O	O
(	(	O	O
EDHF	NNP	O	O
)	)	O	O
-type	NN	O	O
,	,	O	O
were	VBD	O	O
studied	VBN	O	O
in	IN	O	O
rabbit	NN	O	O
iliac	JJ	O	O
artery	NN	O	O
and	CC	O	O
aortic	JJ	O	O
rings	NNS	O	O
using	VBG	O	O
the	DT	O	O
G	NNP	O	O
protein-coupled	JJ	O	O
receptor	NN	O	O
agonist	NN	O	O
acetylcholine	NN	O	O
(	(	O	O
ACh	NNP	O	O
)	)	O	O
and	CC	O	O
by	IN	O	O
cyclopiazonic	JJ	O	O
acid	NN	O	O
(	(	O	O
CPA	NNP	O	O
)	)	O	O
,	,	O	O
which	WDT	O	O
promotes	VBZ	O	O
store-operated	JJ	O	O
Ca	NNP	O	O
(	(	O	O
2+	CD	O	O
)	)	O	O
entry	NN	O	O
by	IN	O	O
inhibiting	VBG	O	O
the	DT	O	O
endothelial	JJ	O	O
SERCA	NNP	O	O
pump	NN	O	O
.	.	O	O

Production	NN	O	O
of	IN	O	O
reactive	JJ	O	O
oxygen	NN	O	O
species	NNS	O	O
(	(	O	O
ROS	NNP	O	O
)	)	O	O
in	IN	O	O
the	DT	O	O
endothelium	NN	O	O
of	IN	O	O
rabbit	NN	O	O
aortic	JJ	O	O
valve	NN	O	O
leaflets	NNS	O	O
and	CC	O	O
endothelium-denuded	JJ	O	O
RIA	NNP	O	O
and	CC	O	O
aortic	JJ	O	O
rings	NNS	O	O
was	VBD	O	O
assessed	VBN	O	O
by	IN	O	O
imaging	VBG	O	O
of	IN	O	O
dihydroethidium	NN	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
iliac	JJ	O	O
artery	NN	O	O
,	,	O	O
exposure	NN	O	O
to	TO	O	O
100muM	CD	O	O
arsenite	NN	O	O
for	IN	O	O
30min	CD	O	O
potentiated	JJ	O	O
EDHF-type	JJ	O	O
relaxations	NNS	O	O
evoked	VBN	O	O
by	IN	O	O
both	DT	O	O
CPA	NNP	O	O
and	CC	O	O
ACh	NNP	O	O
.	.	O	O

Potentiation	NN	O	O
was	VBD	O	O
prevented	VBN	O	O
by	IN	O	O
catalase	NN	O	O
,	,	O	O
the	DT	O	O
catalase/superoxide	NN	O	O
dismutase	NN	O	O
mimetic	JJ	O	O
manganese	JJ	O	O
porphyrin	NN	O	O
and	CC	O	O
the	DT	O	O
NADPH	NNP	O	O
oxidase	NN	O	O
inhibitor	NN	O	O
apocynin	NN	O	O
.	.	O	O

By	IN	O	O
contrast	NN	O	O
in	IN	O	O
aortic	JJ	O	O
rings	NNS	O	O
,	,	O	O
that	IN	O	O
exhibited	VBD	O	O
negligible	JJ	O	O
EDHF-type	JJ	O	O
responses	NNS	O	O
,	,	O	O
endothelium-dependent	JJ	O	O
NO-mediated	JJ	O	O
relaxations	NNS	O	O
evoked	VBN	O	O
by	IN	O	O
CPA	NNP	O	O
and	CC	O	O
ACh	NNP	O	O
were	VBD	O	O
unaffected	VBN	O	O
by	IN	O	O
arsenite	NN	O	O
.	.	O	O

Arsenite	NNP	O	O
induced	VBD	O	O
apocynin-sensitive	JJ	O	O
increases	NNS	O	O
in	IN	O	O
ROS	NNP	O	O
production	NN	O	O
in	IN	O	O
the	DT	O	O
aortic	JJ	O	O
valve	NN	O	O
endothelium	NN	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
in	IN	O	O
the	DT	O	O
media	NNS	O	O
and	CC	O	O
adventitia	NN	O	O
of	IN	O	O
the	DT	O	O
iliac	JJ	O	O
artery	NN	O	O
and	CC	O	O
aorta	NN	O	O
.	.	O	O

Our	PRP$	O	O
results	NNS	O	O
suggest	VBP	O	O
that	IN	O	O
arsenite	NN	O	O
can	MD	O	O
potentiate	VB	O	O
EDHF-type	JJ	O	O
relaxations	NNS	O	O
via	IN	O	O
a	DT	O	O
mechanism	NN	O	O
that	WDT	O	O
is	VBZ	O	O
dependent	JJ	O	O
on	IN	O	O
hydrogen	NN	O	O
peroxide	NN	O	O
,	,	O	O
thus	RB	O	O
demonstrating	VBG	O	O
that	DT	O	O
dismutation	NN	O	O
of	IN	O	O
the	DT	O	O
superoxide	JJ	O	B-PRODUCT-OF
anion	NN	O	O
generated	VBN	O	O
by	IN	O	O
NADPH	NNP	O	B-enzyme
oxidase	NN	O	I-enzyme
can	MD	O	O
potentially	RB	O	O
offset	VB	O	O
loss	NN	O	O
of	IN	O	O
NO	NNP	O	O
bioavailability	NN	O	O
under	IN	O	O
conditions	NNS	O	O
of	IN	O	O
reduced	JJ	O	O
eNOS	JJ	O	O
activity	NN	O	O
.	.	O	O

By	IN	O	O
contrast	NN	O	O
,	,	O	O
selective	JJ	O	O
increases	NNS	O	O
in	IN	O	O
endothelial	JJ	O	O
ROS	NNP	O	O
production	NN	O	O
following	VBG	O	O
exposure	NN	O	O
to	TO	O	O
arsenite	VB	O	O
failed	VBN	O	O
to	TO	O	O
modify	VB	O	O
relaxations	NNS	O	O
mediated	VBN	O	O
by	IN	O	O
endogenous	JJ	O	O
NO	NNP	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Carboxylesterases	NNS	O	B-enzyme
hydrolyze	VBP	O	O
esters	NNS	O	B-SUBSTRATE
,	,	O	O
amides	NNS	O	B-SUBSTRATE
,	,	O	O
and	CC	O	O
thioesters	NNS	O	B-SUBSTRATE
to	TO	O	O
produce	VB	O	O
carboxylic	JJ	O	B-PRODUCT-OF
acids	NNS	O	I-PRODUCT-OF
and	CC	O	O
resulting	VBG	O	O
alcohols	NNS	O	B-PRODUCT-OF
,	,	O	O
amines	NNS	O	B-PRODUCT-OF
,	,	O	O
and	CC	O	O
thiols	NNS	O	B-PRODUCT-OF
,	,	O	O
respectively	RB	O	O
.	.	O	O

Uridine	JJ	O	B-enzyme
5'-diphosphate-	JJ	O	I-enzyme
glucuronosyltransferases	NNS	O	O
are	VBP	O	O
colocalized	VBN	O	O
with	IN	O	O
carboxylesterases	NNS	O	B-enzyme
and	CC	O	O
have	VBP	O	O
the	DT	O	O
potential	NN	O	O
to	TO	O	O
further	JJ	O	O
metabolize	VB	O	O
carboxylic	JJ	O	B-SUBSTRATE
acids	NNS	O	I-SUBSTRATE
to	TO	O	O
acyl	VB	O	B-PRODUCT-OF
glucuronides	NNS	O	I-PRODUCT-OF
,	,	O	O
but	CC	O	O
it	PRP	O	O
is	VBZ	O	O
currently	RB	O	O
unknown	JJ	O	O
if	IN	O	O
acyl	JJ	O	B-PRODUCT-OF
glucuronides	NNS	O	I-PRODUCT-OF
,	,	O	O
being	VBG	O	O
esters	NNS	O	O
,	,	O	O
also	RB	O	O
interact	JJ	O	O
with	IN	O	O
carboxylesterases	NNS	O	O
.	.	O	O

Objective	NN	O	O
:	:	O	O
This	DT	O	O
study	NN	O	O
explores	VBZ	O	O
the	DT	O	O
ability	NN	O	O
of	IN	O	O
acyl	NN	O	B-SUBSTRATE
glucuronides	NNS	O	I-SUBSTRATE
to	TO	O	O
act	VB	O	O
as	IN	O	O
substrates	NNS	O	O
or	CC	O	O
inhibitors	NNS	O	O
of	IN	O	O
human	JJ	O	B-enzyme
carboxylesterases	NNS	O	I-enzyme
1	CD	O	O
(	(	O	O
hCES1	NN	O	B-enzyme
)	)	O	O
and	CC	O	O
2	CD	O	O
(	(	O	O
hCES2	NN	O	B-enzyme
)	)	O	O
.	.	O	O

Methods	NNS	O	O
:	:	O	O
The	DT	O	O
stability	NN	O	O
of	IN	O	O
six	CD	O	O
acyl	NNS	O	B-SUBSTRATE
glucuronides	NNS	O	I-SUBSTRATE
in	IN	O	O
the	DT	O	O
presence	NN	O	O
of	IN	O	O
hCES1	NN	O	B-enzyme
,	,	O	O
hCES2	NN	O	B-enzyme
,	,	O	O
and	CC	O	O
buffer	VB	O	O
alone	RB	O	O
(	(	O	O
100	CD	O	O
mM	NN	O	O
potassium	NN	O	O
phosphate	NN	O	O
,	,	O	O
pH	NN	O	O
7.4	CD	O	O
,	,	O	O
37C	CD	O	O
)	)	O	O
were	VBD	O	O
investigated	VBN	O	O
.	.	O	O

Reversible	JJ	O	O
inhibition	NN	O	O
of	IN	O	O
4-nitrophenyl	JJ	O	O
acetate	JJ	O	O
hydrolysis	NN	O	O
by	IN	O	O
the	DT	O	O
acyl	NN	O	O
glucuronides	NNS	O	O
was	VBD	O	O
also	RB	O	O
studied	VBN	O	O
.	.	O	O

Diclofenac-beta-d-glucuronide	NNP	O	O
was	VBD	O	O
used	VBN	O	O
to	TO	O	O
explore	VB	O	O
potential	JJ	O	O
time-dependent	JJ	O	O
inactivation	NN	O	O
.	.	O	O

Results	NNS	O	O
:	:	O	O
The	DT	O	O
chemical	NN	O	O
stability	NN	O	O
half-life	NN	O	O
values	NNS	O	O
for	IN	O	O
CGP	NNP	O	O
47292-beta-d-glucuronide	JJ	O	O
,	,	O	O
diclofenac-beta-d-glucuronide	JJ	O	O
,	,	O	O
(	(	O	O
R	NNP	O	O
)	)	O	O
-naproxen-beta-d-glucuronide	NN	O	O
,	,	O	O
(	(	O	O
S	NNP	O	O
)	)	O	O
-naproxen-beta-d-glucuronide	NN	O	O
,	,	O	O
ibuprofen-beta-d-glucuronide	JJ	O	O
(	(	O	O
racemic	JJ	O	O
)	)	O	O
,	,	O	O
clopidogrel-beta-d-glucuronide	JJ	O	O
,	,	O	O
and	CC	O	O
valproate-beta-d-glucuronide	NN	O	O
were	VBD	O	O
found	VBN	O	O
to	TO	O	O
be	VB	O	O
0.252	CD	O	O
,	,	O	O
0.537	CD	O	O
,	,	O	O
0.996	CD	O	O
,	,	O	O
1.77	CD	O	O
,	,	O	O
3.67	CD	O	O
,	,	O	O
5.02	CD	O	O
,	,	O	O
and	CC	O	O
15.2	CD	O	O
hours	NNS	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Diclofenac-beta-d-glucuronide	NNP	O	O
,	,	O	O
clopidogrel-beta-d-glucuronide	JJ	O	O
,	,	O	O
ibuprofen-beta-d-glucuronide	JJ	O	O
,	,	O	O
(	(	O	O
R	NNP	O	O
)	)	O	O
-naproxen-beta-d-glucuronide	NN	O	O
,	,	O	O
and	CC	O	O
(	(	O	O
S	NNP	O	O
)	)	O	O
-naproxen-beta-d-glucuronide	VBP	O	O
selectively	RB	O	O
inhibited	VBN	O	O
hCES1	NN	O	O
,	,	O	O
with	IN	O	O
Ki	NNP	O	O
values	NNS	O	O
of	IN	O	O
4.32	CD	O	O
0.47	CD	O	O
,	,	O	O
24.8	CD	O	O
4.2	CD	O	O
,	,	O	O
355	CD	O	O
38	CD	O	O
,	,	O	O
468	CD	O	O
21	CD	O	O
,	,	O	O
707	CD	O	O
64	CD	O	O
M	NN	O	O
,	,	O	O
respectively	RB	O	O
,	,	O	O
but	CC	O	O
did	VBD	O	O
not	RB	O	O
significantly	RB	O	O
inhibit	VB	O	O
hCES2	NN	O	O
.	.	O	O

Valproate-beta-d-glucuronide	NNP	O	O
and	CC	O	O
CGP	NNP	O	O
47292-beta-d-glucuronide	CD	O	O
did	VBD	O	O
not	RB	O	O
inhibit	VB	O	O
either	DT	O	O
hCES	NN	O	O
.	.	O	O

Time-dependent	JJ	O	O
inactivation	NN	O	O
of	IN	O	O
hCES1	NN	O	O
by	IN	O	O
diclofenac-beta-d-glucuronide	NN	O	O
was	VBD	O	O
not	RB	O	O
observed	VBN	O	O
.	.	O	O

Lastly	RB	O	O
,	,	O	O
both	DT	O	O
hCES1	NN	O	O
and	CC	O	O
hCES2	NN	O	O
were	VBD	O	O
shown	VBN	O	O
not	RB	O	O
to	TO	O	O
catalyze	VB	O	O
the	DT	O	O
hydrolysis	NN	O	O
of	IN	O	O
the	DT	O	O
acyl	NN	O	O
glucuronides	NNS	O	O
studied	VBN	O	O
.	.	O	O

Conclusion	NN	O	O
:	:	O	O
Drug-drug	JJ	O	O
interaction	NN	O	O
studies	NNS	O	O
may	MD	O	O
be	VB	O	O
warranted	VBN	O	O
for	IN	O	O
drugs	NNS	O	O
that	WDT	O	O
metabolize	VBP	O	O
to	TO	O	O
acyl	VB	O	O
glucuronides	NNS	O	O
due	JJ	O	O
to	TO	O	O
the	DT	O	O
potential	JJ	O	O
inhibition	NN	O	O
of	IN	O	O
hCESs	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Vascular	JJ	O	O
aging	NN	O	O
is	VBZ	O	O
characterized	VBN	O	O
by	IN	O	O
up-regulation	NN	O	O
of	IN	O	O
NADPH	NNP	O	O
oxidase	NN	O	O
,	,	O	O
oxidative	JJ	O	O
stress	NN	O	O
and	CC	O	O
endothelial	JJ	O	O
dysfunction	NN	O	O
.	.	O	O

Previous	JJ	O	O
studies	NNS	O	O
demonstrate	VBP	O	O
that	IN	O	O
the	DT	O	O
activity	NN	O	O
of	IN	O	O
the	DT	O	O
evolutionarily	RB	O	O
conserved	VBN	O	O
NAD	NNP	O	O
(	(	O	O
+	NNP	O	O
)	)	O	O
-dependent	NN	O	O
deacetylase	NN	O	O
SIRT1	NNP	O	O
declines	VBZ	O	O
with	IN	O	O
age	NN	O	O
and	CC	O	O
that	DT	O	O
pharmacological	JJ	O	O
activators	NNS	O	O
of	IN	O	O
SIRT1	NNP	O	O
confer	NN	O	O
significant	JJ	O	O
anti-aging	JJ	O	O
cardiovascular	JJ	O	O
effects	NNS	O	O
.	.	O	O

To	TO	O	O
determine	VB	O	O
whether	IN	O	O
dysregulation	NN	O	O
of	IN	O	O
SIRT1	NNP	O	O
promotes	NNS	O	O
NADPH	NNP	O	B-enzyme
oxidase-dependent	JJ	O	O
production	NN	O	O
of	IN	O	O
reactive	JJ	O	O
oxygen	NN	O	B-PRODUCT-OF
species	NNS	O	O
(	(	O	O
ROS	NNP	O	O
)	)	O	O
and	CC	O	O
impairs	JJ	O	O
endothelial	JJ	O	O
function	NN	O	O
we	PRP	O	O
assessed	VBD	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
three	CD	O	O
structurally	RB	O	O
different	JJ	O	O
inhibitors	NNS	O	O
of	IN	O	O
SIRT1	NNP	O	O
(	(	O	O
nicotinamide	RB	O	O
,	,	O	O
sirtinol	NN	O	O
,	,	O	O
EX527	NNP	O	O
)	)	O	O
in	IN	O	O
aorta	JJ	O	O
segments	NNS	O	O
isolated	VBN	O	O
from	IN	O	O
young	JJ	O	O
Wistar	NNP	O	O
rats	NNS	O	O
.	.	O	O

Inhibition	NN	O	O
of	IN	O	O
SIRT1	NNP	O	O
induced	VBD	O	O
endothelial	JJ	O	O
dysfunction	NN	O	O
,	,	O	O
as	IN	O	O
shown	VBN	O	O
by	IN	O	O
the	DT	O	O
significantly	RB	O	O
reduced	VBN	O	O
relaxation	NN	O	O
to	TO	O	O
the	DT	O	O
endothelium-dependent	JJ	O	O
vasodilators	NNS	O	O
acetylcholine	NN	O	O
and	CC	O	O
the	DT	O	O
calcium	NN	O	O
ionophore	NN	O	O
A23187	NNP	O	O
.	.	O	O

Endothelial	JJ	O	O
dysfunction	NN	O	O
induced	VBN	O	O
by	IN	O	O
SIRT1	NNP	O	O
inhibition	NN	O	O
was	VBD	O	O
prevented	VBN	O	O
by	IN	O	O
treatment	NN	O	O
of	IN	O	O
the	DT	O	O
vessels	NNS	O	O
with	IN	O	O
the	DT	O	O
NADPH	NNP	O	O
oxidase	NN	O	O
inhibitor	NN	O	O
apocynin	NN	O	O
or	CC	O	O
superoxide	JJ	O	O
dismutase	NN	O	O
.	.	O	O

Inhibition	NN	O	O
of	IN	O	O
SIRT1	NNP	O	B-enzyme
significantly	RB	O	O
increased	VBD	O	O
vascular	JJ	O	O
superoxide	NN	O	B-PRODUCT-OF
production	NN	O	O
,	,	O	O
enhanced	VBD	O	O
NADPH	NNP	O	O
oxidase	NN	O	O
activity	NN	O	O
,	,	O	O
and	CC	O	O
mRNA	JJ	O	O
expression	NN	O	O
of	IN	O	O
its	PRP$	O	O
subunits	NNS	O	O
p22	NN	O	O
(	(	O	O
phox	NN	O	O
)	)	O	O
and	CC	O	O
NOX4	NNP	O	O
,	,	O	O
which	WDT	O	O
were	VBD	O	O
prevented	VBN	O	O
by	IN	O	O
resveratrol	NN	O	O
.	.	O	O

Peroxisome	JJ	O	O
proliferator-activated	JJ	O	O
receptor-alpha	NN	O	O
(	(	O	O
PPARalpha	NNP	O	O
)	)	O	O
activation	NN	O	O
mimicked	VBD	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
resveratrol	NN	O	O
while	IN	O	O
PPARalpha	NNP	O	O
inhibition	NN	O	O
prevented	VBD	O	O
the	DT	O	O
effects	NNS	O	O
of	IN	O	O
this	DT	O	O
SIRT1	NNP	O	O
activator	NN	O	O
.	.	O	O

SIRT1	NNP	O	O
co-precipitated	JJ	O	O
with	IN	O	O
PPARalpha	NNP	O	O
and	CC	O	O
nicotinamide	RB	O	O
increased	VBD	O	O
the	DT	O	O
acetylation	NN	O	O
of	IN	O	O
the	DT	O	O
PPARalpha	NNP	O	O
coactivator	NN	O	O
PGC-1alpha	NNP	O	O
,	,	O	O
which	WDT	O	O
was	VBD	O	O
suppressed	VBN	O	O
by	IN	O	O
resveratrol	NN	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
impaired	JJ	O	O
activity	NN	O	O
of	IN	O	O
SIRT1	NNP	O	O
induces	NNS	O	O
endothelial	JJ	O	O
dysfunction	NN	O	O
and	CC	O	O
up-regulates	JJ	O	O
NADPH	NNP	O	O
oxidase-derived	JJ	O	O
ROS	NNP	O	O
production	NN	O	O
in	IN	O	O
the	DT	O	O
vascular	NN	O	O
wall	NN	O	O
,	,	O	O
mimicking	VBG	O	O
the	DT	O	O
vascular	JJ	O	O
aging	VBG	O	O
phenotype	NN	O	O
.	.	O	O

Moreover	RB	O	O
,	,	O	O
a	DT	O	O
new	JJ	O	O
mechanism	NN	O	O
for	IN	O	O
controlling	VBG	O	O
endothelial	JJ	O	O
function	NN	O	O
after	IN	O	O
SIRT1	NNP	O	O
activation	NN	O	O
involves	VBZ	O	O
a	DT	O	O
decreased	JJ	O	O
PGC-1alpha	JJ	O	O
acetylation	NN	O	O
and	CC	O	O
the	DT	O	O
subsequent	JJ	O	O
PPARalpha	NNP	O	O
activation	NN	O	O
,	,	O	O
resulting	VBG	O	O
in	IN	O	O
both	DT	O	O
decreased	JJ	O	O
NADPH	NNP	O	O
oxidase-driven	JJ	O	O
ROS	NNP	O	O
production	NN	O	O
and	CC	O	O
NO	DT	O	O
inactivation	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

The	DT	O	O
mechanisms	NN	O	O
of	IN	O	O
progression	NN	O	O
from	IN	O	O
Barrett	NNP	O	O
's	POS	O	O
esophagus	NN	O	O
(	(	O	O
BE	NNP	O	O
)	)	O	O
to	TO	O	O
esophageal	VB	O	O
adenocarcinoma	NN	O	O
(	(	O	O
EA	NNP	O	O
)	)	O	O
are	VBP	O	O
not	RB	O	O
known	VBN	O	O
.	.	O	O

Cycloxygenase-2	NNP	O	B-enzyme
(	(	O	O
COX-2	NNP	O	B-enzyme
)	)	O	O
-derived	VBD	O	O
prostaglandin	JJ	O	B-PRODUCT-OF
E2	NNP	O	I-PRODUCT-OF
(	(	O	O
PGE2	NNP	O	B-PRODUCT-OF
)	)	O	O
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
be	VB	O	O
important	JJ	O	O
in	IN	O	O
esophageal	JJ	O	O
tumorigenesis	NN	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
shown	VBN	O	O
that	IN	O	O
COX-2	NNP	O	B-enzyme
mediates	VBZ	O	O
acid-induced	JJ	O	O
PGE2	NNP	O	B-PRODUCT-OF
production	NN	O	O
.	.	O	O

The	DT	O	O
prostaglandin	NN	O	O
E	NNP	O	O
synthase	NN	O	O
(	(	O	O
PGES	NNP	O	O
)	)	O	O
responsible	JJ	O	O
for	IN	O	O
acid-induced	JJ	O	O
PGE2	NNP	O	O
production	NN	O	O
in	IN	O	O
BE	NNP	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
is	VBZ	O	O
not	RB	O	O
known	VBN	O	O
.	.	O	O

We	PRP	O	O
found	VBD	O	O
that	IN	O	O
microsomal	JJ	O	O
PGES1	NNP	O	O
(	(	O	O
mPGES1	NN	O	O
)	)	O	O
,	,	O	O
mPGES2	UH	O	O
,	,	O	O
and	CC	O	O
cytosolic	JJ	O	O
PGES	NNP	O	O
(	(	O	O
cPGES	NN	O	O
)	)	O	O
were	VBD	O	O
present	JJ	O	O
in	IN	O	O
FLO	NNP	O	O
EA	NNP	O	O
cells	NNS	O	O
.	.	O	O

Pulsed	VBN	O	O
acid	JJ	O	O
treatment	NN	O	O
significantly	RB	O	O
increased	VBD	O	O
mPGES1	JJ	O	O
mRNA	NN	O	O
and	CC	O	O
protein	NN	O	O
levels	NNS	O	O
but	CC	O	O
had	VBD	O	O
little	JJ	O	O
or	CC	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
mPGES2	NN	O	O
or	CC	O	O
cPGES	NN	O	O
mRNA	NN	O	O
.	.	O	O

Knockdown	NNP	O	O
of	IN	O	O
mPGES1	NN	O	O
by	IN	O	O
mPGES1	NN	O	O
small	JJ	O	O
interfering	NN	O	O
RNA	NNP	O	O
(	(	O	O
siRNA	NN	O	O
)	)	O	O
blocked	VBD	O	O
acid-induced	JJ	O	O
increase	NN	O	O
in	IN	O	O
PGE2	NNP	O	O
production	NN	O	O
and	CC	O	O
thymidine	JJ	O	O
incorporation	NN	O	O
.	.	O	O

Knockdown	NNP	O	O
of	IN	O	O
NADPH	NNP	O	O
oxidase	NN	O	O
,	,	O	O
NOX5-S	NNP	O	O
,	,	O	O
a	DT	O	O
variant	JJ	O	O
lacking	VBG	O	O
calcium-binding	NN	O	O
domains	NNS	O	O
,	,	O	O
by	IN	O	O
NOX5	NNP	O	O
siRNA	NN	O	O
significantly	RB	O	O
inhibited	VBD	O	O
acid-induced	JJ	O	O
increase	NN	O	O
in	IN	O	O
mPGES1	JJ	O	O
expression	NN	O	O
,	,	O	O
thymidine	JJ	O	O
incorporation	NN	O	O
,	,	O	O
and	CC	O	O
PGE2	NNP	O	O
production	NN	O	O
.	.	O	O

Overexpression	NN	O	O
of	IN	O	O
NOX5-S	NNP	O	O
significantly	RB	O	O
increased	VBD	O	O
the	DT	O	O
luciferase	NN	O	O
activity	NN	O	O
in	IN	O	O
FLO	NNP	O	O
cells	NNS	O	O
transfected	VBN	O	O
with	IN	O	O
a	DT	O	O
nuclear	JJ	O	O
factor	NN	O	O
kappaB	NNP	O	O
(	(	O	O
NF-kappaB	NNP	O	O
)	)	O	O
in	IN	O	O
vivo	NN	O	O
activation	NN	O	O
reporter	NN	O	O
plasmid	JJ	O	O
pNF-kappaB-Luc	NN	O	O
.	.	O	O

Knockdown	NNP	O	O
of	IN	O	O
NF-kappaB1	NNP	O	O
p50	NN	O	O
by	IN	O	O
p50	NN	O	O
siRNA	NN	O	O
significantly	RB	O	O
decreased	VBD	O	O
acid-induced	JJ	O	O
increase	NN	O	O
in	IN	O	O
mPGES1	JJ	O	O
expression	NN	O	O
,	,	O	O
thymidine	JJ	O	O
incorporation	NN	O	O
,	,	O	O
and	CC	O	O
PGE2	NNP	O	O
production	NN	O	O
.	.	O	O

Two	CD	O	O
novel	JJ	O	O
NF-kappaB	JJ	O	O
binding	NN	O	O
elements	NNS	O	O
,	,	O	O
GGAGTCTCCC	NNP	O	O
and	CC	O	O
CGGGACACCC	NNP	O	O
,	,	O	O
were	VBD	O	O
identified	VBN	O	O
in	IN	O	O
the	DT	O	O
mPGES1	NN	O	O
gene	NN	O	O
promoter	NN	O	O
.	.	O	O

We	PRP	O	O
conclude	VBP	O	O
that	IN	O	O
mPGES1	NN	O	B-enzyme
mediates	VBZ	O	O
acid-induced	JJ	O	O
increase	NN	O	O
in	IN	O	O
PGE2	NNP	O	B-PRODUCT-OF
production	NN	O	O
and	CC	O	O
cell	NN	O	O
proliferation	NN	O	O
.	.	O	O

Acid-induced	JJ	O	O
mPGES1	NN	O	O
expression	NN	O	O
depends	VBZ	O	O
on	IN	O	O
activation	NN	O	O
of	IN	O	O
NOX5-S	NNP	O	O
and	CC	O	O
NF-kappaB1	NNP	O	O
p50	NN	O	O
.	.	O	O

Microsomal	NNP	O	O
PGES1	NNP	O	O
may	MD	O	O
be	VB	O	O
a	DT	O	O
potential	JJ	O	O
target	NN	O	O
to	TO	O	O
prevent	VB	O	O
or	CC	O	O
treat	VB	O	O
EA	NNP	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Baicalin	NNP	O	O
has	VBZ	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
possess	VB	O	O
many	JJ	O	O
pharmacological	JJ	O	O
effects	NNS	O	O
,	,	O	O
including	VBG	O	O
antiviral	JJ	O	O
,	,	O	O
antioxidant	JJ	O	O
,	,	O	O
anti-cancer	JJ	O	O
and	CC	O	O
anti-inflammatory	JJ	O	O
properties	NNS	O	O
.	.	O	O

In	IN	O	O
the	DT	O	O
current	JJ	O	O
study	NN	O	O
,	,	O	O
we	PRP	O	O
reveal	VBP	O	O
the	DT	O	O
inhibitory	JJ	O	O
effects	NNS	O	O
of	IN	O	O
baicalin	NN	O	O
on	IN	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
dextromethorphan	NN	O	B-SUBSTRATE
(	(	O	O
DXM	NNP	O	B-SUBSTRATE
)	)	O	O
,	,	O	O
a	DT	O	O
dual	JJ	O	O
probe	NN	O	O
substrate	NN	O	O
of	IN	O	O
CYP2D	NNP	O	B-enzyme
and	CC	O	O
CYP3A	NNP	O	B-enzyme
,	,	O	O
in	IN	O	O
rats	NNS	O	O
.	.	O	O

Lineweaver-Burk	JJ	O	O
plots	NNS	O	O
demonstrated	VBD	O	O
that	IN	O	O
baicalin	NN	O	O
inhibited	VBD	O	O
the	DT	O	O
activities	NNS	O	O
of	IN	O	O
CYP2D	NNP	O	O
and	CC	O	O
CYP3A	NNP	O	O
in	IN	O	O
a	DT	O	O
non-competitive	JJ	O	O
manner	NN	O	O
in	IN	O	O
rat	NN	O	O
liver	NN	O	O
microsomes	NNS	O	O
(	(	O	O
RLMs	NNP	O	O
)	)	O	O
.	.	O	O

Concomitant	JJ	O	O
administration	NN	O	O
of	IN	O	O
baicalin	NN	O	O
(	(	O	O
0.90g/kg	CD	O	O
,	,	O	O
i.v	NN	O	O
.	.	O	O
)	)	O	O

and	CC	O	O
DXM	NNP	O	O
(	(	O	O
10mg/kg	CD	O	O
,	,	O	O
i.v	NN	O	O
.	.	O	O
)	)	O	O

increased	VBD	O	O
the	DT	O	O
maximum	JJ	O	O
drug	NN	O	O
concentration	NN	O	O
(	(	O	O
Cmax	NNP	O	O
)	)	O	O
(	(	O	O
37	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
the	DT	O	O
area	NN	O	O
under	IN	O	O
concentration-time	JJ	O	O
curve	NN	O	O
(	(	O	O
AUC	NNP	O	O
)	)	O	O
(	(	O	O
42	CD	O	O
%	NN	O	O
)	)	O	O
and	CC	O	O
decreased	VBD	O	O
the	DT	O	O
clearance	NN	O	O
(	(	O	O
CL	NNP	O	O
)	)	O	O
(	(	O	O
27	CD	O	O
%	NN	O	O
)	)	O	O
of	IN	O	O
DXM	NNP	O	O
in	IN	O	O
a	DT	O	O
randomised	JJ	O	O
,	,	O	O
crossover	NN	O	O
study	NN	O	O
in	IN	O	O
rats	NNS	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.01	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
change	NN	O	O
in	IN	O	O
the	DT	O	O
AUC	NNP	O	O
of	IN	O	O
DXM	NNP	O	O
was	VBD	O	O
significantly	RB	O	O
correlated	VBN	O	O
with	IN	O	O
the	DT	O	O
Cmax	NNP	O	O
and	CC	O	O
AUC	NNP	O	O
of	IN	O	O
baicalin	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
inhibitory	JJ	O	O
effects	NNS	O	O
of	IN	O	O
multiple	JJ	O	O
doses	NNS	O	O
of	IN	O	O
baicalin	NN	O	O
(	(	O	O
0.90g/kg	CD	O	O
,	,	O	O
i.v.	NN	O	O
,	,	O	O
12days	CD	O	O
)	)	O	O
on	IN	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
DXM	NNP	O	O
were	VBD	O	O
similar	JJ	O	O
to	TO	O	O
those	DT	O	O
observed	VBN	O	O
following	VBG	O	O
a	DT	O	O
single	JJ	O	O
dose	NN	O	O
in	IN	O	O
rats	NNS	O	O
.	.	O	O

The	DT	O	O
activity	NN	O	O
of	IN	O	O
CYP3A	NNP	O	O
in	IN	O	O
excised	JJ	O	O
liver	NN	O	O
samples	NNS	O	O
from	IN	O	O
rats	NNS	O	O
following	VBG	O	O
multiple	JJ	O	O
baicalin	JJ	O	O
treatment	NN	O	O
was	VBD	O	O
significantly	RB	O	O
decreased	VBN	O	O
compared	VBN	O	O
to	TO	O	O
that	DT	O	O
of	IN	O	O
the	DT	O	O
control	NN	O	O
group	NN	O	O
(	(	O	O
P	NNP	O	O
<	NNP	O	O
0.05	CD	O	O
)	)	O	O
,	,	O	O
whereas	JJ	O	O
multiple	JJ	O	O
doses	NNS	O	O
of	IN	O	O
baicalin	NN	O	O
had	VBD	O	O
no	DT	O	O
obvious	JJ	O	O
effect	NN	O	O
on	IN	O	O
the	DT	O	O
activity	NN	O	O
of	IN	O	O
CYP2D	NNP	O	O
.	.	O	O

Taken	VBN	O	O
together	RB	O	O
,	,	O	O
these	DT	O	O
data	NNS	O	O
demonstrate	NN	O	O
that	IN	O	O
baicalin	NN	O	O
inhibits	VBZ	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
DXM	NNP	O	B-SUBSTRATE
in	IN	O	O
a	DT	O	O
concentration-dependent	JJ	O	O
manner	NN	O	O
in	IN	O	O
rats	NNS	O	O
,	,	O	O
possibly	RB	O	O
through	IN	O	O
inhibiting	VBG	O	O
hepatic	JJ	O	O
CYP2D	NNP	O	B-enzyme
and	CC	O	O
CYP3A	NNP	O	B-enzyme
activities	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Oxysterols	NNS	O	O
have	VBP	O	O
been	VBN	O	O
shown	VBN	O	O
to	TO	O	O
interfere	VB	O	O
with	IN	O	O
proliferation	NN	O	O
and	CC	O	O
cause	VB	O	O
the	DT	O	O
death	NN	O	O
of	IN	O	O
many	JJ	O	O
cancer	NN	O	O
cell	NN	O	O
types	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
leukaemia	NN	O	O
,	,	O	O
glioblastoma	NN	O	O
,	,	O	O
colon	NN	O	O
,	,	O	O
breast	NN	O	O
and	CC	O	O
prostate	NN	O	O
cancer	NN	O	O
cells	NNS	O	O
,	,	O	O
while	IN	O	O
they	PRP	O	O
have	VBP	O	O
little	JJ	O	O
or	CC	O	O
no	DT	O	O
effect	NN	O	O
on	IN	O	O
senescent	NN	O	O
cells	NNS	O	O
.	.	O	O

The	DT	O	O
mechanisms	NN	O	O
by	IN	O	O
which	WDT	O	O
oxysterols	NNS	O	O
may	MD	O	O
influence	VB	O	O
proliferation	NN	O	O
are	VBP	O	O
manifold	VBN	O	O
:	:	O	O
they	PRP	O	O
control	VBP	O	O
the	DT	O	O
transcription	NN	O	O
and	CC	O	O
the	DT	O	O
turnover	NN	O	O
of	IN	O	O
the	DT	O	O
key	JJ	O	O
enzyme	NN	O	O
in	IN	O	O
cholesterol	NN	O	O
synthesis	NN	O	O
,	,	O	O
3-hydroxy-3-methylglutaryl	JJ	O	O
CoA	NNP	O	O
reductase	NN	O	O
,	,	O	O
by	IN	O	O
binding	VBG	O	O
to	TO	O	O
Insig-1	NNP	O	O
,	,	O	O
Insig-2	NNP	O	O
and	CC	O	O
liver	RB	O	O
X	NNP	O	O
receptors	NNS	O	O
.	.	O	O

Oxysterols	NNS	O	O
are	VBP	O	O
thought	VBN	O	O
to	TO	O	O
be	VB	O	O
generated	VBN	O	O
in	IN	O	O
proportion	NN	O	O
to	TO	O	O
the	DT	O	O
rate	NN	O	O
of	IN	O	O
cholesterol	NN	O	O
synthesis	NN	O	O
.	.	O	O

Although	IN	O	O
there	EX	O	O
is	VBZ	O	O
no	DT	O	O
consensus	NN	O	O
about	IN	O	O
the	DT	O	O
mechanism	NN	O	O
by	IN	O	O
which	WDT	O	O
these	DT	O	O
oxysterols	NNS	O	O
are	VBP	O	O
generated	VBN	O	O
in	IN	O	O
vivo	NN	O	O
,	,	O	O
it	PRP	O	O
clearly	RB	O	O
has	VBZ	O	O
to	TO	O	O
be	VB	O	O
ubiquitous	JJ	O	O
.	.	O	O

The	DT	O	O
25-	JJ	O	O
and	CC	O	O
the	DT	O	O
27-cholesterol	JJ	O	O
hydroxylases	NNS	O	O
,	,	O	O
present	NN	O	O
in	IN	O	O
almost	RB	O	O
all	DT	O	O
tissues	NNS	O	O
,	,	O	O
are	VBP	O	O
possible	JJ	O	O
candidates	NNS	O	O
.	.	O	O

Cholesterol	NNP	O	B-SUBSTRATE
uptake	VBP	O	O
from	IN	O	O
lipoproteins	NNS	O	B-enzyme
,	,	O	O
intracellular	JJ	O	O
vesicle	NN	O	O
transport	NN	O	O
and	CC	O	O
lipid	JJ	O	O
transfer	NN	O	O
are	VBP	O	O
also	RB	O	O
modified	VBN	O	O
by	IN	O	O
oxysterols	NNS	O	O
.	.	O	O

Oxysterols	NNS	O	O
interfere	RB	O	O
with	IN	O	O
ERK	NNP	O	O
,	,	O	O
hedgehog	NN	O	O
and	CC	O	O
wnt	JJ	O	O
pathways	NNS	O	O
of	IN	O	O
proliferation	NN	O	O
and	CC	O	O
differentiation	NN	O	O
.	.	O	O

When	WRB	O	O
administered	VBN	O	O
in	IN	O	O
vitro	NN	O	O
to	TO	O	O
cancer	NN	O	O
cell	NN	O	O
lines	NNS	O	O
,	,	O	O
oxysterols	VBZ	O	O
invariably	RB	O	O
both	DT	O	O
slow	JJ	O	O
down	RP	O	O
proliferation	NN	O	O
and	CC	O	O
provoke	NN	O	O
cell	NN	O	O
death	NN	O	O
.	.	O	O

Perhaps	RB	O	O
is	VBZ	O	O
it	PRP	O	O
sufficient	JJ	O	O
to	TO	O	O
stop	VB	O	O
proliferation	NN	O	O
of	IN	O	O
a	DT	O	O
cancer	NN	O	O
to	TO	O	O
provoke	VB	O	O
its	PRP$	O	O
eradication	NN	O	O
.	.	O	O

Therefore	RB	O	O
,	,	O	O
the	DT	O	O
two	CD	O	O
facets	NNS	O	O
of	IN	O	O
oxysterol	JJ	O	O
action	NN	O	O
that	WDT	O	O
seem	VBP	O	O
important	JJ	O	O
for	IN	O	O
cancer	NN	O	O
treatment	NN	O	O
,	,	O	O
cytostaticity	NN	O	O
and	CC	O	O
cytotoxicity	NN	O	O
,	,	O	O
will	MD	O	O
be	VB	O	O
discussed	VBN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Multidrug	NNP	O	O
resistance	NN	O	O
proteins	NNS	O	O
(	(	O	O
MRPs	NNP	O	O
)	)	O	O
mediate	VBP	O	O
the	DT	O	O
ATP-dependent	JJ	O	O
efflux	NN	O	O
of	IN	O	O
structurally	RB	O	O
diverse	JJ	O	O
compounds	NNS	O	O
,	,	O	O
including	VBG	O	O
anticancer	NN	O	O
drugs	NNS	O	O
and	CC	O	O
physiological	JJ	O	O
organic	JJ	O	O
anions	NNS	O	O
.	.	O	O

Five	CD	O	O
classes	NNS	O	O
of	IN	O	O
chalcogenopyrylium	JJ	O	O
dyes	NNS	O	O
(	(	O	O
CGPs	NNP	O	O
)	)	O	O
were	VBD	O	O
examined	VBN	O	O
for	IN	O	O
their	PRP$	O	O
ability	NN	O	O
to	TO	O	O
modulate	VB	O	O
transport	NN	O	O
of	IN	O	O
[	NNP	O	B-SUBSTRATE
(	(	O	O
3	CD	O	O
)	)	O	O
H	NNP	O	O
]	NNP	O	O
estradiol	FW	O	O
glucuronide	NN	O	I-SUBSTRATE
(	(	O	O
E217betaG	NNP	O	B-SUBSTRATE
)	)	O	O
(	(	O	O
a	DT	O	O
prototypical	JJ	O	O
MRP	NNP	O	B-enzyme
substrate	NN	O	O
)	)	O	O
into	IN	O	O
MRP-enriched	JJ	O	O
inside-out	JJ	O	O
membrane	NN	O	O
vesicles	NNS	O	O
.	.	O	O

Additionally	RB	O	O
,	,	O	O
some	DT	O	O
CGPs	NNP	O	O
were	VBD	O	O
tested	VBN	O	O
in	IN	O	O
intact	JJ	O	O
transfected	JJ	O	O
cells	NNS	O	O
using	VBG	O	O
a	DT	O	O
calcein	NN	O	O
efflux	NN	O	O
assay	NN	O	O
.	.	O	O

Sixteen	NNP	O	O
of	IN	O	O
34	CD	O	O
CGPs	NNP	O	O
inhibited	VBD	O	O
MRP1-mediated	NNP	O	O
E217betaG	NNP	O	B-SUBSTRATE
uptake	NN	O	O
by	IN	O	O
>	$	O	O
50	CD	O	O
%	NN	O	O
(	(	O	O
IC50	NNP	O	O
's	POS	O	O
0.7-7.6	JJ	O	O
muM	NN	O	O
)	)	O	O
.	.	O	O

Of	IN	O	O
9	CD	O	O
CGPs	NNP	O	O
with	IN	O	O
IC50	NNP	O	O
's	POS	O	O
2	NNP	O	O
muM	NNP	O	O
,	,	O	O
two	CD	O	O
belonged	VBD	O	O
to	TO	O	O
Class	NNP	O	O
I	PRP	O	O
,	,	O	O
two	CD	O	O
to	TO	O	O
Class	NNP	O	O
III	NNP	O	O
and	CC	O	O
five	CD	O	O
to	TO	O	O
Class	NNP	O	O
V.	NNP	O	O
When	WRB	O	O
tested	VBN	O	O
in	IN	O	O
the	DT	O	O
intact	JJ	O	O
cells	NNS	O	O
,	,	O	O
only	RB	O	O
4	CD	O	O
of	IN	O	O
16	CD	O	O
CGPs	NNP	O	O
(	(	O	O
at	IN	O	O
10	CD	O	O
muM	NN	O	O
)	)	O	O
inhibited	VBD	O	O
MRP1-mediated	JJ	O	O
calcein	NN	O	B-SUBSTRATE
efflux	NN	O	O
by	IN	O	O
>	$	O	O
50	CD	O	O
%	NN	O	O
(	(	O	O
III-1	NNP	O	O
,	,	O	O
V-3	NNP	O	O
,	,	O	O
-4	NNP	O	O
,	,	O	O
-6	NNP	O	O
)	)	O	O
while	IN	O	O
a	DT	O	O
fifth	JJ	O	O
(	(	O	O
I-5	NNP	O	O
)	)	O	O
inhibited	VBD	O	O
efflux	JJ	O	O
by	IN	O	O
just	RB	O	O
23	CD	O	O
%	NN	O	O
.	.	O	O

These	DT	O	O
five	CD	O	O
CGPs	NNP	O	O
also	RB	O	O
inhibited	VBD	O	O
[	NNP	O	B-SUBSTRATE
(	(	O	O
3	CD	O	O
)	)	O	O
H	NNP	O	O
]	NNP	O	O
E217betaG	NNP	O	O
uptake	NN	O	O
by	IN	O	O
MRP4	NNP	O	B-enzyme
.	.	O	O

In	IN	O	O
contrast	NN	O	O
,	,	O	O
their	PRP$	O	O
effects	NNS	O	O
on	IN	O	O
MRP2	NNP	O	O
varied	VBD	O	O
with	IN	O	O
two	CD	O	O
(	(	O	O
V-4	NNP	O	O
,	,	O	O
V-6	NNP	O	O
)	)	O	O
inhibiting	VBG	O	O
E217betaG	NNP	O	O
transport	NN	O	O
(	(	O	O
IC50	NNP	O	O
's	POS	O	O
2.0	CD	O	O
,	,	O	O
9.2	CD	O	O
muM	NN	O	O
)	)	O	O
,	,	O	O
two	CD	O	O
(	(	O	O
V-3	NNP	O	O
,	,	O	O
III-1	NNP	O	O
)	)	O	O
stimulating	VBG	O	O
transport	NN	O	O
(	(	O	O
>	JJ	O	O
2-fold	JJ	O	O
)	)	O	O
,	,	O	O
while	IN	O	O
CGP	NNP	O	O
I-5	NNP	O	O
had	VBD	O	O
no	DT	O	O
effect	NN	O	O
.	.	O	O

Strikingly	RB	O	O
,	,	O	O
although	IN	O	O
V-3	NNP	O	O
and	CC	O	O
V-4	NNP	O	O
had	VBD	O	O
opposite	JJ	O	O
effects	NNS	O	O
on	IN	O	O
MRP2	NNP	O	O
activity	NN	O	O
,	,	O	O
they	PRP	O	O
are	VBP	O	O
structurally	RB	O	O
identical	JJ	O	O
except	IN	O	O
for	IN	O	O
their	PRP$	O	O
chalcogen	NN	O	O
atom	NN	O	O
(	(	O	O
Se	NNP	O	O
versus	NNP	O	O
Te	NNP	O	O
)	)	O	O
.	.	O	O

This	DT	O	O
study	NN	O	O
is	VBZ	O	O
the	DT	O	O
first	JJ	O	O
to	TO	O	O
identify	VB	O	O
Class	NNP	O	O
V	NNP	O	O
CGPs	NNP	O	O
with	IN	O	O
their	PRP$	O	O
distinctive	JJ	O	O
methine	NN	O	O
or	CC	O	O
trimethine	JJ	O	O
linkage	NN	O	O
between	IN	O	O
two	CD	O	O
disubstituted	VBD	O	O
pyrylium	NN	O	O
moieties	NNS	O	O
as	IN	O	O
a	DT	O	O
particularly	RB	O	O
potent	JJ	O	O
class	NN	O	O
of	IN	O	O
MRP	NNP	O	O
modulators	NNS	O	O
and	CC	O	O
also	RB	O	O
show	VBP	O	O
that	IN	O	O
within	IN	O	O
this	DT	O	O
core	NN	O	O
structure	NN	O	O
,	,	O	O
differences	NNS	O	O
in	IN	O	O
the	DT	O	O
electronegativity	NN	O	O
associated	VBN	O	O
with	IN	O	O
a	DT	O	O
chalcogen	NN	O	O
atom	NN	O	O
can	MD	O	O
be	VB	O	O
the	DT	O	O
sole	JJ	O	O
determinant	NN	O	O
of	IN	O	O
whether	IN	O	O
a	DT	O	O
compound	NN	O	O
will	MD	O	O
stimulate	VB	O	O
or	CC	O	O
inhibit	VB	O	O
MRP2	NNP	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Explicit	NNP	O	O
data	NNS	O	O
regarding	VBG	O	O
the	DT	O	O
changes	NNS	O	O
in	IN	O	O
adrenocortical	JJ	O	O
reserves	NNS	O	O
during	IN	O	O
hyperthyroidism	NN	O	O
do	VBP	O	O
not	RB	O	O
exist	VB	O	O
.	.	O	O

We	PRP	O	O
aimed	VBD	O	O
to	TO	O	O
document	VB	O	O
the	DT	O	O
capability	NN	O	O
(	(	O	O
response	NN	O	O
)	)	O	O
of	IN	O	O
adrenal	JJ	O	O
gland	NN	O	O
to	TO	O	O
secrete	VB	O	O
cortisol	NN	O	O
and	CC	O	O
DHEA-S	NNP	O	O
during	IN	O	O
hyperthyroidism	NN	O	O
compared	VBN	O	O
to	TO	O	O
euthyroidism	VB	O	O
,	,	O	O
and	CC	O	O
to	TO	O	O
describe	VB	O	O
factors	NNS	O	O
associated	VBN	O	O
with	IN	O	O
these	DT	O	O
responses	NNS	O	O
.	.	O	O

A	DT	O	O
standard-dose	JJ	O	O
(	(	O	O
0.25	CD	O	O
mg/i.v	NN	O	O
.	.	O	O
)	)	O	O

ACTH	NNP	O	O
stimulation	NN	O	O
test	NN	O	O
was	VBD	O	O
performed	VBN	O	O
to	TO	O	O
the	DT	O	O
same	JJ	O	O
patients	NNS	O	O
before	IN	O	O
hyperthyroidism	NN	O	O
treatment	NN	O	O
,	,	O	O
and	CC	O	O
after	IN	O	O
attainment	NN	O	O
of	IN	O	O
euthyroidism	NN	O	O
.	.	O	O

Baseline	NNP	O	O
cortisol	NN	O	O
(	(	O	O
Cor0	NNP	O	O
)	)	O	O
,	,	O	O
DHEA-S	NNP	O	O
(	(	O	O
DHEA-S0	NNP	O	O
)	)	O	O
,	,	O	O
cortisol	JJ	O	O
binding	NN	O	O
globulin	NN	O	O
(	(	O	O
CBG	NNP	O	O
)	)	O	O
,	,	O	O
ACTH	NNP	O	O
,	,	O	O
calculated	VBD	O	O
free	JJ	O	O
cortisol	NN	O	O
(	(	O	O
by	IN	O	O
Coolen	NNP	O	O
's	POS	O	O
equation	NN	O	O
=	NNP	O	O
CFC	NNP	O	O
)	)	O	O
,	,	O	O
free	JJ	O	O
cortisol	NN	O	O
index	NN	O	O
(	(	O	O
FCI	NNP	O	O
)	)	O	O
,	,	O	O
60-min	JJ	O	O
cortisol	NN	O	O
(	(	O	O
Cor60	NNP	O	O
)	)	O	O
,	,	O	O
and	CC	O	O
DHEA-S	NNP	O	O
(	(	O	O
DHEA-S60	NNP	O	O
)	)	O	O
,	,	O	O
delta	JJ	O	O
cortisol	NN	O	O
(	(	O	O
DeltaCor	NNP	O	O
)	)	O	O
,	,	O	O
delta	JJ	O	O
DHEA-S	NNP	O	O
(	(	O	O
DeltaDHEA-S	JJ	O	O
)	)	O	O
responses	NNS	O	O
were	VBD	O	O
evaluated	VBN	O	O
.	.	O	O

Forty-one	CD	O	O
patients	NNS	O	O
[	JJ	O	O
22	CD	O	O
females	NNS	O	O
,	,	O	O
49.5	CD	O	O
15.2	CD	O	O
years	NNS	O	O
old	JJ	O	O
,	,	O	O
32	CD	O	O
Graves	NNS	O	O
disease	NN	O	O
,	,	O	O
nine	CD	O	O
toxic	NN	O	O
nodular	JJ	O	O
goiter	NN	O	O
]	NN	O	O
had	VBD	O	O
similar	JJ	O	O
Cor0	NNP	O	O
,	,	O	O
DHEA-S0	NNP	O	O
,	,	O	O
CFC	NNP	O	O
,	,	O	O
FCI	NNP	O	O
,	,	O	O
and	CC	O	O
DHEA-S60	NNP	O	O
in	IN	O	O
hyperthyroid	NN	O	O
and	CC	O	O
euthyroid	JJ	O	O
states	NNS	O	O
.	.	O	O

Cor60	NNP	O	O
,	,	O	O
DeltaCor	NNP	O	O
,	,	O	O
and	CC	O	O
DeltaDHEA-S	NNS	O	O
were	VBD	O	O
lower	JJR	O	O
in	IN	O	O
hyperthyroidism	NN	O	O
.	.	O	O

In	IN	O	O
four	CD	O	O
(	(	O	O
10	CD	O	O
%	NN	O	O
)	)	O	O
patients	NNS	O	O
the	DT	O	O
peak	JJ	O	O
ACTH-stimulated	JJ	O	O
cortisol	NN	O	B-PRODUCT-OF
values	NNS	O	O
were	VBD	O	O
lower	JJR	O	O
than	IN	O	O
18	CD	O	O
mug/dL	NN	O	O
.	.	O	O

When	WRB	O	O
the	DT	O	O
test	NN	O	O
repeated	VBD	O	O
after	IN	O	O
attainment	NN	O	O
of	IN	O	O
euthyroidism	NN	O	O
,	,	O	O
all	DT	O	O
of	IN	O	O
the	DT	O	O
patients	NNS	O	O
had	VBD	O	O
normal	JJ	O	O
cortisol	JJ	O	O
response	NN	O	O
.	.	O	O

Regression	NN	O	O
analysis	NN	O	O
demonstrated	VBD	O	O
an	DT	O	O
independent	JJ	O	O
association	NN	O	O
of	IN	O	O
Cor60	NNP	O	O
with	IN	O	O
free	JJ	O	O
T3	NNP	O	O
in	IN	O	O
hyperthyroidism	NN	O	O
.	.	O	O

However	RB	O	O
,	,	O	O
the	DT	O	O
predictors	NNS	O	O
of	IN	O	O
CFC	NNP	O	O
,	,	O	O
FCI	NNP	O	O
,	,	O	O
and	CC	O	O
DHEA-S	NNP	O	O
levels	NNS	O	O
were	VBD	O	O
serum	JJ	O	O
creatinine	NN	O	O
levels	NNS	O	O
in	IN	O	O
hyperthyroidism	NN	O	O
,	,	O	O
and	CC	O	O
both	DT	O	O
creatinine	NN	O	O
and	CC	O	O
transaminase	NN	O	O
levels	NNS	O	O
in	IN	O	O
euthyroidism	NN	O	O
.	.	O	O

ACTH-stimulated	JJ	O	O
peak	NN	O	O
cortisol	NN	O	B-PRODUCT-OF
,	,	O	O
delta	NN	O	B-PRODUCT-OF
cortisol	NN	O	I-PRODUCT-OF
,	,	O	O
and	CC	O	O
delta	JJ	O	B-PRODUCT-OF
DHEA-S	NNP	O	O
levels	NNS	O	O
are	VBP	O	O
decreased	VBN	O	O
during	IN	O	O
hyperthyroidism	NN	O	O
,	,	O	O
probably	RB	O	O
due	JJ	O	O
to	TO	O	O
increased	VBN	O	O
turnover	NN	O	O
.	.	O	O

Since	IN	O	O
about	RB	O	O
10	CD	O	O
%	NN	O	O
of	IN	O	O
the	DT	O	O
subjects	NNS	O	O
with	IN	O	O
hyperthyroidism	NN	O	O
are	VBP	O	O
at	IN	O	O
risk	NN	O	O
for	IN	O	O
adrenal	JJ	O	O
insufficiency	NN	O	O
,	,	O	O
clinicians	NNS	O	O
dealing	VBG	O	O
with	IN	O	O
Graves	NNP	O	O
'	POS	O	O
disease	NN	O	O
should	MD	O	O
be	VB	O	O
alert	JJ	O	O
to	TO	O	O
the	DT	O	O
possibility	NN	O	O
of	IN	O	O
adrenal	JJ	O	O
insufficiency	NN	O	O
during	IN	O	O
hyperthyroid	JJ	O	O
stage	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Abstract	JJ	O	O
1	CD	O	O
.	.	O	O
Abstract	JJ	O	O
1	CD	O	O
.	.	O	O

UDP-glucuronosyltransferases	NNS	O	O
(	(	O	O
UGTs	NNP	O	O
)	)	O	O
are	VBP	O	O
versatile	JJ	O	O
and	CC	O	O
important	JJ	O	O
conjugation	NN	O	O
enzymes	NNS	O	O
in	IN	O	O
the	DT	O	O
metabolism	NN	O	O
of	IN	O	O
drugs	NNS	O	O
and	CC	O	O
other	JJ	O	O
xenobiotics	NNS	O	O
.	.	O	O

2	CD	O	O
.	.	O	O
2	CD	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
developed	VBN	O	O
a	DT	O	O
convenient	JJ	O	O
quantitative	JJ	O	O
multi-well	NN	O	O
plate	NN	O	O
assay	NN	O	O
to	TO	O	O
measure	VB	O	O
the	DT	O	O
glucuronidation	NN	O	O
rate	NN	O	O
of	IN	O	O
7-hydroxy-4-trifluoromethylcoumarin	NNP	O	B-SUBSTRATE
(	(	O	O
HFC	NNP	O	B-SUBSTRATE
)	)	O	O
for	IN	O	O
several	JJ	O	O
UGTs	NNP	O	B-enzyme
.	.	O	O

3	CD	O	O
.	.	O	O
3	CD	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
used	VBN	O	O
this	DT	O	O
method	NN	O	O
to	TO	O	O
screen	VB	O	O
11	CD	O	O
recombinant	JJ	O	O
human	JJ	O	B-enzyme
UGTs	NNP	O	I-enzyme
for	IN	O	O
HFC	NNP	O	B-SUBSTRATE
glucuronidation	NN	O	O
activity	NN	O	O
and	CC	O	O
studied	VBD	O	O
the	DT	O	O
reaction	NN	O	O
kinetics	NNS	O	O
with	IN	O	O
the	DT	O	O
most	RBS	O	O
active	JJ	O	O
enzymes	NNS	O	O
.	.	O	O

We	PRP	O	O
have	VBP	O	O
also	RB	O	O
examined	VBN	O	O
the	DT	O	O
HFC	NNP	O	O
glucuronidation	NN	O	O
activity	NN	O	O
of	IN	O	O
liver	NN	O	O
microsomes	NNS	O	O
from	IN	O	O
human	JJ	O	O
,	,	O	O
pig	NN	O	O
,	,	O	O
rabbit	NN	O	O
and	CC	O	O
rat	NN	O	O
.	.	O	O

4	CD	O	O
.	.	O	O

At	IN	O	O
a	DT	O	O
substrate	JJ	O	O
concentration	NN	O	O
of	IN	O	O
20	CD	O	O
M	NNS	O	O
,	,	O	O
the	DT	O	O
most	RBS	O	O
active	JJ	O	O
HFC	NNP	O	B-SUBSTRATE
glucuronidation	NN	O	O
catalysts	NNS	O	O
were	VBD	O	O
UGT1A10	NNP	O	B-enzyme
followed	VBN	O	O
by	IN	O	O
UGT1A6	NNP	O	B-enzyme
>	NNP	O	O
UGT1A7	NNP	O	B-enzyme
>	NNP	O	O
UGT2A1	NNP	O	B-enzyme
,	,	O	O
whereas	VBP	O	O
at	IN	O	O
300	CD	O	O
M	JJ	O	O
UGT1A6	NNP	O	B-enzyme
was	VBD	O	O
about	RB	O	O
10	CD	O	O
times	NNS	O	O
better	RBR	O	O
catalyst	NN	O	O
than	IN	O	O
the	DT	O	O
other	JJ	O	O
recombinant	JJ	O	O
UGTs	NNP	O	B-enzyme
.	.	O	O

The	DT	O	O
activities	NNS	O	O
of	IN	O	O
UGTs	NNP	O	O
1A3	CD	O	O
,	,	O	O
1A8	CD	O	O
,	,	O	O
1A9	CD	O	O
,	,	O	O
2B4	CD	O	O
and	CC	O	O
2B7	CD	O	O
were	VBD	O	O
low	JJ	O	O
,	,	O	O
whereas	JJ	O	O
UGT1A1	NNP	O	O
and	CC	O	O
UGT2B17	NNP	O	O
exhibited	VBD	O	O
no	DT	O	O
HFC	NNP	O	O
glucuronidation	NN	O	O
activity	NN	O	O
.	.	O	O

UGT1A6	NNP	O	B-enzyme
exhibited	VBD	O	O
a	DT	O	O
significantly	RB	O	O
higher	JJR	O	O
Vmax	NNP	O	O
and	CC	O	O
Km	NNP	O	O
values	VBZ	O	O
toward	IN	O	O
both	DT	O	O
HFC	NNP	O	B-SUBSTRATE
and	CC	O	O
UDP-glucuronic	NNP	O	O
acid	NN	O	I-SUBSTRATE
than	IN	O	O
the	DT	O	O
other	JJ	O	O
UGTs	NNP	O	B-enzyme
.	.	O	O

5	CD	O	O
.	.	O	O

Human	NNP	O	O
,	,	O	O
pig	NN	O	O
and	CC	O	O
rabbit	NN	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
rat	VB	O	O
liver	RB	O	O
microsomes	NNS	O	O
,	,	O	O
catalyzed	VBN	O	O
HFC	NNP	O	O
glucuronidation	NN	O	O
at	IN	O	O
high	JJ	O	O
rates	NNS	O	O
.	.	O	O

6	CD	O	O
.	.	O	O

This	DT	O	O
new	JJ	O	O
method	NN	O	O
is	VBZ	O	O
particularly	RB	O	O
suitable	JJ	O	O
for	IN	O	O
fast	JJ	O	O
activity	NN	O	O
screenings	NNS	O	O
of	IN	O	O
UGTs	NNP	O	O
1A6	CD	O	O
,	,	O	O
1A7	CD	O	O
,	,	O	O
1A10	CD	O	O
and	CC	O	O
2A1	CD	O	O
and	CC	O	O
HFC	NNP	O	O
glucuronidation	NN	O	O
activity	NN	O	O
determination	NN	O	O
from	IN	O	O
various	JJ	O	O
samples	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Friedreich	NNP	O	O
's	POS	O	O
ataxia	NN	O	O
(	(	O	O
FRDA	NNP	O	O
)	)	O	O
is	VBZ	O	O
a	DT	O	O
progressive	JJ	O	O
neurodegenerative	JJ	O	O
disease	NN	O	O
characterized	VBN	O	O
by	IN	O	O
ataxia	NN	O	O
,	,	O	O
variously	RB	O	O
associating	VBG	O	O
heart	NN	O	O
disease	NN	O	O
,	,	O	O
diabetes	VBZ	O	O
mellitus	JJ	O	O
and/or	NNS	O	O
glucose	JJ	O	O
intolerance	NN	O	O
.	.	O	O

It	PRP	O	O
results	NNS	O	O
from	IN	O	O
intronic	JJ	O	O
expansion	NN	O	O
of	IN	O	O
GAA	NNP	O	O
triplet	NN	O	O
repeats	NNS	O	O
at	IN	O	O
the	DT	O	O
FXN	NNP	O	O
locus	NN	O	O
.	.	O	O

Homozygous	JJ	O	O
expansions	NNS	O	O
cause	VBP	O	O
silencing	NN	O	O
of	IN	O	O
the	DT	O	O
FXN	NNP	O	O
gene	NN	O	O
and	CC	O	O
subsequent	JJ	O	O
decreased	JJ	O	O
expression	NN	O	O
of	IN	O	O
the	DT	O	O
encoded	JJ	O	O
mitochondrial	JJ	O	O
frataxin	NN	O	O
.	.	O	O

Detailed	JJ	O	O
analyses	NNS	O	O
in	IN	O	O
fibroblasts	NNS	O	O
and	CC	O	O
neuronal	JJ	O	O
tissues	NNS	O	O
from	IN	O	O
FRDA	NNP	O	O
patients	NNS	O	O
have	VBP	O	O
revealed	VBN	O	O
profound	IN	O	O
cytoskeleton	NN	O	O
anomalies	NNS	O	O
.	.	O	O

So	RB	O	O
far	RB	O	O
,	,	O	O
however	RB	O	O
,	,	O	O
the	DT	O	O
molecular	JJ	O	O
mechanism	NN	O	O
underlying	VBG	O	O
these	DT	O	O
cytoskeleton	NN	O	O
defects	VBZ	O	O
remains	VBZ	O	O
unknown	JJ	O	O
.	.	O	O

We	PRP	O	O
show	VBP	O	O
here	RB	O	O
that	IN	O	O
gene	NN	O	O
silencing	VBG	O	O
spreads	NNS	O	O
in	IN	O	O
cis	NN	O	O
over	IN	O	O
the	DT	O	O
PIP5K1B	NNP	O	O
gene	NN	O	O
in	IN	O	O
cells	NNS	O	O
from	IN	O	O
FRDA	NNP	O	O
patients	NNS	O	O
(	(	O	O
circulating	VBG	O	O
lymphocytes	NNS	O	O
and	CC	O	O
primary	JJ	O	O
fibroblasts	NNS	O	O
)	)	O	O
,	,	O	O
correlating	VBG	O	O
with	IN	O	O
expanded	JJ	O	O
GAA	NNP	O	O
repeat	NN	O	O
size	NN	O	O
.	.	O	O

PIP5K1B	NNP	O	B-enzyme
encodes	VBZ	O	O
phosphatidylinositol	JJ	O	B-enzyme
4-phosphate	JJ	O	I-enzyme
5-kinase	JJ	O	O
beta	NN	O	O
type	NN	O	O
I	PRP	O	O
(	(	O	O
pip5k1beta	NN	O	B-enzyme
)	)	O	O
,	,	O	O
an	DT	O	O
enzyme	NN	O	O
functionally	RB	O	O
linked	VBN	O	O
to	TO	O	O
actin	VB	O	O
cytoskeleton	NN	O	O
dynamics	NNS	O	O
that	WDT	O	O
phosphorylates	VBZ	O	O
phosphatidylinositol	JJ	O	B-SUBSTRATE
4-phosphate	JJ	O	I-SUBSTRATE
[	NN	O	O
PI	NNP	O	B-SUBSTRATE
(	(	O	O
4	CD	O	O
)	)	O	O
P	NNP	O	O
]	NNP	O	O
to	TO	O	O
generate	VB	O	O
phosphatidylinositol-4,5-bisphosphate	JJ	O	B-PRODUCT-OF
[	NNP	O	O
PI	NNP	O	B-PRODUCT-OF
(	(	O	O
4,5	CD	O	O
)	)	O	O
P2	NNP	O	O
]	NNP	O	O
.	.	O	O

Accordingly	RB	O	O
,	,	O	O
loss	NN	O	O
of	IN	O	O
pip5k1beta	JJ	O	B-enzyme
function	NN	O	O
in	IN	O	O
FRDA	NNP	O	O
cells	NNS	O	O
was	VBD	O	O
accompanied	VBN	O	O
by	IN	O	O
decreased	JJ	O	O
PI	NNP	O	B-PRODUCT-OF
(	(	O	O
4,5	CD	O	O
)	)	O	O
P2	NN	O	O
levels	NNS	O	O
and	CC	O	O
was	VBD	O	O
shown	VBN	O	O
instrumental	JJ	O	O
for	IN	O	O
destabilization	NN	O	O
of	IN	O	O
the	DT	O	O
actin	NN	O	O
network	NN	O	O
and	CC	O	O
delayed	VBN	O	O
cell	NN	O	O
spreading	VBG	O	O
.	.	O	O

Knockdown	NNP	O	O
of	IN	O	O
PIP5K1B	NNP	O	O
in	IN	O	O
control	NN	O	O
fibroblasts	NNS	O	O
using	VBG	O	O
shRNA	NN	O	O
reproduced	VBD	O	O
abnormal	JJ	O	O
actin	JJ	O	O
cytoskeleton	NN	O	O
remodeling	NN	O	O
,	,	O	O
whereas	IN	O	O
over-expression	NN	O	O
of	IN	O	O
PIP5K1B	NNP	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
FXN	NNP	O	O
,	,	O	O
suppressed	VBD	O	O
this	DT	O	O
phenotype	NN	O	O
in	IN	O	O
FRDA	NNP	O	O
cells	NNS	O	O
.	.	O	O

In	IN	O	O
addition	NN	O	O
to	TO	O	O
provide	VB	O	O
new	JJ	O	O
insights	NNS	O	O
into	IN	O	O
the	DT	O	O
consequences	NNS	O	O
of	IN	O	O
the	DT	O	O
FXN	NNP	O	O
gene	NN	O	O
expansion	NN	O	O
,	,	O	O
these	DT	O	O
findings	NNS	O	O
raise	VBP	O	O
the	DT	O	O
question	NN	O	O
whether	IN	O	O
PIP5K1B	NNP	O	O
silencing	VBG	O	O
may	MD	O	O
contribute	VB	O	O
to	TO	O	O
the	DT	O	O
variable	JJ	O	O
manifestation	NN	O	O
of	IN	O	O
this	DT	O	O
complex	JJ	O	O
disease	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Abstract	JJ	O	O
1	CD	O	O
.	.	O	O
Abstract	JJ	O	O
1	CD	O	O
.	.	O	O

Since	IN	O	O
the	DT	O	O
prevalent	JJ	O	O
hormonal	JJ	O	O
combination	NN	O	O
therapy	NN	O	O
with	IN	O	O
estrogen	NN	O	O
analogues	NNS	O	O
in	IN	O	O
cancer	NN	O	O
patients	NNS	O	O
has	VBZ	O	O
frequency	NN	O	O
and	CC	O	O
possibility	NN	O	O
to	TO	O	O
induce	VB	O	O
the	DT	O	O
cholestasis	NN	O	O
,	,	O	O
the	DT	O	O
frequent	JJ	O	O
combination	NN	O	O
therapy	NN	O	O
with	IN	O	O
17alpha-ethynylestradiol	JJ	O	O
(	(	O	O
EE	NNP	O	O
,	,	O	O
an	DT	O	O
oral	JJ	O	O
contraceptive	NN	O	O
)	)	O	O
and	CC	O	O
doxorubicin	NN	O	O
(	(	O	O
an	DT	O	O
anticancer	NN	O	O
drug	NN	O	O
)	)	O	O
might	MD	O	O
be	VB	O	O
monitored	VBN	O	O
in	IN	O	O
aspect	NN	O	O
of	IN	O	O
efficacy	NN	O	O
and	CC	O	O
safety	NN	O	O
.	.	O	O

Doxorubicin	NNP	O	B-SUBSTRATE
is	VBZ	O	O
mainly	RB	O	O
excreted	VBN	O	O
into	IN	O	O
the	DT	O	O
bile	JJ	O	O
via	IN	O	O
P-glycoprotein	NNP	O	B-enzyme
(	(	O	O
P-gp	NNP	O	B-enzyme
)	)	O	O
and	CC	O	O
multidrug	JJ	O	B-enzyme
resistance-associated	JJ	O	I-enzyme
protein	NN	O	O
2	CD	O	O
(	(	O	O
Mrp2	NNP	O	B-enzyme
)	)	O	O
in	IN	O	O
hepatobiliary	JJ	O	O
route	NN	O	O
and	CC	O	O
metabolized	VBN	O	O
via	IN	O	O
cytochrome	NN	O	B-enzyme
P450	NNP	O	I-enzyme
(	(	O	O
CYP	NNP	O	O
)	)	O	O
3A	CD	O	O
subfamily	RB	O	O
.	.	O	O

Also	RB	O	O
the	DT	O	O
hepatic	JJ	O	O
Mrp2	NNP	O	O
(	(	O	O
not	RB	O	O
P-gp	NNP	O	O
)	)	O	O
and	CC	O	O
CYP3A	NNP	O	O
subfamily	RB	O	O
levels	NNS	O	O
were	VBD	O	O
reduced	VBN	O	O
in	IN	O	O
EE-induced	NNP	O	O
cholestatic	NN	O	O
(	(	O	O
EEC	NNP	O	O
)	)	O	O
rats	NNS	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
we	PRP	O	O
herein	VBP	O	O
report	VB	O	O
the	DT	O	O
pharmacokinetic	JJ	O	O
changes	NNS	O	O
of	IN	O	O
doxorubicin	NN	O	O
with	IN	O	O
respect	NN	O	O
to	TO	O	O
the	DT	O	O
changes	NNS	O	O
in	IN	O	O
its	PRP$	O	O
biliary	JJ	O	O
excretion	NN	O	O
and	CC	O	O
hepatic	JJ	O	O
metabolism	NN	O	O
in	IN	O	O
EEC	NNP	O	O
rats	NNS	O	O
.	.	O	O

2	CD	O	O
.	.	O	O
2	CD	O	O
.	.	O	O

The	DT	O	O
pharmacokinetic	JJ	O	O
study	NN	O	O
of	IN	O	O
doxorubicin	NN	O	O
after	IN	O	O
intravenous	JJ	O	O
administration	NN	O	O
of	IN	O	O
its	PRP$	O	O
hydrochloride	NN	O	O
was	VBD	O	O
conducted	VBN	O	O
along	IN	O	O
with	IN	O	O
the	DT	O	O
investigation	NN	O	O
of	IN	O	O
bile	JJ	O	O
flow	NN	O	O
rate	NN	O	O
and	CC	O	O
hepatobiliary	JJ	O	O
excretion	NN	O	O
of	IN	O	O
doxorubicin	NN	O	O
in	IN	O	O
control	NN	O	O
and	CC	O	O
EEC	NNP	O	O
rats	NNS	O	O
.	.	O	O

3	CD	O	O
.	.	O	O
3	CD	O	O
.	.	O	O

The	DT	O	O
significantly	RB	O	O
greater	JJR	O	O
AUC	NNP	O	O
(	(	O	O
58.7	CD	O	O
%	NN	O	O
increase	NN	O	O
)	)	O	O
of	IN	O	O
doxorubicin	NN	O	O
in	IN	O	O
EEC	NNP	O	O
rats	NN	O	O
was	VBD	O	O
due	JJ	O	O
to	TO	O	O
the	DT	O	O
slower	JJR	O	O
CL	NNP	O	O
(	(	O	O
32.9	CD	O	O
%	NN	O	O
decrease	NN	O	O
)	)	O	O
.	.	O	O

The	DT	O	O
slower	JJR	O	O
CL	NNP	O	O
was	VBD	O	O
due	JJ	O	O
to	TO	O	O
the	DT	O	O
reduction	NN	O	O
of	IN	O	O
hepatic	JJ	O	O
biliary	JJ	O	O
excretion	NN	O	O
(	(	O	O
67.0	CD	O	O
%	NN	O	O
decrease	NN	O	O
)	)	O	O
and	CC	O	O
hepatic	JJ	O	O
CYP3A	NNP	O	B-enzyme
subfamily-mediated	JJ	O	O
metabolism	NN	O	O
(	(	O	O
21.9	CD	O	O
%	NN	O	O
decrease	NN	O	O
)	)	O	O
of	IN	O	O
doxorubicin	NN	O	B-SUBSTRATE
.	.	O	O

These	DT	O	O
results	NNS	O	O
might	MD	O	O
have	VB	O	O
broader	JJR	O	O
implications	NNS	O	O
to	TO	O	O
understand	VB	O	O
the	DT	O	O
altered	JJ	O	O
pharmacokinetics	NNS	O	O
and/or	VBP	O	O
pharmacologic	JJ	O	O
effects	NNS	O	O
of	IN	O	O
doxorubicin	NN	O	O
via	IN	O	O
biliary	JJ	O	O
excretion	NN	O	O
and	CC	O	O
hepatic	JJ	O	O
metabolism	NN	O	O
in	IN	O	O
experimental	JJ	O	O
and	CC	O	O
clinical	JJ	O	O
estrogen-induced	JJ	O	O
cholestasis	NN	O	O
.	.	O	O

-DOCSTART- -X- -X- O

6-Dehydroshogaol	JJ	O	O
(	(	O	O
6-DHSG	JJ	O	O
)	)	O	O
is	VBZ	O	O
a	DT	O	O
bioactive	JJ	O	O
alpha	NN	O	O
,	,	O	O
beta-unsaturated	JJ	O	O
carbonyl	NN	O	O
compound	NN	O	O
isolated	VBD	O	O
from	IN	O	O
fresh	JJ	O	O
ginger	NN	O	O
with	IN	O	O
anti-inflammatory	JJ	O	O
and	CC	O	O
phase	JJ	O	O
II	NNP	O	O
enzyme	NN	O	O
inducing	VBG	O	O
activities	NNS	O	O
.	.	O	O

Here	RB	O	O
we	PRP	O	O
describe	VBP	O	O
the	DT	O	O
glutathione	NN	O	O
(	(	O	O
GSH	NNP	O	O
)	)	O	O
-dependent	VBD	O	O
metabolism	NN	O	O
and	CC	O	O
the	DT	O	O
effect	NN	O	O
of	IN	O	O
this	DT	O	O
metabolic	JJ	O	O
transformation	NN	O	O
on	IN	O	O
the	DT	O	O
biological	JJ	O	O
activities	NNS	O	O
of	IN	O	O
6-DHSG	JJ	O	O
.	.	O	O

Compared	VBN	O	O
with	IN	O	O
other	JJ	O	O
ginger	NN	O	O
compounds	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
6-gingerol	JJ	O	O
and	CC	O	O
6-shogaol	JJ	O	O
,	,	O	O
6-DHSG	JJ	O	O
showed	VBD	O	O
the	DT	O	O
most	RBS	O	O
potent	JJ	O	O
anti-inflammatory	JJ	O	O
effect	NN	O	O
in	IN	O	O
lipopolysaccharide	NN	O	O
(	(	O	O
LPS	NNP	O	O
)	)	O	O
-stimulated	VBD	O	O
RAW	NNP	O	O
264.7	CD	O	O
cells	NNS	O	O
.	.	O	O

The	DT	O	O
biological	JJ	O	O
activities	NNS	O	O
of	IN	O	O
6-DHSG	JJ	O	O
were	VBD	O	O
attenuated	VBN	O	O
by	IN	O	O
sulfhydryl	JJ	O	O
antioxidants	NNS	O	O
such	JJ	O	O
as	IN	O	O
glutathione	NN	O	O
(	(	O	O
GSH	NNP	O	O
)	)	O	O
or	CC	O	O
N-acetyl	JJ	O	O
cysteine	NN	O	O
(	(	O	O
NAC	NNP	O	O
)	)	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
ascorbic	JJ	O	O
acid	NN	O	O
(	(	O	O
ASC	NNP	O	O
)	)	O	O
.	.	O	O

6-DHSG	NN	O	B-SUBSTRATE
was	VBD	O	O
metabolised	VBN	O	O
by	IN	O	O
GSH	NNP	O	O
to	TO	O	O
form	VB	O	O
a	DT	O	O
GSH	NNP	O	O
conjugate	NN	O	O
(	(	O	O
GS-6-DHSG	NNP	O	B-PRODUCT-OF
)	)	O	O
in	IN	O	O
RAW	NNP	O	O
264.7	CD	O	O
cells	NNS	O	O
,	,	O	O
via	IN	O	O
a	DT	O	O
potential	JJ	O	O
mechanism	NN	O	O
involving	VBG	O	O
the	DT	O	O
catalytic	JJ	O	O
activity	NN	O	O
of	IN	O	O
glutathione-S-transferase	NN	O	B-enzyme
(	(	O	O
GST	NNP	O	B-enzyme
)	)	O	O
.	.	O	O

GS-6-DHSG	NN	O	O
showed	VBD	O	O
reduced	JJ	O	O
biological	JJ	O	O
activities	NNS	O	O
compared	VBN	O	O
with	IN	O	O
6-DHSG	JJ	O	O
in	IN	O	O
multiple	JJ	O	O
biological	JJ	O	O
assays	NNS	O	O
.	.	O	O

Together	RB	O	O
,	,	O	O
these	DT	O	O
results	NNS	O	O
indicate	VBP	O	O
that	IN	O	O
GSH	NNP	O	O
conjugation	NN	O	O
attenuates	VBZ	O	O
the	DT	O	O
biological	JJ	O	O
activities	NNS	O	O
of	IN	O	O
6-DHSG	JJ	O	O
and	CC	O	O
other	JJ	O	O
alpha	NN	O	O
,	,	O	O
beta-unsaturated	JJ	O	O
carbonyl	NN	O	O
compounds	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Cyclooxygenase	NNP	O	B-enzyme
(	(	O	O
COX	NNP	O	O
)	)	O	O
-2-derived	VBD	O	O
prostanoids	NNS	O	B-PRODUCT-OF
can	MD	O	O
influence	VB	O	O
several	JJ	O	O
processes	NNS	O	O
that	WDT	O	O
are	VBP	O	O
linked	VBN	O	O
to	TO	O	O
carcinogenesis	NN	O	O
.	.	O	O

We	PRP	O	O
aimed	VBD	O	O
to	TO	O	O
address	VB	O	O
the	DT	O	O
hypothesis	NN	O	O
that	WDT	O	O
platelets	VBZ	O	O
contribute	VBP	O	O
to	TO	O	O
aberrant	VB	O	O
COX-2	NNP	O	O
expression	NN	O	O
in	IN	O	O
HT29	NNP	O	O
colon	NN	O	O
carcinoma	NN	O	O
cells	NNS	O	O
and	CC	O	O
to	TO	O	O
reveal	VB	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
platelet-induced	JJ	O	O
COX-2	NNP	O	O
on	IN	O	O
the	DT	O	O
expression	NN	O	O
of	IN	O	O
proteins	NNS	O	O
involved	VBN	O	O
in	IN	O	O
malignancy	NN	O	O
and	CC	O	O
marker	NN	O	O
genes	NNS	O	O
of	IN	O	O
epithelial-mesenchymal	JJ	O	O
transition	NN	O	O
(	(	O	O
EMT	NNP	O	O
)	)	O	O
.	.	O	O

Human	JJ	O	O
platelets	VBZ	O	O
co-cultured	JJ	O	O
with	IN	O	O
HT29	NNP	O	O
cells	NNS	O	O
rapidly	RB	O	O
adhered	VBD	O	O
to	TO	O	O
cancer	NN	O	O
cells	NNS	O	O
and	CC	O	O
induced	JJ	O	O
COX-2	NNP	O	O
mRNA	NN	O	O
expression	NN	O	O
,	,	O	O
but	CC	O	O
not	RB	O	O
protein	JJ	O	O
synthesis	NN	O	O
which	WDT	O	O
required	VBD	O	O
the	DT	O	O
late	JJ	O	O
release	NN	O	O
of	IN	O	O
platelet	NN	O	O
PDGF	NNP	O	O
and	CC	O	O
COX-2	NNP	O	O
mRNA	NN	O	O
stabilization	NN	O	O
.	.	O	O

Platelet-induced	JJ	O	O
COX-2-dependent	JJ	O	O
PGE2	NNP	O	B-PRODUCT-OF
synthesis	NN	O	O
in	IN	O	O
HT29	NNP	O	O
cells	NNS	O	O
was	VBD	O	O
involved	VBN	O	O
in	IN	O	O
downregulation	NN	O	O
of	IN	O	O
p21	NN	O	O
(	(	O	O
WAF1/CIP1	NNP	O	O
)	)	O	O
and	CC	O	O
upregulation	NN	O	O
of	IN	O	O
cyclinB1	NN	O	O
,	,	O	O
since	IN	O	O
these	DT	O	O
effects	NNS	O	O
were	VBD	O	O
prevented	VBN	O	O
by	IN	O	O
rofecoxib	NN	O	O
(	(	O	O
a	DT	O	O
selective	JJ	O	O
COX-2	NNP	O	O
inhibitor	NN	O	O
)	)	O	O
and	CC	O	O
rescued	VBN	O	O
by	IN	O	O
exogenous	JJ	O	O
PGE2	NNP	O	O
.	.	O	O

Galectin-3	NNP	O	O
,	,	O	O
highly	RB	O	O
expressed	VBN	O	O
in	IN	O	O
HT29	NNP	O	O
cells	NNS	O	O
,	,	O	O
is	VBZ	O	O
unique	JJ	O	O
among	IN	O	O
galectins	NNS	O	O
because	IN	O	O
it	PRP	O	O
contains	VBZ	O	O
a	DT	O	O
collagen-like	JJ	O	O
domain	NN	O	O
.	.	O	O

Thus	RB	O	O
,	,	O	O
we	PRP	O	O
studied	VBD	O	O
the	DT	O	O
role	NN	O	O
of	IN	O	O
galectin-3	JJ	O	O
and	CC	O	O
platelet	JJ	O	O
collagen	NN	O	O
receptors	NNS	O	O
in	IN	O	O
platelet-induced	JJ	O	O
COX-2	JJ	O	O
overexpression	NN	O	O
.	.	O	O

Inhibitors	NNS	O	O
of	IN	O	O
galectin-3	JJ	O	O
function	NN	O	O
(	(	O	O
beta-lactose	JJ	O	O
,	,	O	O
a	DT	O	O
dominant-negative	JJ	O	O
form	NN	O	O
of	IN	O	O
galectin-3	JJ	O	O
,	,	O	O
Gal-3C	NNP	O	O
,	,	O	O
and	CC	O	O
anti-galectin-3	JJ	O	O
antibody	NN	O	O
M3/38	NNP	O	O
)	)	O	O
or	CC	O	O
collagen	JJ	O	O
receptor-mediated	JJ	O	O
platelet	NN	O	O
adhesion	NN	O	O
(	(	O	O
revacept	NN	O	O
,	,	O	O
a	DT	O	O
dimeric	JJ	O	O
collagen	NN	O	O
receptor	NN	O	O
GPVI-Fc	NNP	O	O
)	)	O	O
prevented	VBD	O	O
aberrant	JJ	O	O
COX-2	JJ	O	O
expression	NN	O	O
.	.	O	O

Inhibition	NN	O	O
of	IN	O	O
platelet-cancer	NN	O	O
cell	NN	O	O
interaction	NN	O	O
by	IN	O	O
revacept	NN	O	O
was	VBD	O	O
more	RBR	O	O
effective	JJ	O	O
than	IN	O	O
rofecoxib	NN	O	O
in	IN	O	O
preventing	VBG	O	O
platelet-induced	JJ	O	O
mRNA	NN	O	O
changes	NNS	O	O
of	IN	O	O
EMT	NNP	O	O
markers	NNS	O	O
suggesting	VBG	O	O
that	IN	O	O
direct	JJ	O	O
cell-cell	NN	O	O
contact	NN	O	O
and	CC	O	O
aberrant	JJ	O	O
COX-2	NNP	O	O
expression	NN	O	O
synergistically	RB	O	O
induced	JJ	O	O
gene	NN	O	O
expression	NN	O	O
modifications	NNS	O	O
associated	VBN	O	O
with	IN	O	O
EMT	NNP	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
our	PRP$	O	O
findings	NNS	O	O
provide	VBP	O	O
the	DT	O	O
rationale	NN	O	O
for	IN	O	O
testing	VBG	O	O
blockers	NNS	O	O
of	IN	O	O
collagen	NN	O	O
binding	NN	O	O
sites	NNS	O	O
,	,	O	O
such	JJ	O	O
as	IN	O	O
revacept	NN	O	O
,	,	O	O
and	CC	O	O
galectin-3	JJ	O	O
inhibitors	NNS	O	O
in	IN	O	O
the	DT	O	O
prevention	NN	O	O
of	IN	O	O
colon	NN	O	O
cancer	NN	O	O
metastasis	NN	O	O
in	IN	O	O
animal	NN	O	O
models	NNS	O	O
followed	VBN	O	O
by	IN	O	O
studies	NNS	O	O
in	IN	O	O
patients	NNS	O	O
.	.	O	O

-DOCSTART- -X- -X- O

Cholesterol	NNP	O	B-enzyme
esterase	NN	O	I-enzyme
(	(	O	O
CE	NNP	O	B-enzyme
)	)	O	O
induced	VBD	O	O
surface	JJ	O	O
erosion	NN	O	O
of	IN	O	O
poly	NN	O	B-SUBSTRATE
(	(	O	O
ethylene	JJ	O	O
carbonate	NN	O	I-SUBSTRATE
)	)	O	I-SUBSTRATE
(	(	O	O
PEC	NNP	O	B-SUBSTRATE
)	)	O	O
and	CC	O	O
drug	NN	O	O
release	NN	O	O
from	IN	O	O
PEC	NNP	O	O
under	IN	O	O
mild	JJ	O	O
physiological	JJ	O	O
environment	NN	O	O
was	VBD	O	O
investigated	VBN	O	O
.	.	O	O

The	DT	O	O
degradation	NN	O	O
process	NN	O	O
was	VBD	O	O
monitored	VBN	O	O
by	IN	O	O
changes	NNS	O	O
of	IN	O	O
mass	NN	O	O
and	CC	O	O
molecular	JJ	O	O
weight	NN	O	O
(	(	O	O
MW	NNP	O	O
)	)	O	O
and	CC	O	O
surface	JJ	O	O
morphology	NN	O	O
of	IN	O	O
polymer	NN	O	O
films	NNS	O	O
.	.	O	O

During	IN	O	O
the	DT	O	O
whole	JJ	O	O
period	NN	O	O
of	IN	O	O
degradation	NN	O	O
,	,	O	O
MW	NNP	O	O
of	IN	O	O
PEC	NNP	O	O
was	VBD	O	O
unchanged	JJ	O	O
.	.	O	O

Water	NNP	O	O
uptake	NN	O	O
of	IN	O	O
the	DT	O	O
polymer	NN	O	O
was	VBD	O	O
only	RB	O	O
2.8	CD	O	O
and	CC	O	O
0.2	CD	O	O
%	NN	O	O
for	IN	O	O
PEC	NNP	O	O
with	IN	O	O
the	DT	O	O
MW	NNP	O	O
of	IN	O	O
200	CD	O	O
kDa	NNS	O	O
(	(	O	O
PEC200	NNP	O	O
)	)	O	O
and	CC	O	O
PEC	NNP	O	O
with	IN	O	O
the	DT	O	O
MW	NNP	O	O
of	IN	O	O
41	CD	O	O
kDa	NNS	O	O
(	(	O	O
PEC41	NNP	O	O
)	)	O	O
,	,	O	O
respectively	RB	O	O
.	.	O	O

Degradation	NN	O	O
of	IN	O	O
less	JJR	O	O
hydrophilic	JJ	O	O
PEC41	NNP	O	O
with	IN	O	O
higher	JJR	O	O
density	NN	O	O
was	VBD	O	O
slower	JJR	O	O
than	IN	O	O
that	DT	O	O
of	IN	O	O
PEC200	NNP	O	O
.	.	O	O

By	IN	O	O
this	DT	O	O
mechanism	NN	O	O
,	,	O	O
CE-responsive	JJ	O	O
drug	NN	O	O
in	IN	O	O
vitro	JJ	O	O
release	NN	O	O
from	IN	O	O
PEC	NNP	O	O
in	IN	O	O
situ	NN	O	O
forming	VBG	O	O
depots	NNS	O	O
(	(	O	O
ISFD	NNP	O	O
)	)	O	O
was	VBD	O	O
conducted	VBN	O	O
successfully	RB	O	O
.	.	O	O

As	IN	O	O
expected	VBN	O	O
,	,	O	O
less	JJR	O	O
bovine	JJ	O	O
serum	NN	O	O
albumin	NN	O	O
(	(	O	O
BSA	NNP	O	O
)	)	O	O
was	VBD	O	O
released	VBN	O	O
from	IN	O	O
PEC41	NNP	O	O
compared	VBN	O	O
with	IN	O	O
that	DT	O	O
of	IN	O	O
PEC200	NNP	O	O
in	IN	O	O
the	DT	O	O
same	JJ	O	O
time	NN	O	O
period	NN	O	O
.	.	O	O

In	IN	O	O
conclusion	NN	O	O
,	,	O	O
this	DT	O	O
work	NN	O	O
enabled	VBD	O	O
the	DT	O	O
in	IN	O	O
vitro	JJ	O	O
drug	NN	O	O
release	NN	O	O
evaluation	NN	O	O
of	IN	O	O
existing	VBG	O	O
PEC	NNP	O	O
devices	NNS	O	O
and	CC	O	O
implied	VBD	O	O
a	DT	O	O
new	JJ	O	O
candidate	NN	O	O
for	IN	O	O
the	DT	O	O
development	NN	O	O
of	IN	O	O
enzyme-responsive	JJ	O	O
systems	NNS	O	O
.	.	O	O
